STOCK TITAN

Medirom swings to JPY3.64B net loss in 2025

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
20-F

Rhea-AI Filing Summary

Medirom Healthcare Technologies Inc. (MRM) reported 2025 revenue fell 6.5% to JPY7,761.621 million from JPY8,299.134 million in 2024. Net results shifted to a JPY3,642.581 million net loss from JPY138.191 million net income; operating loss was JPY3,391.721 million versus JPY18.102 million. Adjusted EBITDA was negative JPY190.484 million, compared with positive JPY417.467 million, and impairment losses on long-lived assets and goodwill totaled JPY2,550.953 million.

At December 31, 2025, cash was JPY91.979 million and interest-bearing debt was JPY2,401.507 million, including JPY1,601.548 million due within 12 months; the working capital deficit was JPY3,244.164 million. The company reported substantial doubt about its ability to continue as a going concern and said management’s plans have not alleviated that doubt. It has suspended new salon openings, franchise expansion and acquisitions, while reducing costs, closing or transferring salons and pursuing refinancing and additional financing. In 2025 it sold 43 salons for a JPY1,742.064 million contractual value but recorded JPY540.140 million in cash sale proceeds, and repurchased 47 salons for JPY2,301.371 million.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 4 points

How the balance works

Positive

  • Moderate pointOperating cash outflow narrowed to JPY1,155.007 million from JPY1,331.681 million in 2024.

Negative

  • Major pointNet results shifted to a JPY3,642.581 million loss from JPY138.191 million income in 2024.
  • Major pointMedirom disclosed substantial doubt about its ability to continue as a going concern, with JPY91.979 million in cash at December 31, 2025.
  • Moderate pointTotal revenue fell 6.5% to JPY7,761.621 million from JPY8,299.134 million in 2024.
  • Minor pointImpairment losses rose to JPY2,550.953 million from JPY22.872 million in 2024.

Filing Explained

At the report date, Medirom reported JPY775,000 thousand outstanding under two secured loans due December 30, 2026. The Triple One loan’s original September 15, 2026 maturity had passed before extension, and its rate rose to 14.6% from November 1, 2026, while enforcement could cost the company control of two subsidiaries and revenue from ten salons.

Revenue JPY7,761.621 million Year ended December 31, 2025; down 6.5% from JPY8,299.134 million in 2024.
Net loss JPY3,642.581 million Year ended December 31, 2025; compared with net income of JPY138.191 million in 2024.
Operating loss JPY3,391.721 million Year ended December 31, 2025; compared with an operating loss of JPY18.102 million in 2024.
Adjusted EBITDA Negative JPY190.484 million Year ended December 31, 2025; compared with positive JPY417.467 million in 2024.
Impairment losses on long-lived assets and goodwill JPY2,550.953 million Year ended December 31, 2025; compared with JPY22.872 million in 2024.
Cash and cash equivalents JPY91.979 million As of December 31, 2025; JPY329.399 million as of December 31, 2024.
Interest-bearing debt JPY2,401.507 million As of December 31, 2025; JPY1,601.548 million was scheduled to mature within 12 months.
Net cash used in operating activities JPY1,155.007 million Year ended December 31, 2025; compared with JPY1,331.681 million used in 2024.
going concern financial
"substantial doubt about our ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
Adjusted EBITDA financial
"Adjusted EBITDA was (JPY190,484) thousand"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
working capital deficit financial
"a working capital deficit of JPY3,244,164 thousand"
A working capital deficit occurs when a company's short-term obligations—like bills, supplier payments and near-term debt—are larger than its readily available short-term resources such as cash, money expected from customers, and inventory that can be sold. Like a household whose monthly bills exceed its checking account, it signals potential difficulty paying immediate expenses, which matters to investors because it raises the chance the company will need outside financing or cut operations, affecting risk and value.
valuation allowances financial
"Valuation allowances are provided against deferred tax assets"
A valuation allowance is an accounting reserve companies set against expected future tax benefits when they doubt those benefits will be realized. Think of it like discounting a coupon you might not be able to use: it reduces the reported value of future tax savings on the balance sheet. For investors, increases or decreases in this allowance signal management’s view of future profitability and can materially change reported earnings and equity.
performance obligation financial
"there is only one performance obligation"
A performance obligation is a specific promise in a contract to deliver a good or provide a service to a customer, and it is the unit companies use to decide when and how much revenue to record. Think of it like checklist items in a service agreement: each item completed can trigger part of the payment to be recognized as revenue. Investors care because how obligations are identified and satisfied changes the timing and amount of reported revenue and profits, affecting comparisons and valuation.
as-invoiced practical expedient financial
"elected the ‘as-invoiced’ practical expedient"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was MRM's revenue in 2025?

Medirom's revenue was JPY7,761.621 million for the year ended December 31, 2025, down 6.5% from JPY8,299.134 million in 2024. Relaxation Salon contributed JPY7,051.584 million, Luxury Beauty JPY541.767 million and Digital Preventative Healthcare JPY168.270 million.

What was MRM's net income in 2025?

MRM reported a net loss of JPY3,642.581 million for the year ended December 31, 2025, compared with net income of JPY138.191 million in 2024. The net loss attributable to company shareholders was JPY3,634.280 million, and basic and diluted net loss per share was JPY459.92.

What does MRM say about overdue tax and social insurance payments?

Medirom reported that JPY250.154 million was past due as of December 31, 2025. It said it had agreed revised payment schedules with the relevant Japanese tax and social insurance authorities and was making payments in accordance with those schedules.

How much cash did Medirom receive from salon sales compared with their contractual value?

For 2025, cash sale proceeds were JPY540.140 million, while the contractual value of 43 salons sold was JPY1,742.064 million. The company said the balance was settled through receivables or offsets against amounts payable on contemporaneous repurchases from the same purchaser; it repurchased 47 salons for JPY2,301.371 million.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Falsetrue0001819704FYDecember 31, 2025Medirom Healthcare Technologies Inc.3 Years10 Years3http://fasb.org/us-gaap/2025#ImpairmentOfLongLivedAssetsHeldForUsehttp://fasb.org/us-gaap/2025#Goodwillhttp://fasb.org/us-gaap/2025#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2025#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2025#IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate0001819704us-gaap:TrademarksMember2025-01-012025-12-310001819704us-gaap:EmployeeStockOptionMember2025-01-012025-12-310001819704mrm:LuxuryBeautyMember2023-01-012023-12-310001819704us-gaap:FranchiseMembermrm:RelaxationSalonSegmentMember2025-01-012025-12-310001819704mrm:LuxuryBeautySegmentMember2021-10-210001819704mrm:FranchisorOwnedOutletSoldMemberus-gaap:OperatingSegmentsMember2024-01-012024-12-310001819704mrm:RoyaltyIncomeMembermrm:RelaxationSalonSegmentMember2025-01-012025-12-310001819704us-gaap:FurnitureAndFixturesMember2025-01-012025-12-310001819704srt:WeightedAverageMemberus-gaap:TrademarksMember2024-12-310001819704srt:MinimumMember2025-12-310001819704mrm:KabushikiKaishaNoTrackMembermrm:SellingGeneralAndAdministrativeExpenseMember2023-01-012023-12-310001819704mrm:AccruedExpensesMembermrm:KabushikiKaishaLTWMember2024-12-310001819704srt:WeightedAverageMembermrm:StoreOperatingRightsMember2024-12-310001819704mrm:AccountsReceivableOtherMember2023-01-012023-12-310001819704mrm:UnsecuredShortTermBankLoanMember2025-01-012025-12-310001819704mrm:ThirdUnsecuredConvertibleBondsMember2025-12-120001819704us-gaap:SubsequentEventMember2026-10-130001819704mrm:RelaxationSalonSegmentMember2025-01-012025-12-310001819704mrm:CommonStocksMembermrm:TomoyaOgawaMember2025-12-310001819704mrm:CorporateConvertibleBondMember2024-12-310001819704mrm:CorporateAndEliminationsMemberus-gaap:OperatingSegmentsMember2025-12-310001819704mrm:EmployeesMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310001819704mrm:MEDIROMWellnessCoMember2025-07-310001819704mrm:LuxuryBeautyMemberus-gaap:CustomerRelationshipsMember2025-01-012025-12-310001819704mrm:InvestorBMemberus-gaap:TradeAccountsReceivableMember2025-12-310001819704mrm:RoyaltyIncomeMemberus-gaap:OperatingSegmentsMember2025-01-012025-12-310001819704us-gaap:OperatingSegmentsMembermrm:LuxuryBeautyMember2023-01-012023-12-310001819704us-gaap:CommonClassAMember2025-01-012025-12-310001819704mrm:AccruedExpensesMembermrm:KabushikiKaishaLTWMember2025-12-3100018197042025-03-070001819704mrm:ClassACommonMember2021-03-290001819704mrm:InvestorOwnedMember2024-12-310001819704mrm:SubleaseRevenueMemberus-gaap:OperatingSegmentsMember2024-01-012024-12-310001819704dei:BusinessContactMember2025-01-012025-12-310001819704mrm:AmericanDepositorySharesMembermrm:KoujiEguchiMembermrm:CozyJointVentureMember2023-01-200001819704us-gaap:EmployeeStockOptionMember2025-12-310001819704mrm:RevenueRecognitionMember2023-12-310001819704us-gaap:PropertyPlantAndEquipmentMember2024-01-012024-12-310001819704mrm:OtherFranchiseRevenuesMembermrm:RelaxationSalonSegmentMember2024-01-012024-12-310001819704mrm:KufuCompanyMembermrm:FourthConvertibleBondsMember2025-01-012025-12-310001819704srt:MinimumMembermrm:CapitalizedSoftwareMember2025-12-310001819704us-gaap:TradeAccountsReceivableMember2023-12-310001819704mrm:RevenueRecognitionMember2024-12-310001819704mrm:RelaxationSalonSegmentMember2024-01-012024-12-310001819704mrm:OtherNonMarketableSecuritiesMember2025-12-310001819704us-gaap:OperatingSegmentsMembermrm:DigitalPreventativeHealthcareMember2023-01-012023-12-310001819704us-gaap:NoncontrollingInterestMember2023-01-012023-12-310001819704mrm:SpiritAdvisorsMember2025-01-012025-12-310001819704mrm:MEDIROMWellnessCoMember2025-09-012025-09-300001819704us-gaap:OperatingSegmentsMember2023-12-310001819704mrm:Directly-OperatedSalonsMembermrm:RelaxationSalonSegmentMember2024-01-012024-12-310001819704mrm:OtherRevenuesMember2025-01-012025-12-310001819704mrm:MatrixIndustriesIncMember2021-02-032021-02-030001819704mrm:RevenueRecognitionMember2025-12-310001819704mrm:AoyamaConsultingGroupCoLtdMembermrm:SellingGeneralAndAdministrativeExpenseMember2024-01-012024-12-310001819704us-gaap:CommonStockMember2025-01-012025-12-310001819704mrm:LongTermAccountsReceivableOtherMember2024-01-012024-12-310001819704mrm:LuxuryBeautySegmentMember2025-01-012025-12-3100018197042025-12-310001819704us-gaap:AdditionalPaidInCapitalMember2024-12-310001819704us-gaap:ConvertibleDebtMember2025-12-120001819704us-gaap:SubsequentEventMember2026-12-312026-12-310001819704mrm:MatrixIndustriesIncMember2025-01-012025-12-310001819704us-gaap:ConvertibleDebtMember2024-10-310001819704srt:MaximumMembermrm:CapitalizedSoftwareMember2025-12-310001819704mrm:HeadquartersAssetGroupMember2025-01-012025-12-310001819704us-gaap:SeriesAPreferredStockMembermrm:MEDIROMMOTHERLabsIncMember2024-09-012024-10-310001819704us-gaap:OperatingSegmentsMembermrm:RelaxationSalonSegmentMember2024-12-310001819704us-gaap:VehiclesMember2024-12-310001819704mrm:ThirdConvertibleBondsMembermrm:KufuCompanyMember2025-01-012025-12-310001819704us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-3100018197042022-01-012022-12-310001819704mrm:KufuCompanyHoldingsIncMemberus-gaap:SubsequentEventMember2026-07-140001819704mrm:OtherNonMarketableSecuritiesMember2024-12-310001819704us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-12-310001819704mrm:InvestorOwnedMemberus-gaap:SubsequentEventMember2026-11-112026-11-110001819704us-gaap:RetainedEarningsMember2025-01-012025-12-310001819704us-gaap:EntityOperatedUnitsMember2025-12-310001819704us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2024-12-310001819704us-gaap:OperatingSegmentsMembermrm:OtherRevenuesMember2023-01-012023-12-310001819704mrm:RoyaltyIncomeMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-310001819704us-gaap:ConstructionInProgressMembermrm:HeadquartersAssetGroupMember2025-01-012025-12-310001819704us-gaap:CommonClassAMember2025-12-310001819704us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembermrm:RevenueRecognitionMember2023-01-012023-12-310001819704mrm:OtherFranchiseRevenuesMembermrm:RelaxationSalonSegmentMember2025-01-012025-12-3100018197042024-01-012024-12-310001819704mrm:StaffingServiceRevenueMembermrm:RelaxationSalonSegmentMember2023-01-012023-12-310001819704us-gaap:OperatingSegmentsMembermrm:OtherRevenuesMember2024-01-012024-12-310001819704srt:MaximumMemberus-gaap:CustomerRelationshipsMember2025-12-310001819704srt:MaximumMembermrm:FurnitureAndOtherEquipmentMember2025-12-310001819704mrm:FurnitureAndOtherEquipmentMember2025-12-310001819704mrm:OtherFranchiseRevenuesMembermrm:RelaxationSalonSegmentMember2023-01-012023-12-310001819704mrm:FirstCorporateConvertibleBondMember2025-12-310001819704us-gaap:AccountsReceivableMember2025-12-310001819704mrm:EmployeesMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001819704us-gaap:SubsequentEventMember2027-03-310001819704us-gaap:OperatingSegmentsMembermrm:DigitalPreventativeHealthcareMember2024-01-012024-12-310001819704us-gaap:NoncontrollingInterestMember2024-12-310001819704mrm:StaffingServiceRevenueMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-310001819704mrm:AccountsReceivableOtherMember2024-01-012024-12-310001819704mrm:RegisteredOfferingMember2024-12-110001819704mrm:CorporateAuditorMember2023-12-310001819704mrm:ThirdConvertibleBondsMemberus-gaap:SubsequentEventMember2026-12-252026-12-250001819704mrm:FourthConvertibleBondsMember2025-12-310001819704mrm:CorporateAuditorMember2024-12-310001819704mrm:FourthConvertibleBondsMemberus-gaap:SubsequentEventMember2026-01-010001819704mrm:EmployeesMemberus-gaap:EmployeeStockOptionMember2015-12-212015-12-210001819704mrm:YasuhiroHayamiMembermrm:MEDIROMMOTHERLabsIncMember2024-10-312024-10-310001819704us-gaap:SubsequentEventMember2026-01-300001819704mrm:JapanGeneMedicineCorporationMember2024-06-3000018197042024-06-302024-06-300001819704mrm:StoreOperatingRightsMember2025-12-310001819704mrm:AoyamaConsultingGroupCoLtdMembermrm:AccruedExpensesMember2025-12-310001819704us-gaap:TradeAccountsReceivableMember2024-01-012024-12-310001819704us-gaap:VehiclesMembersrt:MinimumMember2025-12-310001819704mrm:LuxuryBeautyMember2025-01-012025-12-310001819704us-gaap:TreasuryStockCommonMember2023-12-310001819704mrm:SubleaseRevenueMembermrm:RelaxationSalonSegmentMember2025-01-012025-12-310001819704mrm:UnsecuredShortTermBankLoanMember2024-12-310001819704us-gaap:OperatingSegmentsMembermrm:LuxuryBeautyMember2023-12-310001819704mrm:DigitalPreventativeHealthcareMember2025-01-012025-12-310001819704mrm:InvestorOwnedMember2025-12-310001819704mrm:YoshioUekusaMember2025-10-310001819704mrm:MrEguchiMembermrm:MEDIROMWellnessCoMember2025-12-310001819704us-gaap:ConvertibleDebtMember2022-12-310001819704mrm:RehabilitationBusinessMember2025-01-012025-12-310001819704mrm:YasuhiroHayamiMember2025-03-140001819704mrm:FourthUnsecuredConvertibleCorporateBondsMembermrm:KufuCompanyHoldingsIncMember2025-01-012025-12-310001819704mrm:Share-BasedPaymentArrangementsNonemployeeMemberus-gaap:EmployeeStockOptionMember2024-12-112024-12-110001819704mrm:SubleaseRevenueMembermrm:RelaxationSalonSegmentMember2024-01-012024-12-310001819704mrm:AmericanDepositorySharesMembermrm:KoujiEguchiMembermrm:CozyJointVentureMember2023-03-310001819704mrm:MEDIROMMOTHERLabsIncMember2023-11-300001819704mrm:LongTermAccountsReceivableOtherMember2025-01-012025-12-310001819704us-gaap:CommonStockMember2025-12-310001819704mrm:AccountsReceivableOtherMember2022-12-310001819704us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-12-310001819704mrm:RelaxationSalonsMember2025-12-310001819704us-gaap:FranchisedUnitsMember2024-12-3100018197042024-05-310001819704srt:WeightedAverageMembermrm:CapitalizedSoftwareMember2025-12-310001819704mrm:RoyaltyIncomeMembermrm:RelaxationSalonSegmentMember2023-01-012023-12-310001819704mrm:FranchisorOwnedOutletSoldMembermrm:LuxuryBeautyMember2024-01-012024-12-310001819704mrm:OtherRevenuesMembermrm:DigitalPreventativeHealthcareMember2023-01-012023-12-310001819704mrm:FranchisorOwnedOutletSoldMembermrm:RelaxationSalonSegmentMember2025-01-012025-12-310001819704mrm:HeadquartersAssetGroupMemberus-gaap:PropertyPlantAndEquipmentMember2025-01-012025-12-310001819704mrm:ThirdCorporateConvertibleBondMember2025-12-310001819704mrm:SubleaseRevenueMemberus-gaap:OperatingSegmentsMember2025-01-012025-12-310001819704mrm:StaffingServiceRevenueMembermrm:RelaxationSalonSegmentMember2024-01-012024-12-310001819704mrm:RelaxationSalonSegmenMember2025-01-012025-12-310001819704us-gaap:GoodwillMember2025-01-012025-12-310001819704us-gaap:AdditionalPaidInCapitalMember2023-12-310001819704mrm:MEDIROMWellnessCoMember2025-08-012025-08-310001819704mrm:MEDIROMMOTHERLabsIncMember2023-12-310001819704mrm:SellingGeneralAndAdministrativeExpenseMembermrm:KabushikiKaishaLTWMember2024-01-012024-12-310001819704us-gaap:LeaseholdImprovementsMember2024-12-310001819704us-gaap:FairValueInputsLevel3Membersrt:MinimumMember2025-06-300001819704mrm:KufuCompanyHoldingsIncMemberus-gaap:SubsequentEventMember2026-01-302026-01-300001819704srt:WeightedAverageMembermrm:StoreOperatingRightsMember2025-12-310001819704srt:MaximumMember2025-12-310001819704mrm:JapaneseTaxAndSocialInsuranceAuthoritiesMember2025-12-310001819704us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001819704us-gaap:CommonStockMemberus-gaap:CommonClassAMember2025-12-310001819704srt:WeightedAverageMembermrm:CapitalizedSoftwareMember2024-12-310001819704mrm:LuxuryBeautyMember2025-01-012025-12-310001819704mrm:ThirdConvertibleBondsMember2025-01-012025-12-310001819704us-gaap:CommonStockMember2023-01-012023-12-310001819704mrm:UnsecuredShortTermBankLoanMember2025-12-310001819704mrm:TelephoneRightsMember2025-01-012025-12-310001819704mrm:Right-Of-UseAssetsMember2025-01-012025-12-310001819704us-gaap:StateAndLocalJurisdictionMember2025-01-012025-12-310001819704us-gaap:CorporateMember2025-01-012025-12-310001819704us-gaap:OperatingSegmentsMembermrm:RelaxationSalonSegmentMember2023-01-012023-12-310001819704us-gaap:CommonStockMember2024-12-310001819704mrm:CorporateAndEliminationsMemberus-gaap:OperatingSegmentsMember2024-12-3100018197042023-08-070001819704us-gaap:RetainedEarningsMember2023-12-310001819704us-gaap:CommonStockMembermrm:RegisteredOfferingMember2024-12-112024-12-110001819704mrm:RelaxationSalonSegmentMember2024-12-310001819704mrm:SecondConvertibleBondsMemberus-gaap:SubsequentEventMember2026-08-250001819704us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2025-12-310001819704us-gaap:UnsecuredDebtMember2024-07-310001819704us-gaap:SubsequentEventMember2026-10-110001819704mrm:DigitalPreventativeHealthcareMember2023-01-012023-12-310001819704mrm:UnsecuredShortTermBankLoanMember2025-03-310001819704us-gaap:AdditionalPaidInCapitalMember2025-05-302025-05-300001819704mrm:LongTermAccountsReceivableOtherMember2024-12-310001819704us-gaap:CorporateMember2023-01-012023-12-310001819704mrm:Directly-OperatedSalonsMembermrm:LuxuryBeautyMember2024-01-012024-12-310001819704mrm:RoyaltyIncomeMemberus-gaap:OperatingSegmentsMember2024-01-012024-12-310001819704mrm:ReacquiredRightsMembersrt:MaximumMember2025-12-310001819704mrm:MEDIROMWellnessCoMember2025-01-012025-12-310001819704us-gaap:TradeAccountsReceivableMember2025-12-310001819704us-gaap:FranchiseMembermrm:RelaxationSalonSegmentMember2023-01-012023-12-310001819704us-gaap:CommonStockMember2025-01-012025-12-310001819704us-gaap:CommonClassAMember2024-12-310001819704mrm:RelaxationSalonSegmentMember2023-01-012023-12-310001819704us-gaap:FairValueMeasurementsNonrecurringMember2025-01-012025-12-310001819704mrm:FourthUnsecuredConvertibleCorporateBondsMembermrm:KufuCompanyHoldingsIncMember2025-12-310001819704us-gaap:OperatingSegmentsMembermrm:DigitalPreventativeHealthcareMember2025-01-012025-12-310001819704us-gaap:SeriesAPreferredStockMembermrm:MEDIROMMOTHERLabsIncMember2024-10-310001819704us-gaap:SubsequentEventMembermrm:DigitalPreventativeHealthcareMember2026-01-012026-12-310001819704mrm:LuxuryBeautyMemberus-gaap:FranchiseMember2025-01-012025-12-310001819704us-gaap:CommonStockMember2023-12-310001819704mrm:JapanGeneMedicineCorporationMemberus-gaap:SubsequentEventMember2026-10-310001819704us-gaap:CorporateMember2024-01-012024-12-310001819704us-gaap:TradeAccountsReceivableMember2025-01-012025-12-310001819704mrm:SpiritAdvisorsMember2025-12-310001819704mrm:ReacquiredRightsMembersrt:MinimumMember2025-12-310001819704mrm:FranchisorOwnedOutletSoldMemberus-gaap:OperatingSegmentsMember2025-01-012025-12-310001819704us-gaap:EmployeeStockOptionMembermrm:DirectorsMember2020-10-022020-10-020001819704us-gaap:OperatingSegmentsMember2023-01-012023-12-310001819704mrm:DirectorAndEmployeesMemberus-gaap:EmployeeStockOptionMember2016-12-212016-12-210001819704mrm:AoyamaConsultingGroupCoLtdMembermrm:AccruedExpensesMember2024-12-310001819704mrm:LongTermAccountsReceivableOtherMember2023-12-310001819704us-gaap:OtherIntangibleAssetsMember2024-12-310001819704mrm:CorporateAndEliminationsMemberus-gaap:OperatingSegmentsMember2025-01-012025-12-310001819704us-gaap:EntityOperatedUnitsMember2024-12-310001819704us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembermrm:RevenueRecognitionMember2024-01-012024-12-310001819704us-gaap:SubsequentEventMemberus-gaap:FixedIncomeSecuritiesMember2026-11-112026-11-110001819704mrm:OtherNonMarketableSecuritiesMember2024-01-012024-12-310001819704us-gaap:FranchiseMember2023-01-012023-12-310001819704mrm:JapaneseFinancialInstitutionsUnsecuredBankLoansMembersrt:MaximumMember2024-12-310001819704mrm:RyoSaitoMember2025-10-310001819704mrm:DigitalPreventativeHealthcareMember2025-01-012025-12-310001819704us-gaap:EntityOperatedUnitsMember2023-12-310001819704mrm:KufuCompanyHoldingsIncMemberus-gaap:SubsequentEventMember2026-01-300001819704mrm:SubleaseRevenueMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-3100018197042025-01-012025-01-010001819704us-gaap:FranchiseMember2025-01-012025-12-310001819704mrm:FourthUnsecuredConvertibleCorporateBondsMember2025-01-012025-12-310001819704mrm:OtherRevenuesMember2023-01-012023-12-310001819704us-gaap:CustomerRelationshipsMember2025-01-012025-12-310001819704us-gaap:OperatingSegmentsMembermrm:OtherFranchiseRevenuesMember2024-01-012024-12-310001819704us-gaap:CommonClassAMember2024-01-012024-12-310001819704mrm:StaffingServiceRevenueMemberus-gaap:OperatingSegmentsMember2025-01-012025-12-310001819704srt:MaximumMembermrm:StoreOperatingRightsMember2025-12-310001819704us-gaap:TradeAccountsReceivableMember2025-01-012025-12-310001819704mrm:UnsecuredShortTermBankLoanMember2025-06-2300018197042022-12-310001819704us-gaap:FiniteLivedIntangibleAssetsMember2024-12-310001819704srt:MinimumMembermrm:FurnitureAndOtherEquipmentMember2025-12-310001819704mrm:CorporateBondsMember2024-12-310001819704us-gaap:OperatingSegmentsMembermrm:RelaxationSalonSegmentMember2024-01-012024-12-310001819704mrm:JapaneseFinancialInstitutionsUnsecuredBankLoansMembersrt:MaximumMember2025-12-310001819704mrm:InvestorAMember2024-12-310001819704us-gaap:FixedIncomeSecuritiesMember2025-01-012025-12-310001819704us-gaap:NoncontrollingInterestMember2025-01-012025-12-310001819704us-gaap:SubsequentEventMembermrm:MEDIROMWellnessCoMember2026-03-312026-03-3100018197042026-03-312026-03-310001819704us-gaap:TradeAccountsReceivableMember2025-12-310001819704us-gaap:ConvertibleDebtMember2025-12-310001819704us-gaap:DomesticCountryMember2025-01-012025-12-310001819704mrm:OtherRevenuesMembermrm:DigitalPreventativeHealthcareMember2024-01-012024-12-310001819704srt:MinimumMember2025-01-012025-12-310001819704us-gaap:RetainedEarningsMember2023-01-012023-12-310001819704us-gaap:NoncontrollingInterestMember2023-12-310001819704us-gaap:AdditionalPaidInCapitalMember2022-12-310001819704us-gaap:UnsecuredDebtMember2025-01-012025-12-310001819704us-gaap:FairValueInputsLevel3Membersrt:MaximumMember2025-06-300001819704mrm:StoreOperatingRightsMember2024-12-310001819704mrm:RelaxationSalonsMembermrm:TrademarksOfSAWANCoLtdAndMediromRehabSolutionsIncMember2025-01-012025-12-310001819704mrm:Directly-OperatedSalonsMember2024-01-012024-12-310001819704us-gaap:RetainedEarningsMember2024-12-3100018197042025-01-012025-12-310001819704mrm:CapitalizedSoftwareMember2025-01-012025-12-310001819704mrm:CorporateAndEliminationsMember2025-01-012025-12-310001819704mrm:CorporateAndEliminationsMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-310001819704us-gaap:OperatingSegmentsMembermrm:OtherRevenuesMember2025-01-012025-12-310001819704mrm:SecondConvertibleBondsMemberus-gaap:SubsequentEventMember2026-08-252026-08-250001819704mrm:KufuCompanyMembermrm:FourthConvertibleBondsMember2025-12-310001819704mrm:RelaxationSalonSegmentMember2025-12-310001819704us-gaap:OperatingSegmentsMember2025-01-012025-12-310001819704us-gaap:ConstructionInProgressMember2025-01-012025-12-310001819704us-gaap:CommonStockMembermrm:KoujiEguchiMember2025-12-310001819704mrm:AmericanDepositorySharesMember2025-01-012025-12-310001819704us-gaap:OperatingSegmentsMembermrm:DigitalPreventativeHealthcareMember2024-12-310001819704mrm:MEDIROMWellnessCoMember2025-09-300001819704us-gaap:TrademarksMember2025-12-310001819704srt:WeightedAverageMembermrm:ReacquiredRightsMember2025-12-310001819704mrm:ThirdConvertibleBondsMemberus-gaap:SubsequentEventMember2026-12-250001819704mrm:IsseiHoumanMember2024-06-302024-06-300001819704mrm:MatrixIndustriesIncMember2024-12-310001819704mrm:AccountsReceivableOtherMember2024-12-310001819704mrm:AccountsReceivableOtherMember2025-01-012025-12-310001819704mrm:HeadquartersAssetGroupMember2025-01-012025-12-310001819704us-gaap:CommonStockMembermrm:FourthUnsecuredConvertibleCorporateBondsMembermrm:KufuCompanyHoldingsIncMember2025-01-012025-12-310001819704mrm:CommonStocksMembermrm:TomoyaOgawaMember2023-12-310001819704mrm:MMLMember2025-12-310001819704us-gaap:OperatingSegmentsMemberus-gaap:FranchiseMember2023-01-012023-12-310001819704srt:WeightedAverageMemberus-gaap:CustomerRelationshipsMember2025-12-310001819704us-gaap:TreasuryStockCommonMember2024-12-310001819704us-gaap:LeaseholdImprovementsMember2024-01-012024-12-310001819704mrm:LuxuryBeautyMember2025-12-310001819704us-gaap:LeaseholdImprovementsMember2025-12-310001819704us-gaap:FranchiseMember2024-01-012024-12-310001819704mrm:SubleaseRevenueMembermrm:RelaxationSalonSegmentMember2023-01-012023-12-310001819704us-gaap:CommonStockMember2024-01-012024-12-310001819704us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-12-310001819704us-gaap:CommonStockMembermrm:ClassACommonMember2021-03-290001819704mrm:CommonStocksMember2025-12-310001819704us-gaap:SubsequentEventMembermrm:SecondConvertibleBondsMember2026-08-012026-08-310001819704mrm:LuxuryBeautyMember2025-12-310001819704mrm:MatrixIndustriesIncMember2023-01-012023-12-310001819704mrm:CapitalizedSoftwareMember2025-12-310001819704mrm:YoshioUekusaMember2025-12-310001819704mrm:SecondConvertibleBondsMembermrm:KufuCompanyHoldingsIncMemberus-gaap:SubsequentEventMember2026-11-010001819704us-gaap:TreasuryStockCommonMember2022-12-310001819704us-gaap:PropertyPlantAndEquipmentOtherTypesMember2025-01-012025-12-310001819704mrm:StaffingServiceRevenueMembermrm:RelaxationSalonSegmentMember2025-01-012025-12-310001819704mrm:Directly-OperatedSalonsMember2025-01-012025-12-310001819704us-gaap:SubsequentEventMembermrm:SecondConvertibleBondsMember2026-08-310001819704srt:WeightedAverageMemberus-gaap:CustomerRelationshipsMember2024-12-310001819704mrm:SecondCorporateConvertibleBondMember2025-12-310001819704us-gaap:TreasuryStockCommonMember2025-12-310001819704mrm:RoyaltyIncomeMembermrm:RelaxationSalonSegmentMember2024-01-012024-12-310001819704us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2024-01-012024-12-310001819704mrm:Directly-OperatedSalonsMembermrm:RelaxationSalonSegmentMember2023-01-012023-12-310001819704us-gaap:FairValueMeasurementsNonrecurringMember2025-12-310001819704us-gaap:SubsequentEventMember2026-03-310001819704us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001819704mrm:KoujiEguchiMembermrm:CozyJointVentureMember2023-01-200001819704us-gaap:UnsecuredDebtMember2024-07-012024-07-310001819704us-gaap:OperatingSegmentsMember2024-01-012024-12-310001819704us-gaap:TradeAccountsReceivableMember2024-12-310001819704mrm:KabushikiKaishaNoTrackMembermrm:SellingGeneralAndAdministrativeExpenseMember2025-01-012025-12-310001819704mrm:LuxuryBeautyMember2023-12-310001819704us-gaap:FranchisedUnitsMember2023-12-310001819704mrm:InvestorAMember2025-12-310001819704us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001819704mrm:KoujiEguchiMember2025-12-310001819704us-gaap:RetainedEarningsMember2022-12-310001819704srt:MaximumMember2025-01-012025-12-310001819704mrm:UnsecuredShortTermBankLoanMember2025-09-300001819704mrm:MEDIROMWellnessCoMember2025-12-310001819704us-gaap:PropertyPlantAndEquipmentOtherTypesMembersrt:MaximumMember2025-12-310001819704mrm:JapaneseFinancialInstitutionsUnsecuredBankLoansMembersrt:MinimumMember2024-12-310001819704mrm:CommonStocksMembermrm:TomoyaOgawaMember2024-12-310001819704mrm:KufuCompanyMember2025-12-310001819704mrm:ThirdConvertibleBondsMemberus-gaap:SubsequentEventMember2026-01-010001819704us-gaap:FairValueInputsLevel3Member2025-12-310001819704us-gaap:SubsequentEventMember2026-03-312026-03-310001819704mrm:KabushikiKaishaNoTrackMembermrm:SellingGeneralAndAdministrativeExpenseMember2024-01-012024-12-310001819704us-gaap:CommonStockMember2024-01-012024-12-310001819704mrm:InvestorBMember2025-12-310001819704srt:WeightedAverageMemberus-gaap:TrademarksMember2025-12-310001819704us-gaap:SecuredDebtMember2025-12-310001819704us-gaap:OperatingSegmentsMember2024-12-310001819704mrm:CorporateBondsMember2025-12-310001819704us-gaap:ConvertibleDebtMember2024-10-012024-10-310001819704us-gaap:NoncontrollingInterestMember2025-12-310001819704us-gaap:OperatingSegmentsMembermrm:OtherFranchiseRevenuesMember2023-01-012023-12-310001819704us-gaap:OperatingSegmentsMembermrm:Directly-OperatedSalonsMember2023-01-012023-12-310001819704us-gaap:UnsecuredDebtMember2024-09-172024-09-170001819704us-gaap:OperatingSegmentsMemberus-gaap:FranchiseMember2024-01-012024-12-3100018197042023-12-310001819704mrm:FranchisorOwnedOutletSoldMembermrm:RelaxationSalonSegmentMember2023-01-012023-12-310001819704mrm:SellingGeneralAndAdministrativeExpenseMembermrm:KabushikiKaishaLTWMember2023-01-012023-12-310001819704mrm:ReacquiredRightsMember2025-12-310001819704mrm:InvestorOwnedMember2023-12-310001819704mrm:MediromRehabSolutionsIncMembermrm:RehabilitationBusinessMember2024-10-010001819704mrm:CommonStocksMember2024-12-310001819704mrm:CorporateAuditorMember2025-12-310001819704us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2025-01-012025-12-310001819704us-gaap:VehiclesMember2025-12-310001819704mrm:LuxuryBeautyMember2024-01-012024-12-310001819704mrm:AccountsReceivableOtherMember2025-12-310001819704mrm:Directly-OperatedSalonsMembermrm:LuxuryBeautyMember2025-01-012025-12-310001819704mrm:EmployeesMemberus-gaap:EmployeeStockOptionMember2020-10-022020-10-020001819704mrm:KazuyoshiTakahashiMember2025-01-012025-12-310001819704mrm:LongTermAccountsReceivableOtherMember2023-01-012023-12-310001819704mrm:CorporateConvertibleBondMember2025-12-310001819704mrm:Directly-OperatedSalonsMembermrm:RelaxationSalonSegmentMember2025-01-012025-12-310001819704mrm:CapitalizedSoftwareMember2024-12-310001819704mrm:MMLMember2025-12-022025-12-020001819704mrm:FranchisorOwnedOutletSoldMembermrm:RelaxationSalonSegmentMember2024-01-012024-12-310001819704mrm:CorporateAndEliminationsMemberus-gaap:OperatingSegmentsMember2024-01-012024-12-310001819704mrm:Directly-OperatedSalonsMember2023-01-012023-12-310001819704us-gaap:FairValueInputsLevel3Membersrt:MinimumMember2026-06-300001819704us-gaap:AdditionalPaidInCapitalMember2025-12-310001819704mrm:FurnitureAndOtherEquipmentMember2024-12-310001819704us-gaap:TradeAccountsReceivableMember2023-01-012023-12-310001819704us-gaap:FiniteLivedIntangibleAssetsMember2025-12-310001819704us-gaap:RetainedEarningsMember2024-01-012024-12-310001819704mrm:SellingGeneralAndAdministrativeExpenseMembermrm:KabushikiKaishaLTWMember2025-01-012025-12-310001819704mrm:OtherRevenuesMember2024-01-012024-12-310001819704mrm:JapaneseFinancialInstitutionsUnsecuredBankLoansMembersrt:MinimumMember2025-12-310001819704us-gaap:OperatingSegmentsMembermrm:OtherFranchiseRevenuesMember2025-01-012025-12-310001819704mrm:AoyamaConsultingGroupCoLtdMembermrm:SellingGeneralAndAdministrativeExpenseMember2025-01-012025-12-310001819704srt:MinimumMembermrm:StoreOperatingRightsMember2025-12-310001819704srt:MinimumMemberus-gaap:PropertyPlantAndEquipmentOtherTypesMember2025-12-310001819704mrm:RegisteredOfferingMemberus-gaap:AdditionalPaidInCapitalMember2024-12-112024-12-110001819704us-gaap:FixedIncomeSecuritiesMember2025-12-310001819704mrm:DigitalPreventativeHealthcareMember2024-01-012024-12-310001819704us-gaap:TrademarksMember2025-12-310001819704mrm:StoreOperatingRightsMember2024-01-012024-12-310001819704us-gaap:OperatingSegmentsMembermrm:RelaxationSalonSegmentMember2025-01-012025-12-310001819704us-gaap:OperatingSegmentsMembermrm:Directly-OperatedSalonsMember2024-01-012024-12-310001819704mrm:MediromRehabSolutionsIncMembermrm:RehabilitationBusinessMember2024-01-012024-12-310001819704mrm:FranchisorOwnedOutletSoldMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-310001819704mrm:DirectorAndCorporateAuditorMemberus-gaap:EmployeeStockOptionMember2020-10-022020-10-020001819704mrm:AoyamaConsultingGroupCoLtdMembermrm:SellingGeneralAndAdministrativeExpenseMember2023-01-012023-12-310001819704us-gaap:SubsequentEventMembermrm:MEDIROMWellnessCoMember2026-11-300001819704mrm:RelaxationSalonSegmentMember2023-12-310001819704mrm:MMLMember2025-12-3100018197042023-01-012023-12-310001819704mrm:InvestorAMemberus-gaap:TradeAccountsReceivableMember2025-12-310001819704mrm:CommonSharesNoParValueMember2025-01-012025-12-310001819704us-gaap:SubsequentEventMember2026-11-300001819704us-gaap:CommonClassAMember2023-01-012023-12-310001819704mrm:RelaxationSalonsMember2025-01-012025-12-310001819704us-gaap:CommonStockMember2023-01-012023-12-310001819704mrm:LongTermAccountsReceivableOtherMember2022-12-310001819704mrm:HeadquartersAssetGroupMemberus-gaap:FurnitureAndFixturesMember2025-01-012025-12-310001819704us-gaap:CommonStockMember2021-03-290001819704mrm:MMLMember2025-01-012025-12-310001819704mrm:SecondConvertibleBondsMemberus-gaap:SubsequentEventMember2026-11-112026-11-110001819704mrm:KazuyoshiTakahashiMember2025-12-310001819704us-gaap:OperatingSegmentsMember2025-12-310001819704mrm:KabushikiKaishaNoTrackMembermrm:AccruedExpensesMember2024-12-310001819704us-gaap:SecuredDebtMember2024-12-310001819704us-gaap:CustomerRelationshipsMember2025-12-3100018197042024-07-310001819704us-gaap:OperatingSegmentsMembermrm:LuxuryBeautyMember2025-12-310001819704us-gaap:AccountsReceivableMember2024-12-310001819704mrm:LuxuryBeautyMember2024-12-310001819704us-gaap:OperatingSegmentsMembermrm:RelaxationSalonSegmentMember2023-12-310001819704srt:MinimumMemberus-gaap:CustomerRelationshipsMember2025-12-310001819704us-gaap:AdditionalPaidInCapitalMember2025-01-012025-12-310001819704us-gaap:TradeAccountsReceivableMember2022-12-310001819704us-gaap:ConvertibleDebtMember2022-01-012022-12-310001819704us-gaap:OperatingSegmentsMembermrm:LuxuryBeautyMember2024-01-012024-12-310001819704us-gaap:TrademarksMember2024-12-310001819704mrm:MatrixIndustriesIncMember2024-01-012024-12-310001819704us-gaap:FairValueMeasurementsNonrecurringMember2024-01-012024-12-310001819704mrm:Directly-OperatedSalonsMembermrm:LuxuryBeautyMember2023-01-012023-12-310001819704mrm:StoreOperatingRightsMember2025-01-012025-12-310001819704us-gaap:OperatingSegmentsMembermrm:LuxuryBeautyMember2025-01-012025-12-310001819704us-gaap:CommonStockMember2022-12-310001819704us-gaap:VehiclesMembersrt:MaximumMember2025-12-310001819704us-gaap:OperatingSegmentsMembermrm:RelaxationSalonSegmentMember2025-12-310001819704mrm:RegisteredOfferingMember2024-12-112024-12-110001819704us-gaap:OperatingSegmentsMembermrm:Directly-OperatedSalonsMember2025-01-012025-12-310001819704us-gaap:PropertyPlantAndEquipmentMember2023-01-012023-12-310001819704us-gaap:ConvertibleCommonStockMember2025-12-310001819704mrm:LuxuryBeautyMemberus-gaap:FranchiseMember2024-01-012024-12-310001819704us-gaap:NoncontrollingInterestMember2024-01-012024-12-310001819704mrm:MatrixIndustriesIncMember2025-12-310001819704us-gaap:TrademarksMember2025-01-012025-12-310001819704us-gaap:OperatingSegmentsMemberus-gaap:FranchiseMember2025-01-012025-12-310001819704us-gaap:OtherIntangibleAssetsMember2025-12-310001819704us-gaap:SubsequentEventMembermrm:MEDIROMWellnessCoMember2026-03-310001819704mrm:ThirdConvertibleBondsMember2025-12-310001819704mrm:CorporateAndEliminationsMemberus-gaap:OperatingSegmentsMember2023-12-310001819704us-gaap:FranchisedUnitsMember2025-12-310001819704mrm:OtherRevenuesMembermrm:DigitalPreventativeHealthcareMember2025-01-012025-12-310001819704mrm:KabushikiKaishaNoTrackMembermrm:AccruedExpensesMember2025-12-310001819704us-gaap:SubsequentEventMembermrm:MEDIROMWellnessCoMember2027-12-312027-12-310001819704us-gaap:TradeAccountsReceivableMember2024-12-310001819704srt:DirectorMember2025-01-012025-12-310001819704us-gaap:OperatingSegmentsMembermrm:LuxuryBeautyMember2024-12-310001819704mrm:EmployeesMemberus-gaap:EmployeeStockOptionMember2021-01-012021-12-310001819704mrm:FourthCorporateConvertibleBondMember2025-12-310001819704us-gaap:OperatingSegmentsMembermrm:DigitalPreventativeHealthcareMember2023-12-310001819704us-gaap:FairValueInputsLevel3Membersrt:MaximumMember2026-06-3000018197042023-03-310001819704us-gaap:PropertyPlantAndEquipmentMember2025-01-012025-12-310001819704us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembermrm:RevenueRecognitionMember2025-01-012025-12-310001819704mrm:LongTermAccountsReceivableOtherMember2025-12-3100018197042024-12-310001819704us-gaap:RetainedEarningsMember2025-12-310001819704mrm:OtherNonMarketableSecuritiesMember2025-01-012025-12-310001819704mrm:StaffingServiceRevenueMemberus-gaap:OperatingSegmentsMember2024-01-012024-12-310001819704mrm:AccountsReceivableOtherMember2023-12-310001819704mrm:DirectorAndCorporateAuditorMemberus-gaap:EmployeeStockOptionMember2025-07-182025-07-180001819704mrm:ReacquiredRightsMember2024-12-310001819704mrm:MEDIROMMOTHERLabsIncMembermrm:IsseiHoumanMember2024-09-302024-09-300001819704mrm:SecondConvertibleBondsMemberus-gaap:SubsequentEventMember2026-12-302026-12-300001819704us-gaap:CustomerRelationshipsMember2024-12-310001819704us-gaap:FranchiseMembermrm:RelaxationSalonSegmentMember2024-01-012024-12-310001819704us-gaap:OperatingSegmentsMembermrm:DigitalPreventativeHealthcareMember2025-12-31mrm:Salonsiso4217:JPYiso4217:JPYxbrli:sharesxbrli:puremrm:Loanmrm:Segmentxbrli:sharesmrm:Executivesiso4217:USDxbrli:sharesmrm:Itemiso4217:USDmrm:Building

Table of Contents

 

h

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 20-F

☐

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2025

OR

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☐

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 001-39809

 

MEDIROM HEALTHCARE TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

Japan

(Jurisdiction of incorporation or organization)

2-3-1 Daiba,

Minato-ku

Tokyo 135-0091, Japan

(Address of principal executive offices)

Fumitoshi Fujiwara

Chief Financial Officer

Telephone: +81-(0)3-6721-7364

Email: ir@medirom.co.jp

2-3-1 Daiba, Minato-ku,

Tokyo 135-0091, Japan

(Name, Telephone, E-mail and/or Facsimile Number and Address of Company Contact Person)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol

 

Name of each exchange on which registered

 

 

 

 

 

American Depositary Shares, each representing one common share

 

MRM

 

The Nasdaq Stock Market LLC

Common Shares, no par value*

 

 

 

The Nasdaq Stock Market LLC

 

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Securities registered pursuant to Section 12(g) of the Act: None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

 

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 7,901,950 Common Shares.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

 

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934.

Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

 


Table of Contents

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Emerging growth company ☐

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP ☒ International Financial Reporting Standards as issued by the International Accounting Standards Board ☐ Other ☐

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

Item 17 ☐ Item 18 ☐

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐ Yes ☒ No

(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

☐ Yes ☐ No

 

 

 


Table of Contents

 

TABLE OF CONTENTS

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

1

 

 

 

PART I.

 

2

 

 

 

ITEM 1.

IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

2

ITEM 2.

OFFER STATISTICS AND EXPECTED TIMETABLE

2

ITEM 3.

KEY INFORMATION

2

ITEM 4.

INFORMATION ON THE COMPANY

30

ITEM 4.A.

UNRESOLVED STAFF COMMENTS

56

ITEM 5.

OPERATING AND FINANCIAL REVIEW AND PROSPECTS

56

ITEM 6.

DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

73

ITEM 7.

MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

79

ITEM 8.

FINANCIAL INFORMATION

81

ITEM 9.

THE OFFER AND LISTING

82

ITEM 10.

ADDITIONAL INFORMATION

82

ITEM 11.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

90

ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

93

 

 

 

PART II.

 

95

 

 

 

ITEM 13.

DEFAULTS, DIVIDENDS ARREARAGES AND DELINQUENCIES

95

ITEM 14.

MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

95

ITEM 15.

CONTROLS AND PROCEDURES

95

ITEM 16A.

AUDIT COMMITTEE FINANCIAL EXPERT

96

ITEM 16B.

CODE OF ETHICS AND BUSINESS CONDUCT

97

ITEM 16C.

PRINCIPAL ACCOUNTANT FEES AND SERVICES

97

ITEM 16D.

EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

97

ITEM 16E.

PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

97

ITEM 16F.

CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT

97

ITEM 16G.

CORPORATE GOVERNANCE

98

ITEM 16H.

MINE SAFETY DISCLOSURE

98

ITEM 16I.

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

98

ITEM 16J.

INSIDER TRADING POLICIES

98

ITEM 16K.

CYBERSECURITY

98

 

 

 

PART III.

 

100

 

 

 

ITEM 17.

FINANCIAL STATEMENTS

100

ITEM 18.

FINANCIAL STATEMENTS

100

ITEM 19.

EXHIBITS

99

 

i


Table of Contents

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements contained in this annual report, including those that express a belief, expectation or intention, as well as those that are not statements of historical fact, are forward-looking statements. These forward-looking statements may include projections and estimates concerning our possible or assumed future results of operations, financial condition, business strategies and plans, market opportunity, competitive position, industry environment, and potential growth opportunities. In some cases, you can identify forward-looking statements by terms such as “may”, “will”, “should”, “believe”, “expect”, “could”, “intend”, “plan”, “anticipate”, “estimate”, “continue”, “predict”, “project”, “potential”, “target,” “goal” or other words that convey the uncertainty of future events or outcomes. You can also identify forward-looking statements by discussions of strategy, plans or intentions. We have based these forward-looking statements on our current expectations and assumptions about future events. While our management considers these expectations and assumptions to be reasonable, because forward-looking statements relate to matters that have not yet occurred, they are inherently subject to significant business, competitive, economic, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control. These and other important factors, including, among others, those discussed in this annual report under the headings “Risk Factors”, “Operating and Financial Review and Prospects”, and “Business Overview” may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements in this annual report. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this annual report include:

•
our ability to achieve our development goals for our business and execute and evolve our growth strategies, priorities and initiatives;
•
our ability to sell certain of our owned salons to investors, and receive management fees from such sold salons, on acceptable terms;
•
changes in Japanese and global economic conditions and financial markets, including their effects on our expansion in Japan and certain overseas markets;
•
our ability to continue to grow our Digital Preventative Healthcare Segment and achieve and sustain its profitability;
•
the fluctuation of foreign exchange rates, which affects our expenses and liabilities payable in foreign currencies;
•
our ability to hire and train a sufficient number of therapists and place them at salons in need of additional staffing;
•
changes in demographic, unemployment, economic, regulatory or weather conditions affecting the Tokyo region of Japan, where our relaxation salon base is geographically concentrated;
•
any of our past and future acquisitions, minority investments, venture financings, joint ventures and strategic alliances failing to deliver the anticipated benefits or otherwise having an adverse effect on our businesses and results of operations;
•
our ability to maintain and enhance the value of our brands and to enforce and maintain our trademarks and protect our other intellectual property;
•
the financial performance of our franchisees and our limited control with respect to their operations;
•
our ability to raise additional capital on acceptable terms or at all;
•
our level of indebtedness, potential restrictions on us under our debt instruments and our ability to repay or refinance our debt;
•
changes in consumer preferences and our competitive environment;
•
our ability to respond to natural disasters, such as earthquakes and tsunamis, and to global pandemics; and
•
the regulatory environment in which we operate.

Given the foregoing risks and uncertainties, you are cautioned not to place undue reliance on the forward-looking statements in this annual report. The forward-looking statements contained in this annual report are not guarantees of future performance and our actual results of operations and financial condition may differ materially from such forward-looking statements. In addition, even if our results of operations and financial condition are consistent with the forward-looking statements in this annual report, they may not be predictive of results or developments in future periods.

Any forward-looking statement that we make in this annual report speaks only as of the date of this annual report. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements in this annual report, whether as a result of new information, future events or otherwise, after the date of this annual report.

1


Table of Contents

 

PART I.

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

Not applicable.

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE

Not applicable.

ITEM 3. KEY INFORMATION

A.
[Reserved]
B.
Capitalization and Indebtedness

Not applicable.

C.
Reasons for the Offer and Use of Proceeds

Not applicable.

D.
Risk Factors

2


Table of Contents

 

RISK FACTORS

We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. You should carefully consider the factors described below, together with all of the other information contained in this annual report, including the audited and unaudited financial statements and the related notes included in this annual report. These risk factors are not presented in the order of importance or probability of occurrence. If any of the following risks actually occurs, our business, financial condition and results of operations could be materially and adversely affected. Some statements in this annual report, including statements in the following risk factors, constitute forward-looking statements. Please refer to the section entitled “Cautionary Note Regarding Forward-Looking Statements.”

As used this annual report, the terms “the Company”, “Medirom”, “we”, “our” or “us” may, depending upon the context, refer solely to the Company, to one or more of the Company’s consolidated subsidiaries or to all of them taken as a whole.

Our functional currency and reporting currency is the Japanese yen (which we refer to as “JPY” or “¥”). The terms “dollar,” “USD,” “US$” or “$” refer to U.S. dollars, the legal currency of the United States. Convenience translations included in this annual report of Japanese yen into U.S. dollars have been made at the exchange rate of ¥156.8 = US$1.00, which was the foreign exchange rate on December 31, 2025 as reported by the Board of Governors of the Federal Reserve System (which we refer to as the “U.S. Federal Reserve”) in weekly release on January 5, 2026. Historical and current exchange rate information may be found at www.federalreserve.gov/releases/h10/.

Summary Risk Factors

Investing in our company involves significant risks. You should carefully consider all of the information in this annual report before making an investment in our company. These risks include the following:

Risks Related to Our Company and Our Business

Risks and uncertainties related to our Company and our business include, but are not limited to, the following:

•
There is substantial doubt about our ability to continue as a going concern;
•
Our restructuring and shift from expansion to improving profitability may not achieve the anticipated benefits and could result in additional costs, impairments and business disruptions;
•
We have agreed with the relevant authorities on the timing of certain tax and social insurance payments, and our failure to make those payments on the agreed schedule could result in enforcement action against our assets;
•
All of the shares of two of our subsidiaries, and the operating rights of ten of our salons, are pledged as collateral, and enforcement would cause us to lose control of the relevant subsidiary or the affected salons;
•
Sales of our salons to investors could depend heavily on a number of factors, and as a result, our annual revenue from salon sales may vary from year to year;
•
Our Digital Preventative Healthcare Segment may not continue to grow as we intend or achieve or sustain profitability;
•
Our MOTHER Bracelet® and Gateway incorporate various components, and component inflation may increase our cost of producing these products;
•
Our system-wide relaxation salon base is geographically concentrated in the Tokyo metropolitan area of Japan, and we could be negatively affected by conditions specific to that region;
•
Our past and future acquisitions, minority investments, venture financings, joint ventures and strategic alliances could fail to deliver the anticipated benefits or otherwise have an adverse effect on our businesses and results of operations; and

Risks Related to Our Relationships with Franchisees

Risks and uncertainties related to our relationships with franchisees include, but are not limited to, the following:

•
The financial performance of our franchisees can negatively impact our business; and
•
We have limited control with respect to the operations of our franchisees, which could have a negative impact on our business.

3


Table of Contents

 

Risks Related to Our Industry

Risks and uncertainties related to our industry include, but are not limited to, the following:

•
We are vulnerable to changes in consumer preferences and economic conditions that could harm our business, financial condition, results of operations and cash flow;
•
We may not be able to compete successfully with other relaxation salon businesses, which could materially and adversely affect our results of operations;
•
We face significant competition and continuous technological change; and
•
Information technology system failures or breaches of our network security could interrupt our operations and adversely affect our business.

Risks Related to Ownership of the ADSs

Risks and uncertainties related to our ownership of the American Depositary Shares (the “ADSs”) include, but are not limited to, the following:

•
As a “foreign private issuer” we are permitted, and intend to continue, to follow certain home country corporate governance and other practices instead of otherwise applicable SEC and NASDAQ requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers;
•
We do not satisfy certain Nasdaq continued listing requirements, and additional requirements may become operative in the future. Failure to regain or maintain compliance could result in suspension of trading and delisting of our ADSs;
•
We may be, and have in the past been, delayed in complying with our periodic reporting obligation under the Exchange Act;
•
Our Chief Executive Officer owns a “golden share” with key veto rights, thereby limiting a shareholder’s ability to influence our business and affairs; and
•
The requirements of being a U.S. public company may strain our resources and divert management’s attention.

Risks Related to Japan

Risks and uncertainties related to Japan include, but are not limited to, the following:

•
We are incorporated in Japan, and it may be more difficult to enforce judgments against us that are obtained in courts outside of Japan; and
•
Substantially all of our revenues are generated in Japan, but an increase of our international presence could expose us to fluctuations in foreign currency exchange rates, or a change in monetary policy may harm our financial results.

General Risk Factors

Other general risk factors include, but are not limited to, the following:

•
Third party claims with respect to intellectual property assets, if decided against us, may result in competing uses or require adoption of new, non-infringing intellectual property, which may in turn adversely affect sales and revenues.

4


Table of Contents

 

Risks Related to Our Company and Our Business

There is substantial doubt about our ability to continue as a going concern.

Our consolidated financial statements included in this annual report have been prepared assuming that we will continue as a going concern. For the year ended December 31, 2025, we incurred a net loss of JPY3,642,581 thousand and negative cash flows from operating activities of JPY1,155,007 thousand, and as of December 31, 2025, we had a working capital deficit of JPY3,244,164 thousand, an accumulated deficit of JPY3,405,240 thousand, a shareholders’ deficit of JPY2,623,771 thousand and cash and cash equivalents of JPY91,979 thousand. As of the same date, we had total interest-bearing debt of JPY2,401,507 thousand, of which JPY1,601,548 thousand is scheduled to mature within twelve months of December 31, 2025. In addition, as of December 31, 2025, we had taxes and social insurance premiums that were past due in the aggregate amount of JPY250,154 thousand, for which we have agreed revised payment schedules with the relevant Japanese tax and social insurance authorities.

These conditions raise substantial doubt about our ability to continue as a going concern. Our independent registered public accounting firm has included an explanatory paragraph in its report on our consolidated financial statements regarding this substantial doubt. Our consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

Management has developed a plan to address these conditions, which includes reducing operating costs, closing or transferring unprofitable salons, streamlining our organizational structure, refinancing or extending the maturities of our existing indebtedness, and evaluating the disposition of non-core assets. However, there can be no assurance that we will be able to implement this plan successfully, that the actions contemplated by the plan will generate the liquidity we expect, or that we will be able to obtain additional financing on acceptable terms or at all. If we are unable to do so, we may be required to curtail or cease operations, dispose of assets on unfavorable terms, or seek protection under applicable insolvency laws, and holders of the ADSs could lose all or substantially all of their investment.

Our restructuring and shift from expansion to improving profitability may not achieve the anticipated benefits and could result in additional costs, impairments and business disruptions.

In response to recent operating losses and liquidity constraints, we are implementing a comprehensive restructuring plan focused on improving the profitability of our existing salons, reducing costs and generating liquidity. We have suspended new salon openings, franchise expansion and growth through acquisitions. Our initiatives include closing or transferring salons that do not meet our profitability thresholds, reducing headcount, consolidating overlapping corporate functions, reducing selling, general and administrative expenses and evaluating dispositions of non-core businesses and assets. We are also prioritizing revenue growth in our Digital Preventative Healthcare business.

Our ability to improve salon profitability depends on increasing customer visits and average spending, optimizing the mix of employed and contractor therapists, controlling personnel and occupancy costs and revitalizing underperforming salons. These efforts may be adversely affected by changes in laws and regulations, adverse weather, natural disasters and other factors beyond our control. Our Digital Preventative Healthcare business may not generate sufficient revenue growth to offset declines in salon revenue or otherwise support our financial recovery.

Our salon count decreased from 308 as of December 31, 2024 to 292 as of December 31, 2025. For the year ended December 31, 2025, we recognized impairment losses on long-lived assets and goodwill of JPY2,550,953 thousand (US$16,269 thousand), including JPY1,903,458 thousand attributable to our Relaxation Salon segment. We may recognize further impairment losses and incur lease termination payments, restoration obligations, asset disposal losses, severance expenses and other restructuring costs. Salon closures and transfers may reduce revenue faster than we can eliminate associated costs and adversely affect relationships with customers, landlords, salon owners, franchisees and employees. Headcount reductions and organizational consolidation may disrupt operations, impair employee morale and retention, result in the loss of institutional knowledge and expose us to claims under Japanese labor laws.

Potential dispositions depend on identifying willing counterparties, negotiating acceptable terms and obtaining required third-party consents, and may result in proceeds below carrying values. As of the date of this annual report, we have not entered into any definitive agreement for, and our board of directors has not approved, any such disposition.

We may not achieve the anticipated cost savings, profitability improvements or liquidity benefits on the expected timetable, or at all. Implementation costs, business disruptions and revenue declines could outweigh these benefits, materially and adversely affecting our business, financial condition, results of operations and ability to continue as a going concern.

We have agreed with the relevant authorities on the timing of certain tax and social insurance payments, and our failure to make those payments on the agreed schedule could result in enforcement action against our assets.

As of December 31, 2025, we had national and local taxes and social insurance premiums that were past due in the aggregate amount of JPY250,154 thousand, for which we have agreed revised payment schedules with the relevant Japanese tax and social insurance authorities. The agreed schedules principally relate to interim consumption tax payments and withheld income tax. We are making payments in accordance with those schedules.

5


Table of Contents

 

Under Japanese law, tax and social insurance authorities have the power to attach and dispose of a delinquent taxpayer’s assets, including bank deposits and receivables, without obtaining a court judgment. If we fail to make payments in accordance with the agreed schedules, or if the authorities determine that our financial condition has deteriorated, the authorities could withdraw those arrangements and commence enforcement action against our assets. Any such action would disrupt our operations, impair our liquidity, and could constitute an event of default under our financing arrangements. In addition, these arrangements may adversely affect our ability to obtain new financing and to participate in government programs and subsidies.

All of the shares of two of our subsidiaries, and the operating rights of ten of our salons, are pledged as collateral, and enforcement would cause us to lose control of the relevant subsidiary or the affected salons.

On January 30, 2026, we entered into a loan agreement with Kufu Company Holdings Inc. and, to secure our obligations thereunder, pledged all of the shares we hold in MEDIROM MOTHER Labs Inc., our subsidiary, granting the lender a first-priority security interest in those shares. On July 14, 2026, we and the lender amended the loan agreement to refinance the JPY275,000 thousand principal amount of our Fourth Unsecured Convertible-Type Corporate Bonds with Share Options into the loan, increasing the aggregate principal amount outstanding under the loan agreement to JPY475,000 thousand, and amended the share pledge agreement to secure the increased amount. The loan bears interest at 10.0% per annum. The loan agreement provides for repayment by December 30, 2026. We and the lender have also entered into a series of monthly memoranda under which we pay the interest accrued through the preceding month-end and the lender consents to repayment of the loan in full before that date; these memoranda do not change that maturity date. In addition, the loan of JPY300,000 thousand that we owe to Triple One Investment Limited Partnership, which replaced our Second Unsecured Convertible-Type Corporate Bonds with Share Options on August 25, 2026, is secured by a pledge of all of the shares we hold in MEDIROM Rehab Solutions Inc., our subsidiary, and by security over the operating rights of ten salons that we operated when the security was granted. That loan originally bore interest at 5.0% per annum and had a maturity date of September 15, 2026. On November 11, 2026, we and the lender entered into an agreement amending the loan, under which the maturity of the principal was extended to December 30, 2026, with JPY5,000 thousand of the principal repayable on November 30, 2026 and the balance on the maturity date, unless further extended. Pursuant to the amendment, interest accruing on and after November 1, 2026 accrues at 14.6% per annum and is payable monthly at each month-end.

Upon an acceleration of our obligations under either of these loan agreements, the relevant lender may dispose of the pledged shares and any other collateral securing the relevant loan, subject to the notice requirements of the relevant security agreement. MEDIROM MOTHER Labs Inc. develops and sells our MOTHER Bracelet® and REMONY® products and constitutes a substantial part of our Digital Preventative Healthcare Segment. If the pledge were enforced, we would lose control of that subsidiary, we would be required to deconsolidate it from our consolidated financial statements, and our business, financial condition and results of operations would be materially and adversely affected. The existence of the pledge also limits our ability to use those shares to raise additional capital or to effect a disposition of that subsidiary on terms we would otherwise consider favorable. MEDIROM Rehab Solutions Inc. operates the rehabilitation business that we acquired in 2024. If the pledge over its shares were enforced, we would likewise lose control of that subsidiary and be required to deconsolidate it, and if the security over the operating rights of the salons were enforced, we would lose the revenue generated by those salons. Neither lender is committed to extend or refinance its loan beyond its stated maturity date. The loan from Triple One Investment Limited Partnership was not repaid on its original maturity date of September 15, 2026. On November 11, 2026, the lender and we agreed to extend the maturity of the principal to December 30, 2026 and to increase the interest rate on interest accruing on and after November 1, 2026 to 14.6% per annum. The lender is not obliged to agree to any further extension. The loan from Kufu Company Holdings Inc. is repayable by December 30, 2026. The collateral securing each of these loans remains subject to enforcement for so long as the relevant loan remains outstanding. The amount of our secured borrowings that falls due within the next few months has increased: as of the date of this annual report, JPY775,000 thousand was outstanding under these two loans, compared with JPY200,000 thousand owed to Kufu Company Holdings Inc. as of December 31, 2025, at which date the Second Unsecured Convertible-Type Corporate Bonds with Share Options had not yet been refinanced into a loan. As that amount has grown, so has the risk to us if a lender were to demand repayment or decline to extend or refinance its loan, in which case we would be required to repay the relevant amount, we do not expect that our cash on hand would be sufficient to do so, and the lender could enforce its security as described above.

A portion of our recent revenue is attributable to a single commercial arrangement that we expect to be non-recurring.

In December 2025, we entered into arrangements with Tools for Humanity and the World Foundation under which we are responsible for the deployment and operation of “Proof of Human” verification devices in Japan at our salon locations. Revenue from this arrangement is included within other revenues and is reported within our Digital Preventative Healthcare segment, and is not presented as a separate reportable segment.

We expect the revenue generated under this arrangement to be non-recurring in nature. Our counterparties may modify or terminate the arrangement in accordance with its terms. Previously, the arrangement provided for a per verification revenue model. However, since August 2026, following a change in the operating policy of Tools for Humanity, we have operated under a hosting model, under which we receive a fixed fee for each device installed and no longer receive fees based on the number of individuals verified. Accordingly, period-over-period comparisons of our revenue that include amounts attributable to this

6


Table of Contents

 

arrangement may not be indicative of our underlying operating performance or of our future results. If this revenue declines or ceases and we are unable to replace it, our results of operations would be adversely affected.

We may be adversely affected if Japanese and global economic conditions and financial markets deteriorate.

Our financial condition and results of operations may be materially affected by general economic conditions and financial markets in Japan and foreign countries, which would be influenced by changes in various factors. These factors include fiscal and monetary policies, and laws, regulations and policies on financial markets. In the event of an economic downturn in Japan or the United States, consumer spending habits could be adversely affected, and we could experience lower than expected net sales, which could force us to delay or slow our strategy and have a material adverse effect on our business, financial condition, profitability and cash flows. In addition, we could be impacted by increases in interest rates, which would increase our cost of borrowing, and by continued inflation, which would increase our personnel, rent and other operating costs.

We may not achieve our development goals, which could adversely affect our operations and financial results.

Our number of relaxation salons was 292 as of December 31, 2025, which decreased from 308 as of December 31, 2024. We have suspended new salon openings, the development of additional franchises and growth through acquisitions for the time being, and our current priority is to improve the profitability of our existing salons. If our financial condition improves, we may resume increasing our number of salons, either through developing additional directly-operated salons or through acquisitions, in existing or new markets, particularly in Japan. Any such development would involve substantial risks, including the risk of:

•
the inability to identify suitable franchisees;
•
limited availability of financing for our Company and for franchisees at acceptable rates and terms;
•
development costs exceeding budgeted or contracted amounts;
•
delays in completion of construction;
•
the inability to identify, or the unavailability of, suitable sites at acceptable cost and other leasing or purchase terms;
•
developed properties not achieving desired revenue or cash flow levels once opened;
•
the negative impact of a new salon upon sales at nearby existing salons and vice versa;
•
the challenge of developing in areas where competitors are more established or have greater penetration or access to suitable development sites;
•
incurring substantial unrecoverable costs in the event a development project is abandoned prior to completion;
•
impairment charges resulting from underperforming salons or decisions to curtail or cease investment in certain locations or markets;
•
in new geographic markets where we have limited or no existing locations, the inability to successfully expand or acquire critical market presence for our brands, acquire name recognition, successfully market our products or attract new customers;
•
operating cost levels that reduce the demand for, or raise the cost of, developing new salons;
•
the challenge of identifying, recruiting and training qualified salon management;
•
the inability to obtain all required permits;
•
changes in laws, regulations and interpretations; and
•
general economic and business conditions.

Although we manage our growth and development activities to help reduce such risks, we cannot provide assurance that our present or future growth and development activities will perform in accordance with our expectations. Our inability to expand in accordance with our plans or to manage the risks associated with our growth could have a material adverse effect on our results of operations and financial condition.

Our success also depends, in part, on our ability to improve sales, as well as both cost of service and product and operating margins at our directly-operated salons. Same-store sales are affected by average ticket and same-store guest visits. A variety of factors affect same-store guest visits, including the guest experience, salon locations, staffing and retention of therapists and salon leaders, price competition, current economic conditions, marketing programs and weather conditions. These factors may cause our same-store sales to differ materially from prior periods and from our expectations.

We have suspended growth through acquisitions, including any acquisition of similar businesses outside Japan. If we were to enter new geographical markets in the future, which could include the United States and Southeast Asia, we would have little or

7


Table of Contents

 

no prior operating or franchising experience in those markets. The challenges of entering new markets would include: difficulties in hiring experienced personnel; unfamiliarity with local real estate markets and demographics; consumer unfamiliarity with our brand; and different competitive and economic conditions, consumer tastes and discretionary spending patterns that are more difficult to predict or satisfy than in our existing markets. Consumer recognition of our brand has been important in the success of both directly-operated and franchised relaxation salons in our existing markets. Relaxation salons that we may open in new markets could take longer to reach expected sales and profit levels and may have higher construction, occupancy and operating costs than existing relaxation salons, thereby negatively affecting our operating results. Any failure on our part to recognize or respond to these challenges may adversely affect the success of any new relaxation salons. Expanding our franchise system could require the implementation, expense and management of enhanced business support systems, management information systems and financial controls as well as additional staffing, franchise support and capital expenditures and working capital.

Sales of our salons to investors could depend heavily on a number of factors, and as a result, our annual revenue from sale of salons may vary from year to year.

Since December 2021, we have implemented our strategy of selling certain of our owned salons to investors and charging management fees from such sold salons. For the year ended December 31, 2025, the total transaction amount from such salon sales, measured on a gross contractual basis, was JPY1,742 million (US$11 million), compared to JPY2,564 million (US$16 million) for the year ended December 31, 2024. This amount differs from the revenue from the sale of directly-owned salons recognized in our consolidated financial statements. See “Item 5. Operating and Financial Review and Prospects—A. Operating Results” for a description of how this measure is calculated. Our salon sales activities will depend on a number of factors including the interest of potential purchasers in acquiring and holding salon businesses, general economic and financing conditions, including the level of interest rates, and the returns available to purchasers from other business opportunities, none of which we control. In addition, our management fees from the sold salons will depend on the actual contractual terms subject to our negotiation with potential investors in the future.

Furthermore, our ability to successfully implement this strategy will depend on our ability to maintain highly profitable salons, revitalize less profitable salons, and otherwise maintain an appropriate level of salon inventory. The failure to continue to implement this growth strategy will adversely affect our business, financial condition and results of operations.

Our Digital Preventative Healthcare Segment businesses may not continue to grow as we intend or achieve or sustain profitability.

For the fiscal year ended December 31, 2025, 2.2% of our revenue was derived from our Digital Preventative Healthcare Segment, which includes our Lav® application supporting the Specific Health Guidance Program and our MOTHER Bracelet®. By comparison, 90.8% of our revenue was derived from our Relaxation Salon Segment, and 7.0% from our Luxury Beauty Segment during the same period. Our Digital Preventative Healthcare Segment generated a total revenue of JPY168 million (US$1.1 million) for the fiscal year ended December 31, 2025, as compared to a total revenue of JPY154 million (US$1.0 million) for the fiscal year ended December 31, 2024. While we aim to continue to grow our Digital Preventative Healthcare Segment as a proportion of our overall business, we cannot guarantee that we will not experience such development delays or other setbacks in the future, or that our current businesses or any other businesses we develop or acquire in the segment will achieve or increase market acceptance. The degree of market acceptance of our businesses in this segment will depend on a number of factors, including the competitive landscape and the adequacy and success of distribution, sales and marketing efforts. Customers, third-party payors or advertisers in general may be unwilling to accept, utilize or recommend any of our businesses.

Furthermore, the manufacturing of our MOTHER Bracelet® involves a number of third parties and requires our use of a patent license, and we may be adversely affected by any deterioration of business relationships with such third parties or their financial soundness. In particular, the self-charging functionality of our MOTHER Bracelet® is derived from a core semiconductor provided by Matrix Industries, Inc. (“Matrix”), a startup based in California, United States. In addition, we currently rely on a third-party manufacturer in Japan to manufacture the MOTHER Bracelet®. If a natural disaster, a labor strike, or any other accident or incident were to occur at the manufacturer’s facilities or the manufacturer were to significantly increase the assembly price, our sales or profitability could be adversely affected. As a result, we are unable to predict the extent of future losses or the time required to achieve profitability in this business unit, if at all.

Our MOTHER Bracelet® and Gateway incorporate various components, and component price inflation may increase our cost of producing these products.

Following the start of sales of our MOTHER Bracelet® in 2021, we released our “MOTHER Gateway” device in 2023 as well as our device-based monitoring system, “REMONY®”. These electronic devices utilize an array of components, a few of which we directly obtain from suppliers, while the others are indirectly purchased by our contracted assembly factory and shipped to our warehouse in the form of finished goods. Although most of the components other than the core semiconductor provided by Matrix are commodities, there exists the potential for the prices of these components to significantly increase in the future, influenced by foreign currency exchange rates, potential macroeconomic shifts, prospective supply chain disruptions, embargoes or any other trade restrictions resulting from geopolitical issues, tariffs, and potential spikes in global demand. If such an upward trend in the cost of these crucial components were to materialize, it could place upward pressure on our production expenditures. This, in turn, may adversely affect our profit margins, especially if we are unable to pass on any such increased costs to our customers.

8


Table of Contents

 

Our system-wide relaxation salon base is geographically concentrated in the Tokyo metropolitan area of Japan, and we could be negatively affected by conditions specific to that region.

Approximately 65.8% of our relaxation salons, including our directly-owned, franchised, and investor- owned salons, are located in the Tokyo metropolitan area of Japan as of December 31, 2025. Adverse changes in demographic, unemployment, economic, regulatory or weather conditions or natural disasters affecting the Kanto region of Japan have had, and may continue to have, material adverse effects on our business. As a result of our concentration in this market, we have been, and in the future may be, disproportionately affected by these adverse conditions compared to other chain relaxation salons with a greater national footprint.

In addition, our competitors could open additional relaxation salons in the Kanto region of Japan, which could result in reduced market share for us and may adversely impact our profitability.

We do not currently plan to expand into new geographic regions in Japan, as our current priority is to improve the profitability of our existing salons rather than to increase the number of our salons. As a result, we expect our salon base to remain concentrated in the Tokyo metropolitan area.

Our past and future acquisitions, minority investments, venture financings, joint ventures and strategic alliances could fail to deliver the anticipated benefits or otherwise have an adverse effect on our businesses and results of operations.

As part of our business strategy, we have engaged in acquisitions, minority investments, joint ventures and other strategic alliances with third parties to expand our product and service offerings, enter into new business areas and geographies and acquire related technologies, with a primary focus on businesses operating in Japan, and may do so in the future if we resume such activities. For example, on October 1, 2021, we acquired a 60% ownership interest in ZACC, a high-end hair salon company operating in Japan, and we acquired the remaining 40% interest in January 2022. In 2021, we also acquired a 100% ownership interest in SAWAN CO. LTD., which owns the “Ruam Ruam” brand luxury relaxation salons and also operates in Japan. In 2019 we acquired a minority interest in Matrix Industries, Inc., which is based in the United States and develops a thermoelectric generator and boost converter, and we purchased a convertible note from Matrix in February 2021 which subsequently converted into series A preferred stock in April 2023. In addition, our subsidiary MML commenced a series A financing round in August 2024 and entered into capital and business alliances with two Japanese companies in connection with the financing round.

Although we have suspended growth through acquisitions for the time being, we may consider acquisitions and other strategic investments or alliances in the future if our financial condition improves and attractive opportunities emerge, particularly if we find attractive opportunities to enhance or supplement the capabilities or product offerings, expand the geographic reach of our salon business or our luxury brand portfolio, effectively acquire new customers, if we find businesses, technologies, sales forces, or other growth drivers that meet our criteria for investment in the Digital Preventative Healthcare Segment, or if we identify acquisitions that we believe can otherwise allow us to expand into new or related businesses.

As part of our acquisition strategy, we have in the past acquired and may in the future acquire or invest in unprofitable companies or businesses, or may make minority investments in early stage or emerging companies that hold or are developing technologies, intellectual property or capabilities that we believe are important for our own business development. Such prior or future acquisitions or minority investments may adversely affect our consolidated results of operations. In addition, we may have difficulty accurately assessing the future viability and growth trajectory of the acquired businesses, especially if the synergies we expect to realize in connection with the acquisitions or minority investments do not materialize in the amounts we expect or at all, or if we are unable to manage the acquired businesses in an effective manner. We may also face uncertainties when we acquire or invest in companies with limited operating capabilities or a management system that requires improvement, which is often the case for small privately owned businesses, including potential compliance issues or liabilities that were not identified in due diligence, poor management by the former owners, or any continuing management personnel who may lose motivation to meet our financial targets after monetizing their own equity interests in the acquired business. When a subsidiary of ours accepts venture capital or other investment from a third-party investor, there is a risk of future disagreements with the investor relating to strategic focus, long-term vision, corporate governance, future financing expectations, exit opportunities, or other matters.

Acquisitions, strategic investments and alliances entail a number of risks, including, among others:

•
expenses incurred and difficulties in integrating or assimilating the operations, technology, personnel and culture of acquired businesses;
•
the inability to realize the synergy effects, such as technological development, expansion of user or customer base or cost reductions, that were anticipated in connection with the transaction;
•
the potential disruption of, and the distraction of management from, our regular business operations;
•
the potential disruption of the acquired business caused by the acquisition process or the requirements that become applicable to it as a result of having a publicly listed parent company;
•
difficulties and substantial costs in connection with retaining the customers, key management or employees of an acquired company;

9


Table of Contents

 

•
the failure to ensure that the companies we acquire operate in accordance with our regulatory compliance standards;
•
the possibility of overestimating the value of an acquired company, underestimating its legal or contingent liabilities, receiving insufficient indemnification for potential liabilities or being unable to recover such indemnification from the seller;
•
recording significant goodwill and intangible assets that could be subject to future impairment; and
•
incurrence of additional debt in connection with financing acquisitions and investments.

As a result of such risks, we may not be able to fully realize the benefits that we anticipate from any given transaction, including increased revenue and profits and other expected strategic benefits, within the expected timeframe or at all. Although we conduct due diligence reviews of acquisition targets, there can be no assurance that our due diligence process will disclose all relevant risks, legal, compliance or regulatory issues, losses and other liabilities or that our assessment of the target’s risks and liabilities will be accurate.

Our success depends substantially on the value of our brands.

Our success is dependent, in large part, upon our ability to maintain and enhance the value of our brands, our customers’ connection to our brands, and a positive relationship with our franchisees. Brand value can be severely damaged even by isolated incidents, particularly if the incidents receive considerable negative publicity, including via social media, or result in litigation. Some of these incidents may relate to the way we manage our relationship with our franchisees, our growth strategies, our development efforts, or the ordinary course of our, or our franchisees’, business. Other incidents may arise from events that are or may be beyond our ability to control and may damage our brands, such as actions taken (or not taken) by one or more franchisees or their employees relating to health, safety, welfare, or otherwise; litigation and claims; security breaches or other fraudulent activities associated with our payment systems; and illegal activity targeted at us or others. Consumer demand for our products and services and our brands’ value could diminish significantly if any such incidents or other matters erode consumer confidence in us or our products or services, which would likely result in lower sales and, ultimately, lower royalty income, which in turn could materially and adversely affect our business and operating results.

The failure to enforce and maintain our trademarks and protect our other intellectual property could materially adversely affect our business, including our ability to establish and maintain brand awareness.

We regard our trademarks, trade secrets, know-how, and similar intellectual property as critical to our success. As of December 31, 2025, we had registered 51 trademarks, including the names and logos used by our Company, of which 48 were registered with the Japan Patent Office, two of which are registered with the U.S. Patent and Trademark Office and one of which is registered with the China National Intellectual Property Administration. Our principal intellectual property rights include the trademark “Re.Ra.Ku®”, which is our core brand, and “MOTHER Bracelet®”, “Lav®”, and “REMONY®”, which are key brands in our Digital Preventative Healthcare Segment, copyrights in our website and software assets, rights to our domain names, https://medirom.co.jp, https://reraku.jp, and https://mother-bracelet.com, trade secrets and know-how with respect to our training, servicing, sales and marketing and other aspects of our business, and our digital innovations such as the MOTHER application, REMONY® software, Gateway device, and Lav® application. The success of our business strategy depends on our continued ability to use our existing intellectual property in order to increase brand awareness and develop our branded services. If our efforts to protect our intellectual property are not adequate, or if any third party misappropriates or infringes on our intellectual property, whether in print, on the Internet or through other media, the value of our brands may be harmed, which could have a material adverse effect on our business, including the failure of our brands and branded services to achieve and maintain market acceptance. There can be no assurance that the steps we have taken to protect our intellectual property in Japan or outside Japan in relevant foreign countries will be adequate. In addition, in light of our intention to expand internationally, the laws of some foreign countries may not protect intellectual property rights to the same extent as do the laws of Japan. If any of our trademarks, trade secrets or other intellectual property are infringed, our business, financial condition and results of operations could be materially adversely affected.

We may need to raise additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to obtain and could dilute current shareholders’ ownership interests.

We expect that our cash and cash equivalents as of December 31, 2025 of JPY91,979 thousand (US$587 thousand) will not be sufficient to fund our operating expenses, capital expenditure requirements, and debt service obligations for the 12 months following the issuance date of the audit opinion for the financial statements contained in this annual report and that we will require additional capital. These conditions, among others, raise substantial doubt about our ability to continue as a going concern. In the short term, we intend to address this in part by generating cash through the sales of certain of our owned salons. However, such sales may not successfully raise sufficient capital, and are subject to other risks as described in “—Sales of our salons to investors could depend heavily on a number of factors, and as a result, our annual revenue from sale of salons may vary from year to year” for risks related to sale of our owned salons. See Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources—Going Concern.” Accordingly, we may need to raise additional capital to meet our business requirements.

10


Table of Contents

 

Our future capital requirements will depend on many factors, including the speed and geographic area of relaxation salon and other business growth (if any), progress and results of our businesses, the number and development requirements of other businesses that we pursue, including the costs of commercialization activities, including marketing and sales. Because of the numerous risks and uncertainties associated with the development and commercialization of our businesses, we are unable to reasonably estimate the amounts of increased capital outlays and operating expenditures that our business will require. It is likely that we will need to raise additional funds through public or private debt or equity financings to meet various objectives including, but not limited to:

•
pursuing growth opportunities;
•
acquiring complementary businesses;
•
making capital improvements to our infrastructure;
•
hiring qualified management and key employees;
•
responding to competitive pressures;
•
complying with regulatory requirements; and
•
maintaining compliance with applicable laws.

Any additional capital raised through the sale of equity or equity-linked securities may dilute our current shareholders’ ownership in us and could also result in a decrease in the market price of the ADSs. The terms of those securities issued by us in future capital transactions may be more favorable to new investors and may include preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect. Debt securities convertible into equity could be subject to adjustments in the conversion ratio pursuant to which certain events may increase the number of equity securities issuable upon conversion. Preferred shares, if issued, could have a preference with respect to liquidating distributions or a preference with respect to dividend payments that could limit our ability to pay dividends to the holders of the ADSs.

Our failure to timely file this annual report has also made us ineligible to use Form F-3, including for offerings under our existing shelf registration statement. Filing this annual report does not immediately restore that eligibility. While we remain ineligible, a registered offering would require us to use another available registration form, such as Form F-1, which could increase the cost and time required to raise capital. This restriction further reduces our financing flexibility and could adversely affect our ability to obtain funding when needed or on acceptable terms.

Furthermore, any debt or equity financing that we may need may not be available on terms favorable to us, or at all. If we are unable to obtain required additional capital, we may have to curtail our growth plans or cut back on existing business, and we may not be able to continue operating if we do not generate sufficient revenues from operations needed to stay in business.

We may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition. Thus, holders of the ADSs bear the risk that our future offerings may reduce the market price of the ADSs and dilute their shareholdings in us.

If we fail to obtain necessary funds for our operations, we will be unable to maintain and improve our services, other businesses, and technology, and we will be unable to develop and commercialize our services, other businesses, and technologies.

Our present and future capital requirements depend on many factors, including:

•
future revenues and profits generated from the expected launch of new services;
•
the level of research and development investment required to develop our services, and maintain and improve our technology positions;
•
our ability and willingness to enter into new agreements with strategic partners and the terms of these agreements;
•
the costs of recruiting and retaining qualified personnel;
•
the time and costs involved in obtaining regulatory approvals should such be required; and
•
the costs of filing, prosecuting, defending, and enforcing trademark, patent claims and other intellectual property rights.

If we are unable to obtain the funds necessary for our operations, we will be unable to develop and commercialize our services and technologies, which would materially and adversely affect our business, liquidity and results of operations.

11


Table of Contents

 

Our level of indebtedness could materially and adversely affect our business, financial condition and results of operations.

Our total interest-bearing debt as of December 31, 2025 was JPY2,401,507 thousand (US$15,316 thousand) on a consolidated basis, consisting of short-term borrowings of JPY765,227 thousand, long-term borrowings (including the current portion) of JPY631,280 thousand, corporate bonds of JPY30,000 thousand and corporate convertible bonds of JPY975,000 thousand, of which JPY1,601,548 thousand was due within one year. Since December 31, 2025, we have refinanced certain convertible bonds through secured borrowings rather than repaying the principal from operating cash flows. On July 14, 2026, we refinanced JPY275,000 thousand of our Fourth Unsecured Convertible-Type Corporate Bonds with Share Options into our loan from Kufu Company Holdings Inc., increasing the aggregate outstanding principal under that loan to JPY475,000 thousand. The combined principal bears interest at 10.0% per annum and has a stated contractual maturity of December 30, 2026. On August 25, 2026, we redeemed JPY300,000 thousand of convertible bonds held by Triple One Investment Limited Partnership and concurrently borrowed the same principal amount from that lender, with the redemption price and loan proceeds settled by set-off. The replacement loan originally bore interest at 5.0% per annum and had a maturity date of September 15, 2026, which passed without repayment. On November 11, 2026, the lender and we agreed to extend the maturity of the principal to December 30, 2026 and to increase the rate on interest accruing on and after November 1, 2026 to 14.6% per annum, payable monthly. These transactions did not eliminate the corresponding principal obligations and increased the interest rates applicable to the refinanced amounts. We cannot assure you that Triple One will agree to extend the maturity of its loan further or that other lenders will agree to extend or refinance our obligations when due. See “Item 4. Information on the Company—Subsequent Events” and “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources.”

 

We may enter into additional financing arrangements, and may also take on additional indebtedness, depending on the terms and conditions offered by financial institutions and other lenders. Our indebtedness could have significant effects on our business, such as:

•
limiting our ability to borrow additional amounts to fund working capital, capital expenditures, acquisitions, debt service requirements, execution of our growth strategy and other purposes;
•
requiring us to dedicate a substantial portion of our cash flow from operations to pay principal and interest on our debt, which would reduce availability of our cash flow to fund working capital, capital expenditures, acquisitions, execution of our growth strategy and other general corporate purposes;
•
making us more vulnerable to adverse changes in general economic, industry and competitive conditions, in government regulation and in our business by limiting our ability to plan for and react to changing conditions;
•
diluting the economic and voting rights of our existing shareholders, or adversely affecting the trading price of the ADSs, if outstanding convertible securities are converted or if we issue additional equity or equity-linked securities to repay or refinance our indebtedness; and
•
placing us at a competitive disadvantage compared with our competitors that have less debt.

In addition, we may not be able to generate sufficient cash flow from our operations to repay our indebtedness when it becomes due and to meet our other cash needs. Our reliance on refinancing and maturity extensions exposes us to the risk that lenders may decline to renew or extend our obligations, require additional collateral or impose higher interest rates or other less favorable terms. If we are not able to pay our debts as they become due, we will be required to pursue one or more alternative strategies, such as selling assets, refinancing or restructuring our indebtedness or selling additional debt or equity securities. We may not be able to refinance our debt or sell additional debt or equity securities or our assets on favorable terms, if at all, and if we must sell our assets, it may negatively affect our ability to generate revenues. If we cannot obtain sufficient funds to meet our debt obligations, we could default on those obligations, and our ability to continue as a going concern could be adversely affected. See “—There is substantial doubt about our ability to continue as a going concern.”

As of December 31, 2025, JPY191,671 thousand of our bank borrowings bore interest at variable rates and JPY824,930 thousand bore interest at fixed rates. Increases in market interest rates increase interest expense on our floating-rate borrowings and the cost of new or replacement financing, including financing obtained to refinance existing fixed-rate debt. Although we generally seek fixed-rate borrowings, we remain exposed to higher financing costs when existing debt matures or must be refinanced. Higher borrowing costs could further strain our liquidity and adversely affect our financial condition and results of operations. For information regarding our sensitivity to interest rates, see “Item 11. Quantitative and Qualitative Disclosure About Market Risk—Interest Rate Risk.”

Our secured indebtedness and reliance on personal guarantees could limit our financing and operating flexibility and expose important assets to enforcement.

As of December 31, 2025, our short-term borrowings and long-term borrowings (including the current portion) amounted to JPY765,227 thousand and JPY631,280 thousand, respectively, on a consolidated basis. None of the borrowing agreements contain any material financial covenants, although certain of the government-sponsored loans set a limit on the total loan amount we may

12


Table of Contents

 

borrow from other government-sponsored lenders. However, the absence of material financial covenants does not eliminate the risks arising from our collateral and guarantee arrangements.

Our loan from Kufu Company Holdings Inc., the outstanding principal of which increased to JPY475,000 thousand in July 2026, is secured by a first-priority pledge of all 48,219 common shares we hold of MEDIROM MOTHER Labs Inc. In addition, the JPY300,000 thousand loan obtained from Triple One Investment Limited Partnership in August 2026 is secured by a pledge of all shares of MEDIROM Rehab Solutions Inc. that we hold and by a pledge over the operating rights of ten salons. These security arrangements may limit our ability to obtain additional financing secured by the same assets. If we default on the secured obligations, the relevant lenders may be entitled to enforce their security, which could result in the loss of our ownership interests in, or control of, the relevant subsidiaries or the loss of rights relating to the salons. Such enforcement could disrupt our operations and materially adversely affect our business, financial condition and results of operations. See “Item 4. Information on the Company—Subsequent Events.”

We also rely on personal guarantees in connection with certain borrowings. Our Chief Executive Officer is a personal guarantor for six loans (three bank loans of the Company and three disbursements under the loan agreement with Spirit Advisors), the outstanding amount of which was JPY339,330 thousand as of December 31, 2025. In addition, Kazuyoshi Takahashi, the representative director of ZACC Kabushiki Kaisha (“ZACC”), is a guarantor with respect to two loans of ZACC, the outstanding amount of which was JPY25,245 thousand as of December 31, 2025, and Yoshio Uekusa, the representative director of MEDIROM MOTHER Labs Inc., is a guarantor with respect to one loan of MEDIROM MOTHER Labs Inc., the outstanding amount of which was JPY23,556 thousand as of December 31, 2025. If the relevant guarantors become unable or unwilling to provide guarantees for renewed or replacement financing, or if we seek a lender’s agreement to release an existing guarantee, we may be unable to obtain replacement financing or a release on acceptable terms. The relevant lender may require alternative guarantees, additional collateral, higher interest rates or additional restrictions. These requirements could increase our financing costs and limit our ability to obtain financing or our discretion to invest in, use or dispose of our assets.

We depend on key members of our management and advisory team and will need to add and retain additional leading experts.

We are highly dependent on our executive officers, including our Chief Executive Officer, Mr. Kouji Eguchi, our Chief Financial Officer, Mr. Fumitoshi Fujiwara, and other key management and technical personnel. We do not have employment agreements with either Mr. Kouji Eguchi or Mr. Fumitoshi Fujiwara.

Furthermore, our ability to manage our salon expansion will require us to continue to train, motivate, and manage our associates. We will need to attract, motivate, and retain additional qualified executive, managerial, and merchandising personnel and salon associates. Competition for this type of personnel is intense, and we may not be successful in attracting, assimilating, and retaining the personnel required to grow and operate our business profitably. We presently maintain a “key person” life insurance policy only for our Chief Executive Officer. There can be no assurance that we will be able to retain our existing personnel, including our Chief Executive Officer, Chief Financial Officer and other key management personnel, or attract additional qualified employees. The loss of key personnel or the inability to hire and retain additional qualified personnel in the future could have a material adverse effect on our business, financial condition and results of operation.

We may suffer losses from litigation or other claims, including if our services cause harm to customers.

From time-to-time we may be involved in a variety of claims or litigation. Such proceedings may initially be viewed as immaterial but may develop to become significant. Litigation is inherently unpredictable and there is a possibility of unexpectedly large damage awards. Given the inherent uncertainties in litigation, even when we can reasonably estimate the amount of possible loss or range of loss, the actual outcome may differ significantly from our estimates. In addition, such claims or litigation could involve significant expense and diversion of management’s attention and resources from other matters.

In particular, although we screen our customers for major illnesses and injury, our services could potentially cause harm or injury to customers. Unexpected and undesirable side effects caused by our services for which we have not provided sufficient warnings, which may have been performed negligently, could result in the discontinuance of our relaxation services or prevent us from achieving or maintaining market acceptance of our services. Such side effects or injury incidents could also expose us to liability lawsuits. We currently maintain a comprehensive general liability policy; however, if any general liability lawsuits or claims are successfully brought against us, we could suffer from increased insurance premiums. Moreover, if damages exceed our policy limits, we may incur substantial financial losses. These claims could cause negative publicity regarding our Company, or brand, which could in turn harm our reputation and net revenue, which could have a material adverse effect on our business, financial condition, profitability, and cash flows.

Our prepaid cards are heavily regulated under Japanese law and violations of the relevant law could subject us to sanctions.

We began issuing prepaid cards called “Re.Ra.Ku® Cards” to relaxation salon customers on December 1, 2008. Re.Ra.Ku® Card users can continuously use and also replenish their cards at most of our Company’s relaxation salons. Prepaid cards are generally considered “prepaid payment methods” (which we refer to as “PPMs”) under the Act on Settlement of Funds (Act No.

13


Table of Contents

 

59 of 2009) (which we refer to as the “Settlement Act”). PPMs are regulated under the Settlement Act so long as there is a possibility that the cards could be valid for a period of more than six months. The Re.Ra.Ku® Cards do not have expiration dates and therefore are regulated under the Settlement Act. Moreover, the Re.Ra.Ku® Cards can be used at salons operated by franchisees, and because the franchisees are considered third parties for the purposes of the Settlement Act, we fall under the category of a Public Use PPM Provider.

A Public Use PPM Provider must be registered with the relevant Local Financial Bureau and follow detailed deposit procedures to assure that there are adequate funds for the individuals who are effectively loaning their money to the Public Use PPM Provider, including an obligation to deposit half of the prepaid balance to the Legal Affairs Bureau. As of December 31, 2025, the unused balance on Re.Ra.Ku Cards was JPY230,036 thousand (US$1,467 thousand), of which JPY121,527 thousand (US$775 thousand) was on deposit with the Legal Affairs Bureau. If we fail to comply with these procedures, we may be assessed a monetary fine, and in certain circumstances, a member of our Company could face a criminal penalty of imprisonment, which could adversely impact our financial results as well as our brand image.

Furthermore, one of the requirements for issuers of prepaid cards under the Settlement Act is to maintain net assets of not less than JPY100 million based on Japanese GAAP. We were in compliance with the net assets requirement as of December 31, 2025. However, there is no assurance that we can continue to be compliant with it in the future.

Given the heavy burden imposed on us as a Public Use PPM Provider, we decided to introduce a new payment system and developed “Re.Ra.Ku PAY”, a proprietary payment app which works on customers’ smart phones. The most important difference between the Re.Ra.Ku Card and Re.Ra.Ku PAY is that balances on Re.Ra.Ku PAY have an expiration period of 150 days, while Re.Ra.Ku Card balances do not have an expiration date. The Settlement Act regulates only prepaid cards with balances that remain effective for more than six months. Hence, by limiting the expiration period to less than six months, we believe Re.Ra.Ku PAY can be exempted from the regulations and requirements under the Settlement Act, including the net assets requirement and the Legal Affairs Bureau deposit obligation.

We disallowed further balance deposits on Re.Ra.Ku Cards beginning on February 1, 2024. Accordingly, we expect the total balance of funds on Re.Ra.Ku Cards to decrease, as customers can only use their Re.Ra.Ku Cards for payment, and the amounts deposited to the Legal Affairs Bureau will be refunded to us over time as the total balance of funds on Re.Ra.Ku Cards decreases.

Moreover, in October 2024, we introduced several kinds of prepayment tickets, all of which expire within 180 days, for customers who prefer paying with paper-based prepaid tickets over the Re.Ra.Ku PAY application.

However, even after introducing Re.Ra.Ku PAY and the prepaid tickets, we continue to be regulated as a Public Use PPM Provider in connection with Re.Ra.Ku Cards, and there is no assurance that we will be able to continue satisfying the minimum net asset requirement. If we fail to meet this requirement, there is a risk that our registration as an issuer of the prepaid cards (that is, Re.Ra.Ku Cards) may be revoked. While we believe such a revocation would not affect our ability to offer Re.Ra.Ku PAY, we would be required to immediately repay the remaining balances of Re.Ra.Ku Cards. As of December 31, 2025, the total outstanding balance of Re.Ra.Ku Cards and the prepaid tickets was JPY325,318 thousand (US$2,075 thousand).

If we or our franchisees face labor shortages or increased labor costs, our results of operations and our growth could be adversely affected.

Labor is a primary component in the cost of operating our directly-operated and franchised relaxation salons. As of December 31, 2025, we had 351 employees on a full-time basis, 516 employees on a part-time basis, and 87 employees on a fixed-term basis. Most of our employees are therapists who provide services at our directly-operated salons and franchised salons. If we or our franchisees face labor shortages or increased labor costs because of increased competition for employees, higher employee-turnover rates, or increases in the relevant minimum wage, change in employment status standards, or other employee benefits costs (including costs associated with health insurance coverage or workers’ compensation insurance), our and our franchisees’ operating expenses could increase, and our growth could be adversely affected.

If such events occur, we may be unable to increase our prices in order to pass future increased labor costs on to our customers, in which case our margins would be negatively affected. Also, reduced margins of franchisees could make it more difficult to sell franchises. If prices are increased by us and our franchisees to cover increased labor costs, the higher prices could adversely affect transactions which could lower sales and thereby reduce our margins and the royalties that we receive from franchisees.

In addition, our success depends in part upon our and our franchisees’ ability to attract, motivate and retain a sufficient number of well-qualified relaxation salon operators, management personnel and other employees, including relaxation therapists. Qualified individuals needed to fill these positions can be in short supply in some geographic areas. In addition, relaxation salons have traditionally experienced relatively high employee turnover rates. Our and our franchisees’ ability to recruit and retain such individuals may delay the planned openings of new relaxation salons or result in higher employee turnover in existing relaxation salons, which could increase our and our franchisees’ labor costs and have a material adverse effect on our business, financial

14


Table of Contents

 

condition, results of operations or cash flows. If we or our franchisees are unable to recruit and retain sufficiently qualified individuals, our business and our growth could be adversely affected.

Competition for these employees could require us or our franchisees to pay higher wages, which would also result in higher labor costs and adversely affect our results of operation.

We are subject to the risks associated with leasing space subject to long-term non-cancelable leases.

We generally lease the spaces in which our and our franchisees’ relaxation salons operate, and in the case of our franchisees’ salons, we sublease the space to our franchisees. Payments under leases account for a significant portion of our operating expenses and we expect the new salons we operate or franchise in the future will similarly be leased. Our leases generally have terms of three or five years. We enter into one of two types of lease agreements depending on the lessor: regular lease agreements or term lease agreements, both of which are common in Japan. Regular leases can be cancelled by the lessee subject to notice periods defined in the lease agreement. However, in principle, term leases cannot be cancelled by the lessee. If we or a franchisee decide to close a relaxation salon subject to a term lease, including due to a lack of profitability, we may nonetheless be committed to perform our payment obligations under the applicable term lease.

For franchised salons subject to term leases, if the salon is subleased by us to the franchisee, we are exposed to such risk while primarily depending upon the franchisee’s capabilities to maintain the profitable operation of the salon. In addition, as each of our leases expires, we may fail to negotiate renewals, either on commercially acceptable terms or at all, which could cause us to pay increased occupancy costs or to close salons in desirable locations. If we fail to negotiate renewals, we may have to dispose of assets at such salon locations and incur closure costs as well as impairment of property and equipment. Furthermore, if we fail to negotiate renewals, we may incur additional costs associated with moving transferable fixtures and equipment. These potential costs, as well as closures of salons, could materially adversely affect our business, financial condition or results of operations.

Macroeconomic conditions, including economic downturns, may cause landlords of our leases to be unable to obtain financing or remain in good standing under their existing financing arrangements, resulting in failure to perform their lease obligations to us. In addition, other tenants at the shopping centers and commercial areas in which our and our franchisees’ salons are located may fail to operate or may cease operations during an economic slowdown. Decreases in total tenant occupancy in these areas may affect traffic at and around our and our franchisees’ salons. All of these factors could have a material adverse impact on our business, financial condition or results of operations.

We are exposed to the risk of natural disasters, unusual weather conditions, pandemic outbreaks, political events, war and terrorism that could disrupt business and result in lower sales, increased operating costs and capital expenditures.

Our headquarters, directly-operated and franchised relaxation salon locations and other businesses, as well as certain of our vendors and customers, are located in areas which have been and could be subject to natural disasters such as floods, typhoons, tsunamis, tornadoes, fires or earthquakes, as well as global pandemics. Adverse weather conditions or other extreme changes in weather, including resulting electrical and technological failures and even nuclear leaks, in areas where our relaxation salons are concentrated, may disrupt our and our franchisees’ businesses and may adversely affect our and our franchisees’ ability to offer services. Such disruptions could influence customer trends and purchases and negatively impact our and our franchisees’ revenues, properties or operations.

In addition, if we experience the effects of other events, such as natural or other disasters, we could suffer physical damage to one or more of our or our franchisees’ properties, the temporary closure of some or all of our directly-operated relaxation salons and franchised relaxation salons, the temporary lack of an adequate work force in a market, temporary or long-term disruption in the transport of goods, delay in the delivery of goods and supplies to our directly-operated and franchised relaxation salons, disruption of our technology support or information systems, or fuel or electricity shortages or dramatic increases in fuel or electricity prices, all of which would increase the cost of doing business. These events also could have indirect consequences such as increases in the costs of insurance or taxes if they result in significant loss of property or other insurable damage. Any of these factors, or any combination thereof, could adversely affect our operations and our financial results.

If we expand our businesses internationally in the future, we would become subject to foreign laws and regulations, and we could be adversely affected by violations of these laws.

If we expand our business in Japan and other parts of the world, including in the United States, in the future, we would become subject to risks customarily associated with such global operations, including the complexity of laws, regulations, and markets in the countries in which we operate; the uncertainty of enforcement of remedies in certain jurisdictions; the effect of currency exchange rate fluctuations; export control laws; the impact of foreign labor laws and disputes; the ability to attract and retain key personnel; the economic, tax, and regulatory policies of local governments; compliance with applicable anti-money laundering, anti-bribery, and anti-corruption laws that generally prohibit persons and companies and their agents from offering, promising, authorizing, or making improper payments to foreign government officials for the purpose of obtaining or retaining business; and compliance with applicable sanctions regimes regarding dealings with certain persons or countries. Certain of these laws also contain provisions that require accurate recordkeeping and further require companies to devise and maintain an adequate system of internal accounting controls. We cannot assure you that we will be successful in preventing our franchisees or other

15


Table of Contents

 

agents from taking actions in violation of these foreign laws or regulations. Such violations, or allegations of such violations, could disrupt our business and result in a material adverse effect on our financial condition, results of operations and cash flows.

There is a risk that we will be a passive foreign investment company (which we refer to as “PFIC”) for the current or any future taxable year, which could result in material adverse U.S. federal income tax consequences if you are a U.S. holder.

A non-U.S. corporation, such as our Company, is classified as a PFIC for any taxable year in which, after applying relevant look-through rules with respect to the income and assets of its subsidiaries, either: (i) 50% or more of the value of the corporation’s assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets; or (ii) at least 75% of the corporation’s gross income is passive income. “Passive income” generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions. In determining the value and composition of our assets, cash will generally be considered to be held for the production of passive income and thus will be considered a passive asset.

The determination of whether a corporation is a PFIC for a taxable year depends, in part, on the application of complex U.S. federal income tax rules that are subject to differing interpretations. In addition, the determination of whether a corporation will be a PFIC for any taxable year can only be made after the close of such taxable year. Furthermore, because we may value our goodwill based on the market price of the ADSs, a decrease in the market price of the ADSs may also cause us to be classified as a PFIC for the current or any future taxable year. Based upon the foregoing, we do not believe that we were a PFIC for the taxable year ended December 31, 2025. However, as of the date of this annual report, in light of recent declines in the market price of the ADSs, our risk of becoming a PFIC has increased. The market price of the ADSs may continue to fluctuate considerably and, consequently, we cannot assure you of our PFIC status for the current or any future taxable year.

If we are a PFIC for any taxable year during which a U.S. holder (as defined below) owns common shares or ADSs, certain adverse U.S. federal income tax consequences could apply to such U.S. holder. We have not determined, if we were to be classified as a PFIC for a taxable year, whether we will provide information necessary for a U.S. holder to make a “qualified electing fund” election which, if available, would result in tax treatment different from (and generally less adverse than) the general tax treatment for PFICs. Accordingly, U.S. holders should assume that they will not be able to make a qualified electing fund election with respect to the common shares or ADSs. The PFIC rules are complex, and each U.S. holder should consult its own tax advisor regarding the PFIC rules, the elections which may be available to it, and how the PFIC rules may affect the U.S. federal income tax consequences relating to the ownership and disposition of our common shares or ADSs.

Risks Related to Our Relationships with Franchisees

The financial performance of our franchisees can negatively impact our business.

Approximately 24.0% of our relaxation salons were franchised locations as of December 31, 2025. We derive revenues associated with our franchised locations from royalty fees and other fees to franchised locations.

Our financial results are therefore dependent in part upon the operational and financial success of our franchisees. We have established operational standards and guidelines for our franchisees; however, we have limited control over how our franchisees’ businesses are run. While we are responsible for ensuring the success of our entire system of relaxation salons and for taking a longer-term view with respect to system improvements, our franchisees have individual business strategies and objectives, which might conflict with our interests. Our franchisees may not be able to secure adequate financing to continue operating their relaxation salons. If they incur too much debt or if economic or sales trends deteriorate such that they are unable to repay existing debt, our franchisees could experience financial distress or even bankruptcy. If a significant number of franchisees become financially distressed, it could harm our operating results through reduced royalty revenues, and the impact on our profitability could be greater than the percentage decrease in the royalty revenues. Closure of franchised relaxation salons would reduce our royalty revenues and could negatively impact margins, because we may not be able to reduce fixed costs which we continue to incur.

We have limited control with respect to the operations of our franchisees, which could have a negative impact on our business.

Franchisees are independent business operators and are not our employees. Though we have established operational standards and guidelines, they own, operate and oversee the daily operations of their salon locations. We provide training and support to franchisees and set and monitor operational standards, but the quality of franchised relaxation salons may be diminished by any number of factors beyond our control.

Consequently, franchisees may not successfully operate relaxation salons in a manner consistent with our standards and requirements or may not hire and train qualified managers and other relaxation salon personnel, including relaxation therapists. If franchisees do not operate to our expectations, our image and reputation, and the image and reputation of other franchisees, may suffer materially, and franchise-wide sales could decline significantly, which would reduce our royalty revenues, and the impact on profitability could be greater than the percentage decrease in royalties and fees.

16


Table of Contents

 

In addition, our franchisees are subject to the same general economic risks as our Company, and their results are influenced by competition for both guests and therapists, market trends, price competition and disruptions in their markets due to severe weather and other external events. Like us, they rely on external vendors for some critical functions and to protect their company data. They may also be limited in their ability to open new locations by an inability to secure adequate financing, especially since many of them are small businesses with much more limited access to financing than our Company, or by the limited supply of favorable real estate for new salon locations. They may experience financial distress as a result of over-leveraging, which could negatively affect our operating results as a result of delayed payments to us.

We rely on franchise agreements that could be breached and may be difficult to enforce, which could result in franchisees improperly managing relaxation salons.

Although we believe that we take reasonable steps to protect the quality of services provided at our franchised locations, including the use of franchise agreements with detailed and rigorous obligations on the part of franchisees, the agreements can be difficult and costly to enforce. Although we seek to require strict adherence to properly structured franchise agreements, disputes may arise related to revenue, financing, or intellectual property rights associated with our franchise. If a dispute arises, a court may determine that a third party’s rights were infringed. In addition, enforcement of our rights can be costly and unpredictable. We also rely on trade secrets and proprietary know-how that we seek to protect in part by confidentiality agreements with our franchisees, employees, contractors, consultants, advisors or others. Despite the protective measures we employ, we still face the risks that:

•
these agreements may be breached;
•
these agreements may not provide adequate remedies for the applicable type of breach;
•
our trade secrets or proprietary know-how will otherwise become known; and
•
our competitors will independently develop similar technology or proprietary information.

We rely in part on the financial health of our franchisees. If we do not screen and monitor them appropriately, it could adversely affect our operations and financial results if they experience financial hardship.

We rely in part on our franchisees and the manner in which they operate their locations to develop and promote our business. It is possible that some franchisees could under-report sales, file for bankruptcy or become delinquent in their payments to us, which could have a significant adverse impact on our business due to loss or delay in payments of royalties and other fees. Bankruptcies by our franchisees could negatively impact our market share and operating results as we may have fewer well-performing relaxation salons, and adversely impact our ability to attract new franchisees.

Although we have developed criteria to evaluate and screen prospective franchisees, we cannot be certain that the franchisees we select will have the business acumen or financial resources necessary to open and sustainably operate successful franchises in their franchise areas, and Japanese contract laws may limit our ability to terminate or modify these franchise arrangements. Moreover, franchisees may not hire qualified managers or may not successfully operate relaxation salons in a manner consistent with our standards and requirements. The failure of developers and franchisees to open and operate franchises successfully could have a material adverse effect on us, our reputation, our brand and our ability to attract prospective franchisees and could materially adversely affect our business, financial condition, results of operations and cash flows.

Franchisees may not have access to the financial or management resources that they need to open the relaxation salons contemplated by their agreements with us. Franchisees may not be able to negotiate acceptable lease or purchase terms for relaxation salon sites, obtain the necessary permits and government approvals or meet construction schedules. Any of these problems could slow our growth and reduce our franchise revenues. Additionally, our franchisees typically depend on financing from banks and other financial institutions, which may not always be available to them, in order to construct and open new relaxation salons. For these reasons, franchisees may not be able to meet the new relaxation salon opening dates required under franchise agreements.

Franchisee turnover could affect our ability to recruit new franchisees.

Although we make great efforts with the aid of our franchise support team to help franchisees who run into difficulties, we may suffer from low franchisee retention. Low franchisee retention could harm our image and deter prospective franchisees. If franchisee turnover increases and we begin to struggle to recruit new franchisees to take over relinquished salon locations or establish new ones, such an occurrence could harm our financial results.

Premature termination of franchise agreements can cause losses.

Our franchise agreements may be subject to premature termination in certain circumstances, such as failure of a franchisee to cure a monetary default or abandonment of the franchise. If terminations occur for this or other reasons, we may need to enforce our right to damages for breach of contract and related claims, which may cause us to incur significant legal fees and

17


Table of Contents

 

expenses and/or to take back and operate such salons as directly-operated. Any damages we ultimately collect could be less than the projected future value of the fees and other amounts we would have otherwise collected under the franchise agreement. In addition, with many of our brands, we remain liable under the lease and, therefore, will be obligated to pay rent or enter into a settlement with the landlord, and we may not be made whole by the franchisee. A significant loss of franchise agreements due to premature terminations could hurt our financial performance or our ability to grow our business.

The interests of our franchisees may conflict with ours in the future and we could face liability from our franchisees or related to our relationship with our franchisees.

Franchisees, as independent business operators, may from time to time disagree with us and our strategies regarding the business or our interpretation of our respective rights and obligations under the respective franchise agreements and the terms and conditions of the franchisee/franchisor relationship. This may lead to disputes with our franchisees, and we expect such disputes to occur from time to time in the future as we continue to offer franchises. Such disputes may result in legal action against us. To the extent we have such disputes, the attention, time and financial resources of our management and our franchisees will be diverted from our relaxation salons and other businesses, which could have a material adverse effect on our business, financial condition, results of operations and cash flows even if we have a successful outcome in the dispute.

We are subject to various Japanese laws that may affect our relationship with our franchisees.

Various Japanese laws govern our relationship with our franchisees and our potential sale of a franchise.

A franchisee and/or a government agency may bring legal action against us based on the franchisee/franchisor relationships that could result in the award of damages to franchisees and/or the imposition of fines or other penalties against us.

The Act on Prohibition of Private Monopolization and Maintenance of Fair Trade (Act No. 54 of 1947, as amended) (which we refer to as the “Antimonopoly Act”) prohibits any activities that inappropriately induce or mislead customers to enter into a business relationship by demonstrating seemingly preferable trade terms and conditions that could create a false impression over other competitor franchisors. The Japan Fair Trade Commission (which we refer to as the “JFTC”), which enforces the Antimonopoly Act and other Japanese antitrust laws, set forth “Guidelines Concerning the Franchise System Under the Antimonopoly Act” which suggest that a franchisor adequately disclose and explain material trade terms to a potential franchisee (willing to join the franchise relationship) to prevent any material terms and conditions inappropriately inducing or misleading such potential franchisee. In addition, when a franchisor markets its franchise, in the event a franchisor provides a prospective franchisee with an estimate of the revenue or profit that might possibly be earned upon becoming a franchisee, such estimated revenue or profit must be based on a reasonable method of calculation and established facts, such as the results of an existing franchise operating in a similar environment. The franchisor is required to present to the prospective franchisee such methods and facts. The guidelines also suggest that, in explaining business hours and temporary closures, a franchisor should provide to a prospective franchisee then-known information that may adversely impact management of the franchise, such as the occurrence of a shortage of human resources during specified business hours or a rapid increase in personnel costs. If the JFTC finds that any of our activities violate the Antimonopoly Act, including any “deceptive customer inducement” and “abuse of superior bargaining positions”, then the JFTC may order us to cease and desist from engaging in such unlawful activities, delete any relevant unlawful clauses from the franchise contract, or carry out any other measures necessary to eliminate such unlawful activities.

In the event the JFTC suspects any violation of the Antimonopoly Act or alleges our Company has misled or wrongly induced based on any particular trade terms, our Company could be exposed to risks including governmental action against our Company.

Risks Related to Our Industry

We are vulnerable to changes in consumer preferences and economic conditions that could harm our business, financial condition, results of operations and cash flow.

Relaxation salon businesses depend on discretionary consumer spending and are often affected by changes in consumer tastes, national, regional and local economic conditions, and demographic trends.

Factors such as traffic patterns, weather, local demographics, and the type, number and locations of competing salons may adversely affect the performance of individual locations. In addition, economic downturns, rapid inflation, tight labor market conditions and the resulting increase of general wage levels and increases in salon lease expenses could harm the relaxation industry in general and our relaxation salon locations in particular. Adverse changes in any of these factors could reduce consumer traffic or impose practical limits on pricing that could harm our business, financial condition, results of operations and cash flow. There can be no assurance that consumers will continue to regard our brand of relaxation salons favorably or that we will be able to develop new services that appeal to consumer preferences. Our business, financial condition and results of operations depend in part on our ability to anticipate, identify and respond to changing consumer preferences and economic conditions. If we are unable to adapt to changes in consumer preferences and trends, we may lose customers and our revenues may decline.

18


Table of Contents

 

We may not be able to compete successfully with other relaxation salon businesses, which could materially and adversely affect our results of operations.

We may not be able to compete successfully with other relaxation salon businesses. Intense competition in the relaxation industry could make it more difficult to expand our business and could also have a negative impact on our operating results if customers favor our competitors, or if we are forced to change our pricing and other marketing strategies.

The relaxation industry, particularly in Japan, is intensely competitive. In addition, the Tokyo metropolitan area (consisting of Tokyo, Kanagawa, Saitama, and Chiba) of Japan, the primary market in which we compete, contains what we believe to be the most competitive relaxation services market in Japan. We expect competition in this market to continue to be intense because relaxation salons are comparatively inexpensive to start and operate, and new competitors are regularly entering the market due to the low barrier to entry. Competition in our industry is primarily based on price, convenience, quality of service, brand recognition, and location of the relaxation salons. If our directly-operated and franchised relaxation salons cannot compete successfully with other relaxation salon companies in new and existing markets, we could lose customers and our revenues could decline. Our directly-operated and franchised relaxation salons compete with national and regional relaxation salon chains for customers, relaxation salon locations and qualified management and other staff, including licensed relaxation therapists. Some of our competitors may have substantially greater financial and other resources, may have been in business longer, may have greater brand recognition, or may be better established in the markets where our relaxation salons are located or are planned to be located. Any of these competitive factors may materially adversely affect our business, financial condition or results of operations.

We face significant competition and continuous technological change.

In our Digital Preventative Healthcare Segment, if our competitors develop and commercialize services faster than we do or develop and commercialize services that are superior to ours, our commercial opportunities will be reduced or eliminated. The extent to which any of our services achieve market acceptance will depend on competitive factors, many of which are beyond our control. Competition in the relaxation and health technology industries is intense. Our main competitors in the Specific Health Guidance Program, promoted by the Ministry of Health, Labor and Welfare of Japan, include SOMPO Health Support Inc., Benefit One Inc., and FitsPlus Inc.

Information technology system failures or breaches of our network security could interrupt our operations and adversely affect our business.

We and our franchisees rely on our computer systems and network infrastructure across our operations, including point-of-sale processing at our relaxation salons. In addition, our Lav® application and the platform under which we collect data from our MOTHER Bracelets® are heavily dependent on information technology systems. We also use Amazon Web Services Microsoft Azure and Google Cloud Platform as our cloud service providers. Our and our franchisees’ operations depend upon our and our franchisees’ ability to protect our computer equipment and systems against damage from physical theft, fire, power loss, telecommunications failure or other catastrophic events, as well as from internal and external security breaches, viruses, worms and other disruptive problems. Any damage or failure of our computer systems, network infrastructure, or cloud servers that cause an interruption in our operations could have a material adverse effect on our business and subject us to litigation or actions by regulatory authorities. The failure of these systems to operate effectively, maintenance problems, upgrading or transitioning to new platforms, or a material network breach in security of these systems as a result of cyber-attack or any other failure to maintain a continuous and secure cyber network could further result in substantial harm, or in delays in customer service and reduce efficiency in our and our franchisees’ operations. This could include the theft of our intellectual property or trade secrets, or the improper use of personal information or other “identity theft.” While we utilize our personnel, as well as a variety of hardware and software, to monitor our systems, controls, firewalls and encryption and intend to maintain and upgrade our security technology and operational procedures to prevent damage, breaches or other disruptive problems, there can be no assurance that these security measures will be successful. Any such claim, proceeding or action by a regulatory authority, or any adverse publicity resulting from these allegations, could adversely affect our business and results of operations.

Cybersecurity breaches and other disruptions could compromise our information, result in the unauthorized disclosure of confidential guest, employee, Company and/or business partners’ information, damage our reputation, and expose us to liability, which could negatively impact our business.

In the ordinary course of our business, we collect and process sensitive and confidential data, including our proprietary business information and that of our guests, users, suppliers and business partners, and personally identifiable information of our guests, users and employees, in our data centers and on our networks. For example, our customers are asked to complete a survey, often digitally on iPads, prior to first receiving services at our relaxation salons. The surveys contain questions requesting private health-related information of our relaxation salon patrons. In connection with credit and debit card sales, we and our franchisees transmit confidential credit and debit card information by way of secure private retail networks. In addition, we collect a large amount of health-related information from users of our Lav® smartphone application and our MOTHER Bracelet®.

The secure processing, maintenance, and transmission of this information is critical to our operations. We rely on commercially available systems, software, tools, and monitoring to provide security for processing, transmission, and storage of

19


Table of Contents

 

confidential information. Despite the security measures we have in place and continual vigilance in regard to the protection of sensitive information, our systems and those of our third-party service providers may be vulnerable to security breaches, attacks by hackers, acts of vandalism, computer viruses, misplaced or lost data, human errors, or other similar events. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, disrupt our operations, damage our reputation, and cause a loss of confidence in our business, products, and services, which could adversely affect our business, financial condition, profitability, and cash flows.

Furthermore, although we currently carry cyber liability insurance, such insurance has limited coverage to cover liabilities incurred by breaches of our customers’ data caused by security breaches, attacks by hackers, acts of vandalism, computer viruses, misplaced or lost data, human errors, or other similar events. A significant claim not covered by our insurance, in full or in part, may result in significant expenditures by us. Moreover, we may not be able to maintain insurance policies in the future at reasonable costs or on acceptable terms, which may adversely affect our business and the trading price of the ADSs.

Negative publicity could reduce sales at some or all of our relaxation salons.

Although we actively screen all personnel and staff members, including relaxation therapists, who interact with customers, we cannot guarantee that our staff or customers will not engage in illegal or inappropriate behavior that could have a negative effect on our brand image, as well as the health and well-being of our customers or staff, as the case may be. In addition, negative publicity may adversely affect us, regardless of whether the allegations are valid or whether we are held to be responsible. Any such negative impact of adverse publicity relating to one relaxation salon may extend far beyond the relaxation salon involved, especially due to the high geographic concentration of many of our relaxation salons, to affect some or all of our other relaxation salons, including our franchised relaxation salons. The risk of negative publicity is particularly great with respect to our franchised relaxation salons because we are limited in the manner in which we can regulate them, especially on a real-time basis, and negative publicity from our franchised relaxation salons may also significantly impact directly-operated relaxation salons. In addition, the relaxation industry can often be held under legal and legislative scrutiny as a result of some fringe relaxation businesses that engage in illegal or anti-social activities.

Employee claims against us based on, among other things, wage and hour violations, discrimination, harassment, wrongful termination, or similar claims may also create not only legal and financial liability but negative publicity that could adversely affect us and divert our financial and management resources that would otherwise be used to benefit the future performance of our operations. Certain of these types of employee claims, such as tort claims, could be asserted against us by employees of our franchisees. A significant increase in the number of these claims or an increase in the number of successful claims could materially adversely affect our business, financial condition, results of operations and cash flows.

We are potentially subject to government regulations, and we may experience delays in obtaining required regulatory approvals, if required, to market our proposed businesses.

Various aspects of our operations are or may become subject to Japanese law or the laws of another relevant country or jurisdiction, any of which may change from time to time. Costs arising out of any regulatory developments could be time-consuming, expensive and could divert management resources and attention and, consequently, could adversely affect our business operations and financial performance.

Delays in regulatory clearance, approval, limitations in regulatory approval and withdrawals of regulatory approval, if any are required, may have a negative impact on our results. If we experience significant delays in obtaining any regulatory approvals, our business development costs will increase and or our ability to commercialize future businesses will be adversely affected.

Risks Related to Ownership of the ADSs

We are no longer an “emerging growth company,” and as a result we are no longer able to take advantage of the reduced reporting requirements applicable to emerging growth companies, which may increase our costs.

We ceased to be an “emerging growth company,” as defined in the U.S. Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), on December 31, 2025, the last day of the fiscal year following the fifth anniversary of the first sale of our common equity securities pursuant to an effective registration statement. As a result, we are no longer able to take advantage of the exemptions from reporting requirements that are available to emerging growth companies. In particular, we are no longer permitted to use the extended transition period for complying with new or revised financial accounting standards and are required to adopt such standards as of the effective dates applicable to public business entities. Beginning with the consolidated financial statements included in this annual report, we have adopted ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which we had previously elected to defer. Complying with these additional requirements will increase our legal, accounting and other compliance costs and may divert management’s attention from our business.

In addition, although we currently qualify as a non-accelerated filer and are therefore not required to include in our annual reports an attestation report of our independent registered public accounting firm on our internal control over financial reporting

20


Table of Contents

 

under Section 404(b) of the Sarbanes-Oxley Act of 2002, if we become an accelerated filer or a large accelerated filer in the future, we will be required to include such an attestation report. Given the material weaknesses we have identified, our independent registered public accounting firm may be unable to issue an unqualified attestation report, and compliance with this requirement would significantly increase our costs.

As a “foreign private issuer” we are permitted, and intend to continue, to follow certain home country corporate governance and other practices instead of otherwise applicable SEC and NASDAQ requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.

Our status as a foreign private issuer exempts us from compliance with certain SEC laws and regulations and certain regulations of The Nasdaq Capital Market (which we refer to as “NASDAQ”), including certain governance requirements such as independent director oversight of the nomination of directors and executive compensation. Further, consistent with corporate governance practices in Japan, we do not have a standalone compensation committee or nomination and corporate governance committee under our board. In addition, we are not required under the Exchange Act to file current reports and financial statements with the U.S. Securities and Exchange Commission (which we refer to as the “SEC”) as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act, and we are generally exempt from filing quarterly reports with the SEC. Also, we are not required to provide the same executive compensation disclosures regarding the annual compensation of our five most highly compensated senior executives on an individual basis as are required of U.S. domestic issuers. As a foreign private issuer, we are permitted to disclose executive compensation on an aggregate basis and need not supply a Compensation Discussion & Analysis, as is required for domestic companies. Furthermore, as a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These exemptions and accommodations will reduce the frequency and scope of information and protections to which you are entitled as an investor.

We do not satisfy certain Nasdaq continued listing requirements, and additional requirements may become operative in the future. Failure to regain or maintain compliance could result in suspension of trading and delisting of our ADSs.

Our ADSs are listed on the Nasdaq Capital Market, and their continued listing depends on our compliance with applicable Nasdaq financial, trading, and other requirements, subject to available exemptions. We have received notices of noncompliance with Nasdaq’s minimum bid price and periodic reporting requirements, and could receive additional deficiency notices in the future. These deficiencies create a risk that our ADSs may be suspended from trading or delisted.

On October 6, 2026, we received a written notification from Nasdaq stating that we were not in compliance with the minimum bid price requirement of $1.00 per ADS under Nasdaq Listing Rule 5550(a)(2), based on the closing bid price of our ADSs for the 31 consecutive business days from August 24, 2026 through October 5, 2026. Nasdaq provided us with an initial compliance period of 180 calendar days, or until April 5, 2027, to regain compliance. To regain compliance, the closing bid price of our ADSs must be at least $1.00 for a minimum of ten consecutive business days, subject to Nasdaq’s authority to require a longer period. Any additional compliance period would be subject to applicable eligibility requirements and should not be assumed to be available. We previously received a minimum bid price deficiency notice in February 2025 and regained compliance in June 2025, but that prior recovery did not prevent the subsequent deficiency. We cannot assure you that we will regain compliance within the prescribed period or maintain compliance thereafter.

Separately, on May 26, 2026, we received a notice from Nasdaq stating that we were not in compliance with Nasdaq Listing Rule 5250(c)(1) because we had not timely filed this annual report. Nasdaq granted us an extension until November 12, 2026 to regain compliance. According to Nasdaq’s extension letter, in the event the Company does not satisfy the terms, Staff will provide written notification that its securities will be delisted. On November 13, 2026, we received a determination notification from Nasdaq because we had not filed this annual report within the extension period granted by Nasdaq and therefore remained noncompliant with Nasdaq Listing Rule 5250(c)(1). On November, 18, 2026, we timely requested a hearing before a Nasdaq Hearings Panel to appeal the determination and request an extended stay of any trading suspension pending the hearing. However, a timely hearing request will automatically stay the suspension for only 15 days from the date of the request, and there can be no assurance that the Panel will grant an extended stay or relief from delisting, that Nasdaq will determine that the filing of this annual report resolves our periodic reporting deficiency, or that we will regain or maintain compliance with all applicable Nasdaq continued listing requirements.

Nasdaq has also adopted an additional continued listing requirement that, if it becomes operative in its approved form, would require companies listed on the Nasdaq Capital Market to maintain a market value of listed securities of at least $5 million under new Nasdaq Listing Rule 5550(a)(6). The SEC’s Division of Trading and Markets approved the rule change under delegated authority on July 22, 2026, but that approval was stayed on July 29, 2026. On September 11, 2026, the SEC granted petitions for review and continued the stay pending further order. As of the date of this annual report, the requirement remains stayed and is not operative. Under Nasdaq’s subsequent amendment addressing implementation, if the stay is terminated and the requirement becomes operative, the first business day counted toward determining noncompliance would be the business day immediately following termination of the stay; periods before or during the stay would not count.

21


Table of Contents

 

The new $5 million requirement would apply in addition to, rather than as an alternative to, the existing financial standards under Rule 5550(b). Consequently, satisfying the $2.5 million stockholders’ equity standard or the net income standard would not excuse failure to satisfy the additional $5 million market value requirement. If the requirement becomes operative in its approved form and our market value of listed securities remains below $5 million for 30 consecutive business days, Nasdaq could issue a Staff Delisting Determination without providing the ordinary compliance period. Our ADSs could become immediately subject to suspension and delisting, and a request for a hearing would not automatically stay the trading suspension. The Nasdaq Hearings Panel’s ability to grant relief would be limited, including an exception of up to 180 days from the Staff Delisting Determination for us to demonstrate compliance with all applicable initial listing requirements, which are more demanding than the continued listing requirements.

Given our financial condition and the volatility and recent trading price of our ADSs, this additional requirement could materially increase our delisting risk if it becomes operative. Even if we resolve our existing deficiency, we may be unable to maintain the required market value for continued listing. Measures intended to address the minimum bid price requirement would not necessarily increase our aggregate market value or resolve our financial-standard deficiencies. We cannot predict whether or when the stay will be lifted, whether the SEC will affirm or modify the rule, or whether we would satisfy the requirement when it becomes operative.

If our ADSs are suspended or delisted, an active trading market may not develop or be maintained on another exchange or in the over-the-counter market. Trading liquidity could decline substantially, bid-ask spreads and price volatility could increase, and investors could have difficulty selling their ADSs or obtaining reliable price quotations. Delisting, suspension or the prospect of either could also generate negative publicity, reduce analyst coverage and investor interest, impair our ability to raise capital or use our securities in strategic transactions, and undermine confidence among customers, suppliers, business partners and employees. These consequences could materially adversely affect our business, financial condition and the market price of our ADSs.

We may be, and have in the past been, delayed in complying with our periodic reporting obligations under the Exchange Act.

We are subject to the periodic reporting obligations under the Exchange Act. In particular, as our fiscal year ends December 31 of each year, the prescribed due date for us to file our annual report on Form 20-F is, in principle, April 30 of each year. However, we have been delayed in filing our annual report in each of the last several fiscal years. We did not file our annual report for the fiscal year ended December 31, 2022 until May 30, 2023; for the fiscal year ended December 31, 2023 until June 18, 2024; and for the fiscal year ended December 31, 2024 until April 29, 2025. With respect to the fiscal year ended December 31, 2025, we filed a notification of late filing on Form 12b-25 on April 30, 2026 and did not file this annual report until November 18, 2026, in each case due to delays in completing the audit of our consolidated financial statements. While we have taken steps to improve our internal control over financial reporting, material weaknesses in such internal controls remain, and we may be delayed in complying with our periodic reporting obligations in the future. See “—We have identified material weaknesses in our internal control over financial reporting. If we fail to maintain an effective system of internal control to remediate our material weaknesses and establish and maintain effective internal control over financial reporting, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud.”

Further, any failure by us to comply with our SEC reporting obligations in the future may materially and adversely affect investors’ investment in the ADSs. For instance, in the event that we fail to timely file any periodic reports or current reports, investors in the ADSs may not receive up-to-date disclosure of matters affecting their investment decisions, and the ADSs may be considered riskier than those of other issuers as a result. Additionally, under Nasdaq Listing Rule 5250(c)(1), a foreign private issuer listed on Nasdaq is required to timely file all required periodic financial reports with the SEC, and noncompliance creates a risk that the ADSs could be delisted. In the event that the ADSs are delisted from Nasdaq, the value and liquidity of investors’ investment in the ADSs would be materially and adversely affected. See also “—We do not satisfy certain Nasdaq continued listing requirements, and additional requirements may become operative in the future. Failure to regain or maintain compliance could result in suspension of trading and delisting of our ADSs.”

Our Chief Executive Officer owns a “golden share” with key veto rights, thereby limiting a shareholder’s ability to influence our business and affairs.

Kouji Eguchi, our Chief Executive Officer and director, is the sole holder of our Class A common share, which we refer to as a “golden share,” entitling him to certain veto rights on key matters presented to our shareholders. Consequently, Mr. Eguchi is able to control key corporate decisions, thus limiting the ability of the holders of the ADSs to influence matters affecting our Company. As a shareholder, Mr. Eguchi may be able to influence the outcome of matters submitted to shareholders for approval, including amendments of our organizational documents, issuance of additional common shares, approval of any merger, sale of assets, or other major corporate transactions. This may prevent or discourage unsolicited acquisition proposals or offers for our common shares or ADSs that you may feel are in your best interest as one of our shareholders. Circumstances may occur in which the interests of our Chief Executive Officer could be in conflict with your interests or the interests of other shareholders. Accordingly, a shareholder’s ability to fully influence our business and affairs through voting its common shares may be limited.

22


Table of Contents

 

The requirements of being a U.S. public company may strain our resources and divert management’s attention.

As a public company with ADSs listed on NASDAQ, we incur significant legal, accounting, and other expenses that we did not incur as a private company. The reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Act, and the listing standards of NASDAQ as applicable to a foreign private issuer, which are different in some material respects from those required for a U.S. public company, impose various requirements on the corporate governance practices of public companies. Compliance with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly, and increase demand on our systems and resources, particularly now that we are no longer an “emerging growth company.” Further, these rules and regulations may make it more difficult and more expensive for us to obtain directors’ and officers’ liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage, which could make it more difficult for us to attract and retain qualified members of our board of directors.

Pursuant to Section 404 of the Sarbanes-Oxley Act, if we become an accelerated filer or a large accelerated filer, we will be required to furnish an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. When our independent registered public accounting firm is required to undertake an assessment of our internal control over financial reporting, the cost of complying with Section 404 of the Sarbanes-Oxley Act will significantly increase, and management’s attention may be diverted from other business concerns, which could adversely affect our business and results of operations. We may need to hire more employees in the future or engage outside consultants to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, which will further increase our cost and expense. In addition, enhanced legal and regulatory regimes and heightened standards relating to corporate governance and disclosure for public companies result in increased legal and financial compliance costs and make some activities more time-consuming.

As a result of disclosure of information in this annual report and in filings required of a public company, our business and financial condition is more visible as compared to a private company, which may increase the risk to us of threatened or actual litigation, including by competitors, shareholders or third parties. If such claims are successful, our business and operating results could be harmed, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm our business, financial condition and results of operations.

We have identified material weaknesses in our internal control over financial reporting. If we fail to maintain an effective system of internal control to remediate our material weaknesses and establish and maintain effective internal control over financial reporting, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud.

In connection with the preparation of our financial statements for the fiscal year ended December 31, 2025, we identified several material weaknesses and other control deficiencies including significant deficiencies in our internal control over financial reporting. As defined in the standards established by the Public Company Accounting Oversight Board of the United States, or PCAOB, a “material weakness” is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. Management concluded that our internal control over financial reporting was not effective as of December 31, 2025 because of the material weaknesses described below. These material weaknesses had not been remediated as of that date.

•
Insufficiency of effective processes to ensure that all journal entries were properly reviewed and approved prior to posting to the general ledger;
•
Insufficient management review controls over key financial information including lack of evidence of review and approval of financial information;
•
Our user access controls, including provisioning, de-provisioning, and periodic reviews, were not operating effectively, resulting in insufficient segregation of duties and inappropriate access to financially relevant systems and data;
•
Ineffective internal controls over complex or non-routine accounting transactions, due to reliance on limited personnel and insufficient technical expertise, resulted in a material weakness affecting the consistent and timely application of U.S. GAAP; and
•
Insufficient controls over management’s assessment of our ability to continue as a going concern, including the preparation and review of the underlying cash flow forecasts and of the evidence supporting management’s plans, creating a reasonable possibility that a material misstatement in our going-concern assessment or related disclosures would not be prevented or detected on a timely basis.

During the year ended December 31, 2025, we took some additional steps and have continued to implement measures to remediate the material weaknesses identified, including but not limited to, (i) utilization of the systems, (ii) streamlining of business processes, (iii) improving the capacity of the financial closing team through internal personnel assignments and support

23


Table of Contents

 

from external professionals, and (iv) performing user access controls, including provisioning, deprovisioning and periodic reviews. Our ability to implement these measures was, however, constrained. In order to protect group profitability, we did not expand our financial closing team through new or mid-career hiring and instead staffed it by transferring personnel from other departments. Because those personnel have limited accounting experience, their training has required a significant amount of time, and the departure during the year of three employees with accounting experience increased the training required. In addition, the accounting system that we had originally selected did not fit our business, and we therefore changed to the implementation of a different accounting system, which delayed its introduction. The replacement of the workflow system associated with our accounting system was completed in the second half of 2025. We have also begun to introduce additional accounting tools in order to improve the efficiency of our collection and analysis of information and of the preparation of our financial statements.

The material weaknesses described above had not been remediated as of December 31, 2025. We cannot assure you that our remediation measures will be effective or completed in a timely manner, or that additional material weaknesses will not be identified. Remediation requires management attention, appropriate personnel, financial resources and sufficient time to establish and evaluate the operation of the relevant controls.

Section 404 of the Sarbanes-Oxley Act (which we refer to as “Section 404”), requires that as a U.S. public company, we assess the effectiveness of our internal control over financial reporting at the end of each fiscal year. In addition, if we become an accelerated filer or a large accelerated filer, our independent registered public accounting firm will be required to attest to and report on the effectiveness of our internal control over financial reporting. In the event this becomes required, our independent registered public accounting firm, after conducting its own independent testing, our independent auditor would be required to express an adverse opinion on our internal control over financial reporting. In addition, our reporting obligations may place a significant strain on our management, operational and financial resources and systems for the foreseeable future. We may be unable to timely complete our evaluation testing and any required remediation.

We did not timely file this annual report, and we cannot assure you that deficiencies in our financial reporting process will not contribute to further reporting delays. If we fail to remediate our material weaknesses and establish and maintain effective internal control over financial reporting, we may be unable to prepare accurate financial statements or meet our reporting obligations. We could be required to restate previously issued financial statements and could face an increased risk of fraud or misuse of corporate assets. These consequences could undermine investor confidence in our financial reporting, restrict our access to financing and adversely affect the trading price of our ADSs. Any resulting failure to comply with applicable securities laws or Nasdaq listing requirements could also expose us to regulatory investigations, enforcement proceedings, litigation or delisting. See “Item 15. Controls and Procedures.”

An active and liquid trading market for our ADSs may not be sustained, which could adversely affect investors’ ability to sell their ADSs and our ability to raise capital.

Our ADSs are currently listed on The Nasdaq Capital Market under the symbol “MRM.” However, continued listing does not assure that an active and liquid trading market will be sustained. If trading liquidity declines, holders may have difficulty selling their ADSs when desired, in the quantities desired or at an acceptable price, or may be unable to sell them at all.

Suspension of trading or delisting from Nasdaq could further reduce liquidity and adversely affect the trading price of our ADSs. See “—We do not satisfy certain Nasdaq continued listing requirements, and additional requirements may become operative in the future. Failure to regain or maintain compliance could result in suspension of trading and delisting of our ADSs.” If our ADSs are delisted from Nasdaq and do not qualify for another exclusion from the definition of “penny stock,” transactions in our ADSs could become subject to additional broker-dealer disclosure and sales-practice requirements. These requirements could discourage broker-dealers from recommending or effecting transactions in our ADSs and further reduce their liquidity.

Reduced liquidity and a lower trading price could also impair our ability to raise capital through equity or equity-linked financing and reduce the value of equity-based compensation as a means of attracting, retaining and motivating employees.

The price of the ADSs may fluctuate substantially.

The stock market in general, and the price for the ADSs are subject to fluctuation, and changes in the price of our ADSs may be unrelated to our operating performance. Some factors that may cause the market price of the ADSs to fluctuate, in addition to the other risks mentioned in this section of the annual report, are:

•
any failure to meet or exceed revenue and financial projections we provide to the public;
•
actual or anticipated variations in our half-yearly financial condition and operating results or those of other companies in our industry;
•
our failure to meet or exceed the estimates and projections of the investment community;
•
announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;

24


Table of Contents

 

•
additions or departures of our key management personnel;
•
issuances by us of debt or equity securities;
•
litigation involving our Company, including shareholder litigation; investigations or audits by regulators into the operations of our Company; or proceedings initiated by our competitors, franchisees, or customers;
•
changes in the market valuations of similar companies;
•
ADS price and volume fluctuations attributable to inconsistent trading volume levels of the ADSs;
•
significant sales of the ADSs or common shares by our insiders or our shareholders in the future;
•
the trading volume of the ADSs in the United States; and
•
general economic and market conditions.

These and other market and industry factors may cause the market price and demand for the ADSs to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the liquidity of the ADSs. Future market fluctuations may also materially adversely affect the market price of the ADSs.

In the past, following periods of volatility in the market price of a company’s securities, shareholders have often instituted securities class action litigation against that company. Any such class action suit or other securities litigation would divert the attention of our senior management, require us to incur significant expense and, whether or not adversely determined, could materially adversely affect our business, financial condition, results of operations and prospects.

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the price of the ADSs and trading volume could decline.

The trading market for the ADSs depends in part on the research and reports that securities or industry analysts publish about us or our business. If few or no securities or industry analysts cover us, the trading price for the ADSs would be negatively impacted. If one or more of the analysts who covers us downgrades the ADSs, publishes incorrect or unfavorable research about our business, ceases coverage of our Company, or fails to publish reports on us regularly, demand for the ADSs could decrease, which could cause the price of the ADSs or trading volume to decline.

We do not currently intend to pay dividends on our common shares for the foreseeable future.

We currently do not intend to pay any dividends to holders of our common shares for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Any determination to pay dividends in the future will be at the discretion of our board of directors and subject to limitations under applicable law. Therefore, you are not likely to receive any dividends on your ADSs for the foreseeable future, and the success of an investment in the ADSs will depend upon any future appreciation in its value. Moreover, any ability to pay may be restricted by the terms of any future credit agreement or any future debt or preferred equity securities of us or our subsidiaries. Consequently, investors may need to sell all or part of their holdings of our common shares after price appreciation, which may never occur, as the only way to realize any future gains on their investment. There is no guarantee that the ADSs will appreciate in valueor even maintain the price at which our shareholders have purchased the ADSs.

Sales of a substantial number of our common shares or ADSs in the public markets by our existing shareholders in the future could cause the price of the ADSs to fall.

Sales of a substantial number of our common shares or ADSs in the public market in the future or the perception that these sales might occur, could depress the market price of the ADSs and could impair our ability to raise capital through the sale of additional equity securities from time to time. We are unable to predict the effect that any such sales may have on the prevailing market price of the ADSs.

The future issuance of additional common shares in connection with our stock option plan, convertible bonds, acquisitions or otherwise may adversely affect the market of the ADSs.

As of December 31, 2025, there were an aggregate of 736,500 of our common shares issuable upon exercise of outstanding stock options, at a weighted average exercise price of JPY794 (US$5.06) per share. If and when more options are exercised for our common shares, the number of common shares outstanding will increase. Such an increase in our outstanding securities, and any sales of such shares, could have a material adverse effect on the market for the ADSs, and the market price of the ADSs.

On March 8, 2024, our board of directors adopted the MEDIROM Healthcare Technologies Inc. 2024 Equity Incentive Compensation Plan (the “2024 Equity Incentive Plan”), which was approved at our annual meeting of the shareholders held on

25


Table of Contents

 

March 29, 2024. Under the 2024 Equity Incentive Plan, we may grant stock options, stock appreciation rights, restricted stock, restricted stock units and performance share awards to our Company’s directors, internal corporate auditors, officers, employees and consultants. A total of 497,500 shares of common stock are authorized for issuance under the 2024 Equity Incentive Plan. We currently plan to continue granting stock options and other incentives so that we can continue to secure talented personnel in the future. We may issue all of these common shares without any further action or approval by our shareholders, subject to certain exceptions. Any common shares, issued in connection with our stock option plan, the exercise of outstanding stock options, or otherwise, would dilute your ownership interest. During the fiscal year ended December 31, 2025, 377,000 options were granted under the 2024 Equity Incentive Plan.

In addition, we have used in the past, and may in the future use, convertible bonds in our financing activities. For example, on December 12, 2025, we issued our Third Unsecured Convertible-Type Corporate Bonds with Share Options in the aggregate principal amount of JPY400,000 thousand (US$2,551 thousand) to 11 investors. These bonds are unsecured, accrue interest at a rate of 2.0% per annum and are convertible into 1,166,175 of our common shares at a conversion price of JPY343 (US$2.19) per share. The maturity date of the bonds, originally June 30, 2026, has been extended to December 25, 2026 pursuant to our option under the terms of the bonds, and the conversion period has accordingly been extended to December 7, 2026. As of September 30, 2026, none of these bonds had been converted into our common shares. If these bonds are converted in full, the number of our common shares outstanding would increase significantly, which would dilute the ownership interest of our existing shareholders and holders of ADSs and could adversely affect the market price of the ADSs. See “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources.”

We may also issue stock to provide consideration in connection with future acquisitions or other corporate transactions. The conversion of any convertible bonds into our capital stock, or the issuance of our capital stock in connection with corporate transactions, would dilute your ownership interest.

The right of holders of ADSs to participate in any future rights offerings may be limited, especially with respect to offerings other than distributions of cash, which may cause dilution to their holdings and holders of ADSs may not receive cash dividends if it is impractical to make them available to them.

We may, from time to time, distribute rights to our shareholders, including rights to acquire our securities. However, we cannot make any such rights available to the ADS holders in the United States unless we register such rights and the securities to which such rights relate under the Securities Act or an exemption from the registration requirements is available. In addition, the deposit agreement provides that the depositary bank will not make rights available to ADS holders unless the distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act.

The depositary has agreed to pay ADS holders the cash dividends or other distributions it or the custodian receives on our common shares or other deposited securities after deducting its fees and expenses. However, because of these deductions, ADS holders may receive less, on a per share basis with respect to their ADSs than they would if they owned the number of shares or other deposited securities directly. ADSs holders will receive these distributions in proportion to the number of common shares the ADSs represent. In addition, the depositary may, at its discretion, decide that it is not lawful or practical to make a distribution available to any holders of ADSs. For example, the depositary may determine that it is not practicable to distribute certain property through the mail, or that the value of certain distributions may be less than the cost of mailing them. In these cases, the depositary may decide not to distribute such property and ADS holders will not receive such distribution.

Holders of ADSs may be subject to limitations on transfer of their ADSs.

ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason.

We may amend the deposit agreement without consent from holders of ADSs and, if such holders disagree with our amendments, their choices will be limited to selling the ADSs or withdrawing the underlying common shares.

We may agree with the depositary to amend the deposit agreement without consent from holders of ADSs. If an amendment increases fees to be charged to ADS holders or prejudices a material right of ADS holders, it will not become effective until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, ADS holders are considered, by continuing to hold their ADSs, to have agreed to the amendment and to be bound by the amended deposit agreement. If holders of ADSs do not agree with an amendment to the deposit agreement, their choices will be limited to selling

26


Table of Contents

 

the ADSs or cancelling the ADSs and withdrawing the underlying common shares. No assurance can be given that a sale of ADSs could be made at a price satisfactory to the holder in such circumstances.

Holders of ADSs may not receive distributions on our common shares or any value for them if it is illegal or impractical to make them available to such holders.

The depositary of ADSs has agreed to pay holders of ADSs the cash dividends or other distributions it or the custodian for the ADSs receives on common shares or other deposited securities after deducting its fees and expenses. Holders of ADSs will receive these distributions in proportion to the number of our common shares that such ADSs represent. However, the depositary is not responsible for making such payments or distributions if it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act, but that are not properly registered or distributed pursuant to an applicable exemption from registration. The depositary is not responsible for making a distribution available to any holders of ADSs if any government approval or registration required for such distribution cannot be obtained after reasonable efforts made by the depositary. We have no obligation to take any other action to permit distributions on our common shares to holders of ADSs. This means that holders of ADSs may not receive the distributions we make on our common shares if it is illegal or impractical to make them available to such holders. These restrictions may materially reduce the value of the ADSs.

ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action.

The deposit agreement governing the ADSs representing our common shares provides that, to the fullest extent permitted by law, ADS holders waive the right to a jury trial for any claim they may have against us or the depositary arising out of or relating to our common shares, the ADSs or the deposit agreement, which may include any claim under the U.S. federal securities laws.

If we or the depositary were to oppose a jury trial based on this waiver, the court would have to determine whether the waiver was enforceable based on the facts and circumstances of the case in accordance with applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, or by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this would be the case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before investing in the ADSs.

If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us or the depositary. If a lawsuit is brought against us or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have, including outcomes that could be less favorable to the plaintiff(s) in any such action. Nevertheless, if this jury trial waiver is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit agreement or the ADSs serves as a waiver by any holder or beneficial owner of ADSs (including purchasers of the ADSs in the secondary market) or by us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder.

Risks Related to Japan

We are incorporated in Japan, and it may be more difficult to enforce judgments against us that are obtained in courts outside of Japan.

We are incorporated in Japan as a joint stock corporation (kabushiki kaisha) with limited liability. All of our directors are non-U.S. residents, and a substantial portion of our assets and the personal assets of our directors are located outside the United States. As a result, when compared to a U.S. company, it may be more difficult for investors to effect service of process upon us in the United States, or to enforce against us, or our directors or executive officers, judgments obtained in U.S. courts predicated upon civil liability provisions of U.S. federal or state securities laws or similar judgments obtained in other courts outside of Japan. There is doubt as to the enforceability in Japanese courts, in original actions or in actions for enforcement of judgments of U.S. courts, of civil liabilities predicated solely upon U.S. federal and state securities laws.

Substantially all of our revenues are generated in Japan, but an increase of our international presence could expose us to fluctuations in foreign currency exchange rates, or a change in monetary policy may harm our financial results.

27


Table of Contents

 

Our functional currency and reporting currency is the Japanese yen. Substantially all of our revenues are generated in Japan, but an increase in our international presence could expose us to fluctuations in foreign currency exchange rates. We are subject to the effects of exchange rate fluctuations with respect to any of these currencies which, among other factors, may be influenced by governmental policies and domestic and international economic and political developments. If our non-Japanese revenues increase substantially in the future, any significant change in the value of the currencies of the countries in which we do business against the Japanese yen could adversely affect our financial condition and results of operations due to translational and transactional differences in exchange rates.

We cannot predict the effects of exchange rate fluctuations upon our future operating results because of the number of currencies involved, the amount of our revenues that will be generated in other countries, the variability of currency exposures, and the potential volatility of currency exchange rates. We do not take actions to manage our foreign currency exposure, such as entering into hedging transactions.

We have business relationships with enterprises and professionals located outside of Japan and we may make payment to such parties in foreign currency, which exposes us to market risk associated with exchange rate movements of the Japanese yen against the U.S. dollar and other foreign currencies.

Our Japanese yen expenses consist principally of compensation, subcontractor expenses, and rent. While many of our business partners are Japanese domestic enterprises, we also have relationships with foreign enterprises and professionals to which our expenses may be paid in foreign currency. If our business expands overseas in the future, our foreign currency exposure would give rise to more market risk associated with exchange rate movements of the Japanese yen mainly against the U.S. dollar, because most of our revenues are denominated in Japanese yen, while any such expansion outside Japan would cause us to incur more expenses in foreign currencies. Going forward, we anticipate that a certain portion of our expenses will continue to be denominated in foreign currencies. If such expansion efforts outside Japan are successful, however, a substantial amount of revenue could also be denominated in foreign currencies, particularly if we are able to develop and expand sales of MOTHER Bracelet® to markets outside Japan in the future. Our financial position, results of operations and cash flow are subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in such exchange rates.

To date, we have not engaged in hedging our foreign currency exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us from the adverse effects of such fluctuations.

Rights of shareholders under Japanese law may be different from rights of shareholders in other jurisdictions.

Our articles of incorporation and the Companies Act of Japan (which we refer to as the “Companies Act”) govern our corporate affairs. Legal principles relating to matters such as the validity of corporate procedures, directors’ fiduciary duties and obligations, and shareholders’ rights under Japanese law may be different from, or less clearly defined than, those that would apply to a company incorporated in any other jurisdiction. Shareholders’ rights under Japanese law may not be as extensive as shareholders’ rights under the laws of other countries. For example, under the Companies Act, only holders of 3% or more of our total voting rights or our outstanding shares are entitled to examine our accounting books and records. Furthermore, there is a degree of uncertainty as to what duties the directors of a Japanese joint stock corporation may have in response to an unsolicited takeover bid, and such uncertainty may be more pronounced than that in other jurisdictions.

Holders of ADSs have fewer rights than shareholders under Japanese law, and their voting rights are limited by the terms of the deposit agreement.

The rights of shareholders under Japanese law to take actions, including with respect to voting their shares, receiving dividends and distributions, bringing derivative actions, examining our accounting books and records, and exercising appraisal rights, are available only to shareholders of record. Because the depositary, through its custodian agents, is the record holder of our common shares underlying the ADSs, only the depositary can exercise those rights in connection with the deposited common shares. ADS holders will not be able to bring a derivative action, examine our accounting books and records, or exercise appraisal rights through the depositary.

Holders of ADSs may exercise their voting rights only in accordance with the provisions of the deposit agreement. Upon receipt of voting instructions from the ADS holders in the manner set forth in the deposit agreement, the depositary will make efforts to vote the common shares underlying the ADSs in accordance with the instructions of the ADS holders. The depositary and its agents may not be able to send voting instructions to ADS holders or carry out their voting instructions in a timely manner. Furthermore, the depositary and its agents will not be responsible for any failure to carry out any instructions to vote, for the manner in which any vote is cast, or for the effect of any such vote. As a result, holders of ADSs may not be able to exercise their right to vote.

Under the deposit agreement, if you do not vote, the depositary may give us a discretionary proxy to vote the common shares underlying the ADSs at shareholders’ meetings if we have timely provided the depositary with notice of the meeting and related voting materials and (i) we have instructed the depositary that we wish a discretionary proxy to be given, (ii) we have informed the depositary that there is no substantial opposition as to a matter to be voted on at the meeting, and (iii) a matter to be

28


Table of Contents

 

voted on at the meeting would not have a material adverse impact on shareholders. The effect of this discretionary proxy is that you cannot prevent the underlying common shares represented by the ADSs from being voted, except under the circumstances described above. This may make it more difficult for ADS holders to influence the management of the company. Holders of common shares are not subject to this discretionary proxy.

Direct acquisition of our common shares, in lieu of ADSs, is subject to a prior filing requirement under recent amendments to the Japanese Foreign Exchange and Foreign Trade Act and related regulations.

Under recent amendments in 2019 to the Japanese Foreign Exchange and Foreign Trade Act and related regulations (which we refer to as “FEFTA”), direct acquisition of our common shares, in lieu of ADSs, by a Foreign Investor (as defined herein under “Memorandum and Articles of Association—Exchange Controls”) could be subject to the prior filing requirement under FEFTA. A Foreign Investor wishing to acquire direct ownership of our common shares, rather than ADSs, will be required to make a prior filing with the relevant governmental authorities through the Bank of Japan and wait until clearance for the acquisition is granted by the applicable governmental authorities, which approval may take up to 30 days and could be subject to further extension.

A prior filing requirement as set forth above is not triggered for acquiring or trading the ADSs because the depositary received clearance for the acquisition of our common shares underlying the ADS. Without such clearance, the Foreign Investor will not be permitted to acquire our common shares directly. As such, prior to accepting our common shares for deposit, the depositary obtained such pre-clearance from the applicable Japanese governmental authority. In addition, any Foreign Investor expecting to receive delivery of our common shares upon surrender of ADSs must also obtain pre-clearance from the applicable Japanese governmental authority prior to accepting delivery, which approval may take up to 30 days and could be subject to further extension. Although such prior filing requirement is not triggered for trading the ADSs once the depositary receives clearance for the deposit of the underlying common shares, we cannot assure you that there will not be delays for additional Foreign Investors who wish to acquire our common shares or for holders of the ADSs who are Foreign Investors and who wish to surrender their ADSs and acquire the underlying common shares. In addition, we cannot assure you that the applicable Japanese governmental authorities will grant such clearance in a timely manner or at all.

Dividend payments and the amount you may realize upon a sale of ADSs that you hold will be affected by fluctuations in the exchange rate between the U.S. dollar and the Japanese yen.

Cash dividends, if any, in respect of our common shares represented by the ADSs will be paid to the depositary in Japanese yen and then converted by the depositary into U.S. dollars, subject to certain conditions. Accordingly, fluctuations in the exchange rate between the Japanese yen and the U.S. dollar will affect, among other things, the amounts a holder of ADSs will receive from the depositary in respect of dividends, the U.S. dollar value of the proceeds that a holder of ADSs would receive upon sale in Japan of our common shares obtained upon surrender of ADSs, and the secondary market price of ADSs. Such fluctuations will also affect the U.S. dollar value of dividends and sales proceeds received by holders of common shares.

General Risk Factors

Third party claims with respect to intellectual property assets, if decided against us, may result in competing uses or require adoption of new, non-infringing intellectual property, which may in turn adversely affect sales and revenues.

There can be no assurance that third parties will not assert infringement or misappropriation claims against us, or assert claims that our rights in our trademarks, patents and other intellectual property assets are invalid or unenforceable. Any such claims could have a material adverse effect on us or our franchisees if such claims were to be decided against us. If our rights in any intellectual property were invalidated or deemed unenforceable, it could permit competing uses of intellectual property which, in turn, could lead to a decline in relaxation salon, Digital Preventative Healthcare business, and other revenues. If the intellectual property became subject to third party infringement, misappropriation or other claims, and such claims were decided against us, we may be forced to pay damages, be required to develop or adopt non-infringing intellectual property or be obligated to acquire a license to the intellectual property that is the subject of the asserted claim. There could be significant expenses associated with the defense of any infringement, misappropriation, or other third-party claims.

Changes in regulatory requirements, or in application of current regulatory requirements, may have an adverse effect on our business and results of operations.

Relaxation salons such as ours are not currently regulated by the Japanese government. The main law in Japan governing the massage industry is the Act on Practitioners of Massage, Acupressure, Acupuncture and Moxibustion, and etc. (Act No. 217 of 1947) (which we refer to as the “Massage Act”). However, our Company does not market or provide massage, acupressure, acupuncture, moxibustion or other services regulated under the Massage Act, and this information is clearly provided to all customers prior to receiving our services, as well as all franchisees to prevent unauthorized services. Moreover, all of our customers are required to sign a waiver acknowledging this prior to receiving our services. Nevertheless, the Japanese government could later include our industry within the meaning of the Massage Act, or enact a separate law to regulate our industry. If such an occurrence were to happen, our costs associated with licensing and training staff, as well as any additional wages required for hiring licensed staff, as necessary, could add to our expenses and harm our results of operation.

29


Table of Contents

 

Matters relating to employment and labor law may adversely affect our business.

Various Japanese labor laws govern our relationships with our employees and affect operating costs. These laws include employment classifications of employee, independent contractor, or contract worker; minimum wage requirements; employer contributions to social security, unemployment insurance, and workers’ accident compensation insurance, and other wage and benefit requirements. Significant additional government regulations and new laws, including mandating increases in minimum wages, changes in employment status requirements, or other labor law changes could materially affect our business, financial condition, operating results or cash flow. Additionally, if our or our franchisees’ employees unionize, it could materially affect our business, financial condition, operating results or cash flow.

We are also subject in the ordinary course of business to employee claims against us based, among other things, on discrimination, harassment, wrongful termination, or violation of labor laws. Such claims could also be asserted against us by employees of our franchisees. These claims may divert our financial and management resources that would otherwise be used to benefit our operations. The ongoing expense of any resulting lawsuits, and any substantial settlement payment or damage award against us, could adversely affect our business, brand image, employee recruitment, financial condition, operating results or cash flows.

ITEM 4. INFORMATION ON THE COMPANY

A.
History and Development of the Company

Our Company was originally incorporated in Japan on July 13, 2000 under the name “Kabushiki Kaisha Young Leaves.” In November 2001, we changed our name to “ReRaKu Inc.” and in January 2017, we changed our name to “MEDIROM Inc.” In March 2020, our Company’s English name was changed to “MEDIROM Healthcare Technologies Inc.” In December 2020, the Company listed its ADSs representing its common shares on The Nasdaq Capital Market. We are a joint-stock corporation incorporated in Japan under the Companies Act.

Our Company has developed our business both through organic development of our branded relaxation salons (primarily Re.Ra.Ku salons) and through acquisitions. On April 17, 2018, we established Bell Epoc Wellness Inc. (which we refer to as “BEW”). On May 28, 2018, 46 relaxation salons with the brand name “Bell Epoc” were transferred from Kabushiki Kaisha Bell Epoc to BEW for cash. Pursuant to an operating agreement entered into in 2018, by and between Kabushiki Kaisha Bell Epoc and BEW, Kabushiki Kaisha Bell Epoc has continued to manage the relaxation salons and BEW pays operation fees to Kabushiki Kaisha Bell Epoc based on revenue.

On April 20, 2018, we formed JOYHANDS WELLNESS Inc. (which we refer to as “JW”) to acquire the relaxation business operated by Kabushiki Kaisha Joyhands. Kabushiki Kaisha Joyhands was party to a number of outsource agreements with various spa operators, whereby Kabushiki Kaisha Joyhands provided relaxation services to customers of spa facilities. JW began entering into assignment and novation agreements with such spa facility operators, under which JW was substituted for Kabushiki Kaisha Joyhands as the counterparty to the existing outsource agreements with the spa facility operators.

On April 27, 2018, we established Medirom Human Resources Inc. (which we refer to as “MHR”) under the trade name Re.Ra.Ku Wellness Inc. MHR operates our therapist dispatch business. Previously, we hired therapists pursuant to an exemption that allowed us to forego obtaining permission from the Ministry of Health, Labor and Welfare of Japan under the Act for Securing the Proper Operation of Worker Dispatching Undertakings and Improved Working Conditions for Dispatched Workers and dispatched such therapists to our franchisees. When the Ministry of Health, Labor and Welfare of Japan eliminated the exemption in September 2018, we created MHR and transferred the therapist dispatch business to it. We subsequently terminated our therapist dispatch business to franchisees and, as of the date of this annual report, MHR dispatches our therapists only to our directly-operated salons. On October 1, 2018, we acquired Decollte Wellness Corporation (which we refer to as “DW”) from Decollte Corporation for cash.

On May 6, 2021, we acquired SAWAN CO. LTD. (which we refer to as “SAWAN”) by purchasing a 100% ownership interest of SAWAN for cash. As a result, 13 “Ruam Ruam” salons, which is a luxury relaxation salon brand held by SAWAN, became part of our portfolio of directly-operated salons.

In July 2021, in order to speed up the decision-making process, improve business efficiency, and maximize business value, we reorganized and re-designated certain parts of our wholly-owned subsidiaries by business function. As part of the reorganization, DW merged with and into BEW with BEW being the surviving entity, and we transferred our Re.Ra.Ku salon business to BEW. As a result of the reorganization, BEW (currently known as Wing Inc.) now operates the salons previously owned by us and DW, and since July 1, 2021, it has been managing a majority of our relaxation salon operations, excluding those located in spa facilities or under the “Ruam Ruam” brand. In addition, we established Bell Epoc Power Partners Inc., which succeeded to the rights and obligations relating to the salon management entrusted division previously operated by BEW.

In November 2021, BEW changed its name to “Wing Inc.” and Bell Epoc Power Partner Inc. changed its name to “Bell & Joy Power Partners Inc.”

30


Table of Contents

 

On October 1, 2021, we acquired a 60% ownership interest in ZACC Kabushiki Kaisha (which we refer to as “ZACC”), a high-end hair salon company, and we acquired the remaining 40% interest in ZACC in January 2022. ZACC owns and operates four luxury hair salons under three brands (ZACC vie, ZACC raffine, and ZACC ginza), all of which have been recognized by customers for over 30 years for their high level of techniques and hospitality.

On May 31, 2023, our board of directors approved a second reorganization (the “Second Reorganization”), consisting of an incorporation-type company split plan and an absorption-type company split agreement. Under the incorporation-type company split plan, the Company transferred its Digital Preventative Healthcare business to MEDIROM MOTHER Labs Inc. (“MML”), a newly established subsidiary that we wholly owned at the time of establishment, which operates our entire Digital Preventative Healthcare business since the reorganization, and under the absorption-type company split agreement, the Company transferred its existing salon development department, which is responsible for sourcing and setting up store spaces, and general corporate departments, which include accounting, legal, general affairs, human resources, IT and other corporate functions, and had Bell & Joy Power Partners Inc., an existing wholly-owned subsidiary, assume such operations going forward. On the same day, Bell & Joy Power Partners Inc. was renamed Medirom Shared Services Inc. The Second Reorganization became effective on July 3, 2023.

On November 26, 2024, our board of directors approved an additional reorganization, which was completed on January 1, 2025. This reorganization consisted of (i) an absorption-type company split, pursuant to which Wing Inc. acquired the spa business of Joyhands Wellness Inc. and assumed such operations; and (ii) an absorption-type merger, pursuant to which Wing Inc. merged with Medirom Human Resources Inc., with Wing Inc. being the surviving entity and changing its name to “MEDIROM Wellness Co.” Through this reorganization, we aim to allocate our therapist resources among our salons more smoothly, reduce the headcount at our headquarters, and improve the efficiency of inter-company administrative matters.

As part of the consolidation of overlapping corporate functions under our restructuring plan, effective on November 1, 2026, our subsidiary, Medirom Shared Services Inc. merged into MEDIROM Wellness Co., with MEDIROM Wellness Co. as the surviving company. We do not expect the merger to have a material effect on our consolidated financial position or results of operations. See “Item 4. Information of the Company—Business Restructuring” for additional information.

As of December 31, 2023, the Company had entered into six share transfer agreements, pursuant to which we have agreed to sell and transfer an aggregate of 1,781 shares in MML, or approximately 3.56% of its total shares outstanding, to certain third-party investors. The purpose of our 2023 reorganization and the transfer of MML shares was to make quicker decisions and seek external equity financing of MML as a spun-off startup to accelerate its growth. In August 2024, MML entered into a binding agreement with the lead investor for its series A financing round, and in September and October of 2024, MML entered into agreements with additional investors participating in MML’s series A financing round. As a result, approximately 6.3% of MML’s shares were held by third-party investors as of December 31, 2025. See “Item 4. Information on the Company—Capital and Businesses Alliances of MEDIROM MOTHER Labs Inc.” We intend to maintain our status as the controlling shareholder of MML.

As of November 12, 2026, we had the following subsidiaries: MEDIROM Wellness Co., SAWAN CO. LTD., ZACC Kabushiki Kaisha, MEDIROM MOTHER Labs Inc., and MEDIROM Rehab Solutions Inc. The chart below illustrates our corporate structure as of November 12, 2026.

 

img205519096_0.jpg

31


Table of Contents

 

Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168. Our principal executive offices are located in 2-3-1 Daiba, Minato- ku, Tokyo 135-0091, Japan, and our main telephone number is +81(0)3-6721-7364. Our website is https://medirom.co.jp/en/. The information contained in, or that can be accessed through, our website is not incorporated by reference into, and is not a part of, this annual report. You should not consider any information on our website to be a part of this annual report. We have included our website address in this annual report solely for informational purposes.

The SEC maintains an internet site (http://www.sec.gov), which contains reports, information we are required to provide to our shareholders or otherwise make public under our home country laws, and other information regarding us that we file electronically with the SEC.

B.
Business Overview

We are one of the leading holistic health services providers in Japan. Medirom is a franchiser and operator of healthcare salons across Japan, an operator of luxury hair salons in select central Tokyo locations, a preferred platform partner for healthcare service providers and government entities to affect positive health outcomes, and a provider of healthcare technology platforms.

We operate three synergistic lines of businesses: (1) Relaxation Salon Segment; (2) Luxury Beauty Segment; and (3) Digital Preventative Healthcare Segment (HealthTech). By combining brand strength and core retail competencies, including a broad physical footprint in population dense areas across the country, with proprietary technologies and partnerships, our business provides unique, value-added healthcare services to our customers with scale, customization, and cross-network effects that we believe few other companies in the industry can emulate. As of December 31, 2025, all of our principal business activities were focused on Japan.

As of December 31, 2025, the Relaxation Salon Segment had 292 locations across Japan, located within the country’s major cities, primarily in the Tokyo metropolitan area. We utilize our proprietarily customized customer relationship management system to record customer data, facilitate reservations and point-of-sale and business intelligence functions at the 272 salons integrated into such system as of December 31, 2025. Our salons are generally located in metro stations/subways, shopping malls, plazas and high-traffic streets. The Relaxation Salon Segment is our core business and accounted for JPY7,052 million (US$45.0 million), or approximately 90.8% of our total revenue, for the year ended December 31, 2025 and JPY7,446 million (US$47.5 million), or approximately 89.7% of our total revenue, for the year ended December 31, 2024.

The Luxury Beauty Segment consists of ZACC, our high-end hair salon, which accounted for JPY542 million (US$3.5 million), or approximately 7.0% of our total revenue, for the year ended December 31, 2025 and JPY699 million (US$4.5 million), or approximately 8.4% of our total revenue, for the year ended December 31, 2024.

The Digital Preventative Healthcare Segment consists of a government-sponsored Specific Health Guidance program, utilizing our internally-developed on-demand health monitoring smartphone application, Lav®; our MOTHER Bracelet® for fitness and health applications; and preventative healthcare services utilizing our experienced nutritionists and health nurses. The Digital Preventative Healthcare Segment accounted for JPY168 million (US$1.1 million), or approximately 2.2% of our total revenue, for the year ended December 31, 2025 and JPY154 million (US$1.0 million), or approximately 1.9% of our total revenue, for the year ended December 31, 2024.

Consumers increasingly recognize the value of services in the relaxation sector after the COVID-19 pandemic. The relaxation sector continues to offer a service that we believe many consumers view as nearly non-discretionary. Bodily health, joint alignment, and therapeutic bodyworks impact the health and wellness of our customers and require physical contact—continuing to buoy our core relaxation salon business. We believe general interest among consumers in managing and maintaining personal health is also growing, especially with respect to balancing sleep, diet and exercise. With this growing interest in critical factors for health, we believe our services are viewed as a more necessary item of consumer spending that we expect will increase demand for our services given the strength of our brand.

Relaxation Salon Segment

Our goal is to improve our customers’ quality of life by providing alternative, non-invasive wellness care. We use therapeutic techniques encompassing finger-pressure style bodywork therapy, stretch therapy, posture and joint alignment, as well as physical therapy elements. Our salons are designed to appeal to individuals seeking to improve their mental and/or physical well-being. Our customers vary from individuals seeking stress and pain relief to other individuals who are just looking to improve their overall mental and physical health. Our relaxation salons provide a variety of individual services, including traditional Japanese massage therapy, anti-fatigue therapy, athletic support therapy, slim-down therapy and reflexology.

The Relaxation Salon Segment is the core of our business and consists of directly-operated salons (including salons which we have sold to third party investors who then outsource the management of such salons back to us) as well as franchised salons. Developing and selling salons to third-party purchasers, and operating those salons on their behalf under service agreements, is a

32


Table of Contents

 

recurring part of the business model of this segment and forms part of our ongoing major operations. Our salon locations cover major cities throughout Japan, with strong market presence in the Tokyo metropolitan area, which includes Tokyo, Kanagawa, Saitama and Chiba. According to the Survey on Basic Resident Registration System as of October 1, 2022, by the Ministry of Internal Affairs and Communications, the population (registered residents) of the Tokyo metropolitan area was estimated to be 36.9 million. According to the 2022 Yano Report, in terms of the number of salons, we are one of the top three companies, on a consolidated basis, in the Kanto region (Tokyo, Kanagawa, Saitama, Chiba, Gunma, Ibaraki and Tochigi), and in the top four nationwide.

Our salons operate under several brand names. Our core brand is Re.Ra.Ku®. Our salons are generally located in metro stations/subways, shopping malls, plazas and high-traffic streets. As of December 31, 2025, on average, our salons measure approximately 719 square feet (which excludes data from salons in spa facilities and salons where the franchisees have direct contracts with the landlords) and contain a reception area and treatment space. A typical salon under the Re.Ra.Ku® brand is staffed by six relaxation therapists. As of December 31, 2025, we had an average of 6.5 beds per salon, excluding salons located within spa facilities.

We have changed our strategy for our salon business from increasing the number of salons to improving the profitability of each salon. As of December 31, 2025, we had 292 salons in operation throughout Japan, of which 222 were directly-operated salons.

Our largest source of revenue derives from our directly-operated salons. Revenue from operating our directly-operated relaxation salons accounted for 65.1% of our consolidated revenue for the year ended December 31, 2025. Revenue from our franchise business consists of recurring franchise royalties, franchise membership fees, staffing services fees, sublease revenue and other franchise revenues and accounted for 8.2% of our consolidated revenue for the year ended December 31, 2025. We have sold, and plan to continue to sell, certain of our owned salons to investors and charge management fees to the owners of such salons. Our revenue from salon sales accounted for 17.6% of our consolidated revenue for the year ended December 31, 2025.

Our franchisees are expected to meet the same quality and customer service standards as our directly- operated locations. We select potential franchisees based on a set of strict qualification criteria which includes background checks, financial net worth assessment and personal interviews. We enter into a franchise agreement with each of our franchisees, stipulating a standard set of terms and conditions for operating the salons and each party’s duties and responsibilities.

 

img205519096_1.jpg

Customers

Our relaxation salons are designed to appeal to individuals seeking to improve their mental and/or physical well-being. Our customers include individuals who are health conscious and other individuals seeking stress and pain relief, therapeutic reflexology, or to improve their overall mental and physical health. The majority of our customers are employed females with disposable income, but our demographic mix varies by salon and geography. We benefit from and rely on the value and recognition of our Re.Ra.Ku® and other brands which drive word of mouth and direct referrals. Additionally, we utilize an omnichannel advertising strategy across print, affiliate referrals and digital marketing to reach out to and cultivate potential customers.

Services

Our relaxation salons offer a variety of individual services, each with multiple price ranges, including: anti-fatigue therapy; athletic support therapy; slim-down therapy; and reflexology. Anti-fatigue therapy is designed to relieve fatigue and discomfort, and concentrates on the shoulder blades, neck, lower back and posture. We suggest that first-time customers begin with anti-fatigue therapy because most new customers visit our salons with stiff muscles and are unable to do more difficult stretches. Anti-fatigue therapy helps enhance the customer’s stretching ability. Athletic support therapy is intended to provide quick gains in active and passive range of motion to help improve athletic performance and increase flexibility, by performing shoulder blade

33


Table of Contents

 

alignment adjustments and resistance exercise. Slim-down therapy focuses on pelvic and shoulder blade alignment and is intended to help dieting by moving the muscles near the pelvis, which normally get little exercise, thereby increasing metabolism and improving posture. Our reflexology therapy is designed to target specific pressure points and areas on the feet to promote relaxation, improve circulation and reduce pain. While most Re.Ra.Ku® locations offer these four therapies, some individual salons offer other select therapy methods, such as Thai traditional stretching. Pursuant to the terms of our standard franchise agreements, our approval is required for any changes to the services provided in franchised salons.

Our customers can arrive at our salons with or without appointments at times convenient to their schedule. Upon checking in, salon staff provides customers with a questionnaire that asks for their contact information and certain health information to help the therapist identify the service that is most appropriate for the customer and whether the customer is experiencing muscle pain or other health problems. Upon completion of the therapy, the therapist will meet with the customers to obtain feedback on the services provided.

Prepayment Systems and Loyalty Programs

In December 2008, we began issuing prepaid cards, called the Re.Ra.Ku® Card, to relaxation salon customers. Users of the Re.Ra.Ku® Card can continuously use the card at most of our Company’s relaxation salons. The customer receives rewards on a tiered basis, so the more the customer spends on the Re.Ra.Ku® Card, the greater the reward that can be used at Re.Ra.Ku® locations. Following the acquisition of SAWAN, we started issuing another line of prepaid cards called the Free Pass, which can be used at Ruam Ruam branded salons. In addition, in October 2024 we issued various prepaid tickets to customers who prefer paper-based tickets. These prepaid tickets include year-end “Thanksgiving Tickets” and “Value Tickets”, under which customers receive a small premium service credit above the price paid for such ticket and participation rights in a lottery for prizes, depending on marketing campaigns. As of December 31, 2025, customers’ aggregate prepaid balance on the Re.Ra.Ku® Cards, the Free Passes, the Thanksgiving Tickets, and the Value Tickets was JPY325,318 thousand (US$2,075 thousand).

In 2023, the Company decided to decrease our reliance on the Re.Ra.Ku® Card, and in February 2024 the Company introduced a new payment system by launching “Re.Ra.Ku PAY”, a proprietary payment app which works on customers’ smart phones. As of December 31, 2025, Re.Ra.Ku PAY had 18,522 unique users, of which 25.8% were active, which we define as those who have actually made payments using Re.Ra.Ku PAY during the month of December 2025. Customers can charge their balance at our salons or remotely with their credit cards. During the twelve months ended December 31, 2025, the cumulative amount charged by customers through Re.Ra.Ku PAY was JPY843,518 thousand (US$5,380 thousand). An important difference between the Re.Ra.Ku Card and Re.Ra.Ku PAY is that Re.Ra.Ku PAY balances have an expiration period of 150 days, while the Re.Ra.Ku Card balances do not have an expiration date. Moreover, rather than giving customers a certain percentage of points when they charge a certain amount of the card balance on the Re.Ra.Ku Card, we give customers using Re.Ra.Ku PAY a certain percentage of points when they pay with the app in accordance with each customer’s loyalty status, which is either “Bronze”, “Silver”, “Gold”, “Platinum”, or “Diamond”. We believe this approach contributes to more revenue generation by giving customers points at payment rather than at charging. As of December 31, 2025, the outstanding aggregate account balance of all users of Re.Ra.Ku PAY was JPY79,617 thousand (US$508 thousand).

The Company aims to utilize Re.Ra.Ku PAY for various marketing campaigns and to expand the scope of possible payments from only relaxation services at present to merchandise or other uses. We launched Re.Ra.Ku PAY on February 1, 2024, and disallowed further balance deposits on Re.Ra.Ku Cards beginning on the same date. As a result, Re.Ra.Ku Card users can pay with their current balances but cannot add to their balances. Except for limited circumstances, the prepaid balances on the Re.Ra.Ku® Card, the Free Passes, Re.Ra.Ku PAY, and prepaid cards are generally non-refundable. See “—Introduction of New Payment App ‘Re.Ra.Ku PAY’ and Prepaid Cards” for more details.

Market

Most of our relaxation salons are located in the Kanto region of Japan. Kanto is commonly considered the economic and political center of Japan, and includes cities such as Tokyo, Yokohama, and Saitama, among other large cities and prefectures. According to the Statistics Bureau of Japan, as of October 1, 2023, the population of Kanto was 43.5 million, which accounted for 35.0% of the total population of Japan (124.4 million). According to the 2022 Yano Report, which is the most recent report

34


Table of Contents

 

published by Yano on this topic, in terms of the number of salons, we are one of the top three companies, on a consolidated basis, in the Kanto region (Tokyo, Kanagawa, Saitama, Chiba, Gunma, Ibaraki and Tochigi) and in the top four nationwide.

 

img205519096_2.jpg

According to the 2022 Yano Report, growth of the Japanese relaxation sector is expected to continue to outpace overall GDP growth, which is expected to increase 1.72% from JPY114 billion (US$727 million) in 2022 to JPY120 billion (US$765 million) in 2025, while national GDP is expected to grow by 1.2% from 2022 to 2026, according to Daiwa Research Institute Economic Report (dated January 24, 2022).

 

img205519096_3.jpg

Source: 2022 Yano Report

We believe the sector continues to see outsized growth as consumers in an already health-conscious country increasingly value health and wellness of both body and mind. Concurrently, large companies, in partnership with or through subsidies received from the government, increasingly factor in employee wellness for both productivity and for retention, loyalty, and satisfaction with the employer. This has led to the creation of corporate budgets, often with government subsidies, earmarked for employee health and wellness programs, insurance programs, fitness and gym memberships which further increases spend in the market. While 51% of the market is occupied by mid to large chains like ours, most of the market consists of small, locally-owned salons, 68.9% of which are estimated to be individual-run single outlets, according to the 2022 Yano Report.

35


Table of Contents

 

M&A, Consolidation, and Industry Rationalizations

The relaxation sector in Japan faces structural changes that have accelerated mergers and acquisitions and consolidations. As smaller, private operators either fail to grow sufficient revenue to cover costs and owners of larger, established companies seek to exit for retirement or other reasons, an increasing number of sellers have attracted both industry players as well as financial sponsors. We believe the gating factors remain synergies between the acquirer and target, including a pragmatic approach to M&A integration, post- acquisition operations, and preservation of brand and customer base. Purchase price remains a more muted factor which affords compelling value-creation opportunities for the right strategic acquirer.

Our current priority is to improve the profitability of our existing salon network rather than to increase the number of salons. We have suspended, for the time being, new store openings, the development of additional franchises and growth through acquisitions, including any acquisition of similar businesses outside Japan.

 

img205519096_4.jpg

Recruiting and Training

As a complement to our salons, we also operate Re.Ra.Ku® College (which we refer to as the “College”).

The flagship College is located in the Odaiba area in Tokyo. The College offers continuing training for franchise owners, home office staff, and salon staff, covering topics such as customer service, salon operations, and relaxation techniques. The College also provides training for students who wish to become qualified as “Relaxation Therapists”, which is a private qualification granted by the Association of Japan Relaxation Industry, an industry group for relaxation services providers. In addition, franchise owners, salon managers and relaxation therapists engage in recurring monthly education at the College. We do not charge students any fees for the training provided at the College. However, upon completion of the initial training program, we assist students with obtaining employment at our franchised salons in exchange for a fixed monthly payment from the franchise owners. We also employ students at our directly-operated salons. The College enables us to implement and promote our corporate culture and mission and we believe it helps improve job satisfaction and employee retention.

 

img205519096_5.jpg

36


Table of Contents

 

To be admitted into the College, students must pass a qualification check and an interview. This initial qualification program consists of 41 courses that typically extend for a month. The curriculum used at the College teaches 133 skills to students via a combination of live training and online videos. Although there is no qualification requirement for a therapist in Japan, students have to pass this initial qualification program before working at our salons. Currently, our Company has College campuses in Tokyo, Nagoya and Osaka.

Seasonality

Our Relaxation Salon Segment experiences seasonal trends due primarily to changes in weather and in line with holiday schedules. Generally, our revenue is strongest from May to October. Sales tend to slow in November due to the shorter day length and lower temperatures in Japan, but then increase in December for the holiday season. Fewer operating days and cold weather lead to weaker sales figures in January and February. March and April are transition months before the high season. We typically carry out spring sales promotion in April to boost the sales in May.

Franchises

As of December 31, 2025, 70 of our 292 salons were operated by franchisees. We strive to ensure that each of our franchise locations meets the same quality and customer service standards as our directly-operated locations in order to preserve the consistency and reliability of our brand and maintain the trust of our customers.

We are committed to providing the tools that our franchisees need to succeed before, during and after a salon opening, including guidance with site selection and development, training, operations and marketing support. We have a franchisee support team that we use to help provide continuous assistance to franchisees. This support team is sent directly to meet with franchisees to help identify any areas that could be improved with regard to the franchisee’s business, and devise strategies to overcome such obstacles the franchisees may be facing.

We identify potential franchisees through a variety of methods, including word-of-mouth and referrals from existing franchise owners. We also employ qualification criteria in the selection of franchisees, including reviewing the candidates’ backgrounds and financial situations, conducting interviews and determining the candidates’ compatibility with our Company’s culture. Our franchise agreements set forth a high standard of conduct across all franchised locations. As such, our franchisees are curated to confirm with the high standards of quality, expertise, and customer centricity which form the core of our brand and culture. We provide our franchisees with ongoing training and advertising support. We continuously monitor the financial performance of each franchised location using customized software called Peak Manager.

Additionally, all of our franchisees join an organization, the “Franchisees’ Friendship Club”, that facilitates discussion among the franchisees regarding our Company’s business model and shared know-how. The Club also makes proposals to our Company regarding the franchise agreement, Company business and other matters related to the franchisor-franchisee relationship, to maximize mutual benefits. The Franchisees’ Friendship Club holds a meeting once per month. Apart from the Franchisees’ Friendship Club, our Company holds a “Franchise Owners Meeting” every quarter to share our Company’s salon business strategy, key performance indicators, and other matters of common interest. Our Chief Executive Officer attends meetings to interact directly with the franchisees.

Franchise Agreements

Our franchise model requires minimal capital expenditures by our Company while generating recurring revenue streams from franchise fees and salon sales. For each franchised salon, we enter into a franchise agreement stipulating a standard set of terms and conditions.

A franchise agreement allows an owner to open a single salon at a specific location. The initial term of a franchise agreement is five years from the salon’s opening date. Unless either party provides notice of nonrenewal by at least six (6) months prior to the franchise agreement’s expiration, the franchise term extends for an additional five-year period, and the same provision applies thereafter. Franchisees must pay an initial fee for our salons at the time the franchise agreement is signed. Franchisees that renew their franchises after the initial term must pay a renewal fee on a per salon basis. Under our standard franchise agreements, franchisees are also required to pay a monthly royalty fee. The royalty rates vary depending on the number of salons operated by a franchisee, ranging from 6-8% of the total revenue of the franchisee.

Our franchise agreements set forth certain material duties and responsibilities of the franchisees, including, but not limited to: (i) cooperating with our Company’s advertising initiatives prior to and after the opening of a salon; (ii) maintaining the design, layout and equipment of a salon as designated by our Company; (iii) undergoing periodic skills training in accordance with our policies; and (iv) complying with restrictions on transfer of the franchise. We provide our franchisees with license to use our registered trademarks, including CLP CARE LIFE PLANNER®, in connection with the operation of their franchised salons. We utilize this trademark in our franchise agreements to designate therapists who have completed a required technique training program. We retain the right to approve any change to a salon location, the service menu and the types of products sold at the

37


Table of Contents

 

salon other than those products supplied or purchased from us. Franchisees are subject to non-compete provisions during the term of the franchise agreement and for one year after termination thereof. Franchisees are responsible for hiring and compensating their own employees.

We have the right to terminate the franchise agreement for cause, including failure of the franchisees to pay our fees as set forth in the franchise agreement or failing to meet our established profitability metrics.

Either we or the franchisee may terminate the franchise agreement without cause upon six months’ prior written notice to the other party and prior consultation to attempt to resolve any disputes and prior consultation with the franchisees. The franchisee may be required to pay us a termination fee under certain circumstances. The franchise agreement may only be amended upon mutual consent of both parties in writing. In exceptional circumstances, we may temporarily waive our right to receive franchise royalties under a franchise agreement if we have agreed to temporarily take over the operations of a poorly performing franchised salon to turn around the salon’s performance.

Luxury Beauty Segment

Our Luxury Beauty Segment consists of the management and operation of high-end hair salon brands under ZACC. ZACC salons are located in Omote-sando and Ginza, which are fashion center areas in Tokyo. The Aoyama flagship salon located in Omote-sando has 443 square meters of store space and 44 seats. The Ginza salon has 81 square meters of store space and 10 seats.

ZACC operates three luxury hair salon brands, ZACC vie, ZACC raffine, and ZACC ginza. At ZACC’s salons, only qualified “stylists” cut customers’ hair at the salons’ standard prices. “Stylists” are hairdressers who are permitted to provide haircuts after completing a certain period of trainee work experience as “assistants.” In 2023, ZACC began permitting assistants to provide haircuts to consenting customers at a discounted price to accelerate the training of assistants and their qualification as stylists. ZACC is actively recruiting additional talented assistants who have the potential to become top stylists and train the current stylists to better promote their services via various social networking services. For the year ended December 31, 2025, more than 97.8% of ZACC’s customers specifically requested their preferred stylists, compared to more than 96.5% for the year ended December 31, 2024, and more than 85.3% of customers were repeat customers for the year ended December 31, 2025, compared to 81.7% for the year ended December 31, 2024.

Revenue from directly-operated ZACC branded salons and franchise fees decreased by JPY48,134 thousand (US$307 thousand) from JPY589,901 thousand for the year ended December 31, 2024 to JPY541,767 thousand (US$3,455 thousand) for the year ended December 31, 2025 (which include franchise fees of JPY550 thousand and JPY600 thousand, respectively). ZACC had total customers of 37,520 and 35,154 in 2024 and 2025, respectively, and revenue per customer was JPY15,425 (US$98) in the year ended December 31, 2025, compared to JPY15,683 in the year ended December 31, 2024. In addition to salon operation revenue, we sold our ZACC Ginza salon to an investor during the year ended December 31, 2024, which generated revenue of JPY109,400 thousand in that year; there was no revenue from the sale of salons in the Luxury Beauty segment in the year ended December 31, 2025.

For the year ended December 31, 2025, we continued to focus on the sale of merchandise in addition to attracting new customers. We are working to improve ZACC’s financial performance through efforts to hire additional talented assistants who have the potential to become top stylists and train current stylists to better promote their services via social networking services such as Instagram.

Digital Preventative Healthcare Segment

The aim of our diverse health related product and service offerings will help us collect and manage healthcare data from users and customers and enable us to become a leader in big data in the healthcare industry. Our Digital Preventative Healthcare Segment consists of the following businesses.

Specific Health Guidance Program via Lav® Application. We serve small and medium size businesses, large corporations, and government entities in their implementation of health and wellness programs as outlined by the Ministry of Health, Labor and Welfare of Japan’s Specific Health Guidance Program. Japan is confronting a rapidly-aging society, as well as inflation of medical expenses from increasing occurrences of fatal diseases, such as diabetes, heart attack and stroke. To tackle this nationwide issue, the government initiated the Specific Health Guidance Program in April 2008. In this program, 40-through-74-year-old people who have received a diagnosis warning of lifestyle diseases at a health check-up are requested by a doctor to take a series of courses that are tailored to reduce the risk of developing certain lifestyle diseases. Because Japanese citizens and permanent residents are required to maintain health insurance through government or employer sponsored programs, it is the health insurance providers’ responsibility to have participants take the courses if they are requested to do so. By partnering with a number of health insurance providers, we provide support to connect those who need to take the courses with health care professionals via our proprietary on-demand health monitoring application for smartphones called Lav®. We charge fees to health insurance providers, depending on how many participants use the program and which type of program is used. A portion of these fees is subsidized by the Japanese government.

38


Table of Contents

 

Until recently, the goals of health checkups and health guidance have been the early identification and treatment of illnesses. By focusing on visceral-fat obesity and providing health guidance to patients for improving living habits that cause visceral-fat obesity, specific health checkups and specific health guidance are used as preventative measures to decrease the numbers of persons who suffer from, or are at risk of, lifestyle-related conditions such as diabetes. Since lifestyle-related conditions progress with no visible symptoms, specific health checkups, which are comprised of health screenings intended to identify those who require health guidance to prevent lifestyle-related conditions, are considered to be an excellent opportunity to review the individual’s living habits. Health guidance is provided to help the individual change his or her behavior. All those who have undergone specific health checkups are provided with information suited to their own individual circumstances.

Based on the results of specific health checkups, persons eligible for specific health guidance are identified by level (that is, those eligible for motivational support and those eligible for active support) in accordance with their risk levels, by focusing on the degree of visceral fat buildup and the presence of other of risk factors. The goals of specific health guidance are to enable eligible persons to be aware of their own health conditions and make voluntary efforts, on a continual basis, to improve their own living habits. Participants are provided with a variety of motivational information and advice to help them live healthier lifestyles on their own. Motivational support is, in principle, the one-time provision of encouragement for the participant to make improvements in living habits.

The Specific Health Guidance Program provides continual support in multiple sessions over three months or longer. An action plan is prepared with the guidance of the specialists such as doctors, health nurses, and nutritionists, and provides motivational support to improve the patients’ health-related daily habits. We have engaged several experienced nutritionists and healthcare professionals as designated coaches by entering into service agreements for this purpose. These therapists and nutritionists help provide integrated bodywork (physical body-oriented support), encouragement and inspiration (mental support), and dietary guidelines (metabolic/diet support). Specialists provide regular, continual support for efforts to improve living habits over a period of three months or longer.

 

img205519096_6.jpg

In addition to the Specific Health Guidance Program, we provide similar services to younger generations as well. Certain large Japanese companies work in collaboration with their own corporate-sponsored health insurance associations to provide their younger employees, who are not covered by the Specific Health Guidance Program, with services similar to those we provide under the government-sponsored program. We receive payment for these services from the sponsoring companies or their corporate-sponsored health insurance associations. Because these programs are not regulated by the government, we are able to engage our in-house therapists as coaches to provide guidance and feedback to the program participants through the Lav® app.

Lav® Application. We launched an upgraded version of Lav® as a consumer application in July 2021. The updated Lav® application offers options such as detox, weight control, and exercise programs. On this consumer version of the Lav® application, we also currently engage our in-house therapists as coaches to provide guidance and feedback through the app. We also have been promoting the Lav® consumer application to our existing customers at relaxation salon locations.

MOTHER Bracelet®. Our MOTHER Bracelet® fitness device is designed to track and collect the health data of the wearer, such as calorie consumption, activity and sleep patterns. We believe the MOTHER Bracelet® is the only fitness tracker that requires no electric charging, as it utilizes innovative technology such as Gemini TEG (Thermoelectric Generator) and Mercury Boost Converter to enable the user’s body heat to generate electricity. We are not aware of any other wearable devices equipped with near field communication (“NFC”) functionality currently in the market with equivalent capabilities. MOTHER Bracelet® is

39


Table of Contents

 

our registered trademark in Japan. We intend to continue to pursue other opportunities in Japan and the United States for large-scale private label contracts for our device.

 

img205519096_7.jpg

 

Rather than selling MOTHER Bracelet® devices on a stand-alone basis to individual consumers, we believe corporate customers are a more ideal customer base because they are able to benefit from monitoring the health data of a large number of MOTHER Bracelet® users, such as patients in hospitals, residents in nursing homes, drivers or employees in transportation or construction businesses.

Hence, in 2023, we developed a platform consisting of MOTHER Bracelet®, Gateway, which is a telecommunication tool containing a subscriber identity module, and REMONY®, which is a centralized monitoring software system. Through this platform, data are collected from each MOTHER Bracelet® worn by a large number of users, then sent to REMONY® via Gateway, and our business customers can centrally monitor all individual users’ health data on a nearly real time basis. The system is designed to notify facility managers and family members when it detects abnormal health-related signs and signals on the wearers. This platform has been in commercialization and generating revenue since September 2023.

In May 2024, REMONY®, which can only be coupled with the MOTHER Bracelet®, became qualified for the Nursing Robots Implementation Support Subsidy Program, which is sponsored by Kanagawa prefecture, the second most populated prefecture in Japan after Tokyo, with a population of approximately 9.2 million as of June 1, 2024. Under this subsidy program, nursing homes or home care providers can be subsidized for 75% (up to JPY7,500 thousand (US$48 thousand)) of the expenses paid to implement nursing robots that can improve the efficiency of nursing operations and/or reduce the burden of nursing workers. We are aiming to expand the subsidy coverage of our MOTHER platform to other regions and other types of programs and assist our customers in applying for these programs in order to reduce their out-of-pocket costs and increase the number of units ordered by each business customer without decreasing the price per unit.

Our standard character trademark application for MOTHER Bracelet® was approved and registered by the Japan Patent Office in February 2022. The MOTHER Bracelet logo was also approved and registered by the Japan Patent Office in July 2023. As of December 31, 2025, we had 102 clients under contract for our Specific Health Guidance Program provided by Lav®, our on-demand training app, and for our separate lifestyle improvement program via Lav® for people under 40 years of age, counting only once any client that contracts for both programs, of which five were new clients contracted during 2025. The corresponding figures as of December 31, 2024 were 86 clients for the Specific Health Guidance Program, which is provided to corporate insurance associations, and 20 clients for the lifestyle improvement program; those figures are stated separately for each program and so count twice any client that contracted for both. During the year ended December 31, 2025, 3,582 participants began guidance sessions under the two programs combined and 3,244 participants completed them, the difference principally reflecting participants whose programs were completed in January and February 2026. The cumulative number of participants who have begun guidance sessions since the inception of these programs was 12,477 as of December 31, 2025, compared with 8,895 as of December 31, 2024. In addition, we launched an upgraded version of Lav® as a subscription-based consumer application on July 1, 2021. The updated Lav® application offers options such as detox, weight control, and exercise programs. The following graphs

40


Table of Contents

 

show the number of corporate insurance associations we have contracts with as of December 31 of each year, and total number of users of the respective years.

 

img205519096_8.jpg

img205519096_9.jpg

 

Note: The number of clients and the number of users served represent the sum of the number of unique clients in our Specific Health Guidance Program and in our lifestyle improvement programs via Lav® for people under 40 years of age, and the sum of the number of users of each of these programs, respectively.

During the year ended December 31, 2025, we sold a total of 280 MOTHER Bracelet® units, 211 replacement straps and 258 Gateway units. During the year ended December 31, 2024, we sold a total of 2,356 MOTHER Bracelet® units and 254 Gateway units, generating total revenue of JPY153,646 thousand (US$980 thousand). This followed sales of 4,203 units of MOTHER Bracelet® for JPY125,280 thousand (US$799 thousand) in the year ended December 31, 2023. The decrease in MOTHER Bracelet® unit sales in 2025 principally reflects the substantial suspension of transactions with NFES Technologies Inc., which had accounted for a significant majority of the purchase orders we received during 2025, as a result of NFES’s financial condition. In addition, during the year ended December 31, 2025, the monthly numbers of users of our monitoring system, aggregated over the twelve months of the year, totaled 2,491, comprising 613 users under active system usage contracts, 845 users under other system usage contracts and 1,033 users under rental arrangements.

During the first half of 2024, we experienced a temporary suspension of shipments of MOTHER Bracelet® and MOTHER Gateway devices caused by technological issues such as malfunctioning of MOTHER Bracelet® devices due to static electricity generated from friction with blankets in nursing homes in winter, and data connectivity issues between multiple MOTHER Bracelet® and multiple MOTHER Gateway devices. As of the date of this annual report, the data connectivity issue has been fully resolved. In addition, we have implemented a remedial measure for the static electricity issue that does not require changing the design architecture of the affected products, and we will prioritize marketing these products towards spa facilities and factories, where the static electricity issue does not arise, until we fully resolve this issue in the next generation of MOTHER Bracelet®, which is currently in development. During the year ended December 31, 2025, we sold 280 MOTHER Bracelet® units to our business customers, and we had no outstanding purchase orders as of December 31, 2025. In response to growing demand for rental, including in the market for the prevention of heat-related illness, in June 2025 we began, in addition to selling the devices, to offer them on a rental basis for a monthly fee, and we have since focused on that model. The aggregate number of monthly users of devices rented under this model was 1,162 for the period from June to December 2025. Comparisons of unit shipments between periods are accordingly not indicative of the underlying performance of this business. The suspension of shipments attributable to a shortage of semiconductors has been resolved, and the supply of semiconductors from Matrix Industries, Inc. has been restored.

 

 

In August 2024, our subsidiary MML entered into a capital and business alliance with NFES Technologies Inc., under which NFES acted as the lead investor in the series A equity financing round of MML. On August 17, 2026, MML and NFES terminated the capital alliance by mutual agreement. The distribution arrangement under the business alliance remains in effect, on a non-exclusive basis. Transactions with NFES have nevertheless been substantially suspended as a result of NFES’s financial condition, and we do not currently expect NFES to act as a significant distribution channel for MOTHER Bracelet® units. In October 2024, MML entered into a capital and business alliance with Elematec Corporation under which Elematec participated in MML’s series A equity financing round on the same economic terms as NFES and was also granted a right of first offer to handle the procurement of components for, and manufacturing of, any next generation or improved recharge-free wearable devices, and under which Elematec will also sell MOTHER Bracelet® units on a non- exclusive basis. See “Item 4. Information on the Company—Capital and Businesses Alliances of MEDIROM MOTHER Labs Inc.” As of December 31, 2025, MML had raised an

41


Table of Contents

 

aggregate of JPY262,440 thousand (US$1,674 thousand) from its series A equity financing. See “—Our Growth Strategy—The HealthTech Business as a Standalone Startup.” In connection with that termination, NFES transferred all of the 556 series A preferred shares of MML that it held to three third parties on the same date, and NFES is no longer a shareholder of MML. These were transfers of outstanding shares by NFES and did not change MML’s issued share capital or our ownership interest in MML.

Customers

Specific Health Guidance Program. We charge fees to health insurance providers, depending on how many participants use the program and which type of program is used. We plan on continuing to grow both provider count, including corporate sponsors, insurance providers, and government entities, as well as the end-participant pool, which are end users of our Lav® application. Our consumer Lav® application charges fees for fixed-term health coaching services to date.

MOTHER Bracelet ®. As of December 31, 2025, our existing customers are hospitals, nursing homes, acupuncture clinics, sports clubs (gyms), transportation companies, wholesalers to electronics retail stores, foreign government entities as well as individual consumers. As of the date of this annual report, of the purchase orders we received for MOTHER Bracelet® units during 2025, NFES Technologies Inc. was responsible for a significant majority of the orders. Although the distribution arrangement with NFES remains in effect on a non-exclusive basis, transactions with NFES have since been substantially suspended as a result of NFES’s financial condition, and we do not currently expect to receive a significant volume of orders through NFES.

 

img205519096_10.jpg

Services

Specific Health Guidance Program. Through our Lav® application, we provide participants in a health insurance plan the ability to search for professionals tailored to each individual’s preferences, lifestyle, and health conditions. Participants can enjoy benefits from specific health guidance based on provided information. In addition, our therapists, composed of licensed nutritionists and registered dieticians, provide coaching services to program participants. This allows us to leverage idle time from therapists to generate additional revenue, which effectively results in improved efficiency ratios.

 

img205519096_11.jpg

MOTHER Bracelet®. Our MOTHER Bracelet® is designed to monitor and collect the health data of the wearer and can work seamlessly with our Lav® application and most of the other health monitoring applications that are available on the market. We also offer a Software Development Kit, or SDK, to our partners for their application or software development convenience.

42


Table of Contents

 

Market

Our Lav® healthcare application and its Specific Health Guidance Program primarily compete in the Specific Health Guidance Program market sponsored by the Ministry of Health, Labor and Welfare of Japan. According to the Ministry, approximately 1.43 million participants completed the Specific Health Guidance Program in the governmental fiscal year ended March 31, 2024. Based on the participant data from that fiscal year and the assumption (based in part on data from certain local medical associations from the same fiscal year) that the average service fees per participant paid by health insurers is JPY20,000 (US$128), we estimate the market size for the Specific Health Guidance Program is JPY29 billion (US$185 million). In addition, we have been providing similar services through the Lav® healthcare app to members of younger generations who are participants in company-sponsored health insurance programs. The market size of medical services in Japan exceeded JPY48 trillion (US$307 billion) in the governmental fiscal year ended March 31, 2024, and is expected to continue to grow due to Japan’s rapidly aging demographics. As a response, the Japanese government has been focusing more on preventative care. Hence, the preventative healthcare sub-segment of the broader medical and healthcare market in Japan has received proportionally increasing funding from the Japanese government’s health insurance budget, as have the participants in the Specific Health Guidance Program. Secular shifts toward prevention versus treatment, increasing insurance premiums and greater government subsidies make this a growing and attractive submarket to capture.

The Japanese healthcare system itself is well-regarded worldwide, leading most other countries on key outcomes including availability of hospital beds, public expenditure as a percentage of GDP, and infant mortality. These qualities allow leaders in the market to capture significant revenues and receive favorable prioritization in the budgets of both the public and private sectors. One notable deficiency is in the low number of practicing physicians per population density, which reflects both the highly populous cities of Japan and the relative dearth of medical practitioners.

Our Lav® app was created to address the aforementioned shortfall by leveraging co-medical practitioners and therapists to advise patients digitally. We believe this telehealth approach is fortified by our strong brand, retail scale which allows for drop-in appointments, and technical and live support.

Our MOTHER Bracelet® operates in the wearable device space though we focus on specific market segments tailored towards businesses that monitor large groups of employees or clientele and have a strong incentive to monitor their health conditions such as: hospitals, nursing homes and medical facilities serving the elderly population, transportation, construction, and national security sectors where employers have a strong incentive to monitor the health conditions of the their employees or officials.

Integrated Health Solutions, Analytics and Targeting

The Japanese government and major corporate sponsors in the country have accelerated needs for preventative care and ascribing key factors affecting health outcomes. As demographics continue to focus on the elderly and insurance plans face uncertain or insufficient returns relative to premiums, major health insurance companies and the government require solutions to target problems, streamline costs, and save lives through a preventative focus. This has resulted in government budgets and subsidies earmarked for improving employee health and increased incentives for understanding, diagnosing, and creating action plans to address health issues. We believe our platform and technology allow us to serve government and corporate entities with a one-stop shop, data-driven and targeted solution service.

Global Expansion Opportunities

We focus on core competencies within the local markets of Japan, although we opportunistically assess franchising or partnerships abroad for our core salon business, and business-to-business-to-consumer distribution models for MOTHER Bracelet® and other digital businesses through online marketing, commerce, and joint ventures. We believe the wearables market and omnichannel distribution trends, particularly online commerce, remain attractive avenues of growth for our Digital Preventative Healthcare Segment.

Components and Materials

The self-charging functionality of our MOTHER Bracelet® is derived from the core semiconductor provided by Matrix Industries, Inc. (“Matrix”), a startup based in California, United States. Matrix is a developer of a thermoelectric generator and boost converter. In 2019, we made a strategic investment for a minority interest in Matrix. In furtherance of our strategic investment, we entered into a production and development agreement with Matrix on August 4, 2020 to use Matrix’s technology in development and manufacturing of the MOTHER Bracelet®. On May 9, 2025, our subsidiary MEDIROM MOTHER Labs Inc. and Matrix entered into a Master License and Distribution Agreement, which superseded the production and development agreement. Under the new agreement, MEDIROM MOTHER Labs Inc. has an exclusive right to market, sell and distribute wearable devices incorporating Matrix’s products in Japan through December 31, 2027, renewable annually thereafter, and a non-exclusive right to do so worldwide. The exclusivity is subject to minimum purchase volumes, and if those volumes are not met Matrix may terminate the exclusivity on 30 days’ notice, subject to a cure period, while the right to continue selling in Japan would remain.

43


Table of Contents

 

In addition, our MOTHER Bracelet® and “MOTHER Gateway” utilize an array of components, a few of which we directly obtain from suppliers, while the others are indirectly purchased by our contracted assembly factory and shipped to our warehouse in the form of finished goods. Although most of the components other than the core semiconductor provided by Matrix are commodities, the available supply and price of these components are influenced by potential macroeconomic shifts, tariffs, supply chain integrity, embargoes or any other trade restrictions resulting from geopolitical issues, and global demand. See also “Item 3. Key Information—D. Risk Factors—Risks Related to Our Company and Our Business—Our MOTHER Bracelet® and Gateway incorporate various components, and component inflation may increase our cost of producing these products.”

Our Growth Strategy

Our goal is to restore and improve the profitability of our relaxation salon business and to grow revenue in our Digital Preventative Healthcare business. In our relaxation salon business, we have shifted our focus from increasing the number of salons through new store openings and acquisitions to improving the profitability of each salon. The principal elements of this strategy are to: (i) evaluate the profitability of each salon on an ongoing basis and improve the performance of underperforming salons; (ii) close salons that we do not expect to return to profitability, and redeploy the therapists from those salons to our more profitable salons in order to support the further growth of those salons; (iii) suspend, for the time being, new salon openings, the development of additional franchises and growth through acquisitions, so that our management resources are devoted to the profitability of our existing operations; and (iv) evaluate our non-core businesses, including the possibility of withdrawing from, or disposing of, businesses that do not meet our profitability thresholds. As of the date of this annual report, we have not entered into any definitive agreement with respect to, and our board of directors has not approved, any withdrawal from or disposition of a non-core business.

Growth in the Japanese Market. According to the 2022 Yano Report, which is Yano’s most recent report on this topic available as of the date of this report, in terms of the number of salons, we are one of the top three companies, on a consolidated basis, in the Kanto region (Tokyo, Kanagawa, Saitama, Chiba, Gunma, Ibaraki and Tochigi), and in the top four nationwide. The total number of relaxation salons under major brands in Japan, according to the 2022 Yano Report, was 2,944, with the largest operator having 613 salons.

Workforce Optimization to Significantly Improve Margins and Increase Revenue. We currently employ therapists at a large majority of our directly-operated salons under permanent, fixed-term, or part-time employment contracts. A substantial majority of these therapists are paid wages at or close to the statutory minimum wage. From 2012 to 2023, the minimum wage in Tokyo increased by 30.9% from JPY850 (US$5.42) to JPY1,113 (US$7.10), from 2023 to 2024, the minimum wage in Tokyo increased by 4.5% to JPY1,163 (US$7.42), and from 2024 to 2025, it increased by 5.4% to JPY1,226 (US$7.82). We are required to pay certain social security expenses associated with them and must pay for their down time when they are not serving our customers. Alternatively, we typically pay contractor therapists a commission of 42-44% of sales they earn, regardless of how many hours they are present at our salons. The commission percentage varies with the therapist’s qualified skill level and ranges from 40% to 52%. Under these circumstances, the relative cost to serve a customer using a fixed- salary therapist has increased dramatically in recent years compared to that of a commission-based contractor therapist. Accordingly, we believe we can improve our margins at many of our salons by utilizing a greater proportion of such commission-based therapists.

In connection with this objective, our new mid-term business plan emphasizes the strategic reorganization of our salon workforce mix. Specifically, we plan to increase the proportion of contractor therapists at all of our salons, where they will work alongside a certain number of fixed-salary therapists under the supervision of store managers. Our goal is to adjust the workforce mix at each of our directly-operated salons to maximize profitability by considering a number of factors such as the salon’s fixed cost ratio as a percentage of store sales, operation ratio and fluctuations in customer demand. During 2025, we actively converted therapists in our relaxation salon business from employment contracts to commission-based independent contractor agreements, and the number of contractor therapists engaged by us increased to 487 as of December 31, 2025 from 318 as of December 31, 2024, while the number of therapists engaged under employment contracts decreased to 676 from 823 over the same period. As a result, contractor therapists represented 41.9% of the therapists working at our salons as of December 31, 2025, compared to 27.9% as of December 31, 2024.

In addition to cost saving, we also believe employing a larger proportion of commission-based therapists will increase our sales per salon by increasing bed occupancy. Because we must pay wages to our fixed-salary therapists when they are at our salons but are not serving customers, it is costly for us to maintain idle fixed salary therapists, and we must carefully hire and manage the shifts to meet customer demand.

Therefore, a salon consisting only of fixed-salary therapists may not be able to utilize all of the available beds during times of high demand due to a lack of available therapists. Alternatively, with contract therapists, we will be able to maintain more idle therapists at any given time, allowing us to better respond to fluctuations in customer demand and increase bed occupancy.

In order to achieve this initiative and monitor store-by-store workforce optimization, cost-efficiencies, potential to improve profitability, as well as any potential need to shut down certain locations, we established a new division on July 1, 2024 that engages exclusively in store-level analyses and advising our management on these matters. With the insights provided by the new division, we believe that our management will be able to improve its oversight of store-by-store operations.

44


Table of Contents

 

Salons Located at Spa Facilities. Compared to standalone salons and salons located in commercial properties, salons located within spa facilities incur no security deposits and require substantially lower capital expenditures. In addition, salons located at spas are more resilient to large fluctuations in customer visits because a majority of the therapists at such locations are contract therapists. Although our salons located within spas tend to have less monthly revenue compared to a similar standalone salon or a salon located in a commercial property, by focusing on salons located at spas, we aim to generate more stable profits while minimizing capital expenditures.

Suspension of Growth through Acquisitions. We have previously sought to grow through targeted acquisitions in the consolidating Japanese relaxation sector. In light of our operating losses and liquidity constraints, we have suspended this element of our growth strategy for the time being, and we are devoting our management resources to improving the profitability of our existing salons. We may resume acquisitions if and when our financial condition improves.

We believe we have the competitive advantage and negotiating power to structure accretive deals and to integrate the culture and operations of target companies. As described under “—Suspension of Growth through Acquisitions” above, we have suspended acquisitions for the time being. If we resume acquisitions when our financial condition improves, we would expect to focus on salon brands in the domestic relaxation sector that have at least 10 stores.

Growing Salon Sales via Operation Outsourcing Model. In the fourth quarter of 2021, we started an additional business model where we sell our directly-owned salons to investors and enter into service agreements to manage the operations on behalf of the investors. Under this model, the investor acquires the operating rights to the salon, is entitled to the profit that the salon generates and bears any operating losses that it incurs, and we provide salon operation services under a service agreement. The investor retains the profit of the salon up to a target return of 6% to 8% of the purchase price, and we are entitled to a success fee equal to 80% to 90% of the profit in excess of that target return as consideration for our operation services. Through this model, we aim to maximize the return on capital investment, improve operational efficiency by further focusing on salon operations, and generate additional income from the salons that were sold to investors and are under our management. Since the inception of this model, the target return at which we sell salons has gradually decreased. We have no contractual or implied obligation to repurchase a salon that we have sold. Where an investor asks us to repurchase a salon that it holds, we consider the request and determine on a reasonable basis whether to proceed, taking into account the performance of the salon, our liquidity and our business strategy. A salon that we repurchase is not necessarily repurchased with a view to reselling it; depending on the performance of the salon and our operating plans, we may continue to operate it as a directly-operated salon. Separately, where another investor wishes to acquire a particular salon, we negotiate with the investor that then holds that salon, and a transfer occurs only if that investor agrees to sell. As of December 31, 2025, 74 investor-owned salons were under our management, as compared to 57 salons as of December 31, 2024.

Increasing Sales through Marketing and Advertising. We conduct most of our marketing and advertising through our website and through HOT PEPPER Beauty, a dominant web aggregator of salon businesses in Japan. In addition, our salons are strategically located in high density and foot traffic areas near train stations and shopping centers that are advertising and marketing drivers. Furthermore, we are working to enhance our digital marketing initiatives, including through our smart phone apps, to retain our repeat customers and improve the frequency of customer visits. The Re.Ra.Ku® application, which is a specialized app for our relaxation salons, was released in October 2022. The application had 224,647 cumulative downloads as of the end of December 2025, and 12.6% of all reservations at our relaxation salons were made through the application in the month of December 2025.

In addition, we intend to grow through our various loyalty marketing programs. We award customers a certain percentage of points when they pay with Re.Ra.Ku PAY in accordance with the customer’s loyalty status, which is either “Bronze”, “Silver”, “Gold”, “Platinum”, or “Diamond”. We also aim to promote marketing campaigns in which we award customers a certain percentage of points when they purchase points through Re.Ra.Ku PAY. By incentivizing customers to charge more using their Re.Ra.Ku PAY balances, which expire after 150 days, we believe we can induce such customers to visit our salons more frequently.

Furthermore, we aim to expand the scope of possible uses of Re.Ra.Ku PAY points, which are currently limited to payment only for relaxation services and merchandise.

Moreover, in October 2024, we newly introduced several kinds of prepayment tickets, all of which expire within 180 days, for customers who prefer paying with paper-based prepaid tickets over the Re.Ra.Ku PAY application. The total number of such prepayment tickets, other than Re.Ra.Ku Card, purchased by customers was 132,920 in 2025, compared to 42,028 in 2024. The increase principally reflects the fact that these tickets were sold for the full year in 2025, whereas sales commenced in October 2024.

Continued Investment in the Digital Preventative Healthcare Segment. We plan to invest in and grow the Digital Preventative Healthcare Segment and increase the segment’s profit margin. In order to increase revenue from the Specific Health Guidance Program, in addition to our continuous sales efforts to increase the number of contracts with corporate insurance associations, we are renegotiating with existing corporate insurance association clients to transition from initial discounted service prices to standard ones. We also intend to accelerate the production of our MOTHER Bracelet®. We intend to grow our existing sales forces and utilize external sales representatives to obtain larger purchase orders from businesses such as hospitals, nursing

45


Table of Contents

 

homes and medical facilities serving the elderly population, transportation, construction, and national security sectors. In order to accelerate our sales activities, we developed and commercially launched the MOTHER Gateway and REMONY®. Rather than promoting the MOTHER Bracelet® as a standalone product, we intend to emphasize how all these products and services can work as an integrated platform, with the MOTHER Bracelet® collecting health data from a large number of users and sending the data to REMONY® via Gateway, allowing business clients to monitor user health data. We intend to continuously invest in and improve the functionality of the MOTHER Bracelet® by developing algorithms to more accurately measure health data, expand the scope of available health data, improve the data connectivity between a larger number of MOTHER Bracelet® products and Gateway tools at the same time, and improve the user experience of REMONY® software. As part of this strategy, in October 2024, we issued convertible bonds in the aggregate principal amount of JPY300,000 thousand to an investor, and we intend to use a portion of the proceeds from this issuance for investment in our Digital Preventative Healthcare Segment. See “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources—Convertible Bonds.” During the year ended December 31, 2025, we sold 280 MOTHER Bracelet® units to our business customers, and we had no outstanding purchase orders as of December 31, 2025. In response to growing demand for rental, including in the market for the prevention of heat-related illness, in June 2025 we began, in addition to selling the devices, to offer them on a rental basis for a monthly fee, and we have since focused on that model. The aggregate number of monthly users of devices rented under this model was 1,162 for the period from June to December 2025. Comparisons of unit shipments between periods are accordingly not indicative of the underlying performance of this business.

The HealthTech Business as a Standalone Startup. In order to accelerate the growth of our HealthTech business, we transferred our Digital Preventative Healthcare business to our subsidiary MEDIROM MOTHER Labs Inc. in July 2023. We believe this spinoff will allow our Digital Preventative Healthcare business to fulfill its financing needs for its investments in inventory, software development, and marketing activities. In August 2024, MML entered into a capital and business alliance with NFES Technologies Inc., under which NFES purchased 556 newly issued series A preferred shares of MML (approximately 1.1% of MML’s equity ownership immediately after NFES’s investment in MML) for JPY100,080 thousand (US$638 thousand) at a pre- money equity valuation of JPY9 billion (US$57.4 million) as the lead investor in the series A equity financing round of MML. The capital and business alliance agreement with NFES includes certain other commercial terms. In addition, in October 2024, MML and Elematec Corporation, a Japanese joint-stock corporation, entered into a capital and business alliance agreement under which Elematec participated in MML’s series A financing round by purchasing 556 newly issued series A preferred shares of MML for a total price of JPY100,080 thousand (US$638 thousand). Until December 31, 2024, MML had entered into agreements with six investors for aggregate financing of JPY260,280 thousand (US$1,660 thousand). We continuously seek attractive financing opportunities for our Digital Preventative Healthcare business, and may seek to raise additional capital to expand the business, though we intend to continue to be the controlling shareholder of MML. For additional details regarding our capital and business alliance agreements, see “Item 4. Information on the Company—Capital and Businesses Alliances of MEDIROM MOTHER Labs Inc.” In connection with that termination of the capital and business alliance agreement in August 2026, NFES transferred all of the 556 series A preferred shares of MML that it held to three third parties on the same date, and NFES is no longer a shareholder of MML. These were transfers of outstanding shares by NFES and did not change MML’s issued share capital or our ownership interest in MML.

Our Competitive Strengths

Brand Value. We believe our trademarks and other intellectual property create a strong competitive advantage in our Relaxation Salon Segment, Luxury Beauty Segment and Digital Preventative Healthcare Segment. With widespread recognition in the Kanto region and across Japan, our Company benefits from a loyal customer base and brand recognition that enables the growth of our businesses.

Employee Satisfaction. High turn-over rates and difficulty in hiring skilled labor are challenges facing the relaxation industry. We have invested culturally and economically to create a career progression for our therapists so they will stay and grow with our Company. We believe that our employee satisfaction levels contribute to employees’ high morale. This is evidenced by us being awarded the Grand Prix for the relaxation sector’s top therapist and best salon award in Japan in 2019, as well as the Semi-Grand Prix for the individual therapist and the Grand Prix for the best salon award in 2021, which, as of December 31, 2025, is the most recent year these awards were provided due to the impact of COVID-19. This is particularly important as high turnover reduces or disrupts available investment in capital because of the costs associated with hiring and training new employees. We continue to optimize our working environment for therapists in an effort to improve morale and productivity and cultivate a long-term orientation among our therapists toward their work and status within the Company.

Re.Ra.Ku® College. We believe that we own one of the largest in scale and best in-class education and training facilities for relaxation therapists in the Japanese relaxation industry. Re.Ra.Ku® College enables us to provide continuous training to our franchise owners and salon staff, as well as continuous direct access to a pool of newly trained and job-ready staff. We focus on providing continuous training and learning opportunities to all of our therapists to ensure the quality of our services is consistent throughout our salons. We require a certain level of relaxation therapist training before therapists are allowed to work with clients at our salons, and we believe the level of required training for our therapists is one of the highest among leading relaxation service providers in Japan. We find that this rigorous skill training system better prepares our therapists and has proven effective for our salons. We provide 54 hours of training programs. Each training module can be taken on demand, rather than in a series, for the

46


Table of Contents

 

trainee’s convenience. Moreover, we provide follow-up training courses based on how we evaluate and grade the practitioner’s skills.

 

img205519096_12.jpg

Innovative Services Provided by Our Relaxation Salons. Our relaxation salons’ services are innovative and differ from traditional shiatsu-style bodywork. For example, we created our unique wing stretch method, which focuses especially on the shoulder blades. This is important because the shoulder blades are a critical part of the body, as they connect and balance the bones from the neck to the lower back and support the body to ensure the body moves smoothly. Unlike other salons who provide traditional shiatsu-style bodywork and typically use body weight pressure on the muscles, which can cause damage, our relaxation therapists use stretch techniques on the muscles, thereby preventing damage. We believe our non-pressure method mitigates the risk of severe malpractice and other similar claims. Finally, our relaxation therapists are trained to converse with our customers, to ask them questions in order to tailor the therapy to their unique needs, and to promote self-care by communicating about their current body ailments and providing advice for future visits.

 

img205519096_13.jpg

Strong Positioning for the Continued Growth of the Specific Health Guidance Program. We have been engaged in the government-initiated Specific Health Guidance Program for the use of our on-demand health monitoring application, Lav®. Because this is a Ministry of Health, Labour and Welfare subsidized program, participating companies need to maintain quality controls. Partners and service providers are vetted and must adhere to standards that are established by each of the health insurance providers. We believe this business is currently entering a growth phase and that our developed systems and adherence to strict regulation and oversight provides us a competitive advantage in the business. As of December 31, 2025, we had contracts with 102 corporate insurance associations for the use of Lav® in the Specific Health Guidance Program and in our program for individuals below the age of forty, compared with 97 as of December 31, 2024. We have begun to renegotiate these contracts to increase the unit price for our services with existing corporate insurance association clients, who contracted with us at deeply discounted prices, by showing our achievement of the participants’ program completion ratio. In addition, we continue to market and sell our Lav® solution to new potential clients.

Uniqueness of Our Lav® Application for Consumers. We believe that the Lav® application is unique by providing comprehensive support and physician-supervised guidance and methods for not only nutrition but also exercise and sleep. We believe that we have a competitive advantage in securing a sufficient number of coaches as needed because we are able to recruit our existing therapists to become coaches.

47


Table of Contents

 

Uniqueness of Our MOTHER Bracelet®. We believe our MOTHER Bracelet® is the only fitness tracker that requires no electric charging by utilizing the innovative technology of the Gemini TEG (Thermoelectric Generator) and Mercury Boost Converter. These technologies enable the user’s body heat to generate electricity. As of the date of this report, we are not aware of any other wearable devices in the market with equivalent capabilities.

In addition, we believe we have a competitive advantage selling our MOTHER Bracelet® to businesses because of our open Software Development Kit (SDK) policy. By making the SDK publicly available, we allow and encourage software and hardware developers to customize the management of healthcare data for their own purposes.

Employees and Contractors

As of December 31, 2025, we had 351 employees on a full-time basis, 516 employees on a part-time basis, and 87 employees on a fixed-term basis. As of December 31, 2024 and 2023, we had 334 and 430 employees on a full-time basis, respectively, 621 and 561 employees on a part-time basis, respectively, and 96 and 95 employees on a fixed-term basis, respectively. Most of our employees are directly employed by our wholly-owned subsidiary, MEDIROM Wellness Co. Our Company is not currently, and has not in the past, been unionized. As such, neither we nor our franchisees are required to engage in collective bargaining procedures with any unions under Japanese labor laws. As of December 31, 2025, all of our employees were located in Japan.

The majority of our relaxation therapists are employed by us under permanent, term or part-time employment contracts, and all of our relaxation therapists, including those we engage as independent contractors, receive training at Re.Ra.Ku® College before starting work at our salons. Our employees are paid on a salary basis. We also offer various incentive programs which vary based on employment status. Our new incentive program, which became effective on July 1, 2022, aims to reward employees who make continuous efforts to improve their skills and performance and raise the overall quality level of our employees. These rewards are generally provided in the form of a cash bonus, promotion, or both. In addition, we introduced a new equity incentive compensation plan in 2024, under which employees are eligible to receive stock options and other types of equity awards. However, at present, we plan to provide equity compensation awards only to certain key personnel who drive our growth and profitability such as executives, directors, corporate auditors, and certain senior managers. See “Item 6. Directors, Senior Management and Employees—B. Compensation—Employee Stock Options.”

We also engage a portion of our relaxation therapists directly as self-employed independent contractors to work at our salons. As of December 31, 2025, we engaged 487 contractor therapists, compared to 318 as of December 31, 2024, in each case counting only therapists who worked for at least an hour at our salons in December of that year, reflecting our active conversion of therapists from employment contracts to commission-based independent contractor agreements. Contractor therapists are paid a commission as a proportion of the sales they generate, and the commission percentage varies depending on their qualified skill level, ranging from 40% for an intern therapist to 52% for our most experienced therapists.

Competition

We experience significant competition in all aspects of our business, including for highly skilled relaxation therapists and for the best salon locations. Our directly-operated and franchised relaxation salons compete with national and regional relaxation salon chains for customers, relaxation salon locations and qualified management and other staff, including relaxation therapists. Competition in our industry is primarily based on price, convenience, quality of service, brand recognition, and location. We consider our biggest competitors to be K.K. Factory Japan (which does business under the “Karada Factory” brand) and K.K. Bodywork (which does business under the “Raffine” brand), both of which are operators of relaxation salons in Japan.

Although our Luxury Beauty Segment also experiences competition, ZACC is comparatively less susceptible to price competition due to the strength of its brand. A key factor for brand strength is the retention rate of the senior hair stylists employed by ZACC.

In our Digital Preventative Healthcare Segment, we face competition from large incumbents in the traditional and digital advertising space and, to a lesser extent, startups in the health tech industry. Given the unique value proposition and startup nature of our growth segments, we remain focused on transaction level priorities, winning clients through our platform capabilities and features and benefits and leveraging relationships over what other incumbents may be doing in the space.

Property and Equipment

As of December 31, 2025, we had 292 relaxation salons, each of which is leased at train and subway stations, shopping malls, plazas, and high-traffic streets throughout Japan. We invest in leasehold improvement, equipment, and furniture in our directly-operated salons. The terms and conditions of the lease arrangements vary by agreement.

Our corporate headquarters are located at 2-3-1 Daiba, Minato-ku, Tokyo, Japan. The term of our lease for this location was renewed on December 1, 2022 for an additional term of two years. Our Re.Ra.Ku® College is annexed to our corporate headquarters, and we also have branch school locations in Nagoya and Osaka. The lease has since been renewed on the same terms and is scheduled to expire on December 31, 2026.

48


Table of Contents

 

Intellectual Property

To establish and protect our proprietary rights, we rely on a combination of trademarks, confidentiality policies and procedures, non-disclosure agreements with third parties, employee non-disclosure agreements, and other contractual and implicit rights worldwide. As of December 31, 2025 we had registered 51 trademarks, including the names and logos used by our Company, of which 48 were registered with the Japan Patent Office, two of which are registered with the U.S. Patent and Trademark Office and one of which is registered with the China National Intellectual Property Administration. Our principal intellectual property rights include the trademark “Re.Ra.Ku®”, which is our core brand, and “MOTHER Bracelet®”, “Lav®”, and “REMONY®”, which are key brands in our Digital Preventative Healthcare Segment, copyrights in our website and software assets, rights to our domain names, https://medirom.co.jp, https://reraku.jp, and https://mother-bracelet.com, trade secrets and know-how with respect to our training, servicing, sales and marketing and other aspects of our business, and our digital innovations such as the MOTHER application, REMONY® software, Gateway device, and Lav® application.

Our intellectual property is subject to certain risks described under “Item 3. Key Information—D. Risk Factors”, including the risks described under “Item 3. Key Information—D. Risk Factors—Risks Related to Our Company and Our Business—The failure to enforce and maintain our trademarks and protect our other intellectual property could materially adversely affect our business, including our ability to establish and maintain brand awareness.” and “Item 3. Key Information—D. Risk Factors—General Risk Factors—Third party claims with respect to intellectual property assets, if decided against us, may result in competing uses or require adoption of new, non-infringing intellectual property, which may in turn adversely affect sales and revenues.” Furthermore, the manufacturing of our MOTHER Bracelet® requires our use of a patent license, and we may be adversely affected by changes in our business relationship with the licensor or its financial soundness.

Financial Contracts

As of December 31, 2025, we had short-term borrowings of JPY765,227 thousand and long-term borrowings (including the current portion) of JPY631,280 thousand. None of the borrowing agreements contain any material financial covenants, although certain of the government- sponsored loans set a limit on the total loan amount we may borrow from other government-sponsored lenders. See “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources—Business Loans.”

Introduction of New Payment App “Re.Ra.Ku PAY” and Prepaid Cards

One of the requirements for issuers of prepaid cards under the Settlement Act is to maintain net assets of not less than JPY100 million based on Japanese GAAP. As of December 31, 2022, our net assets had fallen below JPY100 million based on Japanese GAAP on a standalone basis. On March 20, 2023, we reported this matter to the Kanto Local Financial Bureau. We have satisfied the net asset requirement at each fiscal year end since then, including as of December 31, 2025.

In order to address this issue, as well as to increase convenience for our customers, the Company decided to introduce a new payment system and developed “Re.Ra.Ku PAY”, a proprietary payment app which works on customers’ smart phones. Customers can charge the balance at our salons or remotely with their own credit cards and use the app to pay at our salons (Re.Ra.Ku PAY can be used at Re.Ra.Ku branded salons, Bell Epoc branded salons, and Ruam Ruam branded salons). The most important difference between the Re.Ra.Ku Card and Re.Ra.Ku PAY is that Re.Ra.Ku PAY balances have an expiration period of 150 days, while the Re.Ra.Ku Card balances do not have an expiration date. The Settlement Act regulates only prepaid cards with balances that remain effective for more than six months. Hence, by limiting the expiration period to less than six months, we believe Re.Ra.Ku PAY can be exempted from the regulations and requirements under the Settlement Act, which include the net assets requirement and an obligation to deposit half of the prepaid balance with the Legal Affairs Bureau.

Moreover, rather than giving customers a certain percentage of points when they charge their card balances on the Re.Ra.Ku Card, we give customers a certain percentage of points when they pay with the Re.Ra.Ku PAY app in accordance with each’s customer loyalty status, which is either “Bronze”, “Silver”, “Gold”, “Platinum”, or “Diamond”. We believe this approach contributes to more revenue generation by giving customers points at payment rather than at charging. The Company aims to utilize Re.Ra.Ku PAY for various marketing campaigns and to expand the scope of possible payments from only relaxation services at present to merchandise or other uses. We launched Re.Ra.Ku PAY on February 1, 2024, and disallowed further balance deposits on Re.Ra.Ku Cards beginning on the same date. As a result, Re.Ra.Ku Card users can pay with their current balances but cannot add to their balances.

As a supplemental alternative to Re.Ra.Ku PAY, primarily for customers who are not familiar with smartphone applications, we also introduced seasonal paper-based prepaid tickets in October 2024. These tickets provide a small discount compared to paying with cash and have expirations of less than 180 days, depending on marketing campaigns.

Although we have introduced Re.Ra.Ku PAY and the prepaid tickets, and disallowed new balance deposits on Re.Ra.Ku Cards, we are still regulated under the Settlement Act because some of our customers still have outstanding Re.Ra.Ku Card balances. However, as of December 31, 2025, our net assets exceeded the JPY100 million threshold on a standalone basis, meaning that we satisfied the net asset test as of that date. See “Item 4. Information on the Company—Regulations Governing Prepaid Cards” for more detail.

49


Table of Contents

 

Legal and Administrative Matters

We are currently not a party to any material legal or administrative proceedings. We may from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of our business, including matters involving our franchisees, among others. Any litigation or other legal or administrative proceedings, regardless of the outcome, are likely to result in substantial costs and a diversion of our resources, including our management’s time and attention.

Termination of Planned Acquisition of Japan Gene Medicine Corporation

On June 30, 2024, we entered into a share transfer agreement to acquire 70% of the issued and outstanding common shares of Japan Gene Medicine Corporation (“JGMC”) for JPY2,000,000 thousand, together with a binding memorandum of understanding granting us an option to acquire the remaining 30% of the issued and outstanding shares of JGMC. On October 31, 2026, we and the seller entered into a termination agreement, pursuant to which the share transfer agreement and the memorandum of understanding were terminated by mutual agreement of the parties, and we no longer intend to acquire any equity interest in JGMC. We did not pay any portion of the purchase price, and we did not recognize any gain or loss in connection with the termination.

Capital and Businesses Alliances of MEDIROM MOTHER Labs Inc.

MEDIROM MOTHER Labs Inc. has entered into two capital and business alliance agreements since August 2024 in connection with its Series A financing as described below. The price per series A preferred share in this financing round of JPY180,000 (US$1,148.0) represents a pre-money valuation of JPY9 billion (US$57.4 million) based on MML’s 50,000 total outstanding shares as of August 31, 2024, prior to the commencement of the Series A financing. As of December 31, 2025, the aggregate amount raised by MML in its series A financing was JPY262,440 thousand (US$1,674 thousand). We continuously seek attractive financing opportunities for our Digital Preventative Healthcare business and may seek to raise additional capital to aggressively expand the business, although we intend to continue to be the controlling shareholder of MML.

Agreement with NFES Technologies Inc.

In August 2024, MML entered into a capital and business alliance with NFES Technologies Inc. (“NFES”), under which NFES purchased 556 newly issued series A preferred shares of MML (approximately 1.1% of MML’s equity ownership immediately after NFES’s investment in MML) for JPY100,080 thousand (US$638 thousand) at a pre-money equity valuation of JPY9 billion (US$57.4 million) as the lead investor in the series A equity financing round of MML. The capital and business alliance agreement with NFES (the “NFES Agreement”) contained certain other commercial terms, including granting NFES certain benefits as the sole designated distributor, and status as one of three main distributors, of MOTHER Bracelet® and MOTHER Gateway products domestically. Furthermore, the NFES Agreement designated NFES as the only third- party distributor of MOTHER Bracelet® and MOTHER Gateway products to end users through e-commerce channels, provided that MML may sell its products directly to end users through its e-commerce stores. On August 17, 2026, MML and NFES terminated the capital alliance by mutual agreement. Transactions under the NFES Agreement have nevertheless been substantially suspended as a result of NFES’s financial condition, and we do not currently expect NFES to act as a significant distribution channel for MML’s products. In connection with that termination, NFES transferred all of the 556 series A preferred shares of MML that it held to three third parties, and NFES is no longer a shareholder of MML. These were transfers of outstanding shares by NFES and did not change MML’s issued share capital or our ownership interest in MML. The transferees of the shares are not parties to the NFES Agreement. The exclusivity arrangements described above ceased to apply upon the termination of the capital alliance, and the distribution arrangement between MML and NFES continues on a non-exclusive basis.

The NFES Agreement required that MML return, to the fullest extent permitted under law, the proceeds of NFES’s investment if MML is unable to obtain any necessary patents, licenses or rights relating to the thermoelectric charging functionality of its products. This provision ceased to apply upon the termination of the capital alliance and NFES’s transfer of its shares in MML on August 17, 2026.

Agreement with Elematec Corporation

In October 2024, MML and Elematec Corporation (“Elematec”) entered into a capital and business alliance agreement (the “Elematec Agreement”). Under the Elematec Agreement, Elematec participated in MML’s series A financing round by purchasing 556 newly issued series A preferred shares of MML for a total price of JPY100,080 thousand (US$638 thousand). The Elematec Agreement also provides, among other commitments, that MML will exclusively outsource to Elematec the procurement of components for and manufacturing of MML’s recharge-free wearable devices that use thermoelectric generator technology (“Recharge-Free Wearables”), such as the MOTHER Bracelet 2.0, and accessory devices such as the MOTHER Gateway. Elematec will also have a right of first offer to handle the procurement of components for, and manufacturing of, any next generation or improved Recharge-Free Wearable devices. In addition, under the Elematec Agreement, Elematec will sell MOTHER Bracelets on a non-exclusive basis.

The Elematec Agreement includes customary termination provisions and may be terminated if MML loses the right to use the thermoelectric generator technology it has licensed from Matrix Industries, Inc. In the event that Elematec terminates the

50


Table of Contents

 

Elematec Agreement, it will have a right to have its series A preferred shares repurchased by MML at the original purchase price of JPY180,000 (US$1,148.0) per share or the fair value of the preferred shares at the time of Elematec’s repurchase demand, whichever is higher. The business alliance with Elematec remains in effect as of the date of this annual report.

Under the Elematec Agreement, MML has made certain commitments regarding the time to be dedicated to MML’s business by Kouji Eguchi, our Chief Executive Officer, and Yoshio Uekusa, the Representative Director of MML. MML has also committed that Messrs. Eguchi and Uekusa will not engage in certain activities that would compete with MML’s business while such persons are a shareholder, officer or employee of MML and for a period of two years thereafter.

Proof of Human Verification Services

In December 2025, we entered into a Master Services Partnership Operator Agreement with Tools for Humanity Corp. and a Master Service Agreement with Tools for Humanity and the World Foundation, under which we are responsible for the deployment and operation of “Orb” biometric verification devices in Japan. Services under these agreements commenced in February 2026, and the agreements remain in effect as of the date of this annual report. During the year ended December 31, 2025, we performed Orb verifications as a subcontractor under the outsourcing arrangement described above. The Orb devices perform “Proof of Human” verifications that issue a World ID to the verified individual. We deploy the devices at our relaxation salon locations.

In January 2026, we entered into a further Master Service Agreement with Tools for Humanity and the World Foundation. The agreement became effective on February 2, 2026. Cumulative verifications performed through Orb devices at our locations surpassed 20,000 as of December 28, 2025 and 50,000 in July 2026.

Since August 2026, following a change in the operating policy of Tools for Humanity, we have provided these services under a hosting model, under which we provide locations for Orb devices and individuals complete the verification on a self-service basis. Under this model, we receive a fixed monthly fee of JPY50,000 for each Orb device installed, at 47 locations, and we no longer receive the fees based on the number of individuals verified that we received previously. See “—Subsequent Events—Change in Operating Model for Proof of Human Verification Services.”

We expect revenue from this arrangement to be non-recurring in nature. Revenue from Proof of Human verification services is included within other revenues of our Digital Preventative Healthcare segment and is not presented as a separate reportable segment. See “Item 3. Key Information—D. Risk Factors—A portion of our recent revenue is attributable to a single commercial arrangement that we expect to be non-recurring.”

Business Restructuring

In response to our operating losses and liquidity constraints, we have been implementing a comprehensive restructuring plan. The principal elements of the plan are (i) closing or transferring relaxation salons that do not meet our profitability thresholds, (ii) consolidating overlapping corporate functions across our group companies and reducing headcount, (iii) reducing selling, general and administrative expenses, including officer compensation, and (iv) evaluating the disposition of non-core businesses and assets. During the year ended December 31, 2025, we opened three salons and closed 19 salons. As of the date of this annual report, we have not entered into any definitive agreement with respect to, and our board of directors has not approved, any disposition of non-core businesses or assets.

Subsequent Events

Financing Arrangements with Kufu Company Holdings Inc.

On January 30, 2026, we entered into a Deemed Loan Agreement with Kufu Company Holdings Inc. (“Kufu”) in the principal amount of JPY200,000 thousand, bearing interest at 10.0% per annum. To secure our obligations under the loan agreement, we pledged all of the shares we hold in MEDIROM MOTHER Labs Inc., granting Kufu a first-priority security interest in those shares. The loan agreement provides for repayment by December 30, 2026. On the same day as the loan agreement, we and Kufu entered into a memorandum of understanding under which Kufu consented in advance to prepayment of the loan and agreed that interest would cease to accrue after March 31, 2026 if we repaid the loan in full by that date. We did not repay the loan by that date, and we and Kufu have since entered into further memoranda on substantially the same terms on a monthly basis, under which we pay the interest accrued through the preceding month-end. These memoranda do not affect the maturity date of December 30, 2026 under the loan agreement. On July 14, 2026, in lieu of cash repayment of our Fourth Unsecured Convertible-Type Corporate Bonds with Share Options in the principal amount of JPY275,000 thousand, we and Kufu amended the loan agreement to refinance the entire principal amount of those bonds as a loan, increasing the aggregate principal amount outstanding under the loan agreement to JPY475,000 thousand, and amended the share pledge agreement to secure the increased amount. The amendment confirmed that the interest rate of 10.0% per annum, the maturity date of December 30, 2026 and the other terms of the original loan agreement apply to the combined principal amount, and the pledge covers 48,219 common shares of MEDIROM MOTHER Labs Inc. Following the refinancing, Kufu ceased to beneficially own any of our common shares.

51


Table of Contents

 

Nasdaq Continued Listing

On May 26, 2026, we received a notice from Nasdaq stating that we were not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of our failure to timely file this annual report. We submitted a compliance plan on a timely basis, and Nasdaq granted us an extension until November 12, 2026 to regain compliance. Pursuant to the extension letter, in the event the Company does not satisfy the terms, Staff will provide written notification that its securities will be delisted. On November 13, 2026, we received a determination notification from Nasdaq because we had not filed this annual report within the extension period granted by Nasdaq and therefore remained noncompliant with Nasdaq Listing Rule 5250(c)(1). On November 18, 2026, we timely requested a hearing before a Nasdaq Hearings Panel to appeal the determination and request an extended stay of any trading suspension pending the hearing.

 

In addition, on October 6, 2026, we received a written notification from Nasdaq stating that we were not in compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), based on the closing bid price of the ADSs for the 31 consecutive business days from August 24, 2026 to October 5, 2026. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided 180 calendar days, or until April 5, 2027, to regain compliance. To regain compliance, the ADSs must have a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. The notification does not affect the listing of the ADSs on The Nasdaq Capital Market at this time. If we do not regain compliance by April 5, 2027, we may be eligible for an additional period to regain compliance, or the ADSs may become subject to delisting. See “Item 3. Key Information—D. Risk Factors.”

Change in Operating Model for Proof of Human Verification Services

Since August 2026, following a change in the operating policy of Tools for Humanity, we have provided our Proof of Human verification services in Japan under a hosting model, under which we provide locations for Orb devices and individuals complete the verification on a self-service basis. Under this model, we receive a fixed monthly fee of JPY50,000 for each Orb device installed, at 47 locations, and we no longer receive the fees based on the number of individuals verified that we received previously. As a result, from August 2026 our revenue from these services no longer varies with the number of verifications performed.

Refinancing of Second Convertible Bonds into a Loan

On August 25, 2026, we entered into a series of agreements with Triple One Investment Limited Partnership, the holder of our Second Unsecured Convertible-Type Corporate Bonds with Share Options in the aggregate principal amount of JPY300,000 thousand, under which we redeemed all of the bonds prior to their maturity and concurrently borrowed JPY300,000 thousand from Triple One Investment Limited Partnership, with our obligation to pay the redemption price and its obligation to advance the loan being settled by set-off. As a result, none of the Second Unsecured Convertible-Type Corporate Bonds with Share Options remains outstanding. The loan originally bore interest at 5.0% per annum, had an initial maturity date of September 15, 2026, and is secured by a pledge over all of the shares of MEDIROM Rehab Solutions Inc. that we hold and by security over the operating rights of ten salons that we operated when the security was granted. The loan was not repaid on its initial maturity date. On November 11, 2026, the lender and we entered into an agreement amending the loan, under which the maturity of the principal was extended to December 30, 2026, of which JPY5,000 thousand is repayable on November 30, 2026 and the balance on the maturity date. Interest accruing on and after November 1, 2026 accrues at 14.6% per annum, calculated on a 365-day year, and is payable monthly at each month-end rather than together with the principal at maturity. If the parties agree to extend the maturity further, JPY15,000 thousand of the principal will be repayable on December 30, 2026 and JPY10,000 thousand at each month-end thereafter, with the balance on the extended maturity date. The amendment does not release or reduce any obligation that had already accrued under the loan. As of the date of this annual report, the principal amount under the loan of JPY300,000 thousand remained outstanding.

Third Convertible Bonds

The maturity date of our Third Unsecured Convertible-Type Corporate Bonds with Share Options in the aggregate principal amount of JPY400,000 thousand, which was originally June 30, 2026, has been extended to December 25, 2026 pursuant to our option under the terms of the bonds, and the conversion period has accordingly been extended to December 7, 2026. As of September 30, 2026, none of these bonds had been converted into our common shares.

Rollover of Bank Borrowings

The unsecured bank loan of JPY350,000 thousand and the bank loan of JPY191,671 thousand that were scheduled to mature on March 31, 2026 have each been rolled over; the JPY191,671 thousand loan now matures on March 31, 2027 and the JPY350,000 thousand loan is currently due on November 30, 2026.

Merger of Subsidiaries

52


Table of Contents

 

As part of the consolidation of overlapping corporate functions under our restructuring plan, Medirom Shared Services Inc. merged into MEDIROM Wellness Co., with MEDIROM Wellness Co. as the surviving company, effective on November 1, 2026. Both companies were our wholly-owned subsidiaries, and we do not expect the merger to have a material effect on our consolidated financial position or results of operations.

Termination of Planned Acquisition of Japan Gene Medicine Corporation

On October 31, 2026, we and the seller entered into a termination agreement, pursuant to which the share transfer agreement dated June 30, 2024 relating to the acquisition of 70% of the issued and outstanding common shares of Japan Gene Medicine Corporation, and the related memorandum of understanding, were terminated by mutual agreement of the parties. As a result, we no longer intend to acquire any equity interest in Japan Gene Medicine Corporation.

Assignment of Long-Term Accounts Receivable

On October 11, 2026, we entered into a receivable assignment agreement with an individual purchaser who is not affiliated with us, pursuant to which we assigned the entire long-term accounts receivable—other due from an unrelated business entity, in the principal amount of JPY197,475 thousand as of December 31, 2025, for a purchase price of JPY100 thousand. The assignment became effective upon our receipt of the purchase price, which we received on October 13, 2026, and we notified the obligor of the assignment by an instrument bearing a certified date, as required to perfect the assignment against the obligor under the Civil Code of Japan. Under the agreement, we are also entitled to receive 20% of any amount that the purchaser collects from the obligor, or receives upon a resale of the receivable, during the three years following the effective date. We had recorded a full allowance for credit losses against this receivable as of December 31, 2025, and the assignment therefore did not have a material effect on our financial position or results of operations.

Regulations Governing our Relaxation Salons

Relaxation salons such as ours are not currently regulated by the Japanese government. The main law in Japan governing the massage industry is the Act on Practitioners of Massage, Acupressure, Acupuncture and Moxibustion, and etc. (Act No. 217 of 1947). However, we do not market or provide massage, finger pressure, acupuncture, moxa-cauterization or other services regulated under this Act, and this information is clearly provided to all customers prior to them receiving our salon services.

Regulations Governing our Franchises

Japan has antitrust laws that protect consumers and regulate how companies operate their businesses. Among the various Japanese antitrust laws, the seminal antitrust law is the Act on Prohibition of Private Monopolization and Maintenance of Fair Trade (Act No. 54 of 1947, as amended) (which we refer to as the “Antimonopoly Act”). The Antimonopoly Act prohibits certain activities that inappropriately induce or mislead persons into entering into a business relationship with us through our granting of seemingly preferable trade terms and conditions that could create false impressions in relation to other franchisors we compete with.

The Japan Fair Trade Commission (which we refer to as the “JFTC”) enforces the Antimonopoly Act and other Japanese antitrust laws. The JFTC issued the “Guidelines Concerning the Franchise System Under the Antimonopoly Act” on April 24, 2002 (last amended on April 28, 2021) (which we refer to as the “Guidelines”), under which the JFTC suggests that, prior to entering into a franchise relationship, a franchisor should adequately disclose and explain material trade terms to a potential franchisee in order to prevent any misunderstanding of the material trade terms, and to prevent such potential franchisee from being misled or improperly induced into entering into such franchise relationship. Material trade terms include terms relating to the following:

•
the supply of products after the party becomes a franchisee (such as a system for recommending suppliers);
•
guidance, procedures, frequency, and cost to the franchisee relating to the business activities of the franchise;
•
nature and amount of payments to be collected when the party joins the franchise, whether the payments are refundable or may be returned, and the conditions for refunding or returning the payments;
•
royalties that the franchisee pays to the franchisor for use of trademarks and trade names and for guidance relating to management procedures, including the amount of, procedure for calculating, and the time and method of payment, of royalties;
•
loans the franchisor extends to the franchisee, including the interest rate and the mechanism and conditions of settlement;
•
compensation for any losses the business incurs, including the details of such compensation and whether there is management support from the franchisor in the event of a decline in business;

53


Table of Contents

 

•
terms of the franchise agreement and the conditions and procedures for renewing or terminating the franchise agreement, including early termination prior to the expiration of its term; and
•
restrictions with respect to the franchisor or other franchisees of the franchise setting up an identical or similar business near the proposed business of the potential party to join the franchise, including whether there are any plans to set up additional businesses and the details of such plans.

In addition, when a franchisor markets its franchise, in the event such franchisor provides a prospective franchisee with an estimate of the revenue or profit that could possibly be generated upon becoming a franchisee, such estimated revenue or profit must be based on a reasonable method of calculation and established facts, such as the results of an existing franchise operating in a similar environment. The franchisor is required to present to the prospective franchisee such methods and facts. The Guidelines also suggest that, in explaining business hours and temporary closures, a franchisor should provide to a prospective franchisee then-known information that may adversely impact management of the franchise, such as the occurrence of a shortage of human resources during specified business hours or a rapid increase in personnel costs.

In terms of trades between a franchisor and franchisees after entry into a franchise agreement, the Guidelines provide suggestions that the franchisor should not place franchisees at an undue disadvantage, which could be deemed an “abuse of superior bargaining position” or other violation of law.

If the JFTC finds any activities that violate the Antimonopoly Act, including any “deceptive customer inducement”, then the JFTC may order the offending franchisor to cease and desist from engaging in such unlawful activities, delete any applicable unlawful clauses from the franchise contract, or carry out any other measures necessary to eliminate such unlawful activities.

In the event the JFTC suspects any violation of the Antimonopoly Act or alleges that we have misled or wrongly induced any of our franchisees based upon any particular trade terms, we could be exposed to risks, including governmental action against us.

Regulations Governing Prepaid Cards

We began issuing our prepaid Re.Ra.Ku® Cards to relaxation salon customers starting in December 2008.

Re.Ra.Ku® Card users can continuously use and, until February 1, 2024, could also replenish their card balances at our relaxation salons. Prepaid cards are generally considered “prepaid payment methods” (which we refer to as “PPMs”) under the Act on Settlement of Funds (Act No. 59 of 2009) (which we refer to as the “Settlement Act”). PPMs are regulated under the Settlement Act so long as there is a possibility that the cards could be valid for a period of more than six months. The Re.Ra.Ku® Cards currently do not have expiration dates and therefore are regulated under the Settlement Act.

Issuers of prepaid cards with a validity of longer than six months are referred to as “PPM Providers.” There are two categories of PPM Providers:

(i)
a provider of prepaid cards that can only be used to purchase goods or services from that same provider or its affiliates, referred to as a “Private Use PPM Provider”; and
(ii)
a provider of prepaid cards that can be used at third party establishments, referred to as “Public Use PPM Providers.”

The Re.Ra.Ku® Card can be used at salons operated by our franchisees, which are considered third parties for the purposes of the Settlement Act. As such, we are considered a Public Use PPM Provider. A Public Use PPM Provider must file an application with the Kanto Local Financial Bureau and be allowed for a registration to issue PPM cards. On September 30, 2016, our registration was accepted by the Kanto Local Financial Bureau.

A PPM Provider typically holds a certain amount of its customers’ cash in the form of prepaid amounts on the cards that have not yet been exchanged for goods or services. The total of such amounts for all customers of a PPM Provider is referred to as the “Outstanding Amount.” A Public Use PPM Provider is required to maintain deposits of at least half of its Outstanding Amount at the local Legal Affairs Bureau (although other arrangements are possible), in order to ensure that there are adequate funds for the card holders who are effectively loaning their money to the Public Use PPM Provider through their purchase of the prepaid card. At the end of March and September each year, the Public Use PPM Provider must calculate its Outstanding Amount and deposit half that amount at the Legal Affairs Bureau within two months. In the following year, if the Outstanding Amount has increased, the Public Use PPM Provider must pay the difference between such Outstanding Amount and the amount deposited with the Legal Affairs Bureau. We made our initial deposit of our Outstanding Amount with the Legal Affairs Bureau on November 28, 2016 and have made additional deposits and adjustments with each semi-annual reporting.

One of the requirements for issuers of prepaid cards under the Settlement Act is to maintain net assets of not less than JPY100 million based on Japanese GAAP. As of December 31, 2022, our net assets had fallen below JPY100 million based on Japanese GAAP on a standalone basis. On March 20, 2023, we reported the matter to the Kanto Local Financial Bureau.

54


Table of Contents

 

However, as of December 31, 2023, our net assets exceeded the JPY100 million threshold on a standalone basis, meaning that we satisfied the net asset test as of that date. We have satisfied the net asset requirement at each fiscal year end since then, including as of December 31, 2025. We have maintained our registration as a Public Use PPM Provider and have continued to comply with the applicable requirements, including the deposit requirement. Deposits are returned to us twice a year to the extent they exceed the amount required based on the Outstanding Amount.

Given the heavy burden imposed on us as a Public Use PPM Provider, we decided to introduce a new payment system and developed “Re.Ra.Ku PAY”, a proprietary payment app which works on customers’ smart phones. The most important difference between the Re.Ra.Ku Card and Re.Ra.Ku PAY is that balances on Re.Ra.Ku PAY have an expiration period of 150 days, while Re.Ra.Ku Card balances do not have an expiration date. The Settlement Act regulates only prepaid cards with balances that remain effective for more than six months. Hence, by limiting the expiration period to less than six months, Re.Ra.Ku PAY can be exempted from the regulations and requirements under the Settlement Act, which include the net assets requirement and an obligation to deposit half of the prepaid balance to the Legal Affairs Bureau.

As a supplemental alternative to Re.Ra.Ku PAY, primarily for customers who are not familiar with smartphone applications, we also introduced seasonal paper-based prepaid tickets in October 2024. These tickets provide a small discount compared to paying with cash and have expirations of less than 180 days, depending on marketing campaigns.

We disallowed further balance deposits on Re.Ra.Ku Cards beginning on February 1, 2024. Accordingly, we expect the total balance of funds on Re.Ra.Ku Cards to decrease, as customers can only use their Re.Ra.Ku Cards for payment, and the deposited amount to the Legal Affairs Bureau to be refunded to us over time as the total balance of funds on Re.Ra.Ku Cards decreases. As of December 31, 2025, the unused balance on Re.Ra.Ku Cards was JPY230,036 thousand (US$1,467 thousand), of which JPY121,527 thousand (US$775 thousand) was on deposit with the Legal Affairs Bureau.

Personal Information Protection

We are subject to laws and regulations regarding privacy and protection of user data and personal information, due to our customer data collection operations in connection with our Digital Preventative Healthcare Segment. The application and interpretation of these and other similar international laws and regulations regarding privacy and protection of user data and personal information is often uncertain, particularly with respect to the new and rapidly evolving industry in which we operate.

In Japan, the Act on the Protection of Personal Information (which we refer to as the “APPI”) and its related guidelines impose various requirements on businesses, including us, that use databases containing personal information. Under the APPI, we are required to lawfully use personal information we have obtained within the purpose of use we have specified and take appropriate measures to maintain the security of such personal information. We are also restricted from providing personal information to third parties without the consent of the applicable user. The APPI also includes regulations relating to the handling of sensitive personal data and anonymous personal data and the transfer of personal information to foreign countries. We collect information from our relaxation salon customers through the questionnaire completed by each first-time customer. Some of the information we collect through that questionnaire could fall under the category of sensitive personal data under the APPI.

We obtained the “PrivacyMark” certification in Japan in July 2022, and we have since renewed the certification, which remains in effect. “PrivacyMark” is a certification which is given to enterprises that take appropriate measures to protect personal information. The “PrivacyMark” System was established by the Japan Information Processing Development Corporation (JIPDEC) in April 1998, and the “PrivacyMark” is certified and granted by JIPDEC as well as other designated organizations. Such private enterprises are granted the right to display “PrivacyMark” in the course of their business activities. The system is in compliance with Japan Industrial Standards (JIS Q 15001: Personal Information Protection Management System - Requirements). This “PrivacyMark” certification is highly valued and provides credibility. Therefore, it is often required by our business associates in the Digital Preventative Healthcare Segment, including health insurance providers, hospitals, and nursing homes. We intend to continue to take actions necessary to maintain this certification.

In connection with the Proof of Human verification services described above, the biometric data used to issue a World ID is collected and processed by Tools for Humanity and the World Foundation through the Orb device. We do not receive, access or retain that data, and the information we are able to obtain through the Orb App is limited to the locations at which verifications are performed and the number of verifications. We do not provide to Tools for Humanity or the World Foundation any personal information of our salon customers, including customers who elect to complete a verification at one of our locations, and we have not received any biometric data from them; the personal information of our salon customers is maintained separately and continues to be handled by us in accordance with the APPI. Under our agreement with Tools for Humanity and the World Foundation, we are required to maintain a privacy compliance program, including a designated point of contact and an incident response process for data breaches, which we maintain, and we would be required to notify them, and to comply with their data processor agreement, if we were to receive personal data of users. We have not received any such data.

55


Table of Contents

 

 

img205519096_14.jpg

 

C.
Organizational Structure

Please see a detailed discussion of our organization structure under “Item 4.A. History and Development of the Company.” Our principal operating subsidiaries as of November 12, 2026 are as follows:

 

 

 

Jurisdiction

 

Percentage
Interest Held

MEDIROM Wellness Co. (formerly Wing Inc.)

 

Japan

 

100%

SAWAN CO. LTD.

 

Japan

 

100%

ZACC Kabushiki Kaisha

 

Japan

 

100%

MEDIROM MOTHER Labs Inc.

 

Japan

 

93.71%

MEDIROM Rehab Solutions Inc.

 

Japan

 

100%

 

D.
Property, Plants and Equipment

Please see a detailed discussion of our property, plants and equipment under “Item 4. Information of the Company—Property and Equipment”.

ITEM 4.A. UNRESOLVED STAFF COMMENTS

None.

ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the sections of this annual report entitled “Information on the Company”, and our consolidated financial statements and related notes thereto, included elsewhere in this annual report. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our current plans, expectations, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this annual report, particularly in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.”

We have prepared our consolidated financial statements in accordance with U.S. GAAP. Our fiscal year ends on December 31 and references to fiscal years 2023, 2024, and 2025 are to the fiscal years ended December 31, 2023, 2024 and 2025, respectively. In accordance with Instruction 6 to Item 5 of Form 20-F, we are omitting from this annual report a discussion of our results of operations for fiscal year 2023. For a discussion of our results of operations for the fiscal year ended December 31, 2024 compared with the fiscal year ended December 31, 2023, see “Item 5. Operating and Financial Review and Prospects—A. Operating Results” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, as filed with the SEC on April 29, 2025.

Overview

Our principal business is to own, develop, operate, manage, and support relaxation salons through franchising, through direct ownership of such salons, or through selling salons to investors and managing such salon operations on behalf of the investors, throughout Japan. We seek to be the leading provider of relaxation and bodywork services in the markets we serve and to become the most recognized brand in our industry through the steady and focused expansion of relaxation salons in key markets throughout Japan and potentially abroad.

We have suspended, for the time being, the opening of new salons and the development of additional franchises. We have also suspended, for the time being, growth through acquisitions, and our current strategy gives the highest priority to improving the profitability of our existing salons and growing revenue in our Digital Preventative Healthcare business. Under this strategy,

56


Table of Contents

 

we evaluate the profitability of each salon on an ongoing basis, seek to improve the performance of underperforming salons, and close or transfer salons that do not meet our profitability thresholds.

As of December 31, 2025, we and our franchisees operated 292 salons, of which 148 were operated as Company-owned salons, 70 were operated by our franchisees, and 74 were investor-owned salons which the Company operated on their behalf. We consider both Company-owned salons and investor-owned salons which are managed by us as “directly-operated salons”.

Key Financial Definitions

Revenue. Revenue consists of the following items: revenue from directly-operated salons, franchise revenue, and other revenues.

Cost of Revenue. The total cost of delivering services to customers consists of the following items: cost of goods sold, subcontract expenses, cost of franchise royalty and affiliation revenue, salon operating cost, salaries for therapists, legal and welfare expenses, provision for paid annual leave, travelling expenses, salon rent, depreciation and amortization, gain/loss from asset retirement obligation, interest expenses for asset retirement obligation, business consignment expenses, and others.

Selling, General and Administrative Expenses. Selling, general and administrative expenses, or SG&A, includes the costs to sell and deliver services and the costs to manage the company as follows: directors’ compensations, salaries and allowances, bonuses, legal welfare expenses, provision for paid annual leave, recruiting expenses, travel expenses, advertising expenses, rent, taxes and duties, commission fees, compensations, depreciation and amortization, provision for doubtful accounts, and others.

Impairment Loss on Long-lived Assets. Long-lived assets include property and equipment, right-of-use lease assets, internal use software, and definite-lived intangible assets. The Company reviews the carrying value of long-lived assets for impairment whenever events or circumstances occur that indicate that the carrying value of the assets may not be recoverable. If the assets are not deemed to be recoverable, an impairment is recorded if the fair value of the asset grouping is less than the carrying value.

Non-U.S. GAAP Measures

Adjusted EBITDA. We define Adjusted EBITDA as net income (loss), adjusted to exclude: (i) dividend and interest income, (ii) interest expense, (iii) gain from bargain purchases, (iv) income tax expense, (v) depreciation and amortization, (vi) losses on sales of directly-owned salons to franchisees, (vii) gains (losses) on disposal of property and equipment, and other intangible assets (viii) impairment loss on long-lived assets and (ix) stock-based compensation expense. Management considers Adjusted EBITDA to be a measurement of performance which provides useful information to both management and investors.

We use Adjusted EBITDA to enhance our understanding of our operating performance, which represents our views concerning our performance in the ordinary, ongoing and customary course of our operations. We historically have found it helpful, and believe that investors have found it helpful, to consider an operating measure that excludes certain expenses relating to transactions not reflective of our core operations. Stock-based compensation expense represents non-cash charges related to equity awards granted by us. Our management believes the measurement of these amounts can vary considerably from period to period and depend substantially on factors that are not direct consequences of the performance of our Company. Therefore, our management believes that excluding these expenses facilitates comparisons of our operational results and financial performances in different periods, as well as comparisons against similarly determined non-GAAP financial measures of comparable companies.

The information about our operating performance provided by this financial measure is used by our management for a variety of purposes. We regularly communicate Adjusted EBITDA results to our board of directors, and we discuss with the board our interpretation of such results. We also compare our Adjusted EBITDA performance against internal targets as a key factor in evaluating our periodic operating performance at each salon level, segment level, and consolidated level, largely because we believe that this measure is indicative of how the fundamental business is performing and is being managed.

Adjusted EBITDA Margin. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA for a period by total revenue for the same period. We believe this measure is useful to investors because it presents Adjusted EBITDA relative to revenue and facilitates comparisons of that relationship across periods. Management uses Adjusted EBITDA margin to assess changes in performance relative to revenue.

Adjusted EBITDA and Adjusted EBITDA margin are supplemental non-U.S. GAAP financial measures and should not be considered in isolation or as substitutes for net income (loss), net income (loss) margin, cash flows from operating activities or other measures prepared in accordance with U.S. GAAP. These measures exclude items that affect our reported results, some of which may recur, and do not represent cash available for discretionary expenditures. Other companies may calculate similarly titled measures differently, limiting their usefulness for comparisons with our measures.

57


Table of Contents

 

Key Performance Indicators

In assessing the performance of our relaxation business, we consider several key performance indicators used by management. We receive monthly performance reports from our system and our relaxation salons which include key performance indicators per salon including sales, number of customers, number of newly-acquired customers, number of repeat customers, sales per customer, and operation ratio. We believe these indicators provide us with useful data with which to measure our performance and to measure the performance of our own and our franchisees’ relaxation salons.

These key indicators include:

•
Number of Salons. The number of relaxation salons, including both directly-operated relaxation salons and franchisees’ relaxation salons.
•
Number of Salons with Data. The number of relaxation salons for which comparable financial and customer data is available because they are integrated with our cloud-based customer relationship management, point of sale and reservation system, “PeakManager.” We refer to such salons as “Salons with Data.” When we expand our services to salons with existing operations, including through acquisitions, we seek to transition such salons to PeakManager when practicable. Accordingly, the proportion of Salons with Data has increased over time compared to the overall Number of Salons.
•
Total Customers Served. The number of customers served at Salons with Data, based on the total number of visits regardless of the customer’s identity.
•
Sales Per Customer. Total salon sales divided by total customer served at Salons with Data.
•
Repeat Ratio. The ratio of customers served who visited multiple times during the applicable month or other stated period to Total Customers Served in the applicable month or other stated period for Salons with Data.
•
Operation Ratio. The ratio of therapists’ in-service time to total therapists’ working hours (including stand-by time) for the applicable month or other stated period for Salons with Data.
•
Sales of store operating rights. The number of specific salon locations for which operating rights have been sold to third-party investors during the applicable period as well as the aggregate gross contractual value from such sales. The sale of store operating rights does not involve the succession or assignment of leases or real estate contracts. Upon the transfer of the operating rights, the purchaser becomes entitled to the profit that the salon generates and bears any operating losses that it incurs. We continue to hold the lease for the salon premises and to operate the salon on the purchaser’s behalf under a service agreement, under which we are reimbursed the costs of operating the salon and are entitled to a success fee out of the profit in excess of the purchaser’s target return. This metric is presented on a gross contractual basis and comprises the aggregate contractual value of the sale contracts we executed in the applicable period. It includes locations that we sold to certain purchasers, subsequently repurchased and then resold to other purchasers, together with the gross contractual value of those transactions, and it includes arrangements that, for accounting purposes, are combined with a contemporaneous repurchase from the same purchaser or are presented on a net basis because we act as an agent. The gross contractual value shown by this metric therefore differs from the revenue from the sale of directly-owned salons recognized in our consolidated financial statements, and this metric is not a substitute for that revenue. See Note 1 to our consolidated financial statements included elsewhere in this annual report. We believe this metric is useful because it helps track our progress in transitioning to a more asset-light business model, a strategy we began to implement in late 2021, and indicates the aggregate value of sales contracts we have executed in the applicable period in connection with this transition.

58


Table of Contents

 

The following table sets forth the above key performance indicators for the periods presented:

 

 

 

Number

 

 

Number

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

of

 

 

of Salons

 

 

Customers

 

 

Sales Per

 

 

Repeat

 

 

Operation

 

 

 

Salons

 

 

with Data

 

 

Served

 

 

Customer

 

 

Ratio

 

 

Ratio

 

January 2023

 

 

312

 

 

 

266

 

 

 

77,657

 

 

JPY

 

6,624

 

 

 

77.9

%

 

 

48.3

%

February 2023

 

 

312

 

 

 

266

 

 

 

71,707

 

 

JPY

 

6,612

 

 

 

78.5

%

 

 

47.3

%

March 2023

 

 

311

 

 

 

273

 

 

 

78,063

 

 

JPY

 

6,680

 

 

 

77.4

%

 

 

45.8

%

April 2023

 

 

313

 

 

 

284

 

 

 

83,130

 

 

JPY

 

6,669

 

 

 

77.0

%

 

 

47.2

%

May 2023

 

 

314

 

 

 

284

 

 

 

86,895

 

 

JPY

 

6,660

 

 

 

75.7

%

 

 

47.5

%

June 2023

 

 

314

 

 

 

287

 

 

 

81,280

 

 

JPY

 

6,801

 

 

 

76.0

%

 

 

46.7

%

July 2023

 

 

315

 

 

 

290

 

 

 

88,240

 

 

JPY

 

6,985

 

 

 

76.0

%

 

 

48.1

%

August 2023

 

 

316

 

 

 

291

 

 

 

87,224

 

 

JPY

 

6,946

 

 

 

74.6

%

 

 

48.0

%

September 2023

 

 

315

 

 

 

290

 

 

 

84,393

 

 

JPY

 

6,991

 

 

 

76.7

%

 

 

47.0

%

October 2023

 

 

315

 

 

 

291

 

 

 

82,249

 

 

JPY

 

6,891

 

 

 

77.4

%

 

 

45.4

%

November 2023

 

 

313

 

 

 

289

 

 

 

75,290

 

 

JPY

 

7,045

 

 

 

77.5

%

 

 

43.9

%

December 2023

 

 

314

 

 

 

290

 

 

 

83,124

 

 

JPY

 

7,271

 

 

 

77.7

%

 

 

46.7

%

January 2024

 

 

311

 

 

 

287

 

 

 

74,533

 

 

JPY

 

7,147

 

 

 

76.8

%

 

 

44.7

%

February 2024

 

 

311

 

 

 

287

 

 

 

71,376

 

 

JPY

 

7,099

 

 

 

77.6

%

 

 

44.9

%

March 2024

 

 

312

 

 

 

288

 

 

 

77,854

 

 

JPY

 

7,190

 

 

 

77.9

%

 

 

45.7

%

April 2024

 

 

308

 

 

 

285

 

 

 

74,621

 

 

JPY

 

7,143

 

 

 

75.9

%

 

 

43.5

%

May 2024

 

 

307

 

 

 

284

 

 

 

80,512

 

 

JPY

 

6,964

 

 

 

74.8

%

 

 

44.9

%

June 2024

 

 

308

 

 

 

285

 

 

 

82,656

 

 

JPY

 

7,061

 

 

 

75.6

%

 

 

47.4

%

July 2024

 

 

309

 

 

 

286

 

 

 

81,580

 

 

JPY

 

7,060

 

 

 

75.0

%

 

 

46.6

%

August 2024

 

 

307

 

 

 

283

 

 

 

83,770

 

 

JPY

 

7,144

 

 

 

75.1

%

 

 

47.3

%

September 2024

 

 

308

 

 

 

284

 

 

 

82,401

 

 

JPY

 

7,158

 

 

 

75.8

%

 

 

48.0

%

October 2024

 

 

307

 

 

 

282

 

 

 

79,571

 

 

JPY

 

6,923

 

 

 

76.6

%

 

 

45.5

%

November 2024

 

 

308

 

 

 

283

 

 

 

75,760

 

 

JPY

 

7,055

 

 

 

77.5

%

 

 

44.6

%

December 2024

 

 

308

 

 

 

283

 

 

 

80,764

 

 

JPY

 

7,384

 

 

 

77.6

%

 

 

45.9

%

January 2025

 

 

308

 

 

 

284

 

 

 

75,451

 

 

JPY

 

7,145

 

 

 

76.4

%

 

 

44.8

%

February 2025

 

 

308

 

 

 

283

 

 

 

69,781

 

 

JPY

 

7,107

 

 

 

77.0

%

 

 

45.5

%

March 2025

 

 

307

 

 

 

283

 

 

 

77,315

 

 

JPY

 

7,208

 

 

 

77.8

%

 

 

45.6

%

April 2025

 

 

304

 

 

 

281

 

 

 

75,391

 

 

JPY

 

7,196

 

 

 

77.6

%

 

 

45.4

%

May 2025

 

 

303

 

 

 

280

 

 

 

80,631

 

 

JPY

 

7,100

 

 

 

76.3

%

 

 

46.1

%

June 2025

 

 

304

 

 

 

281

 

 

 

77,715

 

 

JPY

 

7,266

 

 

 

77.3

%

 

 

46.3

%

July 2025

 

 

302

 

 

 

279

 

 

 

76,544

 

 

JPY

 

7,389

 

 

 

77.0

%

 

 

44.8

%

August 2025

 

 

299

 

 

 

275

 

 

 

82,780

 

 

JPY

 

7,530

 

 

 

76.5

%

 

 

48.4

%

September 2025

 

 

299

 

 

 

274

 

 

 

72,236

 

 

JPY

 

7,498

 

 

 

76.9

%

 

 

44.9

%

October 2025

 

 

295

 

 

 

273

 

 

 

69,669

 

 

JPY

 

7,445

 

 

 

77.8

%

 

 

43.3

%

November 2025

 

 

293

 

 

 

273

 

 

 

67,800

 

 

JPY

 

7,621

 

 

 

79.4

%

 

 

43.9

%

December 2025

 

 

292

 

 

 

272

 

 

 

70,499

 

 

JPY

 

7,926

 

 

 

77.8

%

 

 

44.1

%

 

The following table sets forth sales of store operating rights for the periods presented.

 

 

 

Number of
Locations for Which
Store Operating
Rights Sold

 

 

Gross Contractual
Value from Sales
of Store Operating
Rights (in thousands)

 

Year ended December 31, 2023

 

 

38

 

 

JPY

 

1,710,500

 

Year ended December 31, 2024

 

 

60

 

 

JPY

 

2,563,705

 

Year ended December 31, 2025

 

 

43

 

 

JPY

 

1,742,064

 

 

Our Number of Salons was 292 as of December 31, 2025, compared to 308 as of December 31, 2024. The decrease reflects the closure of 19 salons, partly offset by the opening of three salons, as we closed salons that did not meet our profitability thresholds under our restructuring plan.

The number of Salons with Data was 272 as of December 31, 2025, compared to 283 as of December 31, 2024.

59


Table of Contents

 

Total Customers Served was 895,812 for the year ended December 31, 2025, compared to 945,395 in the year ended December 31, 2024. We believe this decrease was primarily due to a decline in the number of new customers, which we attribute to increased consumer price levels in Japan, and to the decrease in the number of salons we operated.

Sales per Customer were JPY7,364 (US$47) in the year ended December 31, 2025, an increase from JPY7,111 (US$45) in the year ended December 31, 2024. We believe the increase is primarily attributable to our improved ability to recommend courses and treatment plans that match customer needs.

Our Repeat Ratio was 77.3% in the year ended December 31, 2025, an increase from 76.3% in the year ended December 31, 2024. We believe this increase was primarily due to the campaigns we conducted, including sales of discounted prepaid tickets, which increased the frequency of visits by our repeat customers.

Our Operation Ratio was 45.3% in the year ended December 31, 2025, a slight decrease from 45.7% in the year ended December 31, 2024. We believe this decrease was partly due to the allocation of certain operational staff from our salon business to promotional activities related to the issuance of World ID, which we began in September 2025 in collaboration with Tools for Humanity. We also believe the decrease reflects the decline in the number of new customers described above.

We sold the operating rights of 43 salon locations in the year ended December 31, 2025, as compared to 60 locations in the year ended December 31, 2024 and 38 locations in the year ended December 31, 2023. Revenue from the sale of directly-owned salons was JPY1,365,914 thousand (US$8,711 thousand) in the year ended December 31, 2025, as compared to JPY2,328,005 thousand (US$14,847 thousand) in the year ended December 31, 2024. We believe the decrease is primarily attributable to the smaller number of salons sold, reflecting our focus on improving the profitability of our existing salons.

Factors Impacting our Operating Results

We expect that our results of operations will be affected by a number of factors and will primarily depend on the global economy, general market conditions, customer preference, and the competitive environment.

Our revenues, operating results and financial performance are impacted by a multitude of factors, including, but not limited to:

Business Environment. According to the 2022 Yano Report, which is the most recent report on this topic published by Yano, the relaxation market continues to see industry consolidation and notable category entrants from athletic and personal training services, and body stretching. We believe that market share will be further transferred to the category leaders in the industry, as smaller, private operators sell their businesses for retirement and/or market competition reasons, which industry trends, as we believe, may benefit us if realized.

Cost of Services. The cost of service of relaxation business has been increasing. In our relaxation business, a substantial majority of our personnel are paid wages at or close to the statutory minimum wage. For the past decade, such minimum wage has been continuously increasing throughout Japan. In 2012, the minimum wage in Tokyo was JPY850 (US$5.42), but had risen to JPY1,072 (US$6.84) as of December 31, 2022, according to the Ministry of Health, Labor and Welfare. The trend continued in 2023 and in 2024. The minimum wage in Tokyo increased annually by 3.8% to JPY1,113 (US$7.10) as of December 31, 2023, by 4.5% to JPY1,163 (US$7.42) as of December 31, 2024, and by 5.4% to JPY1,226 (US$7.82) as of December 31, 2025. To mitigate the effect of rising wages and the related social insurance premiums, we have been actively converting therapists from employment contracts to independent contractor agreements under which their compensation is linked to the sales they generate. As a result, the number of contractor therapists increased during 2025, and the statutory social insurance and labor insurance premiums for our relaxation salon business decreased by JPY4,862 thousand in the year ended December 31, 2025 compared to the year ended December 31, 2024.

In addition, we are facing inflationary trends in general prices, including utility costs, due to factors such as geo-political developments and the recovery of the Japanese economy. We have updated our service prices in May 2023 as part of a renewal of our primary service lines in order to deal with such increased costs, as well as to adjust to the long-term trend of minimum wage increases. We may also consider further updates to our service prices to reflect such increases in our costs in the future.

Update of Business Model. Since the fourth quarter of 2021, we have sought to become more asset-light by selling our owned salons to third-party investors and continuing to operate these sold salons on behalf of the investors. We believe this model will maximize the return on capital investment in our relaxation salon segment and allow us to accelerate salon openings by reinvesting the proceeds from the sales of salons, improve operational efficiency by focusing on salon operations, and generate additional income from the salons that were sold to investors and are under our management. In 2025, we sold 43 salons, while we sold 60 salons in 2024.

60


Table of Contents

 

Specific Health Guidance Program. In our Digital Preventative Healthcare Segment, we have been continuously involved in the Specific Health Guidance Program, promoted by the Ministry of Health, Labor and Welfare of Japan, which utilizes our upgraded Lav® application. We also provide similar services to employees at large corporations who are below the age of forty and are not eligible for the Specific Health Guidance Program. The total number of active subscription orders from corporate insurance associations, counting each association once even where it has contracted for both programs, was 102 as of December 31, 2025, compared with 97 as of December 31, 2024 and 74 as of December 31, 2023. The total number of users who participated in our Specific Health Guidance Program or the program for younger generations was 3,582 in the year ended December 31, 2025, compared with 3,129 in the year ended December 31, 2024 and 2,803 in the year ended December 31, 2023.

Business Restructuring. In response to our operating losses and liquidity constraints, we began implementing a comprehensive restructuring plan during the year ended December 31, 2025. The plan includes closing or transferring salons that do not meet our profitability thresholds, consolidating overlapping corporate functions across our group companies, and reducing selling, general and administrative expenses. Actions taken under the plan during the year ended December 31, 2025 included closing 19 salons, transferring 43 salons to investor-owners and continuing to convert therapists from employment contracts to commission-based independent contractor agreements. The plan is still being implemented, and the effects of individual actions cannot be separated from the other factors affecting our results of operations, so we have not quantified the effect of the plan as a single amount; its effects are reflected in the individual line items discussed in this section. We expect the plan to continue to affect our results of operations in future periods. See “Item 4. Information on the Company—Business Restructuring.”

Proof of Human Verification Services. Since June 2025, we have performed “Orb” biometric verifications at our salon locations, initially under an outsourcing agreement with a Japanese advertising agency that acts as the primary contractor for Tools for Humanity in Japan, All of the verifications performed during the year ended December 31, 2025 were performed under that outsourcing arrangement. In December 2025, we entered into a Master Services Partnership Operator Agreement directly with Tools for Humanity and the World Foundation, and services under that agreement commenced in February 2026. As of December 31, 2025, Orb devices were installed at 139 of our locations, and the cumulative number of verifications performed at our locations was 20,440. Revenue from these services for the year ended December 31, 2025 was JPY32,619 thousand. Revenue from these arrangements is included within other revenues of our Digital Preventative Healthcare segment. We expect this revenue on per-verification basis to be non-recurring. In addition, since August 2026 we have operated under a hosting model under which we receive a fixed fee for each device installed and no longer receive fees based on the number of individuals verified, as described in “Item 4. Information on the Company—Subsequent Events—Change in Operating Model for Proof of Human Verification Services.” Accordingly, comparisons of our results of operations between periods that include amounts attributable to this arrangement may not be indicative of our underlying operating performance.

Payment Schedule for Taxes and Social Insurance Premiums. As of December 31, 2025, we had national and local taxes and social insurance premiums that were past due in the aggregate amount of JPY250,154 thousand, for which we have agreed revised payment schedules with the relevant authorities, principally relating to interim consumption tax payments and withheld income tax. We are making payments in accordance with those schedules.

Cost of Financing. Our cost of financing increased during the year ended December 31, 2025 and has continued to increase thereafter. Our deemed loan from Kufu Company Holdings Inc. bears interest at 10.0% per annum, compared to an interest rate of 1.875% per annum on our short-term bank loans and a weighted average interest rate of 2.96% per annum on our long-term borrowings as of December 31, 2025.

61


Table of Contents

 

A.
Operating Results

Comparison of the Results for the Year Ended December 31, 2025 and December 31, 2024

 

(in thousands, except change % data and Adjusted EBITDA margin)

 

Year ended December 31,

 

 

Change (2025 vs 2024)

 

Consolidated Statement of Operations:

 

2025($)

 

 

2025(¥)

 

 

2024(¥)

 

 

$

 

 

¥

 

 

%

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Relaxation Salon

 

 

44,972

 

 

¥

7,051,584

 

 

¥

7,446,200

 

 

$

(2,517

)

 

¥

(394,616

)

 

 

(5.3

)%

Luxury Beauty

 

 

3,455

 

 

 

541,767

 

 

 

699,301

 

 

 

(1,005

)

 

¥

(157,534

)

 

 

(22.5

)%

Digital Preventative Healthcare

 

 

1,073

 

 

 

168,270

 

 

 

153,633

 

 

 

93

 

 

¥

14,637

 

 

 

9.5

%

Total revenue

 

 

49,500

 

 

 

7,761,621

 

 

 

8,299,134

 

 

 

(3,428

)

 

¥

(537,513

)

 

 

(6.5

)%

Cost of revenues and operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

38,445

 

 

 

6,028,244

 

 

 

6,052,849

 

 

 

(157

)

 

¥

(24,605

)

 

 

(0.4

)%

Selling, general and administrative expenses

 

 

16,417

 

 

 

2,574,145

 

 

 

2,241,515

 

 

 

2,121

 

 

¥

332,630

 

 

 

14.8

%

Impairment loss on long-lived assets and goodwill

 

 

16,269

 

 

 

2,550,953

 

 

 

22,872

 

 

 

16,123

 

 

¥

2,528,081

 

 

 

—

%

Total cost of revenues and operating expenses

 

 

71,131

 

 

 

11,153,342

 

 

 

8,317,236

 

 

 

18,087

 

 

¥

2,836,106

 

 

 

34.1

%

Operating income (loss)

 

 

(21,631

)

 

¥

(3,391,721

)

 

¥

(18,102

)

 

$

(21,515

)

 

¥

(3,373,619

)

 

 

—

%

Other income (expenses):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dividend income

 

 

0

 

 

 

2

 

 

 

2

 

 

 

—

 

 

 

—

 

 

 

—

%

Interest income

 

 

1

 

 

 

110

 

 

 

8

 

 

 

1

 

 

¥

102

 

 

 

—

%

Interest expense

 

 

(422

)

 

 

(66,185

)

 

 

(49,745

)

 

 

(105

)

 

¥

(16,440

)

 

 

—

%

Gain from sales of salons

 

 

992

 

 

 

155,525

 

 

 

40,631

 

 

 

733

 

 

 

114,894

 

 

 

282.8

%

Other, net

 

 

(231

)

 

 

(36,194

)

 

 

74,919

 

 

 

(709

)

 

¥

(111,113

)

 

 

—

%

Total other income

 

 

340

 

 

 

53,258

 

 

 

65,815

 

 

 

(80

)

 

¥

(12,557

)

 

 

(19.1

)%

Income tax (benefit) expense

 

 

1,940

 

 

 

304,118

 

 

 

(90,478

)

 

 

2,517

 

 

¥

394,596

 

 

 

—

%

Net income (loss)

 

 

(23,231

)

 

 

(3,642,581

)

 

 

138,191

 

 

 

(24,112

)

 

¥

(3,780,772

)

 

 

—

%

Adjusted EBITDA(1)

 

 

(1,215

)

 

¥

(190,484

)

 

¥

417,467

 

 

$

(3,877

)

 

¥

(607,951

)

 

 

—

%

Adjusted EBITDA margin(2)

 

 

(2.5

)%

 

 

(2.5

)%

 

 

5.0

%

 

 

 

 

 

 

 

(7.5)pt.

 

 

(1)
For a reconciliation of Adjusted EBITDA to net loss, the most comparable U.S. GAAP measure, see the following table.

 

Reconciliation of non-GAAP measures:

 

Year ended December 31,

 

(in thousands, except Adjusted EBITDA margin)

 

2025($)

 

 

2025(¥)

 

 

2024(¥)

 

Net income (loss)

 

$

(23,231

)

 

¥

(3,642,581

)

 

¥

138,191

 

 

 

 

 

 

 

 

 

 

 

Dividend income and interest income

 

 

(1

)

 

 

(112

)

 

 

(10

)

Interest expense

 

 

422

 

 

 

66,185

 

 

 

49,745

 

Income tax expense (benefit)

 

 

1,940

 

 

 

304,118

 

 

 

(90,478

)

Depreciation and amortization

 

 

3,397

 

 

 

532,657

 

 

 

290,038

 

(Gains) losses on disposal of property and equipment, net, other
   intangible assets, net and goodwill

 

$

(11

)

 

 

(1,704

)

 

 

7,109

 

Impairment loss on long-lived assets and goodwill

 

 

16,269

 

 

 

2,550,953

 

 

 

22,872

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

 

(1,215

)

 

¥

(190,484

)

 

¥

417,467

 

Net income (loss) margin

 

 

(46.9

)%

 

 

(46.9

)%

 

 

1.7

%

Adjusted EBITDA margin

 

 

(2.5

)%

 

 

(2.5

)%

 

 

5.0

%

 

Revenues

Total revenues decreased by JPY537,513 thousand, or 6.5%, to JPY7,761,621 thousand in the year ended December 31, 2025 from JPY8,299,134 thousand in the year ended December 31, 2024. Revenue from our Relaxation Salon segment decreased by JPY394,616 thousand, or 5.3%. The decrease principally reflected lower revenue from the sale of directly-owned salons, which was JPY1,365,914 thousand in 2025 compared to JPY2,218,605 thousand in 2024, a decrease of JPY852,691 thousand, and lower franchise revenue, which decreased by JPY158,636 thousand. These decreases were partially offset by an increase of JPY616,711 thousand in revenue from our directly-operated salons, from JPY4,435,512 thousand to JPY5,052,223 thousand. Revenue from our Luxury Beauty segment decreased by JPY157,534 thousand, or 22.5%. Revenue from our Digital Preventative Healthcare segment increased by JPY14,637 thousand, or 9.5%. The decrease in revenue from our Luxury Beauty segment principally reflected the absence in 2025 of revenue from the sale of directly-owned salons, which was JPY109,400 thousand in the year ended December 31, 2024, together with a decrease in revenue from directly-operated salons and franchise fees from JPY589,901 thousand to JPY541,767 thousand (which include franchise fees of JPY550 thousand and JPY600 thousand, respectively). The increase in revenue from our Digital Preventative Healthcare segment principally reflected revenue of JPY32,619 thousand from our Proof of Human verification services.

62


Table of Contents

 

Cost of revenues and operating expenses

Cost of revenues remained substantially unchanged at JPY6,028,244 thousand in the year ended December 31, 2025, compared to JPY6,052,849 thousand in the year ended December 31, 2024, despite the decrease in revenue, principally reflecting personnel costs at our directly-operated salons. Within cost of revenues, the cost of revenue from directly-operated salons increased by JPY173,903 thousand, the cost of franchise revenue decreased by JPY119,962 thousand, reflecting the decrease in franchise revenue, and the cost of other revenues decreased by JPY78,546 thousand, principally because sales of MOTHER Bracelet® and Gateway devices, which carry product costs, declined substantially, while the increase in other revenues was attributable to our Proof of Human verification services, which do not involve comparable product costs.

Selling, general and administrative expenses increased by JPY332,630 thousand, or 14.8%, to JPY2,574,145 thousand in the year ended December 31, 2025 from JPY2,241,515 thousand in the year ended December 31, 2024. The increase principally reflected higher depreciation and amortization, which increased by JPY257,548 thousand from JPY176,413 thousand in the year ended December 31, 2024 to JPY433,961 thousand in the year ended December 31, 2025. The inclusion for a full year in 2025, compared with three months in 2024, of the rehabilitation business that MEDIROM Rehab Solutions Inc. acquired on October 1, 2024 increased personnel and advertising expenses, but that increase was more than offset at the consolidated level by decreases elsewhere: our advertising expenses decreased from JPY155,362 thousand to JPY147,747 thousand and the payroll expenses included in selling, general and administrative expenses decreased from JPY718,456 thousand to JPY677,694 thousand. The remaining increase of JPY75,082 thousand was attributable to other components of selling, general and administrative expenses.

Impairment loss on long-lived assets and goodwill was JPY2,550,953 thousand in the year ended December 31, 2025, compared to JPY22,872 thousand in the year ended December 31, 2024. The impairment loss for 2025 comprised JPY1,903,458 thousand in the Relaxation Salon segment (including goodwill impairment of JPY179,385 thousand), JPY392,079 thousand in the Luxury Beauty segment (including goodwill impairment of JPY167,241 thousand), JPY96,656 thousand in the Digital Preventative Healthcare segment and JPY158,760 thousand in corporate and eliminations. See Note 4 and Note 16 to our consolidated financial statements included elsewhere in this annual report.

Operating loss

As a result of the foregoing, we recorded an operating loss of JPY3,391,721 thousand in the year ended December 31, 2025, compared to an operating loss of JPY18,102 thousand in the year ended December 31, 2024.

Other income (expenses)

Total other income decreased by JPY12,557 thousand, or 19.1%, to JPY53,258 thousand in the year ended December 31, 2025 from JPY65,815 thousand in the year ended December 31, 2024. Gain from sales of salons increased to JPY155,525 thousand from JPY40,631 thousand, and subsidies increased to JPY94,565 thousand from JPY13,855 thousand, while we recognized a loss on investment securities of JPY86,918 thousand and a loss on extinguishment of debt of JPY27,998 thousand in 2025. Interest expense increased by JPY16,440 thousand to JPY66,185 thousand, reflecting higher levels of borrowings and higher interest rates.

Income tax expense

We recorded income tax expense of JPY304,118 thousand in the year ended December 31, 2025, compared to an income tax benefit of JPY90,478 thousand in the year ended December 31, 2024, principally reflecting valuation allowances recorded against deferred tax assets. Changes in valuation allowances increased income tax expense by JPY1,392,896 thousand, and our effective income tax rate was (9.1)% in the year ended December 31, 2025, compared to the Japanese statutory tax rate of 34.6%.

Net loss

As a result of the foregoing, we recorded a net loss of JPY3,642,581 thousand in the year ended December 31, 2025, compared to net income of JPY138,191 thousand in the year ended December 31, 2024. Net loss attributable to shareholders of the Company was JPY3,634,280 thousand, and basic and diluted net loss per share was JPY459.92.

Comparison of the Results for the Year Ended December 31, 2024 and December 31, 2023

For a discussion of our results of operations for the fiscal year ended December 31, 2024 compared with the fiscal year ended December 31, 2023, see “Item 5. Operating and Financial Review and Prospects—A. Operating Results” in our annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the SEC on April 29, 2025.

B.
Liquidity and Capital Resources

Liquidity is a measure of our ability to meet potential cash requirements. As of December 31, 2025, we had cash and cash equivalents of JPY91,979 thousand (US$587 thousand), compared to JPY329,399 thousand as of December 31, 2024. We have generally funded our operations with cash flow from operations and sales of relaxation salons, and, when needed, with borrowings

63


Table of Contents

 

from Japanese financial institutions and other debt or equity financings. Our principal uses for liquidity have been to fund development of new salons, acquisitions of salons or relaxation businesses from franchisees or third parties, our daily operations, and general working capital purposes. We have suspended new salon openings for the time being, and we plan to continue to sell salon operating rights to investors to fund our operations and debt service. See “Item 4. Information on the Company—Our Growth Strategy.”

Going Concern

As of December 31, 2025, we had cash and cash equivalents of JPY91,979 thousand (US$587 thousand), a working capital deficit of JPY3,244,164 thousand, an accumulated deficit of JPY3,405,240 thousand and a shareholders’ deficit of JPY2,623,771 thousand. For the year ended December 31, 2025, we incurred a net loss of JPY3,642,581 thousand and had negative cash flows from operating activities of JPY1,155,007 thousand. As of December 31, 2025, our total interest-bearing debt was JPY2,401,507 thousand, of which JPY1,601,548 thousand matures within twelve months of that date. In addition, as of December 31, 2025, we had taxes and social insurance premiums that were past due in the aggregate amount of JPY250,154 thousand, for which we have agreed revised payment schedules with the relevant Japanese tax and social insurance authorities.

We do not expect that our cash and cash equivalents as of December 31, 2025, together with cash expected to be generated from operations, will be sufficient to fund our operating expenses, capital expenditure requirements and debt service obligations for the twelve months following the issuance date of the audit opinion for the financial statements included elsewhere in this annual report. These conditions raise substantial doubt about our ability to continue as a going concern.

Management’s plans to alleviate the conditions that raise substantial doubt include (i) restructuring our operations, including closing or transferring salons that do not meet our profitability thresholds, consolidating overlapping corporate functions and reducing selling, general and administrative expenses, (ii) continuing to sell salon operating rights to investors, (iii) refinancing and extending the maturities of our existing indebtedness, including the refinancing of our First Unsecured Convertible-Type Corporate Bonds with Share Options on December 31, 2025, the refinancing of our Fourth Unsecured Convertible-Type Corporate Bonds with Share Options into a loan on July 14, 2026 and the refinancing of our Second Unsecured Convertible-Type Corporate Bonds with Share Options into a loan on August 25, 2026, (iv) evaluating the disposition of non-core businesses and assets, and (v) seeking additional debt or equity financing. As of the date of this annual report, we have not entered into any definitive agreement with respect to, and our board of directors has not approved, any disposition of non-core businesses or assets.

With respect to clause (ii) above, the cash that our sales of salon operating rights generate is substantially less than the contractual value of those sales, because a significant portion of the consideration is settled other than in cash. For the year ended December 31, 2025, the total contractual value of the 43 salons sold was JPY1,742,064 thousand, whereas proceeds from the sale of salons reflected in our consolidated statements of cash flows were JPY540,140 thousand, with the balance settled through receivables or by offset against amounts payable on contemporaneous repurchases from the same purchaser. Over the same period we repurchased 47 salons for a total repurchase amount of JPY2,301,371 thousand, which exceeded the total contractual value of the salons sold during the year, and cash used for acquisitions of store operating rights, which includes salons repurchased from purchasers, was JPY491,184 thousand. As a result, the net cash generated by this element of our plans in 2025 was substantially smaller than the contractual value of the salons we sold, and the cash that it generates in future periods will depend on the mix of cash and non-cash settlement and on the extent of any repurchases. See Note 1 to our consolidated financial statements for the number of salons sold and repurchased and the related amounts.

Our ability to issue equity securities or obtain debt financing on acceptable terms, or at all, will depend on, among other things, our financial performance, general economic factors, the condition of the credit and capital markets, and the continued listing of the ADSs on Nasdaq, some of which are beyond our control. There are currently no written agreements in place for such funding or issuance of securities, and there can be no assurance that management’s plans will be effectively implemented. Accordingly, management’s plans have not alleviated the substantial doubt about our ability to continue as a going concern.

Cash Flows

The following table sets forth a summary of our cash flows for the periods indicated.

 

(in thousands)

 

Year ended December 31,

 

 

 

2025($)

 

 

2025(¥)

 

 

2024(¥)

 

 

2023(¥)

 

Net (loss) income

 

$

(23,231

)

 

¥

(3,642,581

)

 

¥

138,191

 

 

¥

115,049

 

Net cash used in operating activities

 

 

(7,366

)

 

 

(1,155,007

)

 

 

(1,331,681

)

 

 

(631,737

)

Net cash (used in) provided by investing activities

 

 

(143

)

 

 

(22,456

)

 

¥

361,393

 

 

¥

(328,576

)

Net cash (used in) provided by financing activities

 

 

5,995

 

 

 

940,043

 

 

 

1,193,340

 

 

 

461,206

 

Net (decrease) increase of cash and cash equivalents
   during the period

 

 

(1,514

)

 

 

(237,420

)

 

 

223,052

 

 

 

(499,107

)

Cash and cash equivalents at beginning of period

 

$

2,101

 

 

¥

329,399

 

 

¥

106,347

 

 

 

605,454

 

Cash and cash equivalents at end of period

 

$

587

 

 

¥

91,979

 

 

¥

329,399

 

 

¥

106,347

 

 

64


Table of Contents

 

 

Operating Activities

Net cash used in operating activities was JPY1,155,007 thousand (US$7,366 thousand) for the year ended December 31, 2025, compared to JPY1,331,681 thousand for the year ended December 31, 2024. Net cash used in operating activities in 2025 principally reflected our net loss of JPY3,642,581 thousand, adjusted for non-cash items, including impairment losses on long-lived assets and goodwill of JPY2,550,953 thousand, depreciation and amortization of JPY532,657 thousand, deferred income taxes of JPY285,882 thousand and a change in provision for credit losses of JPY54,913 thousand, and for gain from sales of directly-owned salons of JPY1,072,740 thousand, the proceeds of which are presented within investing activities. Changes in operating assets and liabilities included an increase in accounts receivable-trade of JPY184,142 thousand, which was partially offset by an increase in accounts payable of JPY52,732 thousand, a decrease in accounts receivable-other of JPY266,713 thousand and an increase in other current liabilities of JPY29,843 thousand.

Investing Activities

Net cash used in investing activities was JPY22,456 thousand (US$143 thousand) for the year ended December 31, 2025, compared to net cash provided by investing activities of JPY361,393 thousand for the year ended December 31, 2024. Proceeds from the sale of salons were JPY540,140 thousand (US$3,445 thousand) for the year ended December 31, 2025, compared to JPY908,419 thousand for the year ended December 31, 2024.

Cash used for capital investments for the year ended December 31, 2025 was JPY562,596 thousand (US$3,588 thousand), consisting of JPY491,184 thousand for acquisitions of store operating rights in connection with reacquisitions of salons from investors, JPY61,111 thousand for acquisitions of intangible assets and JPY10,301 thousand for acquisitions of property and equipment. In addition, purchases of store operating rights of JPY285,693 thousand were included in accrued expenses as of December 31, 2025 and are therefore not reflected in net cash used in investing activities for the year.

Financing Activities

Net cash provided by financing activities was JPY940,043 thousand (US$5,995 thousand) for the year ended December 31, 2025, compared to JPY1,193,340 thousand for the year ended December 31, 2024. In 2025, cash flows from financing activities principally consisted of proceeds from short-term borrowings of JPY1,263,338 thousand and repayments of short-term borrowings of JPY789,778 thousand, proceeds from long-term borrowings of JPY180,321 thousand and repayments of long-term borrowings of JPY116,752 thousand, and proceeds of JPY400,000 thousand from the issuance of our Third Unsecured Convertible-Type Corporate Bonds with Share Options in December 2025. In 2024, cash flows from financing activities included proceeds of JPY608,101 thousand from the issuance of common stock in a public offering and JPY260,280 thousand from the issuance of preferred stock by MEDIROM MOTHER Labs Inc.

For a discussion of our cash flows for the fiscal year ended December 31, 2024 compared with the fiscal year ended December 31, 2023, see “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources” in our annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the SEC on April 29, 2025.

Business Loans

As of December 31, 2025, we had short-term borrowings of JPY765,227 thousand (US$4,880 thousand) and long-term borrowings (including the current portion) of JPY631,280 thousand (US$4,026 thousand).

Our short-term borrowings as of December 31, 2025 consisted of (i) an unsecured bank loan of JPY350,000 thousand, bearing interest at 1.875% per annum and maturing on March 31, 2026, which is guaranteed by MEDIROM MOTHER Labs Inc.; (ii) a bank loan with an outstanding balance of JPY191,671 thousand, bearing interest at a floating rate based on the lender’s short-term prime rate, which was 1.875% per annum as of December 31, 2025, and maturing on March 31, 2026; (iii) a loan of JPY200,000 thousand from Kufu Company Holdings Inc. arising from the settlement of our First Unsecured Convertible-Type Corporate Bonds with Share Options on December 31, 2025, bearing interest at 10.0% per annum, maturing on December 30, 2026 and secured by a pledge of shares of MEDIROM MOTHER Labs Inc.; and (iv) a loan obtained by MEDIROM MOTHER Labs Inc. from a third party on June 23, 2025 with an outstanding balance of JPY23,556 thousand, bearing interest at 5.0% per annum, which originally matured on July 31, 2025 and was past due as of December 31, 2025. Interest at 14.6% per annum applied to this loan from December 2, 2025. This loan has subsequently been repaid in full. Our long-term borrowings mature at various dates through 2035 and had a weighted average interest rate of 2.96% per annum as of December 31, 2025. They include loans from Spirit Advisors to MEDIROM Wellness Co., which are denominated in U.S. dollars, bore interest at 8.0% per annum and had an outstanding balance of JPY156,530 thousand as of December 31, 2025, of which US$400 thousand was repayable in a lump sum on December 31, 2025 and US$600 thousand is repayable by December 31, 2027. On March 31, 2026, MEDIROM Wellness Co. and the lender entered into a loan amendment and restructuring agreement under which the loan that matured on December 31, 2025 (US$400 thousand) was restructured, together with accrued interest of US$15 thousand, into a loan bearing interest at 15.0% per annum from January 1, 2026, repayable in monthly installments from April 2026 with the final installment

65


Table of Contents

 

due in September 2027. The remaining loan of US$600 thousand bears interest at 15.0% per annum and must be repaid by December 31, 2027. Kouji Eguchi, our Chief Executive Officer and a director, is a guarantor with respect to six loans (three bank loans of the Company and three disbursements under the loan agreement with Spirit Advisors), the outstanding amount of which was JPY339,330 thousand as of December 31, 2025. Kazuyoshi Takahashi, the representative director of ZACC, is a personal guarantor of two loans of ZACC, the outstanding amount of which was JPY25,245 thousand, and Yoshio Uekusa, the representative director of MEDIROM MOTHER Labs Inc., is a guarantor of one loan of MEDIROM MOTHER Labs Inc., the outstanding amount of which was JPY23,556 thousand. None of the borrowing agreements contain any material financial covenants, although certain of the government-sponsored loans set a limit on the total loan amount we may borrow from other government-sponsored lenders.

Additional information regarding our borrowings is included in Note 6 to our consolidated financial statements, and information regarding certain refinancing transactions since December 31, 2025 is included in “Item 4. Information on the Company—Subsequent Events” and Note 19 to our consolidated financial statements.

In addition, we have a fundamental funding and treasury policy of (i) maintaining a balanced ratio of debt to equity, and (ii) aligning our repayment of loans with our cash flow from business. Historically, our primary use of funds from our loans was capital expenditures on newly opened directly-owned salons, and we sought debt financing with longer than three-year terms and equal monthly repayment amounts of principal and interest in order to align our debt repayment schedule with our cash flows from our salon business operations. Since we suspended new salon openings, we have used borrowings primarily to refinance existing indebtedness, including our convertible bonds, and to fund working capital, and certain of these borrowings are short-term and repayable in a lump sum. In order to avoid interest rate risk during the terms of the loans, we generally enter into borrowings with fixed interest rates, and accordingly do not enter into hedging arrangements. One of our bank loans bears interest at a floating rate based on the lender’s short-term prime rate. Since our primary business operations are in Japan, our borrowings from Japanese financial institutions are denominated in Japanese yen. We also have borrowings from parties that are not financial institutions, including Kufu Company Holdings Inc. and Triple One Investment Limited Partnership, and the loans from Spirit Advisors are denominated in U.S. dollars.

Convertible Bonds

As of December 31, 2025, we had JPY975,000 thousand (US$6,218 thousand) aggregate principal amount of convertible bonds outstanding, consisting of (i) JPY300,000 thousand of convertible bonds that we issued to Triple One Investment Limited Partnership, a Japanese limited liability investment partnership, in October 2024, (ii) JPY400,000 thousand of our Third Unsecured Convertible-Type Corporate Bonds with Share Options that we issued to 11 third-party investors on December 12, 2025, and (iii) JPY275,000 thousand of our Fourth Unsecured Convertible-Type Corporate Bonds with Share Options that we issued to Kufu Company Holdings Inc. on December 31, 2025.

The convertible bonds that we issued to Kufu Company Inc. in December 2022 in the aggregate principal amount of JPY500,000 thousand, the maturity date of which was amended to December 31, 2025 by an agreement dated November 1, 2024, were settled at maturity on December 31, 2025 as follows: (i) JPY275,000 thousand was refinanced through the issuance of our Fourth Unsecured Convertible-Type Corporate Bonds with Share Options to Kufu Company Holdings Inc.; (ii) JPY25,000 thousand was recorded in accounts payable at December 31, 2025 and paid after the year end; and (iii) JPY200,000 thousand was converted into a short-term loan from Kufu Company Holdings Inc., bearing interest at 10.0% per annum and secured by a pledge of shares of MEDIROM MOTHER Labs Inc. The exchange for the Fourth Unsecured Convertible-Type Corporate Bonds with Share Options was accounted for as an extinguishment of debt, and we recognized a loss on extinguishment of debt of JPY27,998 thousand for the year ended December 31, 2025.

The Third Unsecured Convertible-Type Corporate Bonds with Share Options are unsecured, accrue interest at a rate of 2.0% per annum and mature on June 30, 2026, subject to our option to extend the maturity date to December 25, 2026, unless earlier redeemed or converted. They are convertible into 1,166,175 common shares at a conversion price of JPY343 per share from December 12, 2025 to June 10, 2026 (or December 7, 2026 if the maturity date is extended). The Fourth Unsecured Convertible-Type Corporate Bonds with Share Options are unsecured, accrue interest at a rate of 5.0% per annum and mature on June 30, 2026, subject to our option to extend the maturity date to December 25, 2026, unless earlier redeemed or converted, and are convertible into 833,333 common shares at a conversion price of JPY330 per share from December 31, 2025 to June 29, 2026 (or December 24, 2026 if the maturity date is extended). For developments relating to these bonds after December 31, 2025, see “Item 4. Information on the Company—Subsequent Events.”

In October 2024, we issued corporate convertible bonds in the aggregate principal amount of JPY300,000 thousand (US$1,913 thousand) to Triple One Investment Limited Partnership, a Japanese limited liability investment partnership. The bonds are unsecured, accrue interest at a rate of 2.0% per annum, payable on June 30, 2025 and semi-annually thereafter, and will mature on October 29, 2027. At any time between October 25, 2024 and October 29, 2027, Triple One may convert each bond, which are issued in denominations of JPY100,000 thousand and may be converted in whole but not in part, into our common shares at a conversion price of JPY957 per share by exercising stock options that were issued to Triple One in connection with the bonds. In addition, there are certain conditions under the bond indenture, such as our failure to timely pay interest and remedy the

66


Table of Contents

 

nonpayment within a cure period, upon the occurrence of which Triple One is entitled to demand immediate repayment of the bonds. On August 25, 2026, we redeemed all of these bonds prior to their maturity and concurrently borrowed JPY300,000 thousand from Triple One, with the redemption price and the loan being settled by set-off. The loan originally bore interest at 5.0% per annum and had a maturity date of September 15, 2026, and was not repaid on that date. On November 11, 2026, the lender and we entered into an agreement amending the loan, under which the maturity of the principal was extended to December 30, 2026, with JPY5,000 thousand of the principal is repayable on November 30, 2026 and the balance on the maturity date. Interest accruing on and after November 1, 2026 accrues at 14.6% per annum and is payable monthly at each month-end. It is secured by a pledge of all of the shares of MEDIROM Rehab Solutions Inc. that we hold and by a pledge over the operating rights of ten salons that we operated when the security was granted. Two of those salons have since been transferred to third-party investors, and we are in discussions with the lender regarding the terms of the security agreement, which permits us to propose substituting the operating rights of other salons of equivalent value.

Corporate Bonds

On July 22, 2024, we issued corporate bonds in aggregate principal amount of JPY70,000 thousand to Tan Lee, an individual. On September 17, 2024, we repaid JPY40,000 thousand of such bonds. As of December 31, 2025, the outstanding balance of such corporate bonds was JPY30,000 thousand (US$191 thousand). The bonds bear interest at 6.0% per annum (2.0% per annum at issuance) and were scheduled to mature on April 30, 2026. On April 30, 2026, we and the holder agreed to extend the maturity date to December 31, 2026, at which date the amount payable will be JPY34,332 thousand (US$219 thousand), consisting of principal of JPY30,000 thousand and accrued interest of JPY4,332 thousand. The bonds have been neither repaid nor refinanced as of the date of this annual report.

Cash Commitments from Contractual and Other Obligations

Payments of contractual obligations and commitments will require considerable resources. In our ordinary course of business, we routinely enter into commercial commitments and financial obligations for various aspects of our operations. The following tables set forth the amount of our contractual obligations as of December 31, 2025

 

(in thousands JPY)

 

Payments due by period:

 

 

 

Total

 

 

Less than
1 year

 

 

1-3 years

 

 

More than
3 years

 

Long-term borrowings, corporate bonds and
   convertible bonds

 

 

1,636,560

 

 

 

836,321

 

 

 

612,085

 

 

 

188,154

 

Short-term borrowings

 

 

765,227

 

 

 

765,227

 

 

 

—

 

 

 

—

 

Operating lease obligations

 

 

1,807,946

 

 

 

778,051

 

 

 

791,638

 

 

 

238,257

 

Other obligations

 

 

7,583

 

 

 

1,795

 

 

 

5,788

 

 

 

—

 

Total

 

 

4,217,316

 

 

 

2,381,394

 

 

 

1,409,511

 

 

 

426,411

 

 

Research and Development, Patents and Licenses, etc.

Our research and development activities have been focusing on development of Lav® which is our on-demand health monitoring smartphone application, embedded software or smartphone application for our MOTHER Bracelet®, and development of REMONY®, a centralized monitoring system through which health data generated from MOTHER Bracelet® worn by end users can be collected and monitored by the staff of hospitals, nursing homes, and any other business clients. Costs and expenses in connection with these development activities are capitalized as software assets, which are amortized over three to five years.

Trend Information

For a discussion of material trends, uncertainties and other events that are reasonably likely to have a material impact on the Company, see “Operating Results” in Item 5.A. and “Liquidity and Capital Resources” in Item 5.B. above.

E.
Critical Accounting Estimates

Our consolidated financial statements are prepared in accordance with U.S. GAAP, which requires us to make a number of estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. We base our accounting estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. However, actual results may differ from those estimates. Our critical accounting policies are those that materially affect our consolidated financial statements and are subject to complex judgment by our management.

67


Table of Contents

 

Revenue Recognition

Revenues are recognized when control of the promised goods or services are transferred to the customers, in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.

The Company determines revenue recognition through the following steps:

Step 1: identification of the contract with a customer;

Step 2: identification of the performance obligations in the contract;

Step 3: determination of the transaction price;

Step 4: allocation of the transaction price to the performance obligations in the contract;

Step 5: recognition of revenue when, or as, the Company satisfies a performance obligation.

Revenue from Directly-Operated Salons

Revenues from directly-operated salons (including sales in the Luxury Beauty segment) are recognized when services are provided at the salons. The promised services for directly-operated salons are the services ordered by the end customer from the service menu. The services are provided in one appointment. Therefore, there is only one performance obligation. As the customer simultaneously receives and consumes the benefits of the relaxation services, the revenue is recognized over time using the delivery output method.

Revenue from prepaid cards is recognized when the services are transferred. When value is added to a prepaid card, the Company records a contract liability for its performance obligation to stand ready to transfer services in the future (or transfer funds to franchisee who provides service). When the services or funds are transferred, it derecognizes the contract liability and correspondingly recognizes revenue net of any funds transferred to franchisees. The Company expects to be entitled to a certain amount of breakage and recognizes revenue from breakage proportionately to the redemptions exercised by the customer.

The Company also sells salons to third-party investors. Developing and selling salons is a recurring part of the business model of the Relaxation Salon segment (the Company sold 43, 60 and 38 salons in 2025, 2024 and 2023, respectively, representing 18%, 28% and 15% of total revenues); accordingly, the sale of salons is considered part of the Company’s ongoing major or central operations and thus ordinary activities for the Company, and the third-party investors are considered as “customers”.

Therefore, the Company applies ASC 606 to these contracts. The store operating rights transfer agreement and the service agreement with an investor are negotiated as a package and entered into at the same time, and are accounted for as a single contract with two performance obligations: (i) transfer of the salon assets and business rights and (ii) outsourced salon operation services. The transfer price, which is determined based on the estimated profit of the salon and the yield expected by the investor, is allocated to (i), and the cost reimbursements and success fee under the service agreement are allocated to (ii), as these contractual prices represent their standalone selling prices. The revenue for the transfer of salon assets and business rights is recognized at a point in time when control of the salon transfers to the investor at the point of legal transfer. In connection with the sale of salons, the disposition of related salon assets, such as store equipment, leasehold improvements, store operating rights and goodwill, if applicable, is recorded in cost of revenue.

The Company may purchase sold salons back from third-party investors based on those investors’ demands and the Company’s business strategy. These repurchases are not subject to any contractual or implied repurchase obligations and, as such, do not preclude revenue recognition under ASC 606. There is no substantive repurchase right or obligation associated with these transactions, based on the absence of contractual guarantees or economic compulsion. If the Company enters into a salon purchase and sales agreement with the same investor on the same date or near the same date, the Company accounts for the agreements as a combined arrangement, under which the proceeds from the sale of the salon and the payment for the purchase of the salon are offset against each other, and the Company recognizes the noncash consideration and the difference between the carrying value of the sold salon and the transaction amount as other income or loss, which is included in gain from sales of salons in the consolidated statements of operations. Where the Company purchases a salon from one third-party investor and sells it to a different third-party investor on the same date, the Company’s performance obligation is to arrange for the provision of the salon by another party and the seller effectively controls the salon before it is transferred to the new investor; accordingly, the Company is considered to be an agent in these transactions and records the related revenue on a net basis. There is no significant financing component.

The Company classifies both cash inflows from salon sales and cash outflows related to salon repurchases as investing activities in the consolidated statements of cash flows in accordance with ASC 230-10-45-12(c), as they represent disposals and acquisitions of productive assets.

68


Table of Contents

 

The buyers of salons are entitled to enter into Service Agreements with the Company to manage the operations of the salons, for which the Company charges a fee. Revenue from the Service Agreement is recognized over the term of the agreement as services are provided. The customer benefits from the integrated service over the contract term and each time increment is substantially the same. Therefore, the outsourced salon operations are considered a “series” of distinct services and are treated as a single performance obligation. The term of the Service Agreement is typically five years. Under the Service Agreement, the Company is reimbursed for the costs of operating the salon, including leases. Although the Company invoices the investors for such costs annually, the Company’s right to consideration arises monthly as the costs are incurred and corresponds directly with the value of the services performed to date; accordingly, the Company recognizes revenue from the reimbursement of costs using the as-invoiced (right to invoice) practical expedient. The Company also receives, as a success fee, a portion of the salon’s profit in excess of the investor’s target yield. The success fee is consideration for the operation services, as the investor retains the target return and bears any operating losses of the salon, and is considered variable consideration. This success fee is constrained until it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.

Franchise Revenue

Franchise revenue is comprised of (i) franchise fees, (ii) royalty income, (iii) staffing service revenue, (iv) sublease revenue, and (v) other franchise revenues. The Company and the franchisee enter into a franchise agreement which sets forth the standard terms and conditions of operating the franchised salon, as well as the fees and royalties over the term of the agreement. In most cases, an outsourcing agreement is also entered into in conjunction with the franchise agreement that specifies the terms of the sublease arrangement with the franchisee. Upon the franchisee’s request, the Company’s therapists are dispatched to franchise locations and franchisees must pay dispatch fees in accordance with the dispatched employees’ position.

(i)
Franchise fees

The Company receives the entire non-refundable initial franchise fees from the franchisee based on franchise agreement. The franchise agreement typically has an initial term of five years. The services for operating the franchised salon provided by the Company under franchise contract are not separately identifiable within the contract, and are interrelated with the franchise right granted in the franchise agreement. As such the services are considered to represent a single performance obligation. The franchise agreement could be renewed prior to expiration by mutual consent and renewal franchise fees are paid by franchisee upon renewal of agreement. Initial franchise fees and expected renewal franchise fees are recognized as revenue ratably using the time-based input method over the expected average contract life (7 years), instead of the contract term, as there is a material right related to renewals.

(ii)
Royalty income

The Company collects royalties, an amount calculated by multiplying a certain percentage to gross sales, on a monthly basis. The royalties are subject to the sales- and usage-based royalties constraint and are recognized as revenues based on the monthly royalty earned where such amount is determined on the basis of gross sales made from each salon.

(iii)
Staffing service revenue

The Company also generates revenue from providing its therapists to franchisees, which are recognized as revenues based on the total number of working hours of the agency worker during the dispatched period. The Company has elected the ‘as-invoiced’ practical expedient for its staffing services where the fixed rate per hour is invoiced to the customer.

(iv)
Sublease revenue

The Company leases the premises in which the majority of its franchisees operate, where the Company retains the head lease primary obligation, and has entered into corresponding sublease arrangements with franchisees. Revenues from sublease transactions with franchisees are recognized on a straight-line basis over the respective operating lease terms, or at the time of the underlying sales for variable lease payments, in accordance with Accounting Standards Codification (“ASC”) 842 Leases (“ASC 842”).

(v)
Other franchise revenues

Other franchise revenues include other services provided to franchisees separately from the franchise agreements and include advertising, training, studio construction and hiring support. These services are primarily recognized as revenues when services are provided. The Company has elected the ‘as-invoiced’ practical expedient for its studio construction services where the consideration is invoiced to the customer.

69


Table of Contents

 

Other Revenues

Other revenues are primarily from the Digital Preventive Healthcare segment, which includes revenues from serving implementation of health and wellness programs (Specific Health Guidance Program), as well as wearable device service (MOTHER Bracelet®), and are recognized when services are provided or the ownership of products are transferred. The Company offers standard assurance-type warranties for its MOTHER Bracelet® which are not accounted for as a separate performance obligation and do not contain acceptance clauses.

See Note 13 to the consolidated financial statements included elsewhere in this annual report for further disclosures required under ASC 606.

Revenue is recognized net of consumption tax collected from customers and subsequently remitted to governmental authorities.

Leases

The Company considers whether a contract is a lease or if it contains a lease element when a contract is executed. If a contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration, such contract is determined to contain a lease element. When the contract contains a lease element, a lease is either classified as operating lease or finance lease when the Company is a lessee, and a sales-type lease or direct financing lease when the Company is a lessor.

The Company, as a lessee, applies the right-of-use model to account for lease transactions. Under the right-of-use model, right-of-use asset and lease liability are recognized at commencement date. The Company measures its lease liability at present value of future lease payments over the remaining term. The Company uses its incremental borrowing rate for the discount rate to calculate the present value of the payments since it is difficult and not practical to determine the interest rate implicit in the lease. The Company’s incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Right-of-use asset is initially measured as the initial amount of the lease liability, plus any lease payments made to the lessor before the lease commencement date, plus any initial direct costs incurred, minus any lease incentives received. When the Company determines a lease term, if a lease contract contains an option to extend its lease term, the Company is reasonably certain to exercise such option. This is mainly due to the severe economic loss the Company may face for not exercising the right of extension, such as recognizing impairment loss of attached facilities and loss resulting from failure to receive the franchise fee originally obtainable. Therefore, the lease term includes the extended term if the option to extend is exercised. Initial lease terms are generally between three and 10 years.

For operating leases, the Company recognizes the minimum lease payments where it is the lessee and the minimum lease income where it is the lessor on a straight-line basis over the lease term, and reflects them as rental expenses and rental revenues, respectively, in the consolidated statements of operations. The Company elected to separate lease and non-lease components and not to recognize leases with an initial term of 12 months or less.

Operating rental expense includes amortization of right-of-use assets and interests on lease liability. Variable lease expenses are primarily linked to sales and are excluded from the measurement of lease liability.

Rental expenses are recorded in the consolidated statements of (loss) income based on the nature of the underlying lease. Rental expense related to leases for directly-operated salons and for leased properties that are subsequently subleased to franchisees are recorded to “Cost of revenues,” and rental expense related to leases for corporate offices is recorded to “selling, general and administrative expenses.”

Rental income for operating leases on properties subleased to franchisees is recorded to “Franchise revenue”. Terms and conditions of the sublease agreements are arranged to pass through lease obligations under head leases to the franchisees. Sublease income is presented on a gross basis on the accompanying consolidated statements of income, as the Company remains the primary obligor.

For newly executed contracts, renewal and revision related to leases, estimates and certain assumptions are used to determine asset value, useful lives, discount rate, lease term, etc. and these have effects on (1) classification of lease, (2) measurement of rental payments and (3) measurement of lease asset. These results may differ if varying estimates and assumptions are used.

Impairment of Long-lived Assets, Excluding Goodwill

The Company assesses impairment of long-lived assets at the individual salon level, as this is the lowest level for which identifiable cash flows are largely independent of other groups of assets and liabilities. Long-lived assets include property and equipment, right-of-use lease assets, internal use software, and definite-lived intangible assets. The Company reviews the carrying

70


Table of Contents

 

value of long-lived assets for impairment whenever events or circumstances occur that indicate that the carrying value of the assets may not be recoverable.

The assets are considered to be impaired when the estimated undiscounted cash flows expected to result from the use of the assets and their eventual disposition are less than their carrying values. The undiscounted cash flows are estimated over the remaining useful life of the primary asset of the asset group or, for salon asset groups with store operating rights, over 10 years based on the Company’s lease renewal history. The impairment loss is measured as the amount by which the carrying value of the asset or asset group exceeds its fair value. Fair value is determined based on Level 3 inputs. The fair value of salon asset groups with store operating rights reacquired from investors is estimated using a market approach based on EBITDA multiples observed in the Company’s salon transactions with investors, and the fair value of asset groups with negative expected cash flows is estimated to be nil.

We recognized an impairment loss on long-lived assets of JPY2,204,327 thousand (US$14,058 thousand) in 2025 and JPY22,872 thousand (US$146 thousand) in 2024, while we recognized no impairment loss of long-lived assets in 2023. In addition, we recognized goodwill impairment losses of JPY346,626 thousand in 2025.

Income Taxes

Deferred income taxes reflect the impact of temporary differences between assets and liabilities recognized for financial reporting purposes and such amounts recognized for tax purposes and tax loss carryforwards. These deferred taxes are measured using the currently enacted tax rates in effect for the year in which the temporary differences or tax loss carryforwards and tax credits are expected to reverse.

Valuation allowances are provided against deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company considers all available evidence (both positive and negative) when determining whether a valuation allowance is required, with emphasis on its past operating results, the existence of cumulative losses in the most recent years and its forecast of near-term taxable income. The Company recognizes the financial statement effect of uncertain tax positions when it is more likely than not, based on the technical merits, that the tax positions will be sustained upon examination by the tax authorities. Benefits from tax positions that meet the more-likely-than-not recognition threshold are measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon settlement. The Company classifies interest and penalties related to income taxes, including those related to unrecognized tax benefits, if any, within selling, general and administrative expenses in the consolidated statements of operations.

Acquisitions

The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not we have acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.

If an acquisition is determined to be a business combination, the assets acquired and liabilities assumed are recorded at their respective estimated fair values at the date of the acquisition. Any excess of the purchase price over the estimated fair values of the identifiable net assets acquired is recorded as goodwill.

If an acquisition is determined to be an asset acquisition, the cost of the asset acquisition, including transaction costs, are allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. If the cost of the asset acquisition is less than the fair value of the net assets acquired, no gain is recognized in earnings. The excess fair value of the acquired net assets acquired over the consideration transferred is allocated on a relative fair value basis to the identifiable net assets (excluding non-qualifying assets).

Determining estimated fair value requires a significant amount of judgment and estimates. If assumptions change or errors are determined in our calculations, the fair value could materially change resulting in a change in goodwill or identifiable net assets acquired.

71


Table of Contents

 

In 2024, we acquired the rehabilitation business of Y’s Inc., with MEDIROM Rehab Solutions Inc., our 100% subsidiary, as the acquiring entity. For more details of the accounting treatments of the acquisition, see Note 2 to our consolidated financial statements.

Recently Issued Accounting Pronouncements Adopted

Segments

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures. The new standard requires enhanced disclosures about segment information and significant segment expenses. It does not change how a public entity identifies its operating segments. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The new standard has been applied retrospectively to all periods presented in Note 11.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disaggregated information about the effective tax rate reconciliation, using both percentages and reporting currency amounts for specific categories, and income taxes paid by jurisdiction. The Company adopted ASU 2023-09 for the year ended December 31, 2025 on a prospective basis. See Note 12 to our consolidated financial statements included elsewhere in this annual report. The adoption affected disclosures only.

Recently Issued Accounting Pronouncements Not Yet Adopted

Disclosure Improvements

In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements-Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This new standard modified the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC’s regulations. ASU 2023-06 will become effective for each amendment on the effective date of the SEC’s corresponding disclosure rule changes. The Company is currently evaluating the impact on its consolidated financial statements.

Comprehensive Income - Expense Disaggregation

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to disclose additional information about specific expense categories. In January 2025, the FASB issued ASU 2025-01 Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), which clarified the effective date for ASU 2024-03. These amendments are intended to provide more information about types of expenses in commonly presented expense captions. The amendments in this update are effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, and early adoption is permitted. The Company is currently evaluating the impact on the consolidated financial statements and related disclosures.

Debt-Debt with Conversion and Other Options

In November 2024, the FASB issued ASU 2024-04, Debt-Debt with Conversion and Other Options, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for annual reporting periods beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in ASU 2020-06. The Company will adopt ASU 2024-04 on January 1, 2026 and does not expect the adoption to have a material impact on its consolidated financial statements.

Business Combinations and Consolidation

In May 2025, the FASB issued ASU 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity, which requires an entity to consider the general factors in ASC 805 when identifying the accounting acquirer in an acquisition of a VIE that meets the definition of a business. ASU 2025-03 is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years, and is applied prospectively. The Company is currently evaluating the impact on its consolidated financial statements.

72


Table of Contents

 

Credit Losses

In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of current accounts receivable and current contract assets. ASU 2025-05 is effective for annual reporting periods beginning after December 15, 2025, including interim periods within those annual reporting periods, and is applied prospectively. The Company is currently evaluating the impact on its consolidated financial statements.

Internal-Use Software

In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which removes all references to software development project stages and requires capitalization of software costs when management has authorized and committed to funding the software project and it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, including interim periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the impact on its consolidated financial statements.

Government Grants

The FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which establishes guidance on the recognition, measurement and presentation of government grants received by business entities. ASU 2025-10 is effective for public business entities for annual reporting periods beginning after December 15, 2028, and interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-10 on its consolidated financial statements.

ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

A.
Directors and Senior Management

The following table sets forth the names, ages and positions of our executive officers and members of our board of directors and of our board of corporate auditors as of the date of this annual report. The business address of all of persons identified below is 2-3-1 Daiba, Minato-ku, Tokyo 135-0091, Japan.

 

Name

 

Age

 

Position(s) with our Company

Kouji Eguchi

 

51

 

Chief Executive Officer and Representative Director

Fumitoshi Fujiwara

 

59

 

Chief Financial Officer and Director

Akira Nojima

 

60

 

Independent Director

Tomoya Ogawa

 

48

 

Independent Director

Tsukasa Karyu*

 

69

 

Corporate Auditor

Osamu Sato*

 

64

 

Corporate Auditor

Toshiaki Komatsu*

 

51

 

Corporate Auditor

 

* Members of our statutory Board of Corporate Auditors are not members of our Board of Directors.

Biographical Information

The following is a summary of certain biographical information concerning our executive officers, directors, and corporate auditors.

Kouji Eguchi. Mr. Eguchi is the founder of our Company and has served as our Chief Executive Officer and as the representative director since our inception. Prior to founding our Company, he served as the head of the internet division at Carchs Co., Ltd (formerly Jac Holding Co., Ltd.) from April 1998 to April 1999, and as a board member of a subsidiary of Jac Holding Co., Ltd. from 1998 to 2002. Mr. Eguchi has also served as a director of the Association of Japan Relaxation Industry since 2010. In addition, Mr. Eguchi is the representative partner and 100% owner of COZY LLC. Mr. Eguchi received a Bachelor of Science degree in Marine Science and Technology from Tokai University.

Fumitoshi Fujiwara. Mr. Fujiwara has served as our Chief Financial Officer and a director on our board of directors since March 2017. Mr. Fujiwara is also a director of SBC Medical Group Holdings Incorporated, a position he assumed in September 2024. Mr. Fujiwara founded Eaglestone Capital Management and has served as its Chief Executive Officer since 2009, and founded Linden Capital Partners LLC and has served as its Managing Partner since 2023. Prior to Eaglestone, Mr. Fujiwara founded AC Capital Inc., a private equity company, in 2003. During his time at AC Capital, Mr. Fujiwara was instrumental in raising JPY20 billion of investment in Tully’s Coffee Japan leading up to its initial public offering, and also served as a

73


Table of Contents

 

representative director of AC Capital Inc. from June 2002 to June 2009. Prior to AC Capital, Mr. Fujiwara founded Star Capital Partners, Inc. in 2000 and served as its Chief Executive Officer until October 2001. Prior to Star Capital Partners, Mr. Fujiwara served as an executive partner and director of Spiralstar Japan, Inc. from October 2000 to October 2001. Prior to Spiralstar Japan, Mr. Fujiwara founded other companies and also held numerous positions at Shuwa Corporations and Koei Tecmo Holdings Co., Ltd. (formerly Koei Co. Ltd.), including those in the finance, real estate and investor relations departments. Mr. Fujiwara served as a director of the Japanese Association of Turnaround Professionals from 2003 to 2018, and also as an absentee director at Due Diligence Meister Inc., from October 2000 to March 2009. Mr. Fujiwara received a Bachelor of Arts degree in Law from Meiji Gakuin University.

Akira Nojima. Mr. Akira Nojima is an independent director and has served on our board of directors since April 2020. Mr. Nojima is also currently the Chief Executive Officer of No Track Inc. He is concurrently a professor at May Ushiyama Academy’s Hollywood Graduate School, teaching courses including management strategy of beauty salon, creative business theory, salon marketing theory, and bridal business theory. Prior to his current positions, Mr. Nojima worked at Recruit Holdings Co., Ltd. (formerly known as Recruit Co., Ltd.) for 27 years, where he held various positions, including officer in charge of education and learning, branch office president, and media production manager. Mr. Nojima has served as the vice president of Japan Cosmetic Licensing Association and a director of Academy of Beauty Business. Mr. Nojima holds the national license of career consultant and has received the Global Career Development Facilitator (Japan) credential. He is also a licensed workers’ health and safety manager in Japan. Mr. Nojima received a Bachelor of Arts degree in Law from Meiji Gakuin University.

Tomoya Ogawa. Mr. Ogawa is an independent director and has served on our board of directors since March 2014. Mr. Ogawa has diverse professional experience, including serving as the general manager of corporate planning at DeNA Inc. from 2010 to 2014, an attorney at the Abe, Ikubo & Katayama Law Firm from 2007 to 2010, and as a management consultant at Monitor Group from 2001 to 2004. Mr. Ogawa served as a director of Akatsuki Inc. until June 2020 and has been serving as an outside director of iSGS Investment Works Inc. since 2016. Mr. Ogawa currently serves as the CEO of Kreation Inc. Mr. Ogawa received a Juris Doctor degree from Hitotsubashi University School of Law, and a Bachelor of Arts degree in Economics from the University of Tokyo.

Tsukasa Karyu. Mr. Karyu has served as a corporate auditor of our Company since May 2018. Mr. Karyu founded the Karyu Tsukasa Tax Advisor Office in 2016, where he has been serving as outside tax advisor and providing tax related accounting services to various companies in Japan. Prior to founding Karyu Tsukasa Tax Advisor Office, he held various positions, including as Chief Tax Counselor at the Tokyo National Tax Bureau and its tax offices for 42 years until his retirement in 2016. Mr. Karyu received a Bachelor of Business and Commerce degree from Senshu University.

Osamu Sato. Mr. Sato has served as a corporate auditor of our Company since March 2014. Mr. Sato has served as a professor, director and research manager at Aoyama Gakuin University’s School of Business since April 1997. Prior to Aoyama Gakuin University, Mr. Sato was an assistant professor at Aomori Kouritsu University’s Economics Department from April 1993 to March 1997, and an assistant professor at Meijo University’s Commercial Science Department from 1991 to 1993. Mr. Sato has served as an outside director of Sanko Techno Co., Ltd., a Japanese company publicly listed on the Tokyo Stock Exchange, and as a non-executive corporate auditor of I.G.M. Holdings Inc. and Associa Small Amount and Short-Term Insurance Inc. Mr. Sato received a Doctor of Philosophy degree in Economics and Management from Tohoku University.

Toshiaki Komatsu. Mr. Komatsu was elected as a corporate auditor of our Company at the Ordinary General Meeting of Shareholders on March 29, 2021. Previously, Mr. Komatsu worked for Fujitsu Limited, and founded Photocreate Co., Ltd. In 2020. Currently, Mr. Komatsu serves as the chairman of the board of directors at Photocreate Taiwan Corp. and also as the director of IoT Development at Toho International Inc. Mr. Komatsu received a Master of Science from Graduate School of Engineering Science, Osaka University.

There is no family relationship among any of the directors, corporate auditors and officers. There is no arrangement or understanding among any of our directors and corporate auditors or any other person pursuant to which our directors and corporate auditors are appointed

Corporate Governance Practices

We are a “foreign private issuer” as defined under the federal securities laws of the United States and the NASDAQ listing standards. Under the federal securities laws of the United States, foreign private issuers are subject to different disclosure requirements than U.S.-domiciled public companies. We intend to take all actions necessary for us to maintain our status as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley Act, the Exchange Act and other applicable rules adopted by the SEC, and the NASDAQ listing standards. Under the SEC rules and the NASDAQ listing standards, a foreign private issuer is subject to less stringent corporate governance requirements. Subject to certain exceptions, the SEC and the NASDAQ permit a foreign private issuer to follow its home country practice in lieu of their respective rules and listing standards. In general, our articles of incorporation and the Companies Act of Japan (which we refer to as the “Companies Act”) govern our corporate affairs.

74


Table of Contents

 

In particular, as a foreign private issuer, we follow Japanese law and corporate practice in lieu of the corporate governance provisions set out under NASDAQ Rule 5600, the requirement in NASDAQ

Rule 5250(b)(3) to disclose third party director and nominee compensation, and the requirement in NASDAQ Rule 5250(d) to distribute annual and interim reports. Of particular note, the following rules under NASDAQ Rule 5600 differ from Japanese law requirements:

•
NASDAQ Rule 5605(b)(1) requires that at least a majority of a listed company’s board of directors be independent directors, and NASDAQ Rule 5605(b)(2) requires that independent directors regularly meet in executive session, where only independent directors are present. Under our current corporate structure, the Companies Act does not require independent directors. However, our board of directors is currently comprised of four directors, two of whom are considered “independent”, as determined in accordance with the applicable NASDAQ rules. Our independent directors regularly meet in executive sessions, where only the independent directors are present.
•
NASDAQ Rule 5605(c)(2)(A) requires a listed company to have an audit committee composed entirely of not less than three directors, each of whom must be independent. Under Japanese law, a company may have a statutory auditor or a board of auditors. We have a three-member Board of Corporate Auditors, each member of which meets the requirements of Rule 10A-3 under the Exchange Act. See “—Board of Corporate Auditors” below for additional information.
•
NASDAQ Rule 5605(d) requires, among other things, that a listed company’s compensation committee be comprised of at least two members, each of whom is an independent director as defined under such rule. Our board of directors collectively participates in the discussions and determination of compensation for our executives, directors and corporate auditors, and other compensation related matters.
•
NASDAQ Rule 5605(e) requires that a listed company’s nomination and corporate governance committee be comprised solely of independent directors. Our board of directors does not have a standalone nomination and corporate governance committee. Our board of directors collectively participates in the nomination process of potential directors and corporate auditors and oversee our corporate governance practices.
•
NASDAQ Rule 5620(c) sets out a quorum requirement of 331∕3% applicable to meetings of shareholders. In accordance with Japanese law and generally accepted business practices, our articles of incorporation provide that there is no quorum requirement for a general resolution of our shareholders. However, under the Companies Act and our articles of incorporation a quorum of not less than one-third of the total number of voting rights is required in connection with the election of directors, statutory auditors and certain other matters.
B.
Compensation

Compensation of our Directors and Corporate Auditors

In accordance with the Companies Act and our articles of incorporation, the amount of compensation for our directors and corporate auditors is decided by first setting the maximum amount of total compensation for all of our directors and corporate auditors through a resolution adopted by our shareholders at a shareholders meeting. The representative director authorized by our board of directors and our board of directors then decide on the amount of compensation for each director based on certain criteria established by our Company, and the amount of compensation for each corporate auditor is decided through discussions among the corporate auditors.

In December 2016, our shareholders approved an aggregate compensation allowance of no more than JPY200,000,000 per year for our directors, and no more than JPY50,000,000 per year for our corporate auditors.

Remuneration to our directors and corporate auditors is comprised of base compensation and stock options. In the fiscal year ended December 31, 2025, we paid an aggregate of JPY64,900 thousand to our directors and corporate auditors as base compensation. In addition, on June 26, 2025, our board of directors approved the issuance of the 11th series of stock options under our 2024 Equity Incentive Compensation Plan, of which our directors and corporate auditors subscribed for options to purchase an aggregate of 98,000 common shares (Mr. Eguchi and Mr. Fujiwara, 36,500 common shares each, and each of the other five directors and corporate auditors, 5,000 common shares), at a subscription price of JPY2 per option and an exercise price of US$1.74 per share. The options become exercisable from July 18, 2026 through July 17, 2030, subject to the satisfaction of performance conditions, which had not been satisfied as of the date of this annual report. No compensation expense was recognized in respect of these options for the year ended December 31, 2025 because the performance conditions were not considered probable of being satisfied.

75


Table of Contents

 

The following table summarizes the total amount of remuneration paid to each category of our directors and corporate auditors in fiscal year 2025, including by the type of remuneration and the number of persons in each category.

 

 

 

 

 

 

 

 

 

 

(in thousands, except stock options and number of persons in category)

 

Total amount of

 

 

Base

 

 

Number of
persons

Category of directors and corporate auditors

 

remuneration

 

 

compensation

 

 

in category

Executive directors(1)

 

¥

55,000

 

 

¥

55,000

 

 

2

Outside directors(2)

 

 

4,200

 

 

 

4,200

 

 

2

Full-time corporate auditor(3)

 

¥

3,300

 

 

¥

3,300

 

 

1

Outside corporate auditors(4)

 

¥

2,400

 

 

¥

2,400

 

 

2

 

(1)
Consist of Messrs. Kouji Eguchi and Fumitoshi Fujiwara.
(2)
Consist of Messrs. Akira Nojima and Tomoya Ogawa.
(3)
Consist of Mr. Toshiaki Komatsu.
(4)
Consist of Messrs. Tsukasa Karyu and Osamu Sato.

Employee Stock Options

We have granted stock options to purchase our common shares, as authorized by our shareholders in December 2015, December 2016, and August 2020 (the “Pre-2024 Options”). In addition, On March 8, 2024, our board of directors adopted the MEDIROM Healthcare Technologies Inc. 2024 Equity Incentive Compensation Plan (the “2024 Equity Incentive Plan”), which was approved at our annual meeting of shareholders held on March 29, 2024. Under the 2024 Equity Incentive Plan, we may grant stock options, stock appreciation rights, restricted stock, restricted stock units and performance share awards to our Company’s directors, internal corporate auditors, officers, employees and consultants. A total of 497,500 shares of common stock are authorized for issuance under the 2024 Equity Incentive Plan. During the fiscal year ended December 31, 2025, we granted a total of 377,000 stock options under the 2024 Equity Incentive Plan.

The purpose of these stock option grants and other equity-based awards is to enable our directors, corporate auditors, officers, employees and consultants to share in our success and to reinforce a corporate culture that aligns employee interests with those of our shareholders. Stock options granted prior to 2015 have all expired without having been exercised. The transfer of our Pre-2024 Options is generally prohibited, and the transfer of awards granted under the 2024 Equity Incentive Plan is also generally prohibited. A holder of Pre-2024 Options forfeits such stock options if they are no longer a director, corporate auditor, or employee of our Company, except under limited circumstances or as otherwise determined by our board of directors. Similarly, the 2024 Equity Incentive Plan provides that awards generally terminate upon the termination of an award recipient’s continuous service relationship with the Company and its affiliates, and following termination the award recipient will have a limited window in which to exercise awards that have vested, except that in the case of termination for cause the award recipient will forfeit their awards.

The following table summarizes the stock options outstanding as of December 31, 2025:

 

Name of Issuance

 

Issuance Date

 

Expiration Date

 

Exercise Price
(per share)

 

 

Number of
Common
Shares Outstanding

 

Seventh Series

 

12/22/2016

 

12/21/2026

 

¥

2,000

 

 

 

66,500

 

Eighth Series

 

10/30/2020

 

9/30/2026

 

¥

2,000

 

 

 

150,000

 

Tenth Series(1)

 

12/11/2024

 

12/9/2029

 

$

2.1875

 

 

 

143,000

 

Eleventh Series(2)

 

7/18/2025

 

7/17/2030

 

$

1.74

 

 

 

377,000

 

 

(1)
The Tenth series was issued to ThinkEquity LLC, as representative’s warrants, on December 11, 2024 in connection with the public offering of our ADSs that closed on the same date.
(2)
The Eleventh series stock options were granted on July 18, 2025 under the 2024 Equity Incentive Plan and become exercisable from July 18, 2026 through July 17, 2030, subject to the satisfaction of performance conditions, which had not been satisfied as of the date of this annual report.
(3)
Excludes 76,500 stock options that were forfeited or expired during the fiscal year ended December 31, 2025.

For additional details, see Note 10 to our audited consolidated financial statements as of and for the years ended December 31, 2025 and 2024 included elsewhere in this annual report.

76


Table of Contents

 

The following table summarizes the outstanding stock options with respect to our common shares that we had granted to our directors and corporate auditors as of December 31, 2025:

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

 

Total Number

 

 

 

 

 

 

 

 

 

 

 

 

Number of

 

 

 

of Common

 

 

 

 

 

 

 

End of

 

Exercise

 

 

Stock

 

 

 

Shares

 

 

 

 

 

Beginning of

 

Exercise

 

Price

 

 

Options

 

 

 

Underlying

 

Name

 

Grant Date

 

Exercise Period

 

Period

 

(per share)

 

 

Granted

 

 

 

Stock Options

 

Kouji Eguchi

 

10/30/2020

 

10/1/2021

 

9/30/2026

 

¥

2,000

 

 

 

150,000

 

(2)

 

 

150,000

 

Kouji Eguchi

 

7/18/2025

 

7/18/2026

 

7/17/2030

 

$

1.74

 

 

 

36,500

 

(2)

 

 

36,500

 

Fumitoshi Fujiwara

 

7/18/2025

 

7/18/2026

 

7/17/2030

 

$

1.74

 

 

 

36,500

 

(2)

 

 

36,500

 

Tomoya Ogawa

 

7/18/2025

 

7/18/2026

 

7/17/2030

 

$

1.74

 

 

 

5,000

 

(2)

 

 

5,000

 

Akira Nojima

 

7/18/2025

 

7/18/2026

 

7/17/2030

 

$

1.74

 

 

 

5,000

 

(2)

 

 

5,000

 

Toshiaki Komatsu

 

7/18/2025

 

7/18/2026

 

7/17/2030

 

$

1.74

 

 

 

5,000

 

(2)

 

 

5,000

 

Osamu Sato

 

7/18/2025

 

7/18/2026

 

7/17/2030

 

$

1.74

 

 

 

5,000

 

(2)

 

 

5,000

 

Tsukasa Karyu

 

7/18/2025

 

7/18/2026

 

7/17/2030

 

$

1.74

 

 

 

5,000

 

(2)

 

 

5,000

 

 

(1)
Each stock option is exercisable for 500 common shares.
(2)
Each stock option is exercisable for one common share
C.
Board Practices

Board of Directors

Our board of directors has the ultimate responsibility for the administration of our affairs. Our board of directors meets no less than once every three months. Under the Companies Act and our articles of incorporation, our Company must have at least three, but no more than ten, directors on our board of directors. Our board of directors is currently comprised of four directors. Directors are typically nominated at the board level and are elected at general meetings of the shareholders. The term of office of any director expires at the close of the ordinary general meeting of shareholders held with respect to the last fiscal year ended within one year after such director’s election to office. Our directors may, however, serve any number of consecutive terms.

Our board of directors appoints from among its members one or more representative directors, who serve as head administrator(s) over our Company’s affairs and represent our Company in accordance with the resolutions of our board of directors. Mr. Kouji Eguchi, our Chief Executive Officer and a director, is currently the sole representative director of our Company. Our board of directors may appoint from among its members a chairman, a president or one or more deputy presidents, senior managing directors, or managing directors.

Under our Company’s current corporate structure, the Companies Act does not require our board of directors to have any independent directors. However, our board of directors is currently comprised of four directors, two of whom (Messrs. Akira Nojima and Tomoya Ogawa), are considered “independent”, as determined in accordance with the applicable NASDAQ rules, and also satisfy the requirements for an outside (or independent) director under the Companies Act.

Board of Corporate Auditors

As permitted under the Companies Act, we have elected to structure our corporate governance system as a company with a separate board of corporate auditors instead of an audit committee of our board of directors. Our articles of incorporation provide for not more than three corporate auditors. Corporate auditors are typically nominated at the board level and are elected at general meetings of shareholders by a majority of shareholders entitled to vote, where a quorum is established by shareholders holding one-third or more of the voting rights of those who are entitled to vote being present at the shareholders’ meeting. The normal term of office of any corporate auditor expires at the close of the annual general meeting of shareholders held with respect to the last fiscal year ended within four years after such corporate auditor’s election to office.

Our corporate auditors may, however, serve any number of consecutive terms. Corporate auditors may be removed by a special resolution of a general meeting of shareholders.

Our corporate auditors are not required to be certified public accountants. Our corporate auditors may not concurrently serve as directors, employees or accounting advisors (kaikei sanyo) of our Company or any of our subsidiaries or serve as corporate officers of our subsidiaries. Under the Companies Act, at least one-half of the corporate auditors of a company must be persons who satisfy the requirements for an outside corporate auditor, and at least one of the corporate auditors must be a full-time corporate auditor.

The function of our board of corporate auditors and each corporate auditor is similar to that of independent directors, including those who are members of the audit committee of a U.S. public company. Each corporate auditor has a statutory duty to supervise the administration by the directors of our affairs, to examine our financial statements and business reports to be submitted by a representative director at the general meetings of shareholders, and to prepare an audit report. Our corporate

77


Table of Contents

 

auditors are obligated to participate in meetings of our board of directors and, if necessary, to express their opinion at such meetings, but are not entitled to vote. Our corporate auditors must inspect the proposals, documents and any other materials to be submitted by our board of directors to the shareholders at the shareholders’ meeting. If a corporate auditor finds a violation of statutory regulations or our articles of incorporation, or another significant improper matter, such auditor must report those findings to the shareholders at the shareholders’ meeting.

Furthermore, if a corporate auditor believes that a director has engaged in, or is likely to engage in, misconduct or acts that are significantly improper, or that there has been a violation of statutory regulations or our articles of incorporation, the corporate auditor: (i) must report that fact to our board of directors; (ii) can demand that a director convene a meeting of our board of directors; and (iii) if no such meeting is convened in response to the demand, can convene the meeting under the corporate auditor’s own authority. If a director engages in, or is likely to engage in, an activity outside the scope of the objectives of our Company or otherwise in violation of laws or regulations or our articles of incorporation, and such act is likely to cause significant damage to our Company, then a corporate auditor can demand that the director cease such activity.

Our board of corporate auditors has a statutory duty to prepare an audit report based on the audit reports issued by the individual corporate auditors and submit such audit reports to a relevant director and, in the case of audit reports related to financial statements, the independent auditors of our Company each year. A corporate auditor may note an opinion in an audit report issued by our board of corporate auditors, if the opinion expressed in such corporate auditor’s individual audit report is different from the opinion expressed in the audit report issued by our board of corporate auditors. Our board of corporate auditors is empowered to establish the audit principles, the method of examination by our corporate auditors of our affairs and financial position, and any other matters relating to the performance of our corporate auditors’ duties.

Additionally, our corporate auditors must represent our Company in: (i) any litigation between our Company and a director; (ii) dealing with shareholders’ demands seeking a director’s liability to our Company; and (iii) dealing with notices of litigation and settlement in a derivative suit seeking a director’s liability to our Company. A corporate auditor can file court actions relating to our Company within the authority of our corporate auditors, such as an action to nullify the incorporation of our Company, the issuance of shares, or a merger, or to cancel a resolution at a shareholders’ meeting.

Risk Management

One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through our board of directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure, including risks associated with cybersecurity and data protection, and our board of corporate auditors is responsible for overseeing and evaluating our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our board of corporate auditors also reviews legal, regulatory and compliance matters that could have a significant impact on our financial statements. While each standing committee of our board of directors will be responsible for evaluating certain risks and overseeing the management of such risks, our entire board of directors will be regularly informed through committee reports about such risks.

Code of Business Conduct

Our board of directors has adopted a written code of business conduct that applies to our directors, corporate auditors, officers, and employees (including our principal executive officer, principal financial officer, principal accounting officer or controller, and other persons performing similar functions), and our agents. Our code of business conduct is publicly available on our website at https://medirom.co.jp/en/business_conduct.

Limitation of Liability of Directors and Corporate Auditors

In accordance with Article 27 and Article 35 of our articles of incorporation, and pursuant to the provisions of Article 427 of the Companies Act, we are authorized to enter into agreements with our non- executive directors and corporate auditors, respectively, to limit his or her liability to our Company for any losses or damages arising from the conduct specified under Article 423 of the Companies Act; provided, that, the amount of such limited liability is either: (i) an amount set out in an agreement which shall be not less than one million (1,000,000) yen, or (ii) the amount stipulated in applicable laws and regulations, whichever is higher. Messrs. Akira Nojima and Tomoya Ogawa are considered independent, non-executive directors within the meaning of the Companies Act. We have not, however, executed any such limitation of liability agreements with any of our non-executive directors or corporate auditors.

Our articles of incorporation include limitation of liability provisions for independent directors and corporate auditors, pursuant to which our board of directors can authorize our Company to exempt the independent directors and corporate auditors from liabilities arising in connection with any failure to execute their respective duties in good faith or due to simple negligence (excluding gross negligence and willful misconduct), within the limits stipulated by applicable laws and regulations, including Article 426, Paragraph 1 of the Companies Act.

78


Table of Contents

 

D.
Employees

Most of our Company’s group employees are employed by our wholly-owned subsidiary, MEDIROM Wellness Co. As of December 31, 2025, we had 351 employees on a full-time basis, 516 employees on a part-time basis, and 87 employees on a fixed-term basis. In connection with our reorganization on July 3, 2023, we transferred our employees of the parent company to our subsidiaries. As a result, as of December 31, 2025, MEDIROM Healthcare Technologies Inc. did not have any employees. See “Item 4. Information on the Company—Employees and Contracts” for additional information.

We do not use contract employees hired by any third-party agencies in our relaxation salons. We dispatch therapists and other employees to our franchisees from time to time and receive a fee for such services. Our employees are paid on a salary basis. We also offer an incentive program whereby relaxation therapists earn points for various reasons such as continuing as a Medirom relaxation therapist for certain designated periods of time or taking additional relaxation courses at our College. As the number of collected points increase, the relaxation therapist’s salary also increases.

E.
Share ownership

For information regarding the share ownership of our directors and executive officers, please see “Item 7.A. Major Shareholders.”

For information regarding employee stock options and our Equity Incentive Plan, see “—B. Compensation—Employee Stock Options.”

F.
Disclosure of a registrant’s action to recover erroneously awarded compensation

Not applicable.

ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

A.
Major Shareholders

The following table and accompanying footnotes set forth certain information with respect to the beneficial ownership of our common shares as of September 30, 2026 for:

•
each of our named executive officers, directors, and corporate auditors;
•
all of our named executive officers, directors, and corporate auditors as a group; and
•
each person or entity (or group of affiliated persons or entities) known by us to be the beneficial owner of 5% or more of our common shares.

To our knowledge, each shareholder named in the table has sole voting and investment power with respect to all of our common shares shown as “beneficially owned” (as determined by the rules of the SEC) by such shareholder, except as otherwise set forth in the footnotes to the table. The SEC has defined “beneficial” ownership of a security to mean the possession, directly or indirectly, of voting power and/or investment power and such term includes common shares that can be acquired within 60 days of September 30, 2026.

The calculations of percentage ownership in the table below are based on 7,901,950 common shares issued and outstanding as of September 30, 2026 (7,994,450 common shares issued, less 92,500 common shares held in treasury). In computing the number of common shares beneficially owned by a person and the percentage ownership of that person, common shares that such person has the right to acquire within 60 days of September 30, 2026, including through the exercise of stock options or the

79


Table of Contents

 

conversion of convertible bonds, are deemed outstanding for that person, but are not deemed outstanding for the purpose of computing the percentage ownership of any other person.

 

 

 

Common Shares

 

 

 

Beneficially Owned(1)

 

Name of Beneficial Owner

 

Shares

 

 

Percentage

 

Named Executive Officers, Directors, and
   Corporate Auditors:

 

 

 

 

 

 

Kouji Eguchi(2)

 

 

1,845,058

 

 

 

23.3

%

Fumitoshi Fujiwara

 

 

40,000

 

 

*

 

Akira Nojima

 

 

1,200

 

 

*

 

Tomoya Ogawa(4)

 

 

28,500

 

 

*

 

Tsukasa Karyu

 

 

1,200

 

 

*

 

Osamu Sato

 

 

17,500

 

 

*

 

Toshiaki Komatsu

 

—

 

 

*

 

All named executive officers, directors, and
   corporate auditors as a group (seven persons)

 

 

1,933,458

 

 

 

24.5

%

5% or more Shareholders:

 

 

 

 

 

 

Kouji Eguchi(2)

 

 

1,845,058

 

 

 

23.3

%

 

* Represents less than 1% of the number of common shares outstanding.

(1)
In the table above, beneficial ownership is determined such that a person is deemed to be the beneficial owner of any common shares if that person has or shares voting power or investment power with respect to those shares or has the right to acquire beneficial ownership at any time within 60 days.
(2)
Mr. Kouji Eguchi also holds one Class A Share with special voting rights. See “Item 10.B. Memorandum and Articles of Association.” The aggregate number of common shares beneficially owned by Mr. Kouji Eguchi reflects (i) 1,797,515 common shares held directly and (ii) 25,000 common shares and 22,543 ADSs held by COZY LLC, a private company 100% owned by Mr. Eguchi. The stock options held by Mr. Eguchi are not included because his options under the Eighth Series expired unexercised on September 30, 2026 and his options under the Eleventh Series are subject to performance conditions that had not been satisfied as of that date.
(3)
The aggregate number of common shares beneficially owned by Mr. Tomoya Ogawa consists of 28,500 common shares held by Mr. Ogawa. His options under the Fifth Series, which were exercisable for 12,500 common shares, expired on December 21, 2025, and his options under the Eleventh Series are subject to performance conditions that had not been satisfied as of September 30, 2026.

As of September 30, 2026, 5,703,878 of our common shares were held of record by two holders with registered addresses in the United States. Of these common shares, 5,623,933 are held by The Bank of New York Mellon, as depositary for our ADS program. We are not aware of any arrangement that may, at a subsequent date, result in change of control of our Company. To our knowledge, we are not directly or indirectly owned or controlled by another corporation(s), by any foreign government, or by any other natural or legal person(s) severally or jointly.

For additional information about our principal shareholders, please see “—Related Party Transactions” below.

B.
Related Party Transactions

Arrangements with our Founder

Kouji Eguchi, our founder and Chief Executive Officer, is a guarantor with respect to certain of our bank borrowings. As of December 31, 2025, Mr. Eguchi was a guarantor for six loans (three bank loans of the Company and three disbursements under the loan agreement with Spirit Advisors), and the outstanding amount of the loans guaranteed by Mr. Eguchi was JPY339,330 thousand, including the loans from Spirit Advisors, the outstanding amount of which was JPY156,530 thousand. See Note 6 and Note 18 to our consolidated financial statements included elsewhere in this annual report.

In June 2020, we entered into a Trademark License Agreement with Mr. Eguchi, pursuant to which Mr. Eguchi has granted us a non-exclusive, non-royalty bearing license to use CLP CARE LIFE PLANNER® in connection with the operation of our franchised salons in Japan. We utilize this mark in our franchise agreements to define therapists who have completed a required technique training program. The Trademark License Agreement provides that its term will expire upon the expiration of the trademark registration. At present, the trademark registration is scheduled to expire on October 24, 2033, and the registration can be further extended by the timely submission of an application for extension to the Japan Patent Office. We may not grant a sub-license to use the trademark to a third party without the prior written consent of Mr. Eguchi. Either party may terminate the Trademark License Agreement without notice in the event of a breach by the other party of its obligations (without cure) under the agreement, bankruptcy, reorganization, insolvency, dissolution, fraud, or criminal acts, among other events, as set forth in further detail in the Trademark License Agreement.

80


Table of Contents

 

ZACC Loan Guarantees

Arrangements with our Directors and Corporate Auditors

Akira Nojima, our independent director, is the sole owner of Kabushiki Kaisha No Track; Tomoya Ogawa, our independent director, is the sole owner of Kabushiki Kaisha LTW; and Osamu Sato, our corporate auditor, is a part-time employee of Ebis 20 Co., Ltd. We paid no consulting fees to any of these entities in the years ended December 31, 2025 and 2024, and there were no outstanding accrued expenses to any of them as of December 31, 2025 and 2024.

Mr. Kazuyoshi Takahashi, the representative director of ZACC, is the guarantor for two loans on behalf of ZACC, which were borrowed by ZACC from Japan Finance Corporation prior to the acquisition of ZACC. As of the date of this annual report, Mr. Takahashi’s guarantee has not been released, and the outstanding amount of the loans guaranteed by Mr. Takahashi was JPY25,245 thousand (US$161 thousand) as of December 31, 2025.

Investment by Senior Executives in Subsidiary

During the year ended December 31, 2025, MEDIROM MOTHER Labs Inc. (“MML”) issued series A preferred shares to its directors as follows: six shares to Yasuhiro Hayami (paid on March 14, 2025) and three shares each to Ryo Saito and Yoshio Uekusa, the representative director of MML (paid on October 31, 2025), in each case at JPY180 thousand per share, for a total of JPY2,160 thousand, at the same price as that paid by third-party investors in the same financing. Mr. Uekusa is also a guarantor with respect to certain borrowings of MML.

C.
Relationships

There is no family relationship among any of the directors, corporate auditors and officers.

ITEM 8. FINANCIAL INFORMATION

A.
Consolidated Statements and Other Financial Information

See the Consolidated Financial Statements and the Notes to the Consolidated Financial Statements and Financial Statements Schedules in Item 18 of this annual report.

Legal Proceedings

For information about our legal proceedings, see Note 17 to our audited consolidated financial statements included elsewhere in this annual report and “Item 4. Information on the Company— Legal and Administrative Matters.

Dividend Policy

We currently intend to retain any future earnings to finance the development and expansion of our businesses and, therefore, do not intend to pay any cash dividends in the foreseeable future. Since our inception, we have not declared or paid any cash dividends on our common shares. Any decision to pay dividends in the future will be subject to a number of factors, including our financial condition, results of operations, the level of our retained earnings, capital demands, general business conditions, and other factors our board of directors may deem relevant. Accordingly, we cannot give any assurance that any dividends may be declared and paid in the future.

If declared, holders of outstanding common shares on a dividend record date will be entitled to the full dividend declared without regard to the date of issuance of the common shares or any transfer of the common shares subsequent to the dividend payment date. Payment of declared annual dividends in respect of a particular year, if any, will be made in the following year after approval by our shareholders at the annual general meeting of shareholders, subject to certain provisions of our articles of incorporation. Any dividend we declare will be paid by the depositary bank to the holders of ADSs, subject to the terms of the deposit agreement, to the same extent as holders of our common shares, to the extent permitted by applicable law and regulations, less the fees and expenses payable under the deposit agreement.

B.
Significant Changes

See Note 19 to the Consolidated Financial Statements in Item 18 for a disclosure of events subsequent to year end and prior to the date of filing.

81


Table of Contents

 

ITEM 9. THE OFFER AND LISTING

A.
Offer and Listing Details

Our ADSs have been listed on The Nasdaq Capital Market under the symbol “MRM” since December 29, 2020. Prior to that date, there was no public trading market for our ADSs.

B.
Plan of Distribution

Not applicable.

C.
Markets

See “Item 9.A. Offer and Listing Details” above.

D.
Selling Shareholders

Not applicable.

E.
Dilution

Not applicable.

F.
Expenses of the Issue

Not applicable.

ITEM 10. ADDITIONAL INFORMATION

A.
Share Capital

Not applicable.

B.
Memorandum and Articles of Association

The information set forth in Exhibit 2.3 “Description of Securities” to this annual report is incorporated herein by reference.

C.
Material Contracts

During the year ended December 31, 2025 and subsequent to that date, we entered into the following material contracts outside the ordinary course of business:

On December 12, 2025, we issued our Third Unsecured Convertible-Type Corporate Bonds with Share Options in the aggregate principal amount of JPY400,000 thousand to 11 investors. These bonds are unsecured, accrue interest at a rate of 2.0% per annum and are convertible into 1,166,175 of our common shares at a conversion price of JPY343 (US$2.19) per share. The maturity date of the bonds, originally June 30, 2026, has been extended to December 25, 2026 pursuant to our option under the terms of the bonds, and the conversion period has accordingly been extended to December 7, 2026.

On December 31, 2025, we issued our Fourth Unsecured Convertible-Type Corporate Bonds with Share Options in the aggregate principal amount of JPY275,000 thousand to Kufu Company Holdings Inc. (“Kufu”) in connection with the refinancing of our First Unsecured Convertible-Type Corporate Bonds with Share Options. The Fourth Unsecured Convertible-Type Corporate Bonds with Share Options are unsecured, accrue interest at a rate of 5.0% per annum and mature on June 30, 2026, subject to our option to extend the maturity date to December 25, 2026, unless earlier redeemed or converted, and are convertible into 833,333 common shares at a conversion price of JPY330 per share from December 31, 2025 to June 29, 2026 (or December 24, 2026 if the maturity date is extended).

On January 30, 2026, we entered into a Deemed Loan Agreement with Kufu in the principal amount of JPY200,000 thousand. The loan bears interest at 10.0% per annum. To secure our obligations under the loan agreement, we pledged all of the shares we hold in MEDIROM MOTHER Labs Inc., granting Kufu a first-priority security interest in those shares. The loan agreement provides for repayment by December 30, 2026.

On March 31, 2026, Kufu and we entered into a Memorandum of Understanding extending from March 31, 2026 to April 30, 2026 the date by which repayment of the loan in full would entitle us to Kufu’s consent to prepayment and would cause interest to cease to accrue, and providing that interest accrued through March 31, 2026 would be paid promptly following execution. Kufu and we have since entered into further memoranda on substantially the same terms on a monthly basis, each

82


Table of Contents

 

extending that date by approximately one month and providing for payment of the interest accrued through the preceding month-end. These memoranda do not affect the maturity date of December 30, 2026 under the loan agreement.

On July 14, 2026, in lieu of cash repayment of our Fourth Unsecured Convertible-Type Corporate Bonds with Share Options in the principal amount of JPY275,000 thousand, we and Kufu amended the loan agreement to refinance the entire principal amount of those bonds as a loan, increasing the aggregate principal amount outstanding under the loan agreement to JPY475,000 thousand, and amended the share pledge agreement to secure the increased amount. The amendment confirmed that the interest rate of 10.0% per annum, the maturity date of December 30, 2026 and the other terms of the original loan agreement apply to the combined principal amount, and the pledge covers 48,219 common shares of MEDIROM MOTHER Labs Inc.

On August 25, 2026, we entered into a Money Loan Agreement, Security Agreement, Corporate Bond Cancellation Agreement, and Set-Off Agreement, each with Triple One Investment Limited Partnership (“Triple One”), pursuant to which we redeemed all of the Second Unsecured Convertible-Type Corporate Bonds with Share Options prior to their maturity and concurrently borrowed JPY300,000 thousand from Triple One, with our obligation to pay the redemption price and its obligation to advance the loan being settled by set-off. As a result, none of the Second Unsecured Convertible-Type Corporate Bonds with Share Options remains outstanding. The loan originally bore interest at 5.0% per annum, had an initial maturity date of September 15, 2026, and is secured by a pledge over all of the shares of MEDIROM Rehab Solutions Inc. that we hold and by security over the operating rights of ten salons that we operated when the security was granted.

On October 31, 2026, we and the seller entered into a termination agreement, pursuant to which the share transfer agreement dated June 30, 2024 relating to the acquisition of 70% of the issued and outstanding common shares of Japan Gene Medicine Corporation, and the related memorandum of understanding, were terminated by mutual agreement of the parties. As a result, we no longer intend to acquire any equity interest in Japan Gene Medicine Corporation.

On November 11, 2026, Triple One and we entered into an agreement amending the loan with Triple One, pursuant to which the maturity of the principal was extended to December 30, 2026, with JPY5,000 thousand of the principal repayable on November 30, 2026 and the balance on the maturity date. Interest accruing on and after November 1, 2026 accrues at 14.6% per annum, calculated on a 365-day year, and is payable monthly at each month-end rather than together with the principal at maturity. If the parties agree to extend the maturity further, JPY15,000 thousand of the principal will be repayable on December 30, 2026 and JPY10,000 thousand at each month-end thereafter, with the balance on the extended maturity date. The amendment does not release or reduce any obligation that had already accrued under the loan. See “Item 4. Information on the Company—Subsequent Events.”

We have not entered into any other material contracts for the two years immediately preceding publication of this report, other than in the ordinary course of business and those described in “Item 4. Information on the Company.”

D.
Exchange Controls

The Foreign Exchange and Foreign Trade Act and related regulations (which we refer to as “FEFTA”) regulate certain transactions involving a “Non-Resident of Japan” or a “Foreign Investor”, including “inward direct investments” by Foreign Investors, and payments from Japan to foreign countries or by residents of Japan to Non-Residents of Japan.

“Non-Residents of Japan” are defined as individuals who are not residents in Japan and corporations whose principal offices are located outside of Japan. Generally, branches and other offices of Japanese corporations which are located outside of Japan are regarded as Non-Residents of Japan, and branches and other offices of non-resident corporations which are located within Japan are regarded as residents of Japan.

“Foreign Investors” are defined as:

•
individuals who are Non-Residents of Japan;
•
entities which are organized under the laws of foreign countries or whose principal offices are located outside of Japan;
•
companies of which 50% or more of their voting rights are held by individuals who are Non-Residents of Japan and/or corporations which are organized under the laws of foreign countries or whose principal offices are located outside of Japan;
•
partnerships engaging in investment activities and investment limited partnerships (including partnerships formed under the laws of foreign countries) which satisfy one of the following conditions:
•
50% or more of contributions to the partnership were made by (i) individuals who are Non-Residents of Japan, (ii) entities which are organized under the laws of foreign countries or whose principal offices are located outside of Japan, (iii) companies of which 50% or more of their voting rights are held by individuals who are Non-Residents of Japan and/or corporations which are organized under the laws of foreign countries or whose principal offices are located outside of Japan, (iv) entities a majority of whose officers, or officers having the power of representation, are individuals who are Non-Residents of Japan, or (v) partnerships a majority of whose executive partners fall within items (i) through (iv) above;

83


Table of Contents

 

•
a majority of the executive partners of the partnership are (A) any persons or entities who fall within items (i) through (v) above, (B) any partnerships to which 50% or more of contribution were made by persons or entities who fall within items (i) through (v) above, or (C) limited partnerships a majority of whose executive partners fall within Non-Residents of Japan, persons or entities who fall within (A) or (B), or any officers of entities which fall within (A) or (B); and
•
entities, a majority of whose officers are individuals who are Non-Residents of Japan.

Under FEFTA, among other triggering events, a Foreign Investor who desires to acquire shares in a Japanese company which is not listed on any stock exchange in Japan, is subject to a prior filing requirement, regardless of the acquired amount of shares, if such Japanese company engages any business in certain industries related to the national security. Such industries include, among other things, manufacturing in relation to weapons, aircraft, space, and nuclear power, as well as agriculture, fishery, mining, and utility service. Additionally, due to today’s growing awareness of cybersecurity, the recent amendment to FEFTA expanded the scope of the prior filing requirement, broadly covering industries related to data processing businesses and information and communication technologies service. Since our Digital Preventative Healthcare Segment could potentially involve the processing of data by collecting, processing, and retaining customers’ health information, direct acquisition of our common shares, rather than ADSs, by a Foreign Investor could be subject to the prior filing requirement under FEFTA.

A Foreign Investor wishing to acquire or hold our common shares directly will be required to make a prior filing with the relevant government authorities through the Bank of Japan and wait until clearance for the acquisition is granted by the applicable governmental authorities. Without such clearance, the Foreign Investor will not be permitted to acquire or hold our common shares directly. Once clearance is obtained, the Foreign Investor may acquire shares in the amount and during the period indicated in the filing. While the standard waiting period to obtain clearance is 30 days, the waiting period could be expedited to two weeks, at the discretion of the applicable governmental authorities, depending on the level of potential impact to national security.

In addition to the prior filing requirement above, when a Foreign Investor who completed a prior filing and received clearance has acquired shares in accordance with the filed information, such Foreign Investor will be required to make a post-acquisition notice filing to report the completed purchase. Such post-acquisition notice filing must be made no later than 45 days after the acquisition of the shares.

Under FEFTA, in each case where a resident of Japan receives a single payment of more than JPY30 million from a Non-Resident of Japan for a transfer of shares in a Japanese company, such resident of Japan is required to report each receipt of payment to the Minister of Finance of Japan.

E.
Taxation

The following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition of our common shares, including the ADSs. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any local, state, foreign, including Japan, or other taxing jurisdiction.

Taxation in Japan

Generally, a non-resident of Japan or non-Japanese entity (which we refer to as a “Non-Resident Holder”) is subject to Japanese withholding tax on dividends paid by Japanese corporations. Stock splits are not subject to Japanese income tax. A conversion of retained earnings or legal reserve (but not additional paid-in capital, in general) into stated capital (whether made in connection with a stock split or otherwise) is not treated as a deemed dividend payment to shareholders for Japanese tax purposes. Thus, such a conversion does not trigger Japanese withholding taxation.

Pursuant to the Convention Between the Government of the United States of America and the Government of Japan for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income (which we refer to as the “Treaty”), dividend payments made by a Japanese corporation to a U.S. resident or entity, unless the recipient of the dividend has a “permanent establishment” in Japan, and the common shares or ADSs with respect to which such dividends are paid are effectively connected with such “permanent establishment”, are generally subject to a withholding tax at rate of: (i) 10% for portfolio investors who are qualified U.S. residents eligible for benefits of the Treaty; and (ii) 0% (i.e., no withholding) for pension funds which are qualified U.S. residents eligible for benefits of the Treaty, provided that the dividends are not derived from the carrying on of a business, directly or indirectly, by such pension funds. Japan is a party to a number of income tax treaties, conventions and agreements, (which we refer to collectively as the “Tax Treaties”), whereby the maximum withholding tax rate for dividend payments is set at, in most cases, 15% for portfolio investors who are Non-Resident Holders. Specific countries with which such Tax Treaties have been entered into include Canada, Denmark, Finland, Germany, Ireland, Italy, Luxembourg, New Zealand, Norway, Republic of Singapore, and Spain. Japan’s income tax treaties with Australia, Belgium, France, The Netherlands, Sweden, Switzerland and the United Kingdom have been amended to generally reduce the maximum withholding tax rate to 10%.

84


Table of Contents

 

On the other hand, unless one of the applicable Tax Treaties reducing the maximum rate of withholding tax applies, the standard tax rate applicable to dividends paid with respect to listed shares, such as those paid by our Company on shares or ADSs, to Non-Resident Holders is 15% under the Japanese Income Tax Law, except for dividends paid to any individual shareholder who holds 3% or more of the issued shares, in which case the applicable rate is 20% (Article 182(ii) of the Japanese Income Tax Law and Article 9-3(i) of the Japanese Special Tax Measures Law, including its relevant temporary provision for these withholding rates). On December 2, 2011, the “Special Measures Act to Secure the Financial Resources Required to Implement Policy on Restoration of the East Japan Earthquake” (Act No. 117 of 2011) was promulgated and special surtax measures on income tax and withholding tax were introduced thereafter to fund the restoration effort for the earthquake. Income tax and withholding taxpayers need to pay a surtax, calculated by multiplying the standard tax rate by 2.1% for 25 years starting from January 1, 2013 (which we refer to as “Surtax”). As a result, the withholding tax rate applicable to dividends paid with respect to listed shares to Non-Resident Holders increased to 15.315% (which we refer to as “Withholding Tax Rate”) which is applicable for the period from January 1, 2013 until December 31, 2037.

The treaty rate normally overrides the domestic rate, but due to the so-called “preservation doctrine” under Article 1(2) of the Treaty, and/or due to Article 3-2 of the Special Measures Law for the Income Tax Law, Corporation Tax Law and Local Taxes Law with respect to the Implementation of Tax Treaties, if the tax rate under the domestic tax law is lower than that promulgated under the applicable income tax treaty, then the domestic tax rate is still applicable. Currently, the tax rate under the applicable tax treaty (i.e., 15% rate or 10% for eligible U.S. residents subject to the Treaty and/or eligible residents subject to other similarly renewed treaties mentioned above) is lower than that under the domestic tax law (i.e., Withholding Tax Rate, except for dividends paid to any individual holder who holds 3% or more of the total issued shares, in which case the applicable rate is 20.42% (standard tax rate of 20% imposed by Surtax)) and thus the treaty override treatment applies. As such, the tax rate under the Treaty applies for most holders of shares or ADSs who are U.S. residents or entities. In the case where the treaty rate is applicable, no Surtax is imposed, but in order to enjoy the lower treaty rate, the taxpayer must file a treaty application in advance with the Japanese National Tax Agency through our Company. Gains derived from the sale outside Japan of a Japanese corporation’s shares or ADSs by Non-Resident Holders, or from the sale of a Japanese corporation’s shares or ADSs within Japan by a non-resident of Japan as an occasional transaction or by a non-Japanese entity not having a permanent establishment in Japan, are generally not subject to Japanese income or corporation taxes, provided that the seller is a portfolio investor. Japanese inheritance and gift taxes at progressive rates may apply to an individual who has acquired a Japanese corporation’s shares or ADSs as a distributee, legatee or donee.

Certain U.S. Federal Income Tax Considerations for U.S. Holders

The following discussion is a summary of U.S. federal income tax considerations generally applicable to the ownership and disposition of our common shares or ADSs by a U.S. holder (as defined below). This summary is for general information purposes only and does not purport to be a complete discussion of all potential tax considerations that may be relevant to a particular person’s decision to acquire common shares or ADSs.

This summary is based on the U.S. Internal Revenue Code of 1986, as amended (the “Code”), the regulations promulgated under the Code (the “U.S. Treasury Regulations”), the income tax treaty between Japan and the United States (the “Treaty”), published rulings of the U.S. Internal Revenue Service (the “IRS”), published administrative positions of the IRS, and U.S. court decisions that are applicable and, in each case, as in effect and available, as of the date hereof. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied on a retroactive or prospective basis which could affect the U.S. federal income tax considerations described in this summary. There can be no assurance that the IRS or a court will not take a contrary position to those in this summary.

For purposes of this discussion, a “U.S. holder” is a beneficial owner of the common shares or ADSs that is, for U.S. federal income tax purposes:

•
an individual who is a citizen or resident of the United States;
•
a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) that is created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;
•
an estate the income of which is includable in gross income for U.S. federal income tax purposes regardless of its source; or
•
a trust (i) the administration of which is subject to the primary supervision of a court within the United States and which has one or more U.S. persons who have the authority to control all substantial decisions of the trust, or (ii) that has validly elected to be treated as a U.S. person under the Code or applicable U.S. Treasury Regulations.

If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds the common shares or ADSs, the U.S. federal income tax consequences to such partnership and its partners of the ownership and disposition of the common shares or ADSs generally will depend in part on the activities of the partnership and the status of such partners. This summary does not address the tax consequences to any such partner or partnership. Partners of entities or arrangements that are classified as partnerships for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences of the ownership and disposition of the common shares or ADSs.

85


Table of Contents

 

This discussion applies only to a U.S. holder that holds common shares or ADSs as “capital assets” under the Code (generally, property held for investment). Unless otherwise provided, this summary does not discuss reporting requirements. In addition, this discussion does not address any tax consequences other than U.S. federal income tax consequences, such as U.S. state and local tax consequences, U.S. estate and gift tax consequences, and non-U.S. tax consequences, and does not describe all of the U.S. federal income tax consequences that may be relevant in light of a U.S. holder’s particular circumstances, including minimum tax consequences, the Medicare tax on certain net investment income, and tax consequences to holders that are subject to special provisions under the Code, including, but not limited to, holders that:

•
are tax exempt organizations, qualified retirement plans, individual retirement accounts, or other tax deferred accounts;
•
are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies;
•
are brokers or dealers in securities or currencies or holders that are traders in securities that elect to apply a mark-to-market accounting method;
•
have a “functional currency” for U.S. federal income tax purposes that is not the U.S. dollar;
•
own common shares or ADSs as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than one position;
•
acquire common shares or ADSs in connection with the exercise of employee stock options or otherwise as compensation for services;
•
are partnerships or other pass-through entities for U.S. federal income tax purposes (or investors in such partnerships and entities);
•
own or will own (directly, indirectly, or constructively) 10% or more of our total combined voting power or value;
•
hold the common shares or ADSs in connection with trade or business conducted outside of the United States or in connection with a permanent establishment or other fixed place of business outside of the United States; or are former U.S. citizens or former long-term residents of the United States.

Each U.S. holder is urged to consult its tax advisor regarding the application of U.S. federal taxation to its particular circumstances, and the state, local, non-U.S. and other tax considerations of the ownership and disposition of our common shares or ADSs.

Treatment of ADSs

For U.S. federal income tax purposes, a U.S. holder of ADSs generally will be treated as the beneficial owner of the underlying shares represented by the ADSs. The remainder of this discussion assumes that a U.S. holder of the ADSs will be treated in this manner. Accordingly, deposits or withdrawals of common shares for ADSs generally will not be subject to U.S. federal income tax.

Passive Foreign Investment Company Considerations

A non-U.S. corporation, such as our company, is classified as a passive foreign investment company (“PFIC”) for any taxable year in which, after applying relevant look-through rules with respect to the income and assets of its subsidiaries, either: (i) 50% or more of the value of the corporation’s assets either produce passive income or are held for the production of passive income, generally based on the quarterly average of the fair market value of such assets; or (ii) at least 75% of the corporation’s gross income is passive income. “Passive income” generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions. In determining the value and composition of our assets, cash will generally be considered to be held for the production of passive income and thus will be considered a passive asset.

The determination of whether a corporation is a PFIC for a taxable year depends, in part, on the application of complex U.S. federal income tax rules that are subject to differing interpretations. In addition, the determination of whether a corporation will be a PFIC for any taxable year can only be made after the close of such taxable year. Furthermore, because we may value our goodwill based on the market price of the ADSs, a decrease in the market price of the ADSs may also cause us to be classified as a PFIC for the current or any future taxable year. Based upon the foregoing, we do not believe that we were a PFIC for the taxable year ended December 31, 2025. However, in light of recent declines in the market price of our ADSs, our risk of becoming a PFIC has increased. The market price of the ADSs may continue to fluctuate considerably and, consequently, we cannot assure you of our PFIC status for the current or any future taxable year.

We must make a separate determination each year as to whether we are a PFIC. As a result, our PFIC status may change. If we are a PFIC for any year during which you hold the common shares or ADSs, we will generally continue to be treated as a PFIC for all succeeding years during which you hold such common shares or ADSs. However, if we cease to be a PFIC, provided that

86


Table of Contents

 

you have not made a mark-to-market election, as described below, you may avoid some of the adverse effects of the PFIC regime by making a deemed sale election with respect to the common shares or ADSs, as applicable.

The discussion below under “—Distributions on the Common Shares or ADSs” and “—Sale or Other Disposition of the Common Shares or ADSs” is written on the basis that we will not be classified as a PFIC for U.S. federal income tax purposes. The U.S. federal income tax rules that generally would apply if we are treated as a PFIC are discussed below under “—Passive Foreign Investment Company Rules.”

Distributions on the Common Shares or ADSs

The gross amount of any distributions paid on our common shares or ADSs will generally be included in the gross income of a U.S. holder as dividend income on the date actually or constructively received by the U.S. holder, in the case of common shares, or by the depositary, in the case of ADSs, but only to the extent that the distribution is paid out of our current or accumulated earnings and profits (computed on the basis of U.S. federal income tax principles). Because we do not intend to determine our earnings and profits on the basis of U.S. federal income tax principles, we expect that distributions will generally be reported to U.S. holders as dividends. Dividends received on our common shares or ADSs generally will not be eligible for the dividends received deduction allowed to corporations in respect of dividends received from U.S. corporations.

Individuals and other non-corporate U.S. holders will be subject to tax on any such dividends at the lower capital gains tax rate applicable to “qualified dividend income,” provided that certain conditions are satisfied, including that (i) the common shares or ADSs on which the dividends are paid are readily tradable on an established securities market in the United States or we are eligible for the benefits of the Treaty, (ii) we are not a PFIC nor treated as such with respect to a U.S. holder (as discussed below) for either our taxable year in which the dividend was paid or for the preceding taxable year, and (iii) certain holding period requirements are met. As mentioned above, on October 6, 2026, we received a further written notification from NASDAQ that we are not in compliance with the minimum bid price requirement. To regain compliance, the ADSs must have a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by April 5, 2027, the Company may be eligible for additional time to regain compliance or may face delisting.

There is no assurance that we will be able to regain compliance and remain in compliance with the listing requirements of NASDAQ in the future. See “Item 3. Key Information—D. Risk Factors—Risks Related to Ownership of the ADSs—We do not satisfy certain Nasdaq continued listing requirements, and additional requirements may become operative in the future. Failure to regain or maintain compliance could result in suspension of trading and delisting of our ADSs.” For this purpose, ADSs listed on the NASDAQ will generally be considered to be readily tradable on an established securities market in the United States. Only the ADSs and not the common shares will be listed on the NASDAQ. Consequently, dividends received with respect to common shares that are not represented by ADSs may not be treated as qualified dividends. You should consult your tax advisor regarding the availability of the lower rate for dividends paid with respect to our common shares or ADSs.

For U.S. foreign tax credit purposes, dividends paid on our common shares or ADSs generally will be treated as foreign source income and generally will constitute passive category income. The amount of a dividend will include any amounts withheld by us in respect of Japanese income taxes. Subject to applicable limitations, some of which vary depending upon the U.S. holder’s particular circumstances, Japanese income taxes withheld from dividends on the common shares or ADSs, at a rate not exceeding any reduced rate pursuant to the Treaty, may be creditable against the U.S. holder’s U.S. federal income tax liability. However, as a result of changes to the U.S. foreign tax credit rules, a withholding tax generally will need to satisfy certain additional requirements in order to be considered a creditable tax for a U.S. holder. We have not determined whether these requirements have been met with respect to Japanese withholding taxes that may be imposed on dividends paid by us and, accordingly, no assurance can be given that such taxes will be creditable. In lieu of claiming a foreign tax credit, U.S. holders may, at their election, deduct foreign taxes, including any Japanese income taxes, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. The rules governing foreign tax credits are complex and U.S. holders should consult their tax advisers regarding the creditability or deductibility of foreign taxes in their particular circumstances.

The amount of any dividend paid in Japanese yen will equal the U.S. dollar value of the Japanese yen received, calculated by reference to the exchange rate in effect on the date the dividend is received by you, in the case of common shares, or by the depositary, in the case of ADSs, regardless of whether the Japanese yen are converted into U.S. dollars. If the Japanese yen received as a dividend are converted into U.S. dollars on the date of receipt, a U.S. holder generally will not be required to recognize foreign currency gain or loss in respect of the dividend income. If the Japanese yen received as a dividend are not converted into U.S. dollars on the date of receipt, a U.S. holder will have a basis in the Japanese yen equal to their U.S. dollar value on the date of receipt. Any gain or loss realized on a subsequent conversion or other disposition of the Japanese yen will be treated as U.S. source ordinary income or loss.

Sale or Other Disposition of the Common Shares or ADSs

A U.S. holder will recognize gain or loss on the sale or other disposition of a common share or ADS equal to the difference between the amount realized for the common share or ADS and the holder’s tax basis in the common share or ADS. Such gain or loss will generally be capital gain or loss and will be long-term capital gain or loss if the U.S. holder’s holding period for such

87


Table of Contents

 

common share or ADS was more than one year as of the date of the sale or other disposition. Long-term capital gain recognized by a non-corporate U.S. holder is subject to U.S. federal income tax at rates lower than the rates applicable to ordinary income and short-term capital gains, while short-term capital gains are subject to U.S. federal income tax at the rates applicable to ordinary income. The deductibility of capital losses is subject to various limitations. Any gain or loss recognized will generally be U.S. source gain or loss for foreign tax credit purposes. Consequently, a U.S. holder may not be able to use the foreign tax credit arising from any Japanese tax imposed on the disposition of the common share or ADS unless such credit can be applied (subject to applicable limitations) against tax due on other income treated as derived from non-U.S. sources.

Passive Foreign Investment Company Rules

If we are a PFIC for any taxable year during which you hold our common shares or ADSs, you will be subject to special tax rules with respect to any “excess distribution” that you receive and any gain you realize from a sale or other disposition (including a pledge) of the common shares or ADSs, unless you make a mark-to-market election as discussed below. Distributions you receive from us in a taxable year that are greater than 125% of the average annual distributions you received from us during the shorter of the three preceding taxable years or your holding period for the common shares or ADSs will be treated as an excess distribution. Under these special tax rules:

•
the excess distribution or gain will be allocated ratably over your holding period for the common shares or ADSs,
•
the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which we became a PFIC, will be treated as ordinary income, and
•
the amount allocated to each of the other taxable years will be subject to tax at the highest rate of tax in effect for you for such year and will be increased by an additional tax calculated as an interest charge on the resulting tax deemed deferred with respect to each such other taxable year at the rates generally applicable to underpayments of tax payable in those years.

If we are a PFIC for any taxable year during which a U.S. holder holds our common shares or ADSs and any of our subsidiaries or other corporate entities in which we own equity interests is also a PFIC, such U.S. holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC for purposes of the application of these rules. U.S. holders are urged to consult their tax advisors regarding the application of the PFIC rules to any of our subsidiaries.

As an alternative to the foregoing rules, a U.S. holder may make a mark-to-market election with respect to our common shares or ADSs, provided such common shares or ADSs are treated as “marketable stock.” The common shares or ADSs generally will be treated as marketable stock if the common shares or ADSs are regularly traded on a “qualified exchange or other market,” as defined in applicable U.S. Treasury Regulations. The ADSs will be marketable stock as long as they remain listed on the NASDAQ, which is a qualified exchange for this purpose, and are regularly traded. As mentioned above, on October 6, 2026, we received a further written notification from NASDAQ that we are not in compliance with the minimum bid price requirement. To regain compliance, the ADSs must have a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by April 5, 2027, the Company may be eligible for additional time to regain compliance or may face delisting. There is no assurance that we will be able to regain compliance and remain in compliance with the listing requirements of NASDAQ in the future. See “Item 3. Key Information—D. Risk Factors—Risks Related to Ownership of the ADSs—We do not satisfy certain Nasdaq continued listing requirements, and additional requirements may become operative in the future. Failure to regain or maintain compliance could result in suspension of trading and delisting of our ADSs.” We anticipate that the ADSs should qualify as being regularly traded but no assurances can be given in this regard. Only the ADSs and not the common shares will be listed on the NASDAQ. Consequently, a U.S. holder of common shares that are not represented by ADSs generally will not be eligible to make the mark-to-market election.

If a U.S. holder makes a valid mark-to-market election with respect to the ADSs, the holder generally will (i) include as ordinary income for each taxable year that we are a PFIC the excess, if any, of the fair market value of ADSs held at the end of the taxable year over the adjusted tax basis of such ADSs and (ii) deduct as an ordinary loss in each such taxable year the excess, if any, of the adjusted tax basis of the ADSs over the fair market value of such ADSs held at the end of the taxable year, but such deduction will only be allowed to the extent of the net amount previously included in income as a result of the mark-to-market election. The U.S. holder’s adjusted tax basis in the ADSs would be adjusted to reflect any income or loss resulting from the mark-to-market election. If a U.S. holder makes a mark-to-market election in respect of the ADSs and we cease to be classified as a PFIC, the holder will not be required to take into account the gain or loss described above during any period that we are not classified as a PFIC. If a U.S. holder makes a mark- to-market election, any gain such U.S. holder recognizes upon the sale or other disposition of the ADSs in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as ordinary loss, but such loss will only be treated as ordinary loss to the extent of the net amount previously included in income as a result of the mark-to-market election.

Because a mark-to-market election cannot be made for any lower-tier PFICs that we may own, a U.S. holder may continue to be subject to the general PFIC rules described above with respect to such U.S. holder’s indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S. federal income tax purposes.

88


Table of Contents

 

We have not determined whether, if we were to be classified as a PFIC for a taxable year, we will provide information necessary for a U.S. holder to make a “qualified electing fund” election which, if available, would result in tax treatment different from (and generally less adverse than) the general tax treatment for PFICs described above. Accordingly, U.S. holders should assume that they will not be able to make a qualified electing fund election with respect to the common shares or ADSs.

If a U.S. holder owns common shares or ADSs during any year in which we are a PFIC, the holder generally must file an annual report containing such information as the U.S. Treasury may require on IRS Form 8621 (or any successor form). A failure to file this report generally will suspend the statute of limitations with respect to any tax return, event, or period to which such report relates (potentially including with respect to items that do not relate to a U.S. holder’s investment in common shares or ADSs).

The PFIC rules are complex, and each U.S. holder should consult its own tax advisor regarding the PFIC rules, the elections which may be available to it, and how the PFIC rules may affect the U.S. federal income tax consequences relating to the ownership and disposition of common shares or ADSs.

Reporting Obligations for Certain Owners of Foreign Financial Assets

Certain U.S. holders may be required to file information returns with respect to their investment in common shares or ADSs. For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. holders that hold certain specified foreign financial assets in excess of certain thresholds. The definition of “specified foreign financial assets” includes not only financial accounts maintained in non-U.S. financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person, and any interest in a non-U.S. entity.

U.S. holders may be subject to these reporting requirements unless their common shares or ADSs are held in an account at certain financial institutions.

The discussion of reporting obligations set forth above is not intended to constitute an exhaustive description of all reporting obligations that may apply to a U.S. holder. A failure to satisfy certain reporting obligations may result in an extension of the period during which the IRS can assess a tax, and under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting obligation. Penalties for failure to comply with these reporting obligations are substantial. U.S. holders should consult with their own tax advisors regarding their reporting obligations under these rules, including the requirement to file an IRS Form 8938.

U.S. Holders should consult their tax advisors regarding any reporting obligations that may arise with respect to the acquisition, ownership or disposition of our common shares or the ADSs. Failure to comply with applicable reporting requirements could result in substantial penalties.

The foregoing discussion of certain U.S. federal income tax considerations is for general information only and is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our common shares or the ADSs. U.S. Holders should consult their own tax advisors concerning the tax consequences applicable to their particular situations.

F.
Dividends and Paying Agents

Not applicable.

G.
Statement by Experts

Not applicable.

H.
Documents on Display

We are subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers and under those requirements we file reports with the SEC. Those reports may be inspected without charge on the websites described below. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. Nevertheless, we will file with the SEC an Annual Report on Form 20-F containing financial statements that have been examined and reported on, with and opinion expressed by an independent registered public accounting firm.

89


Table of Contents

 

We maintain a corporate website at https://medirom.co.jp/en/. We intend to post our Annual Report on our website promptly following it being filed with the SEC. Information contained on, or that can be accessed through, our website does not constitute a part of this annual report. We have included our website address in this annual report solely as an inactive textual reference.

The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements and other information regarding registrants, such as Medirom, that file electronically with the SEC.

With respect to references made in this annual report to any contract or other document relating to Medirom, such references are not necessarily complete and you should refer to the exhibits attached or incorporated by reference to this annual report for copies of the actual contract or document.

I.
Subsidiary Information

Not applicable.

J.
Annual Report to Security Holders

If we are required to provide an annual report to security holders in response to the requirements of Form 6-K, we will submit the annual report to security holders in electronic format in accordance with the EDGAR Filer Manual.

ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market Risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: interest rate risk, currency risk and other price risk, such as equity price risk and commodity risk. Financial instruments affected by market risk include borrowings and other financial liabilities. The sensitivity analyses in the following sections relate to our positions as of December 31, 2025.

The sensitivity analyses have been prepared on the basis that the amount of net debt, the ratio of fixed to floating interest rates of the debt and derivatives, and the proportion of financial instruments in foreign currencies are all constant, and on the basis of the hedge designations in place as of December 31, 2025. The analyses exclude the impact of movements in market variables on provisions. The analyses also assume that the sensitivity of the relevant statement of profit or loss item is the effect of the assumed changes in respective market risks. This is based on the financial assets and financial liabilities held on December 31, 2025, including the effect of hedge accounting.

For a discussion of market risk relating to our positions as of December 31, 2024, see “Item 11. Quantitative and Qualitative Disclosure About Market Risk” from our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, as filed with the SEC on April 29, 2025.

Interest Rate Risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Our exposure to the risk of changes in market interest rates relates primarily to our long-term debt obligations with floating interest rates. We manage our interest rate risk by having a balanced portfolio of fixed and variable rate borrowings.

Japanese interest rates have been at historically low levels during the past two decades. The environment in which we operate our business is subject to the Japanese government’s stimulus-oriented monetary policy, which is characterized by these low interest rates. Despite recent policy changes and statements by the Bank of Japan regarding a potential further shift in its interest rate policies, we expect Japanese monetary policy to continue to be expansionary or stimulative in the near future. In addition, with respect to most of our borrowings, our interest rates have been fixed to mitigate interest rate risk. Therefore, we believe that our present exposure to interest rate risk is manageable, as is reflected in the sensitivity analysis below.

Our bank borrowings of JPY1,016,601 thousand (US$6,483 thousand) as of December 31, 2025 consist of fixed interest rate loans of JPY824,930 thousand (US$5,261 thousand) and variable interest rate loans of JPY191,671 thousand (US$1,222 thousand). Based on our borrowings as of December 31, 2025, an increase of interest rates by 100 basis points on our variable interest rate loans would increase our interest expense by JPY1,917 thousand (US$12 thousand). If the increase were applied to all the fixed interest rate loans, the total impact to our interest expense would be JPY8,249 thousand (US$53 thousand).

Foreign Currency Exchange Risk

Our foreign currency exposures give rise to market risk associated with exchange rate movements of the Japanese yen mainly against the U.S. dollar, and vice versa, because most of our expenses are denominated in Japanese yen.

90


Table of Contents

 

Our Japanese yen expenses consist principally of compensation, subcontractor expenses, and rent. We anticipate that a sizable portion of our expenses will continue to be denominated in Japanese yen. Our financial position, results of operations and cash flow are subject to fluctuations due to changes in foreign currency exchange rates. Our results of operations and cash flow are, therefore, subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign currency exchange rates.

While many of our business partners are Japanese domestic enterprises, we also have relationships with foreign enterprises and professionals to which our expenses may be paid in foreign currency. If our business expands overseas in the future, our foreign currency exposure would give rise to more market risk associated with exchange rate movements of the Japanese yen mainly against the U.S. dollar, because most of our revenues are denominated in Japanese yen, while any such expansion outside Japan would cause us to incur more expenses in foreign currencies. Going forward, we anticipate that a certain portion of our expenses will continue to be denominated in foreign currencies. If such expansion efforts outside Japan are successful, however, a substantial amount of revenue could also be denominated in foreign currencies, particularly if we are able to develop and expand sales of MOTHER Bracelet® to markets outside Japan in the future. If our non- Japanese revenues increase substantially in the future, any significant change in the value of the currencies of the countries in which we do business against the Japanese yen could adversely affect our financial condition and results of operations due to translational and transactional differences in exchange rates. During the year ended December 31, 2025 a hypothetical 10% depreciation in the value of the Japanese yen to the U.S. dollar would have resulted in a JPY22,413 thousand (US$143 thousand) decrease in our net income (before income tax).

To date, we have not engaged in hedging our foreign currency exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us from the adverse effects of such fluctuations.

Credit Risk

Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. We are exposed to credit risk from our operating activities, primarily with respect to trade receivables, and from our financing activities, including with respect to deposits with banks and financial institutions, and other financial instruments.

Our primary customers are consumers who visit our Company-owned relaxation salons, franchisees who have payment obligations for our franchise services such as initial membership fees, recurring royalties, training fees, and therapist staffing fees, public bath operators and other business clients for whom we operate their salons on their behalf. With respect to consumer credit risk, consumers pay in cash or with credit cards for the services we provide them. For our salons located in shopping malls, all the daily service fees are collected by the shopping mall operators, reported to us as revenue on a monthly basis, and paid to us in the following month. As such, we are exposed to credit risk of the shopping mall operators and credit card companies for our salon services.

With respect to credit risk of our franchisees, we are at risk of unpaid franchise services charges.

However, in most cases, we control the daily bank accounts of franchised salons, from which we can collect our franchise service charges and pay to franchises their net proceeds after such deductions. We believe this can mitigate the credit risk with respect to our franchisees. Regardless of that, we are still exposed to credit risk with respect to our franchisees, especially in cases where they terminate their franchise contracts or declare bankruptcy without paying franchise service charges which exceed the balances of their bank accounts under our control, and without paying their salon lease obligations and rental property restoration obligations they owe to us in cases where they subleased salons which we have leased from property owners.

We also operate salons for public bath operators and other business clients. We are exposed to the risk of uncollectible receivables to the extent that these clients delay payments to us after their salons under our operation have collected relaxation service fees from consumers.

Customer credit risk is managed by each business unit subject to our established policies, procedures and controls relating to customer credit risk management. Credit quality of a customer is assessed based on an extensive credit rating scorecard, and individual credit limits are defined in accordance with this assessment. Outstanding customer receivables are regularly monitored.

An impairment analysis is performed at each reporting date for major accounts on an individual basis. The maximum exposure to credit risk at the reporting date is the carrying value of each class of financial assets disclosed in Note 1 to our audited consolidated financial statements as of December 31, 2025 and 2024 and for the years ended December 31, 2025, 2024 and 2023 included elsewhere in this annual report. We do not hold collateral as security. We believe that the concentration of risk with respect to trade receivables is low, since our receivables from consumers are collected directly at salons or through credit card companies or shopping malls, whose credit ratings are quite high, we control the daily bank accounts of our franchisees, and the geographic location of public bath operators and other business clients are highly diversified. No single customer accounted for 10% or more of our total revenue for the years ended December 31, 2023, 2024 and 2025.

91


Table of Contents

 

Financial instruments and cash deposits

We manage credit risk with respect to balances with banks and financial institutions in accordance with our policies. Investments of surplus funds are made only with approved counterparties and within credit limits assigned to each counterparty. The limits are set to minimize the concentration of risks, and therefore mitigate financial loss through a counterparty’s potential failure to make payments.

Emerging Growth Company Status

We ceased to be an “emerging growth company,” as defined in the JOBS Act, on December 31, 2025. Prior to that date, we had elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2) of the JOBS Act. As a result of the loss of our emerging growth company status, we are required to adopt new or revised accounting standards as of the effective dates applicable to public business entities, and we have adopted ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, in the consolidated financial statements included in this annual report. See Note 1 to our consolidated financial statements included elsewhere in this annual report.

92


Table of Contents

 

ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

A.
Debt Securities

Not applicable.

B.
Warrants and Rights

Not applicable.

C.
Other Securities

Not applicable.

D.
American Depositary Shares

The Bank of New York Mellon, as depositary, registers and delivers American Depositary Shares, also referred to as ADSs. Each ADS represents one common share (or a right to receive one common share) deposited with MUFG Bank Ltd., as custodian for the depositary in Japan. Each ADS also represents any other securities, cash or other property that may be held by the depositary. The deposited shares together with any other securities, cash or other property held by the depositary are referred to as the deposited securities. The depositary’s office at which the ADSs will be administered and its principal executive office are located at 240 Greenwich Street, New York, New York 10286.

The form of deposit agreement for the ADSs and the form of ADRs that represents an ADS have been incorporated by reference as exhibits to this annual report.

Fees and Expenses

 

Persons depositing or withdrawing common

 

shares or ADS holders must pay:

 

For:

$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)

 

Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates

$.05 (or less) per ADS

 

Any cash distribution to ADS holders

A fee equivalent to the fee that would be payable if securities distributed to you had been common shares and the common shares had been deposited for issuance of ADSs

 

Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders

$.05 (or less) per ADS per calendar year

Depositary services

Registration or transfer fees

 

Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares

Expenses of the depositary

Cable (including SWIFT) and facsimile transmissions (when expressly provided in the deposit agreement) Converting foreign currency to U.S. dollars

Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or common shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes

 

As necessary

Any charges incurred by the depositary or its agents for servicing the deposited securities

 

As necessary

 

The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

93


Table of Contents

 

From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.

The depositary may convert currency itself or through any of its affiliates, or the custodian or we may convert currency and pay U.S. dollars to the depositary. Where the depositary converts currency itself or through any of its affiliates, the depositary acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary’s obligation to act without negligence or bad faith. The methodology used to determine exchange rates used in currency conversions made by the depositary is available upon request. Where the custodian converts currency, the custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that the method by which that rate will be determined will be the most favorable to ADS holders, and the depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate. In certain instances, the depositary may receive dividends or other distributions from the us in U.S. dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by us and, in such cases, the depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor we make any representation that the rate obtained or determined by us is the most favorable rate and neither it nor we will be liable for any direct or indirect losses associated with the rate.

Payment of Taxes

You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until those taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.

94


Table of Contents

 

PART II.

ITEM 13. DEFAULTS, DIVIDENDS ARREARAGES AND DELINQUENCIES

None.

ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

None.

ITEM 15. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We have performed an evaluation of the effectiveness of our disclosure controls and procedures that are designed to ensure that the material financial and non-financial information required to be disclosed to the SEC is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Based on our evaluation, our management, including the chief executive officer and chief financial officer, has concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of December 31, 2025 were not effective due to the material weaknesses in our internal control over financial reporting discussed below. In reaching this conclusion, our management also took into account the delays in completing our financial reporting and audit process that resulted in the untimely filing of this annual report. See “Item 3. Key Information—D. Risk Factors—We may be, and have in the past been, delayed in complying with our periodic reporting obligations under the Exchange Act.”

Management’s Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended). Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness of our internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

Our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our internal control over financial reporting as of December 31, 2025, based on criteria established in the framework in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Based on this evaluation, our management has concluded that our internal control over financial reporting was not effective as of December 31, 2025 because of the material weaknesses described below.

Material weaknesses

•
Insufficiency of effective processes to ensure that all journal entries were properly reviewed and approved prior to posting to the general ledger;
•
Insufficient management review controls over key financial information including lack of evidence of review and approval of financial information;
•
Our user access controls, including provisioning, de-provisioning, and periodic reviews, were not operating effectively, resulting in insufficient segregation of duties and inappropriate access to financially relevant systems and data;
•
Ineffective internal controls over complex or non-routine accounting transactions, due to reliance on limited personnel and insufficient technical expertise, resulted in a material weakness affecting the consistent and timely application of U.S. GAAP; and
•
Insufficient controls over management’s assessment of our ability to continue as a going concern, including the preparation and review of the underlying cash flow forecasts and of the evidence supporting management’s plans, creating a reasonable possibility that a material misstatement in our going-concern assessment or related disclosures would not be prevented or detected on a timely basis.

95


Table of Contents

 

Notwithstanding the material weaknesses discussed above, our management, including our CEO and CFO, has concluded that the audited consolidated financial statements included in this Annual Report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States.

Attestation Report of the Registered Public Accounting Firm

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm because, as a non-accelerated filer, we are not subject to the attestation requirement of Section 404(b) of the Sarbanes-Oxley Act of 2002.

Remediation Plan

During the year ended December 31, 2025, we took some additional steps and have continued to implement measures in the financial reporting process to remediate control deficiencies that result in material weaknesses including but not limited to, (i) utilization of the systems, (ii) streamlining of business processes, (iii) improving the capacity of the financial closing team through internal personnel assignments and support from external professionals, and (iv) performing user access controls, including provisioning, de-provisioning and periodic reviews.

During the year ended December 31, 2025, our ability to implement these measures was constrained. In order to protect group profitability, we did not expand our financial closing team through new or mid-career hiring and instead staffed it by transferring personnel from other departments. Because those personnel have limited accounting experience, their training has required a significant amount of time, and the departure during the year of three employees with accounting experience increased the training required. With respect to systems, the accounting system that we had originally selected did not fit our business, and we therefore changed to the implementation of a different accounting system, which delayed its introduction, and we will need to continue to prepare for that implementation. The replacement of the workflow system associated with our accounting system was completed in the second half of 2025. In addition, we have begun to introduce additional accounting tools in order to improve the efficiency of our collection and analysis of information and of the preparation of our financial statements. Accordingly, the material weaknesses described above had not been remediated as of December 31, 2025.

However, we cannot assure you that we will remediate our material weaknesses in a timely manner. The process of designing and implementing an effective financial reporting system is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments in which we operate and to expend significant resources to maintain a financial reporting system that is adequate to satisfy our reporting obligation.

See “Item 3. Key Information—D. Risk Factors—We have identified material weaknesses in our internal control over financial reporting. If we fail to maintain an effective system of internal control to remediate our material weaknesses and establish and maintain effective internal control over financial reporting, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud.”

Changes in Internal Control over Financial Reporting

During the year ended December 31, 2025, we identified an additional material weakness relating to management’s assessment of our ability to continue as a going concern, as described above, and the material weaknesses previously reported were not remediated during the year. As part of our remediation efforts, we completed the replacement of the workflow system associated with our accounting system in the second half of 2025 and staffed our financial closing team by transferring personnel from other departments. These changes were reasonably likely to materially affect our internal control over financial reporting. We are currently in the process of remediating the material weaknesses described above. We are continuing to implement additional measures to remediate them. Other than the material weaknesses and remediation measures as described above, there were no other changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the year ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT

Under the Companies Act, we have elected to structure our corporate governance system as a company with a separate board of corporate auditors and therefore do not have an audit committee. The function of our board of corporate auditors and each corporate auditor is similar to that of independent directors, including those who are members of the audit committee of a U.S. public company. Our board of corporate auditors is comprised of three corporate auditors, each member of which will meet the requirements of Rule 10A-3 under the Exchange Act.

96


Table of Contents

 

ITEM 16B. CODE OF ETHICS AND BUSINESS CONDUCT

Our board of directors has adopted a written code of ethics and business conduct that applies to our directors, corporate auditors, officers, and employees (including our principal executive officer, principal financial officer, principal accounting officer or controller, and other persons performing similar functions), and our agents. Our code of ethics and business conduct is available on our website at https://medirom.co.jp/en/. If we amend the provisions of our code of ethics and business conduct that apply to our directors, corporate auditors, officers, and employees (including our principal executive officer, principal financial officer, principal accounting officer or controller, and other persons performing similar functions), and our agents, or if we grant any waiver of such provisions, we will disclose such amendment or waiver on our website at the same address.

ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The following table sets out the aggregate fees for professional audit services and other services rendered by GuzmanGray, our independent registered public accounting firm since December 24, 2024, TAAD, LLP, our independent registered public accounting firm prior to the appointment of GuzmanGray and Baker Tilly US, LLP, our independent registered public accounting firm prior to the appointment of TAAD, LLP, for each of the years ended December 31, 2025 and 2024. The engagements of the auditors are pre-approved by the Board of the Company’s Corporate Auditors with consideration of the auditor’s independence, capabilities, understanding of our business and Japanese commercial customs, and audit and other audit-related service fees.

 

 

 

Year ended December 31,

 

(in thousands)

 

2025

 

 

2024

 

Audit Fees (1)

 

¥

84,798

 

 

¥

101,779

 

Audit-Related Fees (2)

 

 

—

 

 

 

18,135

 

Tax Fees (3)

 

 

—

 

 

—

 

All Other Fees (4)

 

 

—

 

 

—

 

 

(1)
Audit Fees for 2025 and 2024 were for professional services associated with the annual audit of our audited consolidated financial statements, the reviews of our semi-annual condensed consolidated financial statements and the issuance of consents and comfort letters in connection with registration statement filings with the SEC.
(2)
Audit-related fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under “Audit Fees.” As part of our public offering of common shares represented by ADSs, which closed on December 11, 2024, we engaged TAAD, LLP and Baker Tilly US, LLP for provision of their auditor consents and comfort services in connection with our registration statement for the offering. In 2025, the fees for the auditor consent issued in connection with our shelf registration statement on Form F-3 (File No. 333-290161), which we filed on September 10, 2025 and which was declared effective on September 22, 2025, are included in “Audit Fees” above.
(3)
Tax Fees consist of fees for tax compliance, tax advice and tax planning. No such services were incurred in 2025 or 2024.
(4)
All Other Fees include any fees billed that are not audit, audit-related or tax fees. No such services were incurred in 2025 or 2024.

ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

Under the Companies Act, we have elected to structure our corporate governance system as a company with a separate board of corporate auditors and therefore do not have an audit committee. For foreign private issuers, use of a board of corporate auditors in compliance with home country rules is permitted under Rule 10A-3(c)(3) of the Exchange Act. Our reliance on Rule 10A-3(c)(3) does not, in our opinion, materially adversely affect the ability of our board of corporate auditors to act independently and to satisfy the other requirements of Rule 10A-3.

ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

Not applicable.

ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT

There has been no change in independent accountants for our Company during the two most recent fiscal years or any subsequent interim period except as previously reported in our Report of Foreign Private Issuer on Form 6-K (File No. 001-39809), filed with the SEC on December 27, 2024. There have been no disagreements of the type required to be disclosed by Item 16F(b).

97


Table of Contents

 

ITEM 16G. CORPORATE GOVERNANCE

We are a “foreign private issuer” as defined under the federal securities laws of the United States and the NASDAQ listing standards. Under the federal securities laws of the United States, foreign private issuers are subject to different disclosure requirements than U.S.-domiciled public companies. We intend to take all actions necessary for us to maintain our status as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley Act, the Exchange Act and other applicable rules adopted by the SEC, and the NASDAQ listing standards. Under the SEC rules and the NASDAQ listing standards, a foreign private issuer is subject to less stringent corporate governance requirements. Subject to certain exceptions, the SEC and the NASDAQ permit a foreign private issuer to follow its home country practice in lieu of their respective rules and listing standards. In general, our articles of incorporation and the Companies Act of Japan (which we refer to as the “Companies Act”) govern our corporate affairs.

In particular, as a foreign private issuer, we follow Japanese law and corporate practice in lieu of the corporate governance provisions set out under NASDAQ Rule 5600, the requirement in NASDAQ Rule 5250(b)(3) to disclose third party director and nominee compensation, and the requirement in NASDAQ Rule 5250(d) to distribute annual and interim reports. Of particular note, the following rules under NASDAQ Rule 5600 differ from Japanese law requirements:

•
NASDAQ Rule 5605(b)(1) requires that at least a majority of a listed company’s board of directors be independent directors, and NASDAQ Rule 5605(b)(2) requires that independent directors regularly meet in executive session, where only independent directors are present. Under our current corporate structure, the Companies Act does not require independent directors. However, our board of directors is currently comprised of four directors, two of whom are considered “independent”, as determined in accordance with the applicable NASDAQ rules. We expect our independent directors to regularly meet in executive sessions, where only the independent directors are present.
•
NASDAQ Rule 5605(c)(2)(A) requires a listed company to have an audit committee composed entirely of not less than three directors, each of whom must be independent. Under Japanese law, a company may have a statutory auditor or a board of auditors. We have a three-member Board of Corporate Auditors, each member of which will meet the requirements of Rule 10A-3 under the Exchange Act. See “—Board of Corporate Auditors” below for additional information.
•
NASDAQ Rule 5605(d) requires, among other things, that a listed company’s compensation committee be comprised of at least two members, each of whom is an independent director as defined under such rule. Our board of directors will collectively participate in the discussions and determination of compensation for our executives, directors and corporate auditors, and other compensation related matters.
•
NASDAQ Rule 5605(e) requires that a listed company’s nomination and corporate governance committee be comprised solely of independent directors. Our board of directors will not have a standalone nomination and corporate governance committee. Our board of directors will collectively participate in the nomination process of potential directors and corporate auditors and oversee our corporate governance practices.
•
NASDAQ Rule 5620(c) sets out a quorum requirement of 331∕3% applicable to meetings of shareholders. In accordance with Japanese law and generally accepted business practices, our articles of incorporation provide that there is no quorum requirement for a general resolution of our shareholders. However, under the Companies Act and our articles of incorporation a quorum of not less than one-third of the total number of voting rights is required in connection with the election of directors, statutory auditors and certain other matters.

ITEM 16H. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

ITEM 16J. INSIDER TRADING POLICIES

We have adopted written Insider Trading Policies governing the purchase, sale, and other dispositions of our securities by our directors, corporate auditors, executive officers, employees, and our agents that are designed to promote compliance with applicable insider trading laws, rules and regulations in the United States and Japan, and the Nasdaq listing standards. A copy of our Insider Trading Policies is included in Exhibit 11.2 to this Annual Report.

ITEM 16K. CYBERSECURITY

We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats. We have processes in place to assess, identify, manage, and address material cybersecurity threats and incidents, and management regularly assesses risks from cybersecurity and technology threats and monitors our information systems for potential

98


Table of Contents

 

vulnerabilities and have integrated cybersecurity risk management into our broader risk management framework. We monitor our information systems for cybersecurity incidents on an ongoing basis using security software supplied by third-party vendors and deployed within the Company. We do not engage outside consultants, auditors or other third parties to assess, test or otherwise assist with our cybersecurity program. We seek to identify and manage risks arising from our use of third-party service providers by including security provisions in our contracts with them and by reviewing those providers in connection with the annual renewal of each contract.

As of the date of this report, we did not identify any cybersecurity incidents that materially affected or are reasonably likely to materially affect our business strategy, results of operations, or financial condition.

We acknowledge that cybersecurity threats are continually evolving, and the possibility of future cybersecurity incidents remains. For additional information, see “Item 3. Key Information—D. Risk Factors—Risks Related to Our Industry—Cybersecurity breaches and other disruptions could compromise our information, result in the unauthorized disclosure of confidential guest, employee, Company and/or business partners’ information, damage our reputation, and expose us to liability, which could negatively impact our business.”

Our board of directors has overall responsibility for the oversight of risk management, which includes cybersecurity risks. Members of the board of directors receive updates on a regular basis regarding matters of risk management, including cybersecurity, as applicable. Our IT Office is the department responsible for assessing and managing material risks from cybersecurity threats on a day-to-day basis, and the general manager of our IT Office, who has more than ten years of experience in information systems, has primary responsibility for our cybersecurity program. The general manager is informed about, and monitors the prevention, detection, mitigation and remediation of, cybersecurity incidents through the security software described above, and reports any matters requiring the attention of our board of directors at its regular meetings, which are held monthly.

99


Table of Contents

 

PART III.

ITEM 17. FINANCIAL STATEMENTS

See Item 18 of this annual report.

ITEM 18. FINANCIAL STATEMENTS

The financial statements required by this item are found at the end of this annual report, beginning on page F-1.

100


Table of Contents

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

CONSOLIDATED FINANCIAL STATEMENTS OF MEDIROM HEALTHCARE TECHNOLOGIES INC.

 

Consolidated Financial Statements as of and for the years ended December 31, 2025, 2024 and 2023

 

 

 

 

 

Report of Independent Registered Public Accounting Firm (PCAOB ID No. 7143)

 

F-2

 

 

 

Report of Independent Registered Public Accounting Firm (PCAOB ID No. 05854)

 

F-4

 

 

 

Consolidated Balance Sheets as of December 31, 2025 and 2024

 

F-5

 

 

 

Consolidated Statements of Operations for the Years Ended December 31, 2025, 2024 and 2023

 

F-6

 

 

 

Consolidated Statements of Shareholders’ Equity (Deficit) for the Years Ended December 31, 2025, 2024 and 2023

 

F-7

 

 

 

Consolidated Statements of Cash Flows for the Years Ended December 31, 2025, 2024 and 2023

 

F-8

 

 

 

Notes to Consolidated Financial Statements for the Years Ended December 31, 2025, 2024 and 2023

 

F-10

 

F-1


Table of Contents

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and the Board of Directors of MEDIROM Healthcare Technologies Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of MEDIROM Healthcare Technologies Inc. (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of operations, shareholders’ equity (deficit), and cash flows for each of the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.

The consolidated financial statements of the Company for the year ended December 31, 2023, before the effects of the retrospective adjustments to the disclosures for the adoption of ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) discussed in Note 11, were audited by other auditors whose report, dated June 18, 2024, expressed an unqualified opinion on those statements. We have also audited the retrospective adjustments to the disclosures for the adoption of ASU 2023-07 discussed in Note 11. In our opinion, such adjustments are appropriate and have been properly applied. We were not engaged to audit, review, or apply any procedures related to the Company’s 2023 consolidated financial statements other than with respect to the adjustments and, accordingly, we do not express an opinion or any other form of assurance on the 2023 consolidated financial statements as a whole.

Explanatory Paragraph – Going Concern

The consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 1, the Company has incurred a significant net loss, has a significant working capital deficiency and a shareholders’ deficit, and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Impairment of Store Operating Rights

F-2


Table of Contents

 

Description of the Matter

As described in Notes 1, 4 and 16 to the consolidated financial statements, the Company tests salon asset groups that include store operating rights for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the year ended December 31, 2025, the Company recognized an impairment loss of ¥1,284,489 thousand on store operating rights.

Auditing the Company’s impairment assessment of store operating rights was especially challenging and subjective because of the significant judgment involved in estimating the expected future cash flows and fair values of the salon asset groups, in particular the adjustment to 2025 salon EBITDA to reflect the level of salon performance expected to continue and the price multiples derived from the Company’s sales of salons to investors, given the absence of an active market for salons. Changes in these assumptions could have a significant effect on the impairment loss.

How We Addressed the Matter in Our Audit

Our audit procedures related to the Company’s impairment assessment of store operating rights included the following, among others:

We obtained an understanding of the Company’s process for identifying impairment indicators and measuring impairment.

We tested the completeness and accuracy of the salon operating data used in the assessment.

We evaluated the adjustment to 2025 salon EBITDA by comparing it with trends in salon performance, with alternative bases for the adjustment, and with the minutes of meetings of the board of directors.

We evaluated the price multiples by testing the underlying salon transactions, including whether the buyers were unrelated parties and whether the consideration was for the store operating rights only, and comparing the resulting multiples to those derived from other comparable transactions.

We evaluated the appropriateness of the valuation method used to measure fair value, including its consistency with ASC 820, Fair Value Measurement.

We performed sensitivity analyses of the impairment loss to changes in the significant assumptions.

We recalculated the impairment loss for each salon asset group.

/s/ GuzmanGray

We have served as the Company’s auditor since 2024.

Costa Mesa, California

November 12, 2026, except for Note 19, as to which the date is November 18, 2026

F-3


Table of Contents

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the board of directors of MEDIROM Healthcare Technologies Inc:

Opinion on the Financial Statements

We have audited, before the effects of the retrospective adjustments to the disclosures for the adoption of ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) discussed in Note 11, the accompanying consolidated balance sheets of MEDIROM Healthcare Technologies Inc. (the “Company”) as of December 31, 2023, the related consolidated statements of operations, shareholders’ equity and cash flows, for the year ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”), the 2023 financial statements before the effects of the adjustments discussed in Notes 11 to the financial statements are not presented herein. In our opinion, the consolidated financial statements, before the effects of the retrospective adjustments to the disclosures for the adoption of ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) discussed in Note 11, present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

We were not engaged to audit, review, or apply any procedures to the retrospective adjustments to the disclosures for the adoption of ASU 2023-07 discussed in Notes 11 and, accordingly, we do not express an opinion or any other form of assurance about whether such retrospective adjustments are appropriate and have been properly applied. Those retrospective adjustments were audited by GuzmanGray.

Going Concern Matter

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has a net working capital deficiency that raises substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ TAAD, LLP

We served as the Company's auditor from 2022 to 2024.

Diamond Bar, California

June 18, 2024

F-4


Table of Contents

 

MEDIROM HEALTHCARE TECHNOLOGIES INC.

CONSOLIDATED BALANCE SHEETS

AS OF DECEMBER 31, 2025 AND 2024

(Yen in thousands, except share data)

 

 

 

December 31,

 

 

 

2025

 

 

2024

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

¥

91,979

 

 

¥

329,399

 

Time deposits

 

 

6,157

 

 

 

6,156

 

Accounts receivable-trade, net

 

 

671,663

 

 

 

1,355,489

 

Accounts receivable-other, net

 

 

385,617

 

 

 

646,207

 

Inventories

 

 

156,619

 

 

 

151,637

 

Prepaid expenses and other current assets

 

 

178,036

 

 

 

217,174

 

Total current assets

 

 

1,490,071

 

 

 

2,706,062

 

Property and equipment, net

 

 

154,620

 

 

 

435,659

 

Goodwill

 

 

—

 

 

 

389,131

 

Store operating rights, net

 

 

855,041

 

 

 

830,838

 

Other intangible assets, net

 

 

11,135

 

 

 

308,459

 

Investments

 

 

500

 

 

 

87,418

 

Long-term accounts receivable-other, net

 

 

—

 

 

 

84,338

 

Right-of-use asset - operating lease, net

 

 

1,297,639

 

 

 

2,073,763

 

Lease and guarantee deposits

 

 

782,969

 

 

 

808,550

 

Deferred tax assets, net

 

 

—

 

 

 

285,882

 

Other assets

 

 

91,965

 

 

 

80,571

 

Total assets

 

¥

4,683,940

 

 

¥

8,090,671

 

LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY (DEFICIT)

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

¥

1,040,961

 

 

¥

1,014,205

 

Accrued expenses

 

 

515,959

 

 

 

325,544

 

Short-term borrowings

 

 

1,440,227

 

 

 

491,667

 

Current portion of long-term borrowings

 

 

161,321

 

 

 

620,813

 

Accrued income taxes

 

 

19,612

 

 

 

58,572

 

Current portion of contract liability

 

 

28,492

 

 

 

53,485

 

Advances received

 

 

325,318

 

 

 

409,710

 

Current portion of operating lease liability

 

 

762,667

 

 

 

792,781

 

Other current liabilities

 

 

439,678

 

 

 

414,704

 

Total current liabilities

 

 

4,734,235

 

 

 

4,181,481

 

Borrowings - net of current portion

 

 

799,959

 

 

 

764,200

 

Deposit received

 

 

182,115

 

 

 

236,179

 

Contract liability - net of current portion

 

 

16,095

 

 

 

36,913

 

Operating lease liability - net of current portion

 

 

976,961

 

 

 

1,287,509

 

Asset retirement obligation

 

 

384,578

 

 

 

378,907

 

Other liabilities

 

 

13,608

 

 

 

17,424

 

Total liabilities

 

 

7,107,551

 

 

 

6,902,613

 

Mezzanine equity: Redeemable noncontrolling interests

 

 

200,160

 

 

 

200,160

 

COMMITMENTS AND CONTINGENCIES (NOTE 17)

 

 

 

 

 

 

SHAREHOLDERS’ EQUITY (DEFICIT):

 

 

 

 

 

 

Common stock, no par value; 19,899,999 shares authorized; 7,994,450 shares issued and 7,901,950 shares outstanding at December 31, 2025 and 2024

 

 

7,504

 

 

 

352,523

 

Class A common stock, no par value; 1 share authorized; 1 share issued and 1 share outstanding at December 31, 2025 and 2024

 

 

100

 

 

 

100

 

Treasury stock, at cost- 92,500 common shares at December 31, 2025 and 2024

 

 

(3,000

)

 

 

(3,000

)

Additional paid-in capital

 

 

728,376

 

 

 

354,605

 

Retained earnings (accumulated deficit)

 

 

(3,405,240

)

 

 

229,040

 

Total equity (deficit) attributable to shareholders of the Company

 

 

(2,672,260

)

 

 

933,268

 

Noncontrolling interests

 

 

48,489

 

 

 

54,630

 

Total equity (deficit)

 

 

(2,623,771

)

 

 

987,898

 

Total liabilities, mezzanine equity and shareholders' equity (deficit)

 

¥

4,683,940

 

 

¥

8,090,671

 

 

The accompanying notes are an integral part of the consolidated financial statements.

F-5


Table of Contents

 

MEDIROM HEALTHCARE TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

(Yen in thousands, except share and per share data)

 

 

 

Years Ended December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

Revenues:

 

 

 

 

 

 

 

 

 

Revenue from directly-operated salons

 

¥

6,959,304

 

 

¥

7,352,868

 

 

¥

5,656,519

 

Franchise revenue

 

 

634,047

 

 

 

792,633

 

 

 

971,027

 

 Other revenues

 

 

168,270

 

 

 

153,633

 

 

 

200,397

 

Total revenues

 

 

7,761,621

 

 

 

8,299,134

 

 

 

6,827,943

 

Cost of revenues and operating expenses:

 

 

 

 

 

 

 

 

 

Cost of revenue from directly-operated salons

 

 

5,749,471

 

 

 

5,575,568

 

 

 

4,552,408

 

Cost of franchise revenue

 

 

196,693

 

 

 

316,655

 

 

 

523,330

 

Cost of other revenues

 

 

82,080

 

 

 

160,626

 

 

 

183,337

 

Selling, general and administrative expenses

 

 

2,574,145

 

 

 

2,241,515

 

 

 

1,960,447

 

Impairment loss on goodwill

 

 

346,626

 

 

 

—

 

 

 

—

 

Impairment loss on long-lived assets

 

 

2,204,327

 

 

 

22,872

 

 

―

 

Total cost of revenues and operating expenses

 

 

11,153,342

 

 

 

8,317,236

 

 

 

7,219,522

 

Operating income (loss)

 

 

(3,391,721

)

 

 

(18,102

)

 

 

(391,579

)

Other income (expense):

 

 

 

 

 

 

 

 

 

Dividend income

 

 

2

 

 

 

2

 

 

 

2

 

Interest income

 

 

110

 

 

 

8

 

 

 

1,111

 

Interest expense

 

 

(66,185

)

 

 

(49,745

)

 

 

(36,868

)

Loss on investment securities

 

 

(86,918

)

 

 

—

 

 

 

—

 

Loss on extinguishment of debt

 

 

(27,998

)

 

 

—

 

 

 

—

 

Gain from sales of salons

 

 

155,525

 

 

 

40,631

 

 

 

413,678

 

Subsidies

 

 

94,565

 

 

 

13,855

 

 

 

21,376

 

Foreign currency exchange gain (loss)

 

 

(7,437

)

 

 

18,121

 

 

 

26,825

 

Other, net

 

 

(8,406

)

 

 

42,943

 

 

 

(13,923

)

Total other income

 

 

53,258

 

 

 

65,815

 

 

 

412,201

 

(Loss) income before income tax expense

 

 

(3,338,463

)

 

 

47,713

 

 

 

20,622

 

 

 

 

 

 

 

 

 

 

 

Income tax expense (benefit)

 

 

304,118

 

 

 

(90,478

)

 

 

(94,427

)

 

 

 

 

 

 

 

 

 

 

Net (loss) income

 

 

(3,642,581

)

 

 

138,191

 

 

 

115,049

 

Less: Net loss attributable to noncontrolling interests

 

 

(8,301

)

 

 

(10,572

)

 

 

(355

)

Net (loss) income attributable to shareholders of the Company

 

¥

(3,634,280

)

 

¥

148,763

 

 

¥

115,404

 

 

 

 

 

 

 

 

 

 

 

Net (loss) earnings per share attributable to shareholders of the Company

 

 

 

 

 

 

 

 

 

Basic

 

¥

(459.92

)

 

¥

29.13

 

 

¥

23.64

 

Diluted

 

¥

(459.92

)

 

¥

28.52

 

 

¥

22.34

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

 

 

Basic

 

 

7,901,951

 

 

 

5,107,405

 

 

 

4,882,501

 

Diluted

 

 

7,901,951

 

 

 

5,851,516

 

 

 

5,166,653

 

 

The accompanying notes are an integral part of the consolidated financial statements.

F-6


Table of Contents

 

MEDIROM HEALTHCARE TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (DEFICIT)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

(Yen in thousands, except share data)

 

 

 

 

 

 

Class A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

 

common stock

 

 

Treasury stock

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

Additional
paid-in
capital

 

Retained
earnings
(accumulated
deficit)

 

Noncontrolling
interest

 

Total

 

Balance, December 31, 2022

 

 

4,975,000

 

 

¥

1,223,134

 

 

1

 

 

¥

100

 

 

 

92,500

 

 

¥

(3,000

)

 

¥

1,265,456

 

 

¥

(2,545,068

)

 

¥

—

 

 

¥

(59,378

)

Reduction in common stock and additional paid-in capital

 

―

 

 

 

(1,203,234

)

 

―

 

 

―

 

 

―

 

 

―

 

 

 

(1,306,707

)

 

 

2,509,941

 

 

―

 

 

―

 

Net income

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

 

115,404

 

 

 

(355

)

 

 

115,049

 

Gain on sale of shares of subsidiaries

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

 

154,853

 

 

―

 

 

 

5,437

 

 

 

160,290

 

Balance, December 31, 2023

 

 

4,975,000

 

 

¥

19,900

 

 

1

 

 

¥

100

 

 

 

92,500

 

 

¥

(3,000

)

 

¥

113,602

 

 

¥

80,277

 

 

¥

5,082

 

 

¥

215,961

 

Issuance of common stock from stock option exercises

 

 

159,450

 

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

 

21,362

 

 

―

 

 

―

 

 

 

21,362

 

Issuance of common stock from public offering

 

 

2,860,000

 

 

 

332,623

 

 

―

 

 

―

 

 

―

 

 

―

 

 

 

219,641

 

 

―

 

 

―

 

 

 

552,264

 

Subsidiary's Series A Preferred Stock Issuance

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

 

60,120

 

 

 

60,120

 

Net income

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

―

 

 

 

148,763

 

 

 

(10,572

)

 

 

138,191

 

Balance, December 31, 2024

 

 

7,994,450

 

 

¥

352,523

 

 

1

 

 

¥

100

 

 

 

92,500

 

 

¥

(3,000

)

 

¥

354,605

 

 

¥

229,040

 

 

¥

54,630

 

 

¥

987,898

 

Subsidiary's Series A Preferred Stock Issuance

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

2,160

 

 

 

2,160

 

Reduction in common stock and additional paid-in capital

 

 

—

 

 

 

(345,019

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

345,019

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of stock acquisition rights

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

754

 

 

 

—

 

 

 

—

 

 

 

754

 

Premium on 4th convertible bonds

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

27,998

 

 

 

—

 

 

 

—

 

 

 

27,998

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(3,634,280

)

 

 

(8,301

)

 

 

(3,642,581

)

Balance, December 31, 2025

 

 

7,994,450

 

 

¥

7,504

 

 

 

1

 

 

¥

100

 

 

 

92,500

 

 

¥

(3,000

)

 

¥

728,376

 

 

¥

(3,405,240

)

 

¥

48,489

 

 

¥

(2,623,771

)

 

Note : Changes in the redeemable noncontrolling interests are not included in this table.

The accompanying notes are an integral part of the consolidated financial statements.

F-7


Table of Contents

 

MEDIROM HEALTHCARE TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

(Yen in thousands)

 

 

 

Years Ended December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

Net (loss) income

 

¥

(3,642,581

)

 

¥

138,191

 

 

¥

115,049

 

Adjustments to reconcile net (loss) income to net cash used in operating activities:

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

532,657

 

 

 

290,038

 

 

 

252,595

 

Gain from sales of directly-owned salons

 

 

(1,072,740

)

 

 

(1,697,112

)

 

 

(1,244,240

)

Change in provision for credit losses

 

 

54,913

 

 

 

49,780

 

 

 

1,958

 

Foreign currency exchange (gain) loss

 

 

10,802

 

 

 

(8,969

)

 

 

(17,402

)

(Gains) losses on disposal of property and equipment, net, other intangible assets, net and goodwill

 

 

(1,704

)

 

 

7,109

 

 

 

(2,648

)

Impairment loss on goodwill

 

 

346,626

 

 

 

—

 

 

 

—

 

Impairment loss on long-lived assets

 

 

2,204,327

 

 

 

22,872

 

 

―

 

Loss on investment securities

 

 

86,918

 

 

 

—

 

 

 

—

 

Loss on extinguishment of debt

 

 

27,998

 

 

 

—

 

 

 

—

 

Deferred income taxes, net

 

 

285,882

 

 

 

(188,706

)

 

 

(101,636

)

Other non-cash losses – net

 

 

(6,225

)

 

 

53,146

 

 

 

45,718

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

Accounts receivable-trade, net

 

 

(184,142

)

 

 

339,120

 

 

 

580,681

 

Accounts receivable-other, net

 

 

266,713

 

 

 

(39,159

)

 

 

43,382

 

Inventories

 

 

(4,982

)

 

 

(10,612

)

 

 

(25,873

)

Prepaid expenses and other current assets

 

 

(12,576

)

 

 

(2,362

)

 

 

(530

)

Lease and guarantee deposits

 

 

25,142

 

 

 

46,853

 

 

 

46,652

 

Accounts payable

 

 

52,732

 

 

 

876,508

 

 

 

(69,884

)

Accrued expenses

 

 

97,340

 

 

 

(1,048,548

)

 

 

97,045

 

Accrued income taxes

 

 

(38,960

)

 

 

43,684

 

 

 

(45,006

)

Contract liability

 

 

(45,811

)

 

 

(90,042

)

 

 

(64,999

)

Advances received

 

 

(84,391

)

 

 

(27,939

)

 

 

(104,663

)

Other current liabilities

 

 

29,843

 

 

 

22,740

 

 

 

(77,447

)

Deposit received

 

 

(54,064

)

 

 

(25,743

)

 

 

(42,656

)

Other assets and other liabilities – net

 

 

(28,724

)

 

 

(82,530

)

 

 

(17,833

)

Net cash used in operating activities

 

 

(1,155,007

)

 

 

(1,331,681

)

 

 

(631,737

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

Purchases of time deposits

 

 

—

 

 

 

(5,656

)

 

―

 

Proceeds from maturities of time deposits

 

 

—

 

 

 

26,004

 

 

―

 

Acquisition of investments

 

 

—

 

 

―

 

 

 

(3,094

)

Proceeds from sale of investment securities

 

 

—

 

 

 

3,558

 

 

―

 

Acquisition of property and equipment

 

 

(10,301

)

 

 

(71,408

)

 

 

(135,840

)

Acquisition of intangible assets

 

 

(61,111

)

 

 

(13,483

)

 

 

(60,945

)

Acquisition of store operating rights

 

 

(491,184

)

 

 

(479,922

)

 

 

(725,233

)

Proceeds from sale of salons

 

 

540,140

 

 

 

908,419

 

 

 

584,768

 

Acquisition of businesses – net of cash acquired

 

 

—

 

 

 

(21,348

)

 

―

 

Payment received on short-term loans receivable

 

 

—

 

 

―

 

 

 

113

 

Payment received on long-term accounts receivable-other, net

 

 

—

 

 

 

15,229

 

 

 

11,655

 

Net cash (used in) provided by investing activities

 

 

(22,456

)

 

 

361,393

 

 

 

(328,576

)

 

The accompanying notes are an integral part of the consolidated financial statements.

F-8


Table of Contents

 

MEDIROM HEALTHCARE TECHNOLOGIES INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS—(CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

(Yen in thousands)

 

 

 

Years Ended December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock, net of issuance costs

 

¥

—

 

 

¥

608,101

 

 

¥

—

 

Proceeds from issuance of preferred stock

 

 

2,160

 

 

 

260,280

 

 

―

 

Proceeds from short-term borrowings

 

 

1,263,338

 

 

 

710,000

 

 

 

400,000

 

Repayment of short-term borrowings

 

 

(789,778

)

 

 

(588,333

)

 

―

 

Proceeds from long-term borrowings

 

 

180,321

 

 

 

300,000

 

 

―

 

Repayment of long-term borrowings

 

 

(116,752

)

 

 

(96,708

)

 

 

(99,084

)

Proceeds from issuance of convertible bonds

 

 

400,000

 

 

 

—

 

 

 

—

 

Proceeds from issuance of stock acquisition rights

 

 

754

 

 

 

—

 

 

 

—

 

Proceeds from sale of subsidiary stock

 

 

—

 

 

―

 

 

 

160,290

 

Net cash provided by financing activities

 

 

940,043

 

 

 

1,193,340

 

 

 

461,206

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

 

(237,420

)

 

 

223,052

 

 

 

(499,107

)

Cash and cash equivalents at beginning of year

 

 

329,399

 

 

 

106,347

 

 

 

605,454

 

Cash and cash equivalents at end of year

 

¥

91,979

 

 

¥

329,399

 

 

¥

106,347

 

 

 

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid during the year for:

 

 

 

 

 

 

 

 

 

Interest

 

¥

52,756

 

 

¥

47,558

 

 

¥

34,575

 

Income taxes

 

 

59,318

 

 

 

12,777

 

 

 

52,105

 

 

 

 

 

 

 

 

 

 

Non-cash investing and financing activities:

 

 

 

 

 

 

 

 

 

Right-of-use assets obtained in exchange for lease liabilities

 

¥

598,303

 

 

¥

901,202

 

 

¥

931,521

 

Purchases of property and equipment included in accrued expenses

 

 

18,404

 

 

 

12,304

 

 

 

4,624

 

Purchases of intangible assets included in accrued expenses

 

 

913

 

 

 

12,000

 

 

 

9,480

 

Purchases of store operating rights included in accrued expenses

 

 

285,693

 

 

 

81,000

 

 

 

—

 

Sales of salons included in accounts receivable

 

 

412,417

 

 

 

1,135,127

 

 

 

455,464

 

Deferred stock issuance costs included in accrued expenses

 

 

—

 

 

 

84,339

 

 

―

 

Acquisition of store operating rights through offsetting of accounts payable and accounts receivable-trade

 

 

1,563,096

 

 

 

437,401

 

 

 

291,250

 

Acquisition of store operating rights through transfer of prepaid expenses

 

 

48,418

 

 

 

—

 

 

 

—

 

Exchange of the 1st convertible bonds for the 4th convertible bonds

 

 

275,000

 

 

 

—

 

 

 

—

 

Settlement of the 1st convertible bonds through a short-term loan

 

 

200,000

 

 

 

—

 

 

 

—

 

Redemption of the 1st convertible bonds included in accounts payable

 

 

25,000

 

 

 

—

 

 

 

—

 

Settlement of short-term borrowings through offsetting of accounts receivable-trade from sales of salons

 

 

400,000

 

 

 

—

 

 

 

—

 

Reduction in common stock and additional paid-in capital

 

 

345,019

 

 

―

 

 

 

2,509,941

 

 

Refer to Note 8, “Leases” for supplemental cash flow information related to leases.

The accompanying notes are an integral part of the consolidated financial statements.

F-9


Table of Contents

 

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

1.
Basis of Presentation and Summary of Significant Accounting Policies

Description of Business

MEDIROM Healthcare Technologies Inc. (“Parent”) and its six subsidiaries (collectively, the “Company”) are one of the leading holistic health services providers in Japan. The Company is a franchisor and operator of healthcare salons across Japan and is a preferred platform partner for large consumer brands, healthcare service providers, and government entities to effect positive health outcomes. The Company primarily engages in three lines of business: Relaxation Salon Segment (retail), Luxury Beauty (retail) and Digital Preventative Healthcare Segment (healthtech). Refer to description below and Note 11 for segment information.

Parent was originally incorporated in Japan on July 13, 2000 under the name “Kabushiki Kaisha Young Leaves.” In January 2017, Parent changed Parent’s name to “MEDIROM Inc.” In March 2020, Parent changed Parent’s name to “MEDIROM Healthcare Technologies Inc.”

Relaxation Salon Segment (See Note 11 for segment information)

The Relaxation Salon Segment is the core of our business, whereby we own, develop, operate, or franchise and support relaxation salons. As part of this business, the Company develops salons, sells directly-operated salons to third-party investors, continues to operate the sold salons under service agreements with the investors, and repurchases salons from investors. The segment also includes rehabilitation services provided by MEDIROM Rehab Solutions Inc. (“MRS”), which acquired a rehabilitation business in October 2024. The salon locations cover major cities throughout Japan, with strong market presence in the Tokyo metropolitan area. The Segment includes several Relaxation Salon brands including Re.Ra.Ku®, and as of December 31, 2025, 2024 and 2023, it has a total of 292, 308 and 314 salons, respectively. The following table presents total number of salons by operation type:

 

 

 

Number of

 

 

 

Relaxation Salons

 

 

 

2025

 

 

2024

 

 

2023

 

Directly-operated

 

 

222

 

 

 

220

 

 

 

217

 

Franchised

 

 

70

 

 

 

88

 

 

 

97

 

Total

 

 

292

 

 

 

308

 

 

 

314

 

 

The number of salons in Directly-operated includes 74, 57 and 41 investor-owned salons as of December 31, 2025, 2024 and 2023, respectively. The number of investor-owned salons represents the salons held by investors at each year end and does not roll forward with the numbers of salons sold and repurchased presented under “Revenue from Directly-Operated Salons” below. The number of salons sold includes salons transferred under combined arrangements, for which the related gain is presented in gain from sales of salons. Accordingly, the total sales amount of the salons sold in 2025 (¥1,365,914 thousand) excludes the consideration of ¥376,150 thousand for the seven salons transferred under combined arrangements. The number of investor-owned salons is also reduced by the closure of salons during the year.

Digital Preventative Healthcare Segment (See Note 11 for segment information)

The Digital Preventative Healthcare Segment mainly consists of the following operations: government-sponsored Specific Health Guidance program, utilizing our internally-developed on-demand health monitoring smartphone application, or Lav®; our MOTHER Bracelet® for fitness applications.

Luxury Beauty Segment (See Note 4 for goodwill impairment and Note 11 for segment information)

The Luxury Beauty Segment is a business line acquired in October 2021 and operates high-end hair salons in the central areas of Tokyo through ZACC Kabushiki Kaisha (“ZACC”), including 3 luxury hair salon brands (ZACC vie, ZACC raffine, and ZACC ginza).

Basis of Presentation

The accompanying consolidated financial statements are presented in Japanese yen, the currency of the country in which the Company is incorporated and principally operates. The accompanying consolidated financial statements have been prepared on the basis of accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain prior-year amounts have been reclassified to conform to the current-year presentation. The significant reclassifications are the separate presentation of

F-10


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

store operating rights from other intangible assets in the consolidated balance sheets and in Note 4, the separate presentation of purchases of intangible assets in the consolidated statements of cash flows, the separate presentation of corporate bonds and corporate convertible bonds in Note 6, and the removal of accumulated impairment from the accumulated depreciation and amortization line in the property and equipment table in Note 3. These reclassifications had no effect on total assets, total liabilities, net loss or cash flows for any period presented.

Going Concern and Liquidity

The Company had a working capital deficit of ¥3,244,164 thousand, an accumulated deficit of ¥3,405,240 thousand and a total deficit of ¥2,623,771 thousand (deficit attributable to shareholders of the Company of ¥2,672,260 thousand) as of December 31, 2025, and has had a working capital deficit as of the end of each of the last three years. The Company incurred a net loss of ¥3,642,581 thousand and had negative cash flows from operations of ¥1,155,007 thousand for the year ended December 31, 2025. We expect that our cash and cash equivalents as of December 31, 2025 of ¥91,979 thousand will not be sufficient to fund our operating expenses, capital expenditure requirements, and debt service obligations within one year after the date that the financial statements are issued. These conditions, among others, raise substantial doubt about the ability of the Company to continue as a going concern. The continuation as a going concern is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and the success of its future operations.

As of December 31, 2025, the Company had debt obligations of ¥1,601,548 thousand maturing within 12 months, consisting of short-term borrowings of ¥1,440,227 thousand and the current portion of long-term borrowings of ¥161,321 thousand. These include the 3rd and 4th convertible bonds of ¥400,000 thousand and ¥275,000 thousand (maturing on June 30, 2026, extendable to December 25, 2026), bank loans of ¥350,000 thousand and ¥191,671 thousand maturing on March 31, 2026, a loan of ¥200,000 thousand from Kufu Company Holdings Inc., a loan of ¥23,556 thousand obtained by MML, corporate bonds of ¥30,000 thousand maturing on April 30, 2026 and the current portion of the loans from Spirit Advisors of ¥35,629 thousand. Subsequent to December 31, 2025, the bank loans of ¥350,000 thousand and ¥191,671 thousand were rolled over, the MML loan was repaid in full, the maturity of the corporate bonds was extended to December 31, 2026 and the maturity of the 3rd convertible bonds was extended to December 25, 2026. The principal of the 4th convertible bonds was added to the loan from Kufu Company Holdings Inc., increasing the loan to ¥475,000 thousand, which bears interest at 10.0% per annum, is repayable by December 30, 2026 and is secured by a pledge of all of the shares of MML held by the Company. The 2nd convertible bonds of ¥300,000 thousand were refinanced in August 2026 into a loan from the bondholder, which originally bore interest at 5.0% per annum and had a maturity date of September 15, 2026 and was not repaid on that date. On November 11, 2026, the Company and the lender agreed to extend the maturity of the principal to December 30, 2026, with ¥5,000 thousand repayable on November 30, 2026 and the balance on the maturity date, and to increase the rate on interest accruing on and after November 1, 2026 to 14.6% per annum, payable monthly. The loan is secured by a pledge of the shares of MRS held by the Company and by security over the operating rights of ten salons operated by the Company when the security was granted. In addition, as of December 31, 2025, the Company had taxes and social insurance premiums that were past due in the aggregate amount of ¥250,154 thousand, for which the Company has agreed revised payment schedules with the relevant Japanese tax and social insurance authorities. The Company has also received notices from Nasdaq regarding non-compliance with its continued listing requirements (see Note 19). Management’s plans also include the sale of salons to investors, the success of which depends on the operating performance of the salons, which deteriorated in 2025 as described in Notes 3 and 4.

Management plans to alleviate the conditions that raise substantial doubt by raising additional capital through the issuance of common stock, other equity or debt financings, or refinancing of existing debt obligations. In addition, the Company has implemented plans to reduce the operating, and overhead and administrative expenses, including but not limited to cutting discretionary spending, renegotiating contracts to lower service costs, switching to less expensive suppliers. However, the Company’s ability to issue equity securities or obtain debt financing on acceptable terms, or at all, will depend on, among other things, its financial performance, general economic factors, including inflation and then-current interest rates, the condition of the credit and capital markets and other events, some of which may be beyond the Company’s control. See Note 19 for further detail. There are currently no written agreements in place for such funding or issuance of securities except for the debt refinancings and extensions described above and in Note 19 and there can be no assurance that such financing plans will be effectively implemented. Accordingly, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued.

The Company’s consolidated financial statements as of December 31, 2025, were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.

Consolidation and Variable Interest Entities

On May 31, 2023, the board of directors approved a reorganization, which consists of (i) an Incorporation-type Company Split Plan, pursuant to which the Company spun off the Digital Preventative Healthcare business and transferred and assigned it to MEDIROM MOTHER Labs Inc. (“MML”), a newly established wholly-owned subsidiary, which is expected to solely conduct

F-11


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

the Digital Preventative Healthcare business going forward; and (ii) an Absorption-type Company Split Agreement, pursuant to which the Company spun off the existing salon development department (which is responsible for sourcing and setting up store spaces) and general corporate department (which includes accounting, legal, general affairs, human resources, IT and any other corporate functions) and had Bell & Joy Power Partners Inc., an existing wholly-owned subsidiary, assume such operations going forward (on the same day, Bell & Joy Power Partners Inc. was renamed into Medirom Shared Services Inc.). As these subsidiaries were under common control, there was no impact to the consolidated financial statements. The reorganization became effective on July 3, 2023.

The Company implemented an organizational restructuring through a business combination of its wholly-owned subsidiaries, effective January 1, 2025. Wing Inc. succeeded in all rights and obligations of Medirom Human Resources Inc. through an absorption-type merger, and succeeded in all rights and obligations held by JOYHANDS WELLNESS Inc. regarding its hot spring spa business operations through an absorption-type demerger. Effective on the same date, Wing Inc. changed its name to MEDIROM Wellness Co. As these subsidiaries were under common control, there was no impact to the consolidated financial statements.

Separately, on January 1, 2025, the Company sold all of its shares of JOYHANDS WELLNESS Inc. to a third party and deconsolidated JOYHANDS WELLNESS Inc. as of that date. The Company recognized a gain on the sale of ¥2,650 thousand, which is included in other, net in the consolidated statements of operations for the year ended December 31, 2025.

The consolidated financial statements for the year ended December 31, 2025 include the accounts of Parent and the following subsidiaries: MEDIROM Wellness Co. (formerly Wing Inc.), Medirom Shared Services Inc., SAWAN Co., Ltd., ZACC, MEDIROM MOTHER Labs Inc. (“MML”), and MEDIROM Rehab Solutions Inc. (“MRS”). For those consolidated subsidiaries where the Company’s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as “Net income attributable to noncontrolling interests” in the Consolidated Statements of Operations. All intercompany transactions have been eliminated in consolidation. Investments in companies over which the Company has significant influence but not control are accounted for by the equity method. The Company evaluates its investments and other significant relationships to determine whether any investee is a variable interest entity (“VIE”). If the Company concludes that an investee is a VIE, the Company evaluates its power to direct the activities of the investee, its obligation to absorb the expected losses of the investee and its right to receive the expected residual returns of the investee to determine whether the Company is the primary beneficiary of the investee. If the Company is the primary beneficiary of a VIE, the Company consolidates such entity and reflects the noncontrolling interest of other beneficiaries of that entity. There is no VIE where the Company is the primary beneficiary as of December 31, 2025 and 2024.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in the consolidated financial statements include, but are not limited to, the allowance for credit losses, fair value of intangible assets acquired through business combination, impairment of long-lived assets and goodwill, asset retirement obligations, valuation of stock-based compensation, going concern, valuation of deferred tax assets, useful life for long-lived assets and valuation of investments. Management bases these estimates on assumptions that it believes to be reasonable under the circumstances.

As a result of the impairment losses recognized in 2025, the carrying amounts of certain asset groups approximate their fair values. As of December 31, 2025, the carrying amounts of store operating rights, right-of-use assets and property and equipment were ¥855,041 thousand, ¥1,297,639 thousand and ¥154,620 thousand, respectively. If the operating performance of the Company’s salons continues to deteriorate, or if the EBITDA multiples or other assumptions used in the fair value measurements decline, it is reasonably possible that additional impairment losses will be recognized in the near term.

Foreign Currency Translation

The Company uses Japanese yen as its functional and reporting currency. Assets and liabilities denominated in foreign currencies are translated into Japanese yen at the respective year-end exchange rates. All revenue and expenses from assets and liabilities denominated in foreign currencies are converted to Japanese yen at the exchange rate prevailing when transactions occur. Exchange gains and losses resulting from foreign currency transactions and the conversion of monetary assets and liabilities denominated in foreign currencies are included in foreign currency exchange gain (loss) in the consolidated statements of operations.

F-12


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

Noncontrolling Interests

Noncontrolling interests represent the portion of profit or loss, net assets, and comprehensive income or loss that is not allocable to the Company as a result of the sale of ownership interest in MML to certain third-party investors. At the end of each reporting period, the Company determines the amount of equity (at book value) that is allocable to noncontrolling interests based upon the respective ownership interests.

In September and October 2024, MEDIROM MOTHER Labs Inc., a subsidiary of the Company, issued series A preferred stock to third-party investors and two senior executives for ¥260,280 thousand in its equity financing. Although the preferred stock has no dividend rights, it has a right of payment equivalent to the amount paid per share of the stocks before the common stock shareholder when distributing residual assets. Certain noncontrolling interests related to these Series A Preferred Stock are redeemable interests subject to put rights upon the occurrence of certain contingent events. The rights are triggered by events preventing the subsidiary's technological or legal capacity to commercialize its products. As redemption of the noncontrolling interest is not solely in the control of the Company, it is recorded between liabilities and equity on the consolidated balance sheets at its redemption value. No event that would trigger the put rights occurred during the year ended December 31, 2025. Redeemable noncontrolling interests of ¥200,160 thousand were recognized upon issuance in 2024, and there were no changes during the year ended December 31, 2025.

During the year ended December 31, 2025, MML issued an additional 12 shares of series A preferred stock at ¥180 thousand per share, for total proceeds of ¥2,160 thousand, to three directors of MML. The Company concluded that these shares are classified in permanent equity and recorded the proceeds in noncontrolling interests. No stock-based compensation expense was recognized because the shares were issued at the same price as the shares issued to third-party investors in 2024.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash on hand or other highly liquid investments placed with banks or other financial institutions which are unrestricted as to withdrawal or use and have original maturities of less than three months. There are no cash equivalent balances for the periods presented.

Time Deposits

Time deposits presented in the consolidated balance sheets are short-term investments, whose maturity dates are longer than three months but less than one year. Time deposits with maturity dates of longer than one year are included in other assets in the consolidated balance sheets.

Accounts Receivable—Trade, Net

The accounts receivable-trade on the Company’s consolidated balance sheets primarily includes accounts receivables from third-party investors and franchisees. The balance is presented net of an allowance for expected credit losses (i.e., doubtful accounts), primarily related to receivables from third-party investors and the Company’s franchisees. The Company evaluates receivables on an individual customer basis and records an allowance for the full amount of balances that have been outstanding for more than one year, and considers delinquencies, aging trends and expectations of forward-looking loss estimates for other balances. The allowance for expected credit losses is the Company’s best estimate of expected credit losses over the contractual life of the receivables. The allowance for credit losses related to accounts receivable-trade was ¥17,793 thousand and ¥70,495 thousand at December 31, 2025 and 2024, respectively.

Accounts Receivable—Other, Net and Long-Term Accounts Receivable—Other, Net

The accounts receivable—other on the Company’s consolidated balance sheets primarily includes accounts receivable from commercial facility landlords and credit card companies related to directly-operated salon’s revenue and franchisee’s revenue collected by these entities on behalf of the Company. As of December 31, 2025 and 2024, accounts receivable from commercial facilities and credit card companies of ¥376,230 thousand and ¥454,545 thousand, respectively, are included in the accounts receivable—other, net on the consolidated balance sheets. The balance is presented net of an allowance for expected credit losses (i.e., doubtful accounts). The Company monitors the financial condition of its debtors and records provisions for estimated losses on receivables when it believes debtors are unable to make their required payments based on factors such as delinquencies and aging trends. The allowance for credit losses is the Company’s best estimate of expected credit losses over the contractual life of the receivables. As of December 31, 2025 and 2024, the allowance for credit losses related to accounts receivable-other was ¥9,334 thousand and ¥457 thousand, respectively.

F-13


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

The changes in the allowance for credit losses for the years ended December 31, 2025, 2024 and 2023 were as follows:

 

 

 

Thousands of Yen

 

 

 

Accounts
receivable-
trade

 

 

Accounts
receivable-
other

 

 

Long-term
accounts
receivable-
other

 

 

Total

 

Balance at December 31, 2022

 

¥

5,873

 

 

¥

—

 

 

¥

124,699

 

 

¥

130,572

 

Provision for credit losses, net

 

 

10,052

 

 

 

457

 

 

 

(8,152

)

 

 

2,357

 

Balance at December 31, 2023

 

¥

15,925

 

 

¥

457

 

 

¥

116,547

 

 

¥

132,929

 

Provision for credit losses, net

 

 

54,570

 

 

 

—

 

 

 

(4,791

)

 

 

49,779

 

Balance at December 31, 2024

 

¥

70,495

 

 

¥

457

 

 

¥

111,756

 

 

¥

182,708

 

Provision for credit losses, net

 

 

(36,736

)

 

 

84,168

 

 

 

98,738

 

 

 

146,170

 

Write-offs

 

 

(15,966

)

 

 

(75,291

)

 

 

—

 

 

 

(91,257

)

Balance at December 31, 2025

 

¥

17,793

 

 

¥

9,334

 

 

¥

210,494

 

 

¥

237,621

 

 

The provision for credit losses, net, of ¥146,170 thousand for 2025 primarily consisted of an additional allowance of ¥98,738 thousand to fully reserve the long-term accounts receivable-other, for which no repayment agreement has been reached, allowances of ¥75,428 thousand for receivables from two counterparties, which were subsequently written off, and other provisions of ¥16,538 thousand, partially offset by the reversal of the allowance of ¥44,534 thousand for receivables from a customer of MML, which were settled through the return of products. Write-offs of ¥91,257 thousand consisted of the ¥75,428 thousand above and the remaining ¥15,829 thousand of receivables from the customer of MML.

Long-term accounts receivable—other mainly consists of a non-interest bearing receivable due from an unrelated business entity, with a monthly repayment amount of ¥1,200 thousand and maturity of July 31, 2038. As of December 31, 2025 and 2024, the total principal balance due was ¥197,475 thousand and ¥197,475 thousand, respectively, of which nil and ¥14,400 thousand, respectively, was current and included in accounts receivable-other, net in the consolidated balance sheets. No repayments were received in 2025, and the entire balance was classified as non-current as of December 31, 2025. Long-term accounts receivable—other includes other long-term accounts receivable of ¥13,019 thousand and ¥13,019 thousand as of December 31, 2025 and 2024, respectively. The Company monitors the financial condition of its obligor and records provisions for expected credit losses on receivables when it believes the obligors are unable to make their required payments. As of December 31, 2025 and 2024, the related allowance for credit losses on long-term accounts receivable—other was ¥210,494 thousand and ¥111,756 thousand, respectively. During the year ended December 31, 2025, the Company recorded a full allowance against the long-term accounts receivable—other balance based on its assessment of the obligor’s ability to pay.

Concentrations

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash. The Company primarily places its cash with high-credit quality financial institutions. The Company’s cash deposits of up to ¥10,000 thousand are insured by the Japanese government. From time to time, the Company has deposits in excess of the insured amounts.

Sale of Salons, Repurchases, and Accounts Receivable Concentration

As of December 31, 2025, accounts receivable – trade related to salon sales included approximately ¥120 million and ¥111 million due from two investors, representing approximately 11% and 10% of total accounts receivable-trade, net and accounts receivable-other, net, respectively. For comparison, as of December 31, 2024, accounts receivable – trade related to salon sales included approximately ¥313 million due from one of the investors (“Investor A”), representing approximately 16% of total accounts receivable-trade, net and accounts receivable-other, net. The Company evaluated the collectibility of the 2025 receivables considering the investors’ payment history and collections after the balance sheet date. As of May 18, 2026, the entire balances had been collected or settled, including by offset against amounts payable to one of those investors for salons the Company repurchased from that investor, and the Company did not record an allowance for credit losses on these receivables as of December 31, 2025.

These transactions are aligned with the Company’s recurring strategy of developing and monetizing its salon portfolio while maintaining operational continuity through long-term service agreements. The Company continues to provide management services for many of the salons sold. Refer to “Revenue Recognition” and Note 13 for further details.

F-14


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

Inventories

Inventories consist principally of finished goods and raw materials of Mother Bracelet. As of December 31, 2025 and 2024, inventories consisted of merchandise of ¥33,747 thousand and ¥34,149 thousand, finished goods of ¥34,202 thousand and ¥23,051 thousand, and raw materials of ¥88,670 thousand and ¥94,437 thousand, respectively. Inventories are stated at the lower of cost or net realizable value, cost being determined by the first-in, first-out method for merchandise. The Company reviews its inventories for obsolete or unsalable items and adjusts the carrying value to reflect estimated net realizable values.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets include prepaid expenses of ¥123,084 thousand and ¥125,577 thousand as of December 31, 2025 and 2024, respectively.

Investments

Investments in equity securities, in which the Company does not have significant influence, and for which there is not a readily determinable fair value, are recorded at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments in the same issuer.

When the Company evaluates whether these non-marketable equity securities are impaired or not, the Company evaluates first whether an event or change in circumstances has occurred in the period that may have a significant adverse effect on the fair value of the securities (an impairment indicator).

The Company uses such impairment indicators as follows:

(1)
A significant deterioration in the earnings performance or business prospects of the investee.
(2)
A significant adverse change in the regulatory, economic, or technological environment of the investee.
(3)
A significant adverse change in the general market condition of either the geographic area or the industry in which the investee operates.
(4)
A recent example of the new issuance of a security, in which the issue price is less than our cost.
(5)
Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants.

The Company estimates the fair value of the non-marketable equity securities when an impairment indicator is present. The fair value is determined as a result of considering various unobservable inputs which are available to the Company, including expectation of future income of the investees, net asset value of the investees, and material unrealized losses to be considered in assets and liabilities held by the investees. The Company recognizes impairment of non-marketable equity securities when the fair value is below the carrying amount. During the year ended December 31, 2025, the Company recognized an impairment loss of ¥86,918 thousand on its investment (see Note 5), which is presented as loss on investment securities in the consolidated statements of operations.

Leases

The Company considers whether a contract is a lease or if it contains a lease element when a contract is executed. If a contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration, such contract is determined to contain a lease element. When the contract contains a lease element, a lease is either classified as operating lease or finance lease when the Company is a lessee, and a sales-type lease or direct financing lease when the Company is a lessor.

The Company, as a lessee, applies the right-of-use model to account for lease transactions. Under the right-of-use model, right-of-use asset and lease liability are recognized at commencement date. The Company measures its lease liability at present value of future lease payments over the remaining term. The Company uses its incremental borrowing rate for the discount rate to calculate the present value of the payments since it is difficult and not practical to determine the interest rate implicit in the lease. The Company’s incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Right-of-use asset is initially measured as the initial amount of the lease liability, plus any lease payments made to the lessor before the lease commencement date, plus any initial direct costs incurred, minus any lease incentives received. When the Company determines a lease term, if a lease contract contains an option to extend its lease term, the Company is reasonably certain to exercise such option. This is

F-15


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

mainly due to the severe economic loss the Company may face for not exercising the right of extension, such as recognizing impairment loss of attached facilities and loss resulting from failure to receive the franchise fee originally obtainable. Therefore, the lease term includes the option to extend. Initial lease terms are generally between 3 and 10 years.

For operating leases, the Company recognizes the minimum lease payments where it is the lessee and the minimum lease income where it is the lessor on a straight-line basis over the lease term, and reflects them as rental expenses and rental revenues, respectively, in the consolidated statements of operations. The Company elected to separate lease and non-lease components and not to recognize leases with an initial term of 12 months or less.

Operating rental expense includes amortization of right-of-use assets and interest on lease liability. Variable lease expenses are primarily linked to sales and are excluded from the measurement of lease liability.

Rental expenses are recorded in the consolidated statements of operations based on the nature of the underlying lease. Rental expense related to leases for directly-operated salons and for leased properties that are subsequently subleased to franchisees are recorded to cost of revenue from directly-operated salons and cost of franchise revenue, respectively, and rental expense related to leases for corporate offices is recorded to selling, general and administrative expenses.

Rental revenue for operating leases on properties subleased to franchisees is recorded to franchise revenue. Terms and conditions of the sublease agreements are arranged to pass through lease obligations under head leases to the franchisees. Sublease income is presented on a gross basis on the accompanying consolidated statements of operations, as the Company remains the primary obligor.

For newly executed contracts, renewal and revision related to leases, estimates and certain assumptions are used to determine asset value, useful lives, discount rate, lease term, etc. and these have effects on (1) classification of lease, (2) measurement of rental payments and (3) measurement of lease asset. These results may differ if varying estimates and assumptions are used.

Property and Equipment, Net

Property and equipment are recorded at cost, less accumulated depreciation. Depreciation of property and equipment is computed principally using the straight-line method based on the estimated useful life of the assets.

The useful lives for depreciation by major asset classes are as follows:

 

Leasehold improvements

 

Lesser of 15 years or the remaining lease term

Vehicles

 

2-6 years

Tools, furniture and fixtures

 

3-13 years

 

Other Intangible Assets, Net

Other intangible assets with finite useful lives consist primarily of capitalized software, reacquired franchise rights, definite-lived trademarks and customer relationships. The Company capitalizes both eligible internal and external costs of developing or obtaining computer software for internal use. Costs incurred to develop internal-use software during the application development stage are capitalized until the software is substantially complete and ready for its intended use. Costs related to data conversion, training and maintenance costs associated with internal-use software are expensed as incurred. Capitalized software is amortized over the estimated useful life (3-5 years) using the straight-line method. The Company amortizes the fair value of reacquired franchise rights over the remaining contractual terms of the reacquired franchise rights at the time of the acquisition, which generally range from 1-5 years. The Company amortizes the fair value of trademarks over the estimated useful life (10 years). The Company amortizes the fair value of customer relationships and store operating rights over the estimated useful life (3-7 years). Indefinite-lived intangibles should be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.

Crypto Assets — The Company holds crypto assets of ¥2,244 thousand as of December 31, 2025, which are included in other intangible assets, net.

Change in Accounting Estimate

In 2024, considering the unwinding of the COVID-19 pandemic, the Company completed an assessment of the useful life of our store operating rights and determined it should increase the estimated useful life from three to seven years. The Company applied this change in estimate on a prospective basis. This change in accounting estimate was effective beginning the fiscal year

F-16


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

2024. The effect of this change in estimate for the year ended December 31, 2024, was a reduction in an amortization expense of ¥150,732 thousand, an increase in cost of sale of salons of ¥47,083 thousand and an increase in net income of ¥103,648 thousand, or ¥20.29 per share basic and ¥17.71 per share diluted. The per share amounts disclosed above for the year ended December 31, 2024 have been corrected from the amounts previously reported. The correction affects only this disclosure and has no effect on the consolidated financial statements for any period presented.

In connection with the impairment tests performed as of December 31, 2025 (see Notes 3 and 4), the Company reviewed the remaining useful lives of its store operating rights in accordance with ASC 360-10-35-22 and concluded that the estimated useful life of seven years remains appropriate.

Impairment of Long-lived Assets

The Company assesses impairment of long-lived assets at the individual salon level, as this is the lowest level for which identifiable cash flows are largely independent of other groups of assets and liabilities. Trademarks and customer relationships that support a brand as a whole are tested together with the salons of that brand. Long-lived assets include property and equipment, right-of-use lease assets, internal use software, and definite-lived intangible assets. The Company reviews the carrying value of long-lived assets for impairment whenever events or circumstances occur that indicate that the carrying value of the assets may not be recoverable. Indicators of impairment for salon asset groups include negative EBITDA for two consecutive years, a decision to close the salon and, for salons with store operating rights reacquired from investors, EBITDA below the expected profit implied by the reacquisition price. Corporate assets that do not generate separately identifiable cash flows are tested for impairment at the entity level. The assets are considered to be impaired when the estimated undiscounted cash flows expected to result from the use of the assets and their eventual disposition are less than their carrying values. The undiscounted cash flows are estimated over the remaining useful life of the primary asset of the asset group. The impairment loss is measured as the amount by which the carrying value of the asset or asset group exceeds its fair value. Fair value is determined based on Level 3 inputs as described in Note 16. The fair value of salon asset groups with store operating rights reacquired from investors is estimated using a market approach based on EBITDA multiples observed in the Company’s salon transactions with investors, and the fair value of asset groups with negative expected cash flows is estimated to be nil. As of December 31, 2025, an impairment indicator was identified for the headquarters asset group because the Company’s outlook for 2026 demonstrated continuing losses. The asset group was not recoverable, and because a market participant would not attribute value to the headquarters assets other than vehicles, the Company measured their fair value at nil and recognized an impairment loss of ¥173,013 thousand. As of December 31, 2025, the Company performed recoverability tests for its salon asset groups, the MOTHER asset group, the brand-level asset groups and the headquarters asset group (entity level) and recorded long-lived asset impairment charges of ¥176,831 thousand on property and equipment (including construction in progress of ¥39,930 thousand), ¥462,569 thousand on right-of-use assets, ¥1,284,489 thousand on store operating rights, ¥120,774 thousand on internal-use software, ¥100,366 thousand on trademarks, ¥58,929 thousand on customer relationships and ¥369 thousand on telephone rights. During 2024, long-lived assets impairment charges of ¥134 thousand and ¥22,738 thousand were recorded on leasehold improvements and store operating rights, respectively. There was no impairment loss in the year ended December 31, 2023. Long-lived assets impairments are recorded in impairment loss on long-lived assets in the consolidated statements of operations.

Acquisitions

The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not we have acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.

If an acquisition is determined to be a business combination, the assets acquired and liabilities assumed are recorded at their respective estimated fair values at the date of the acquisition. Any excess of the purchase price over the estimated fair values of the identifiable net assets acquired is recorded as goodwill.

If an acquisition is determined to be an asset acquisition, the cost of the asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. If the cost of the asset acquisition is less than the fair value of the net assets acquired, no gain is recognized in earnings. The excess fair value of the net assets acquired over the consideration transferred is allocated on a relative fair value basis to the identifiable net assets (excluding non-qualifying assets). The Company often purchases salons from third-party investors and franchisees through salon operation right transfer agreement, and the Company recognizes store operating rights and reacquired rights, respectively from the salon purchase transactions.

F-17


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

Determining estimated fair value requires a significant amount of judgment and estimates. If assumptions change or errors are determined in our calculations, the fair value could materially change resulting in a change in goodwill or identifiable net assets acquired.

Goodwill

Goodwill represents the excess of cost over fair value of identifiable net assets acquired and assumed in business combinations. The Company records goodwill when the Company acquires other entities. Goodwill and intangible assets that are deemed to have indefinite useful lives are subject to impairment testing. Impairment testing is performed annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. Goodwill impairment assessments are performed at the reporting unit level, which is the same as the Company’s operating segments. The Company may first assess qualitative factors to determine whether a quantitative goodwill impairment test is necessary. If a quantitative test is considered necessary based on the qualitative factors, the Company compares the estimated fair value of a reporting unit to its carrying value. The carrying value of each reporting unit is based on the assets and liabilities associated with the operations of the reporting unit. For 2025, the Company estimated the fair values of the reporting units using an income approach, by capitalizing an annual cash flow, being the 2025 EBITDA of the Relaxation Salon reporting unit excluding the gross margin on sales of salons and the annualized EBITDA of the Luxury Beauty reporting unit for the six months ended June 30, 2026, in each case after the head office costs of the entities in the reporting unit, over a range of discount rates (10% to 15%) and long-term growth rates (minus 1% to plus 1%). If the carrying amount of a reporting unit exceeds its fair value, a loss will be recorded for the excess of the carrying value of the reporting unit over the fair value of the reporting unit, limited to the total amount of goodwill allocated to that reporting unit. During the year ended December 31, 2025, the Company recognized goodwill impairment losses of ¥179,385 thousand and ¥167,241 thousand related to the Relaxation Salon and Luxury Beauty reporting units, respectively. The Company did not recognize impairment losses for any goodwill during the years ended December 31, 2024 and 2023. Goodwill impairment losses are presented as impairment loss on goodwill in the consolidated statements of operations.

Asset Retirement Obligations

The Company records asset retirement obligations when the obligation is incurred. The obligation is measured at fair value and included in asset retirement obligations. When the liability is initially recorded, the Company capitalizes the related cost by increasing the carrying amount of the related long-lived asset. The liability is accreted to its present value, and the capitalized cost is depreciated over the asset’s useful life.

Revenue Recognition

Revenues are recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

The Company determines revenue recognition through the following steps:

Step 1: identification of the contract with a customer;

Step 2: identification of the performance obligations in the contract;

Step 3: determination of the transaction price;

Step 4: allocation of the transaction price to the performance obligations in the contract;

Step 5: recognition of revenue when, or as, the Company satisfies a performance obligation.

Revenue from Directly-Operated Salons

Revenues from directly-operated salons (including sales in the Luxury Beauty segment) are recognized when services are provided at the salons. The promised services for directly-operated salons are the services ordered by the end customer from the service menu. The services are provided in one appointment. Therefore, there is only one performance obligation. As the customer simultaneously receives and consumes the benefits of the relaxation services, the revenue is recognized as the service is delivered using the delivery output method.

Revenue from prepaid cards is recognized when the services are transferred. When value is added to a prepaid card, the Company records advances received for its performance obligation to stand ready to transfer services in the future (or transfer funds to franchisee who provides service). When the services or funds are transferred, it derecognizes the advances received and correspondingly recognizes revenue. The Company expects to be entitled to a certain amount of breakage and recognizes revenue

F-18


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

from breakage proportionately to the redemptions exercised by the customer. The amount of breakage recognized for the years ended December 31, 2025, 2024 and 2023 was ¥1,375 thousand, ¥10,751 thousand and ¥46,426 thousand, respectively.

The Company also sells salons to third-party investors. Developing and selling salons is a recurring part of the business model of the Relaxation Salon segment (the Company sold 43, 60 and 38 salons in 2025, 2024 and 2023, respectively, representing 18%, 28% and 15% of total revenues); accordingly, the sale of salons is considered part of the Company’s ongoing major or central operations and thus ordinary activities for the Company, and the third-party investors are considered as “customers”. Therefore, the Company applies ASC 606 to these contracts. The store operating rights transfer agreement and the service agreement with an investor are negotiated as a package and entered into at the same time, and are accounted for as a single contract with two performance obligations: (i) transfer of the salon assets and business rights and (ii) outsourced salon operation services. The transfer price, which is determined based on the estimated profit of the salon and the yield expected by the investor, is allocated to (i), and the cost reimbursements and success fee under the service agreement are allocated to (ii), as these contractual prices represent their standalone selling prices. The revenue for the transfer of salon assets and business rights is recognized at a point in time when control of the salon transfers to the investor at the point of legal transfer. In connection with the sale of salons, the disposition of related salon assets, such as store equipment, leasehold improvements, store operating rights and goodwill, if applicable, is recorded in cost of revenue.

Furthermore, the Company may purchase the sold salons from the third-party investors from the initial salon sales based on the third-party investors’ demands and the Company’s business strategy. These repurchases are not subject to any contractual or implied repurchase obligations, and as such, do not preclude revenue recognition under ASC 606. There is no substantive repurchase right or obligation associated with these transactions, based on the absence of contractual guarantees or economic compulsion. Depending on the negotiation with the investors, the Company may sell additional salons to the third-party investors, which can be on the same date of the salon purchase or in the future.

If the Company enters into a salon purchase and sales agreement with the same investor on the same date or near the same date, the Company recognizes the salon purchase and sales agreements as a combined arrangement. Under the combined arrangement, the proceeds from the sale of salon and the payment for the purchase of salon are offset with each other. Therefore, the Company recognizes the noncash consideration and the difference of the carrying value of the sold salon and the transaction of salon sales as other income or loss, which is included in gain from sales of salons in the consolidated statements of operations.

Furthermore, the Company often enters into a salon purchase agreement with a third-party investor and sells the purchased salon to a different third-party investor on the same date. When these transactions happen, the Company’s performance obligation is to make an arrangement for the provision of the good by another, and the seller effectively controls the salon before it is sold to the new third-party investor. Therefore, the Company is considered to be an agent in this type of transaction and the Company records the revenue resulting from this type of transaction at net. There is no significant financing component.

The Company classifies both cash inflows from salon sales and cash outflows related to salon repurchases as investing activities in the consolidated statements of cash flows. These cash flows relate to the acquisition and disposal of long-lived assets. Cash proceeds from the sale and repurchase of salons (included in the acquired intangible assets) are classified as investing activities in the consolidated statements of cash flows in accordance with ASC 230-10-45-12(c), as they represent disposals and acquisitions of productive assets.

Also, the buyers of salons are entitled to enter into Service Agreements with the Company to manage the operations of the salons and the Company charges a fee for the management services to be provided. Revenue from the Service Agreement is recognized over the term of the agreement as services are provided. The customer benefits from the integrated service over the contract term and each time increment is substantially the same. Therefore, the outsourced salon operations are considered a “series” of distinct services and are treated as a single performance obligation. The term of the Service Agreement is typically five years. Under the Service Agreement, the Company is reimbursed for the costs of operating the salon including leases. Although the Company invoices the investors for such costs annually, the Company’s right to consideration arises monthly as the costs are incurred and corresponds directly with the value of the services performed to date; accordingly, the Company recognizes revenue from the reimbursement of costs using the as-invoiced (right to invoice) practical expedient. Furthermore, the Company receives as a success fee a portion of the salon’s profit in excess of the investor’s target yield. The success fee is consideration for the operation services, as the investor retains the target return and bears any operating losses of the salon, and is considered variable consideration. This success fee is constrained until it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.

F-19


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

The following table summarizes the sales of salons and repurchases of salons for the years ended December 31, 2025, 2024 and 2023:

 

 

 

Thousands of Yen, except Number of salons

 

 

 

2025

 

 

2024

 

 

2023

 

Number of salons sold

 

 

43

 

 

60

 

 

 

38

 

Total sales amount

 

¥

1,365,914

 

 

¥

2,328,005

 

 

¥

1,007,800

 

Number of salons repurchased

 

 

47

 

 

22

 

 

 

20

 

Total repurchase amount

 

¥

2,301,371

 

 

¥

949,088

 

 

¥

959,940

 

 

Revenue from rehabilitation services is recognized when the services are rendered to the customer. The Company primarily enters into contracts with customers to provide rehabilitation services over a contract period, and the customer receives the services continuously for the duration of the contract. Under such contracts, the performance obligation is satisfied over time, and revenue is recognized based on the time elapsed. Consideration received at the time of the contract is recorded as advances received and recognized as revenue as the services are rendered.

Franchise Revenue

Franchise revenue is comprised of (i) franchise fees, (ii) royalty income, (iii) staffing service revenue, (iv) sublease revenue, and (v) other franchise revenues. The Company and the franchisee enter into a franchise agreement which sets forth the standard terms and conditions of operating the franchised salon, as well as the fees and royalties over the term of the agreement. In most cases, an outsourcing agreement is also entered into in conjunction with the franchise agreement that specifies the terms of the sublease arrangement with the franchisee. Upon the franchisee’s request, the Company’s therapists are dispatched to franchise locations and franchisees must pay dispatch fees in accordance with the dispatched employees’ position.

(i)
Franchise fees

The Company receives the entire non-refundable initial franchise fees from the franchisee based on franchise agreement. The franchise agreement typically has an initial term of five years. The services for operating the franchised salon provided by the Company under franchise contract are not separately identifiable within the contract and are interrelated with the franchise right granted in the franchise agreement. As such, the services are considered to represent a single performance obligation. The franchise agreement could be renewed prior to expiration by mutual consent and renewal franchise fees are paid by franchisee upon renewal of agreement. Initial franchise fees and expected renewal franchise fees are recognized as revenue ratably using the time-based input method over the expected average contract life (7 years), instead of the contract term, as there is a material right related to renewals.

(ii)
Royalty income

The Company collects royalties, an amount calculated by multiplying a certain percentage to gross sales, on a monthly basis. The royalties are subject to the sales-based royalties constraint and are recognized as revenues based on the monthly royalty earned where such amount is determined on the basis of gross sales made from each salon.

(iii)
Staffing service revenue

The Company also generates revenue from providing its therapists to franchisees, which are recognized as revenues based on the total number of working hours of the agency worker during the dispatched period. The Company has elected the ‘as-invoiced’ practical expedient for its staffing services where the fixed rate per hour is invoiced to the customer.

(iv)
Sublease revenue

The Company leases the premises in which the majority of its franchisees operate, where the Company retains the head lease primary obligation, and has entered into corresponding sublease arrangements with franchisees. Revenues from sublease transactions with franchisees are recognized on a straight-line basis over the respective operating lease terms, or at the time of the underlying sales for variable lease payments, in accordance with Accounting Standards Codification (“ASC”) 842 Leases (“ASC 842”).

F-20


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

(v)
Other franchise revenues

Other franchise revenues include other services provided to franchisees separately from the franchise agreements and include advertising and training. These services are primarily recognized as revenues when services are provided.

Other Revenues

Other revenues are primarily from the Digital Preventative Healthcare segment, which include revenues from serving implementation of health and wellness programs (Specific Health Guidance Program), as well as wearable device service (MOTHER Bracelet®), and are recognized when services are provided or the ownership of products is transferred. The Company offers standard assurance-type warranties for its MOTHER Bracelet® which are not accounted for as a separate performance obligation and do not contain acceptance clauses.

See Note 13 for further disclosures required under ASC 606.

Revenue is recognized net of consumption tax collected from customers and subsequently remitted to governmental authorities.

Advertising Expenses

Advertising costs are expensed as incurred and are recorded in selling, general and administrative expenses in the consolidated statements of operations. Advertising expenses for the years ended December 31, 2025, 2024 and 2023 were ¥147,747 thousand, ¥155,362 thousand, and ¥162,033 thousand, respectively.

Stock-Based Compensation

The Company measures the cost of employee services received in exchange for an award of equity instruments at the fair value of the award on the grant date and recognizes the cost over the requisite service period which the employee is required to provide services in exchange for the award. Compensation expenses are recognized on a straight-line basis over the requisite service period of the awards which are expected to be vested. The Company accounts for forfeitures as they occur. The Company uses option pricing methods that require the input of subjective assumptions, including the expected term, expected volatility, dividend yield and risk-free interest rate.

The Company estimates the likelihood and the rate of achievement for performance sensitive stock-based awards at the end of each reporting period. Changes in the estimated rate of achievement can have a significant effect on the recorded stock-based compensation expense as the effect of a change in the estimated achievement level is recognized in the period the change occurs.

Income Taxes

Deferred income taxes reflect the impact of temporary differences between assets and liabilities recognized for financial reporting purposes and such amounts recognized for tax purposes and tax loss carryforwards. These deferred taxes are measured using the currently enacted tax rates in effect for the year in which the temporary differences or tax loss carryforwards and tax credits are expected to reverse.

Valuation allowances are provided against deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company considers all available evidence (both positive and negative) when determining whether a valuation allowance is required, with emphasis on its past operating results, the existence of cumulative losses in the most recent years and its forecast of near-term taxable income. The Company recognizes the financial statement effect of uncertain tax positions when it is more likely than not, based on the technical merits, that the tax positions will be sustained upon examination by the tax authorities. Benefits from tax positions that meet the more-likely-than-not recognition threshold are measured at the largest amount of benefit that is greater than 50% likely of being realized upon settlement.

The Company classifies interest and penalties related to income taxes, including those related to unrecognized tax benefits, if any, within selling, general and administrative expenses in the consolidated statements of operations.

Convertible Bonds

The Company accounts for convertible bonds as a single liability measured at amortized cost in accordance with ASC 470-20, unless the embedded conversion option is required to be bifurcated as a derivative under ASC 815. Conversion options that are

F-21


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

indexed to the Company’s own stock and meet the conditions for equity classification qualify for the scope exception in ASC 815-10-15-74(a) and are not bifurcated. When convertible bonds are issued at a substantial premium, the premium is recorded in additional paid-in capital in accordance with ASC 470-20-25-13. Modifications and exchanges of debt are evaluated under ASC 470-50, and an exchange is accounted for as an extinguishment of debt when the terms are substantially different.

Government Assistance

The Company receives government subsidies, primarily the Human Resources Development Support Subsidy granted by the Ministry of Health, Labour and Welfare of Japan through the Prefectural Labour Bureaus, which partially reimburses training costs and wages of employees attending qualifying training programs. As there is no effective U.S. GAAP guidance for government grants to business entities, the Company accounts for such subsidies by analogy to IAS 20, Accounting for Government Grants and Disclosure of Government Assistance. Subsidies are recognized when there is reasonable assurance that the Company has complied with the attached conditions and that the subsidies will be received, and are presented as “Subsidies” in other income (expense) in the consolidated statements of operations. Subsidies recognized were ¥94,565 thousand, ¥13,855 thousand and ¥21,376 thousand for the years ended December 31, 2025, 2024 and 2023, respectively.

Earnings (Loss) Per Share

Basic and diluted earnings (loss) attributable to the Company’s shareholders per common share are presented in conformity with the two-class method required for participating securities. Basic net income (loss) attributable to the Company’s shareholders per common share is computed by dividing net income (loss) attributable to the Company by the weighted-average number of shares of common stock outstanding during the year. Diluted net income (loss) attributable to the Company’s shareholders per common share reflects the potential dilutive effect of stock options and convertible bonds (using the if-converted method). (See Note 14)

Recently Issued Accounting Pronouncements Adopted

Segments

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures. The new standard requires enhanced disclosures about segment information and significant segment expenses. It does not change how a public entity identifies its operating segments. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The new standard has been applied retrospectively to all periods presented in Note 11.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disaggregated information about the effective tax rate reconciliation, using both percentages and reporting currency amounts for specific categories, and income taxes paid by jurisdiction. The Company adopted ASU 2023-09 for the year ended December 31, 2025 on a prospective basis. See Note 12. The adoption affected disclosures only.

Recently Issued Accounting Pronouncements Not Yet Adopted

Disclosure Improvements

In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements-Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This new standard modified the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC’s regulations. ASU 2023-06 will become effective for each amendment on the effective date of the SEC’s corresponding disclosure rule changes. The Company is currently evaluating the impact on its consolidated financial statements.

Comprehensive Income - Expense Disaggregation

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to disclose additional information about specific expense categories. In January 2025, the FASB issued ASU 2025-01 Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), which clarified the effective date for ASU 2024-03. These amendments are intended to provide more information about types of expenses in commonly presented expense captions. The

F-22


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

amendments in this update are effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, and early adoption is permitted. The Company is currently evaluating the impact on the consolidated financial statements and related disclosures.

Debt-Debt with Conversion and Other Options

In November 2024, the FASB issued ASU 2024-04, Debt-Debt with Conversion and Other Options, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for annual reporting periods beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in ASU 2020-06. The Company will adopt ASU 2024-04 on January 1, 2026 and does not expect the adoption to have a material impact on its consolidated financial statements.

Business Combinations and Consolidation

In May 2025, the FASB issued ASU 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity, which requires an entity to consider the general factors in ASC 805 when identifying the accounting acquirer in an acquisition of a VIE that meets the definition of a business. ASU 2025-03 is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years, and is applied prospectively. The Company is currently evaluating the impact on its consolidated financial statements.

Credit Losses

In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of current accounts receivable and current contract assets. ASU 2025-05 is effective for annual reporting periods beginning after December 15, 2025, including interim periods within those annual reporting periods, and is applied prospectively. The Company is currently evaluating the impact on its consolidated financial statements.

Internal-Use Software

In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which removes all references to software development project stages and requires capitalization of software costs when management has authorized and committed to funding the software project and it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, including interim periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the impact on its consolidated financial statements.

Government Grants

The FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which establishes guidance on the recognition, measurement and presentation of government grants received by business entities. ASU 2025-10 is effective for public business entities for annual reporting periods beginning after December 15, 2028, and interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-10 on its consolidated financial statements.

2.
Business Combinations and Deconsolidation

Acquisition of rehabilitation business

On June 10, 2024, the Company established MEDIROM Rehab Solutions Inc. (“MRS”) as a subsidiary to serve as the recipient of a business transfer. On July 10, 2024, MRS entered into an agreement to purchase a rehabilitation business from Y’s, Inc., a Japanese corporation. Pursuant to the agreement, MRS completed the acquisition of the rehabilitation business from Y’s, Inc., on October 1, 2024 for a total cash consideration of ¥21,348 thousand. The scope of the transfer includes assets and liabilities related to the business, as well as certain contracts previously entered by Y’s, Inc., which are now assumed by the Company. The acquisition was accounted for by the acquisition method.

F-23


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

The results of operations, and assets and liabilities, of the rehabilitation business were included in the consolidated financial statements from the date of acquisition. The purchase price allocation was based on the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date.

The estimated fair values of the assets acquired and liabilities assumed at the acquisition date were as follows:

 

 

 

Thousands of Yen

 

 

 

Fair value of
assets/liabilities

 

Accounts Receivable

 

¥

10,921

 

Other Current Assets

 

 

1,780

 

Property and Equipment

 

 

28,089

 

Intangible Assets

 

 

14,064

 

Right-of-use Assets

 

 

34,453

 

Lease and Guarantee Deposits

 

 

7,626

 

Total assets acquired

 

 

96,933

 

Accrued expenses and other current liabilities

 

 

55,005

 

Asset Retirement Obligations

 

 

3,991

 

Lease liability

 

 

34,453

 

Deferred tax liability

 

 

4,460

 

Total liabilities assumed

 

 

97,909

 

Net liabilities assumed

 

 

976

 

Fair value of the consideration transferred

 

 

21,348

 

Goodwill

 

¥

22,324

 

 

The goodwill is primarily attributable to the expected future profitability of the acquired business due to synergies with the Company’s healthcare business. Almost all of the goodwill is expected to be deductible for income tax purposes.

Acquisition related costs are immaterial and included in selling, general and administrative expenses in the consolidated statements of operations. The amount of revenue and earnings from the acquisition included in the Company’s results of operations for the year ended December 31, 2024 (from the acquisition date) was ¥156,006 thousand and ¥30,675 thousand, respectively. Pro forma information is not presented because the acquisition was not material to the Company’s consolidated financial statements.

Sale of JOYHANDS WELLNESS Inc.

On January 1, 2025, the Company sold all of its shares of JOYHANDS WELLNESS Inc., a wholly-owned subsidiary, to a third party and deconsolidated the subsidiary as of that date. Prior to the sale, the hot spring spa business of JOYHANDS WELLNESS Inc. was transferred to MEDIROM Wellness Co. through an absorption-type demerger. The Company recognized a gain on the sale of ¥2,650 thousand, which is included in other, net in the consolidated statements of operations. The sale did not represent a strategic shift and was not presented as a discontinued operation.

3.
Property and Equipment, Net

As of December 31, 2025 and 2024, property and equipment, net consists of the following:

 

 

 

Thousands of Yen

 

 

 

2025

 

 

2024

 

Leasehold improvements

 

¥

398,262

 

 

¥

563,625

 

Vehicles

 

 

11,588

 

 

 

22,313

 

Tools, furniture and fixtures

 

 

132,482

 

 

 

210,083

 

Total

 

 

542,332

 

 

 

796,021

 

Accumulated depreciation and amortization

 

 

(387,712

)

 

 

(360,362

)

 

 

¥

154,620

 

 

¥

435,659

 

 

Depreciation expense was ¥83,190 thousand, ¥100,462 thousand and ¥107,040 thousand for the years ended December 31, 2025, 2024 and 2023, respectively.

F-24


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

For the years ended December 31, 2025, 2024 and 2023, the Company recognized impairment losses of ¥89,527 thousand, ¥134 thousand and nil, respectively, for the Relaxation Salon segment on property and equipment used in certain relaxation salons, respectively. During 2025, the operating performance of certain directly operated relaxation salons deteriorated significantly, primarily due to continued increases in labor costs and pressure on discretionary consumer spending. As a result, as of December 31, 2025, ten asset groups (including one rehabilitation center) had negative EBITDA for two consecutive years, nine salons (including one rehabilitation center) were committed to closure, and 35 salons with store operating rights reacquired from investors generated EBITDA below the level implied by the reacquisition price. The Company tested these asset groups for recoverability, determined that their carrying amounts were not recoverable, and recognized impairment losses measured as the excess of the carrying amounts over their fair values, determined as described in Note 16. Impairment losses were also recognized for four salons in the six months ended June 30, 2025. In addition, for the year ended December 31, 2025, the Company recognized an impairment loss of ¥8,244 thousand on tools, furniture and fixtures (including rental devices) of the MOTHER asset group in the Digital Preventative Healthcare segment (see Note 4). The impairment of the MOTHER asset group resulted from EBITDA losses of the MOTHER business for two consecutive years (2024 and 2025). In addition, for the year ended December 31, 2025, the Company recognized an impairment loss of ¥79,060 thousand on property and equipment of the headquarters asset group (leasehold improvements and tools, furniture and fixtures of ¥39,130 thousand and construction in progress of ¥39,930 thousand), excluding vehicles (see Note 1).

4.
Goodwill, Store Operating Rights and Other Intangible Assets, Net

The components of intangible assets as of December 31, 2025 and 2024 are as follows:

 

 

 

Thousands of Yen

 

 

 

2025

 

 

2024

 

Intangible assets subject to amortization:

 

 

 

 

 

 

Software for internal use

 

¥

267,911

 

 

¥

233,717

 

Customer relationship

 

 

180,000

 

 

 

180,000

 

Reacquired rights

 

 

2,750

 

 

 

—

 

Trademark

 

 

172,894

 

 

 

172,894

 

Other

 

 

750

 

 

 

750

 

Total

 

 

624,305

 

 

 

587,361

 

Accumulated amortization and impairment

 

 

(615,414

)

 

 

(279,271

)

Net carrying amount

 

 

8,891

 

 

 

308,090

 

 

 

 

 

 

 

Intangible assets not subject to amortization:

 

 

 

 

 

 

Goodwill

 

 

—

 

 

 

389,131

 

Telephone rights

 

 

—

 

 

 

369

 

Crypto assets

 

 

2,244

 

 

 

—

 

Total

 

 

2,244

 

 

 

389,500

 

Total goodwill and other intangible assets

 

¥

11,135

 

 

¥

697,590

 

Store operating rights

 

 

1,257,615

 

 

 

925,334

 

Accumulated amortization

 

 

(402,574

)

 

 

(94,496

)

Store operating rights, net

 

 

855,041

 

 

 

830,838

 

 

During the year ended December 31, 2025, the Company acquired store operating rights of ¥2,294,868 thousand through the repurchase of salons, with a weighted average amortization period of seven years.

The aggregate amortization expense for other intangible assets and store operating rights was ¥443,145 thousand, ¥183,525 thousand and ¥145,555 thousand for the years ended December 31, 2025, 2024 and 2023, respectively, of which amortization of store operating rights was ¥367,514 thousand for the year ended December 31, 2025. The gross carrying amount of store operating rights is presented net of accumulated impairment losses. As of December 31, 2025 and 2024, the weighted average amortization period was as follows: internal-use software – 5 years, customer relationships – 7 years, store operating rights – 7 years and trademark – 10 years for both years. The weighted average amortization period of reacquired rights acquired in 2025 was 3 years.

The Company recorded impairment losses of ¥1,284,489 thousand and ¥22,738 thousand on store operating rights for the years ended December 31, 2025 and 2024, respectively. The 2025 amount comprises ¥1,191,623 thousand for certain relaxation salons in the Relaxation Salon segment and ¥92,866 thousand for a salon in the Luxury Beauty segment. The impairment losses on store operating rights in the Relaxation Salon segment relate to 35 salons reacquired from investors (29 salons operated by MEDIROM Wellness Co. and six salons of SAWAN Co., Ltd.), whose EBITDA for 2025 fell below the level implied by the

F-25


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

reacquisition prices and declined further in the six months ended June 30, 2026, and to three other salons, two of which were committed to closure and one of which was impaired in the six months ended June 30, 2025. The impairment loss in the Luxury Beauty segment relates to a salon of ZACC whose EBITDA for 2025 was below the level implied by its reacquisition price and declined further in the six months ended June 30, 2026. The Company determined that the carrying amounts of these asset groups were not recoverable and measured the impairment losses based on fair values determined as described in Note 16. There were no impairment charges recorded during the year ended December 31, 2023. In addition, for the year ended December 31, 2025, the Company recorded an impairment loss of ¥88,412 thousand on internal-use software, including software in progress, of the Digital Preventative Healthcare segment, impairment losses of ¥48,616 thousand on the trademarks of SAWAN Co., Ltd. and MRS in the Relaxation Salon segment, impairment losses of ¥51,750 thousand on the trademark and ¥58,929 thousand on the customer relationship of ZACC in the Luxury Beauty segment, and impairment losses of ¥32,362 thousand on internal-use software and ¥369 thousand on telephone rights of the headquarters asset group (see Note 1). The impairment of internal-use software of the Digital Preventative Healthcare segment resulted from EBITDA losses of the MOTHER business for two consecutive years (see Note 3). The trademarks of SAWAN Co., Ltd. and MRS and the trademark and customer relationship of ZACC support their respective brands as a whole and were tested together with the salons of those brands. These brand-level asset groups were not recoverable because the annualized EBITDA of each brand entity for the six months ended June 30, 2026 was negative.

The estimated aggregate amortization expense for other intangible assets and store operating rights for the next five years and thereafter is as follows: Software in progress of ¥1,280 thousand is not amortized until it is ready for its intended use and is excluded from the table below.

 

 

 

Thousands of Yen

 

Year ending December 31:

 

 

 

2026

 

¥

147,849

 

2027

 

 

147,411

 

2028

 

 

144,823

 

2029

 

 

143,197

 

2030

 

 

142,568

 

Thereafter

 

 

136,804

 

Total

 

¥

862,652

 

 

The following table shows changes in carrying amount of goodwill by reportable segment for the years ended December 31, 2025 and 2024:

 

 

 

Thousands of Yen

 

 

 

Relaxation
Salon

 

 

Luxury
Beauty

 

 

Digital
Preventative
Healthcare

 

 

Total

 

Balance at December 31, 2023

 

¥

317,323

 

 

¥

167,241

 

 

¥

—

 

 

¥

484,564

 

Acquisition of rehabilitation business

 

 

22,324

 

 

 

—

 

 

 

—

 

 

 

22,324

 

Sale of directly-owned salons, and closure of directly-owned salons

 

 

(117,757

)

 

 

—

 

 

 

—

 

 

 

(117,757

)

Balance at December 31, 2024

 

¥

221,890

 

 

¥

167,241

 

 

¥

—

 

 

¥

389,131

 

Sale of directly-owned salons, and closure of directly-owned salons

 

 

(42,505

)

 

 

—

 

 

 

—

 

 

 

(42,505

)

Impairment

 

 

(179,385

)

 

 

(167,241

)

 

 

—

 

 

 

(346,626

)

Balance at December 31, 2025

 

¥

—

 

 

¥

—

 

 

¥

—

 

 

¥

—

 

Gross carrying amount

 

 

179,385

 

 

 

167,241

 

 

 

—

 

 

 

346,626

 

Accumulated impairment losses

 

 

(179,385

)

 

 

(167,241

)

 

 

—

 

 

 

(346,626

)

 

There were no accumulated impairment losses as of December 31, 2024 and 2023. Goodwill of the rehabilitation business was allocated to the Relaxation Salon reporting unit.

As of December 31, 2025, due to the significant deterioration in the operating results of the Luxury Beauty reporting unit in 2025 and the six months ended June 30, 2026 and the Company’s overall operating results, the Company performed a quantitative goodwill impairment test for the Luxury Beauty reporting unit and determined that its carrying amount exceeded its fair value. As a result, the Company recognized a goodwill impairment loss of ¥167,241 thousand, representing the entire goodwill of the Luxury Beauty reporting unit. In addition, as of December 31, 2025, the Company also performed a quantitative goodwill impairment test for the Relaxation Salon reporting unit after recognizing the long-lived asset impairment losses described above,

F-26


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

and determined that its carrying amount exceeded its fair value. As a result, the Company recognized a goodwill impairment loss of ¥179,385 thousand, representing the entire goodwill of the Relaxation Salon reporting unit. No impairment losses on goodwill were recognized for the years ended December 31, 2024 and 2023.

5.
Investments

Investments at Cost

The breakdown of non-marketable securities as of December 31, 2025 and 2024 is as follows:

 

 

 

Carrying amount

 

 

 

 

 

 

 

 

 

Thousands of Yen

 

 

Ownership

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Matrix Industries, Inc.

 

¥

—

 

 

¥

86,918

 

 

 

2.80

%

 

 

2.80

%

Other

 

 

500

 

 

 

500

 

 

 

—

 

 

 

—

 

Total

 

¥

500

 

 

¥

87,418

 

 

 

 

 

 

 

 

The Company acquired a convertible note from Matrix Industries, Inc. for ¥52,520 thousand on February 3, 2021. In 2023, the Company converted the convertible note into shares. The carrying amount of non-marketable securities is recorded at cost as fair value is not readily determinable. During the year ended December 31, 2025, the Company identified impairment indicators for its investment in Matrix Industries, Inc., as the investee’s financial condition deteriorated, and recognized an impairment loss of ¥86,918 thousand, reducing the carrying amount to nil. The carrying amount as of December 31, 2024 of ¥86,918 thousand included the accrued interest on the convertible note that was converted into shares in 2023 and the remeasurement of this U.S. dollar-denominated investment at the year-end exchange rates, including an increase of ¥8,969 thousand for the year ended December 31, 2024. The Company did not recognize any impairments for the years ended December 31, 2024 and 2023.

6.
Borrowings

The Company has borrowings with financial institutions. Some borrowings are secured. As of December 31, 2025 and 2024, time deposits with an aggregate book value of ¥6,157 thousand and ¥6,156 thousand, respectively, are pledged as collateral. Some borrowings are guaranteed by Credit Guarantee Association, a Japanese governmental affiliate agency which supplements private companies with credit. The borrowings accrue interest using interest rates of 0.20% – 14.60% and 0.21% – 1.60% per annum as of December 31, 2025 and 2024, respectively. Debt issuance costs related to these borrowings are immaterial.

The Company issued corporate convertible bonds in the aggregate amount of ¥500,000 thousand to Kufu Company Inc., a Japanese company, in December 2022. The bonds are unsecured, accrue interest at a rate of 5.0% per annum, payable on June 30, 2023 and semi-annually thereafter, and will mature on December 28, 2027, unless earlier redeemed or converted. At any time between the six-month anniversary date of December 28, 2022 (which may be earlier in case of the limited event provided for in the indenture) and before the close of business on December 28, 2027, Kufu Company Inc., as the bond holder, may convert the bonds at its option, in whole or in part, into common shares. The Company granted a total of 40 share options, and one share option is attached to each bond equivalent to ¥12,500,000. The price per share used to calculate the number of the Company’s common shares to be delivered upon the exercise of the share options shall be ¥755. The bond holder may also exercise its put option to demand the redemption of the bonds by the Company, in whole or in part, any time after the six-month anniversary date of December 28, 2022. On November 1, 2024, the Company and Kufu Company Inc. agreed to amend the terms of the bonds to shorten the maturity date to December 31, 2025, and the conversion period ended on December 30, 2025. At maturity on December 31, 2025, the ¥500,000 thousand principal amount was settled as follows: (i) ¥275,000 thousand was exchanged for the 4th Unsecured Convertible-Type Corporate Bonds with Share Options issued to Kufu Company Holdings Inc.; (ii) ¥25,000 thousand became payable in cash and was included in accounts payable as of December 31, 2025; and (iii) ¥200,000 thousand was converted into a short-term loan from Kufu Company Holdings Inc. under a loan agreement entered into on January 30, 2026 (see Note 19).

The Company issued the 2nd corporate convertible bonds in the aggregate amount of ¥300,000 thousand to Triple One Investment Partnership, a Japanese investment limited partnership, in October 2024. The bonds are unsecured, accrue interest at a rate of 2.0% per annum, and will mature on October 29, 2027, unless earlier redeemed or converted. At any time between October 25, 2024 and before the close of business on October 29, 2027, Triple One Investment Partnership, as the bond holder, may convert the bonds at its option, in whole or in part, into common shares. The Company granted a total of three share options, and one share option is attached to each bond equivalent to ¥100,000,000. The price per share used to calculate the number of the Company’s common shares to be delivered upon the exercise of the share options shall be ¥957.

F-27


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

On December 12, 2025, the Company issued the 3rd Unsecured Convertible-Type Corporate Bonds with Share Options in the aggregate amount of ¥400,000 thousand (40 units of ¥10,000 thousand each) to 11 third-party investors, none of whom is a related party of the Company. The bonds are unsecured, accrue interest at a rate of 2.0% per annum, and will mature on June 30, 2026 (the Company has an option to extend the maturity date to December 25, 2026), unless earlier redeemed or converted. The bonds are convertible into 1,166,175 common shares at a conversion price of ¥343 per share from December 12, 2025 to June 10, 2026 (or December 7, 2026 if the maturity date is extended). The Company concluded that the embedded conversion option qualifies for the scope exception in ASC 815-10-15-74(a) and is not bifurcated from the host debt instrument.

On December 31, 2025, the Company issued the 4th Unsecured Convertible-Type Corporate Bonds with Share Options in the aggregate amount of ¥275,000 thousand to Kufu Company Holdings Inc. The bonds are unsecured, accrue interest at a rate of 5.0% per annum, and will mature on June 30, 2026 (the Company has an option to extend the maturity date to December 25, 2026), unless earlier redeemed or converted. The bonds are convertible into 833,333 common shares at a conversion price of ¥330 per share from December 31, 2025 to June 29, 2026 (or December 24, 2026 if the maturity date is extended). The Company evaluated the embedded conversion option and concluded that, although it meets the definition of a derivative, it qualifies for the scope exception in ASC 815-10-15-74(a) and therefore is not bifurcated from the host debt instrument. The 4th bonds were issued in exchange for ¥275,000 thousand of the bonds issued to Kufu Company Inc. in December 2022. Because the change in the fair value of the embedded conversion option was at least 10 percent of the carrying amount of the original bonds, the exchange was accounted for as an extinguishment of debt under ASC 470-50. Neither Kufu Company Inc. nor Kufu Company Holdings Inc. is a related party of the Company, and the exchange was therefore not accounted for as a capital transaction. The 4th bonds were initially recognized at their fair value of ¥302,998 thousand, and a loss on extinguishment of debt of ¥27,998 thousand was recognized for the year ended December 31, 2025 and is presented as a separate line item in other income (expense) in the consolidated statements of operations. Because the 4th bonds were issued at a substantial premium, the premium of ¥27,998 thousand over their face amount was recorded in additional paid-in capital in accordance with ASC 470-20-25-13, and the bonds are carried at their face amount of ¥275,000 thousand.

The convertible bonds are carried at their principal amounts with no unamortized premium, discount or issuance costs. Accordingly, the effective interest rate of each series equals its stated rate, and interest expense on the convertible bonds of ¥31,416 thousand, ¥26,101 thousand and ¥24,998 thousand for the years ended December 31, 2025, 2024 and 2023, respectively, consisted entirely of contractual interest.

Short-term borrowings as of December 31, 2025 consisted of (i) an unsecured loan of ¥350,000 thousand from a bank, bearing interest at 1.875% per annum and maturing on March 31, 2026, which is guaranteed by MML (the loan was originally obtained on March 7, 2025 and refinanced on June 30, 2025); (ii) a loan from a bank with an outstanding balance of ¥191,671 thousand, which was refinanced on September 30, 2025 in the amount of ¥216,670 thousand, bears interest at a floating rate based on the lender’s short-term prime rate, which was 1.875% per annum as of December 31, 2025, and matures on March 31, 2026; (iii) a loan of ¥200,000 thousand from Kufu Company Holdings Inc. arising from the settlement of the 1st convertible bonds on December 31, 2025, the terms of which were set out in a loan agreement entered into on January 30, 2026 (see Note 19); and (iv) a loan of ¥30,000 thousand obtained by MML from a third party on June 23, 2025, bearing interest at 5.0% per annum and originally maturing on July 31, 2025 (see below), with an outstanding balance of ¥23,556 thousand, which is guaranteed by the representative director of MML. The 3rd and 4th convertible bonds of ¥675,000 thousand, which had an original maturity of less than one year, are included in short-term borrowings in the consolidated balance sheet as of December 31, 2025, whereas the current portion of convertible bonds of ¥500,000 thousand as of December 31, 2024, which had an original maturity of more than one year, is included in current portion of long-term borrowings. The weighted average interest rate on short-term borrowings was 3.69% (including the 3rd and 4th convertible bonds) and 1.56% as of December 31, 2025 and 2024, respectively.

In July 2025, MEDIROM Wellness Co. entered into a loan agreement with Spirit Advisors, a third party, for a total of US$1,200 thousand, disbursed in three installments in July and September 2025, of which US$200 thousand has been repaid. The loans bore interest at 8.0% per annum. Of the total, US$600 thousand was repayable in a lump sum on December 31, 2025, of which US$200 thousand was repaid in August 2025, and the remaining US$600 thousand is repayable by December 31, 2027. The loans are denominated in U.S. dollars and are translated at the year-end exchange rate (¥156.53 to US$1.00). The outstanding balance as of December 31, 2025 was ¥156,530 thousand, of which ¥35,629 thousand is included in current portion of long-term borrowings. The loans are secured by the operating rights of two salons operated by MEDIROM Wellness Co. and are personally guaranteed by Mr. Eguchi. In March 2026, the loans were restructured (see Note 19).

On July 22, 2024, the Company issued unsecured corporate bonds of ¥70,000 thousand to an individual, of which ¥40,000 thousand was repaid on September 17, 2024. The bonds bear interest at 6.0% per annum (2.0% at issuance) and mature on April 30, 2026. In June 2025, MRS obtained a ¥5,000 thousand loan from Japan Finance Corporation, bearing interest at 1.6% per annum and maturing on August 31, 2029.

F-28


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

The carrying value of the Company’s borrowings as of December 31, 2025 and 2024 are as follows:

 

 

 

Thousands of Yen

 

 

 

2025

 

 

2024

 

Short-term borrowings

 

¥

765,227

 

 

¥

491,667

 

Borrowings (due through 2035 with weighted average
   interest rates of
2.96% as of December 31, 2025,
   due through 2035 with weighted average interest
   rates of
0.23% as of December 31, 2024)

 

 

631,280

 

 

 

555,012

 

Corporate bonds

 

 

30,000

 

 

 

30,000

 

Corporate convertible bonds

 

 

975,000

 

 

 

800,000

 

Current portion of corporate convertible bonds

 

 

(675,000

)

 

 

(500,000

)

Current portion of borrowings

 

 

(926,548

)

 

 

(612,479

)

Borrowings, net of current portion

 

¥

799,959

 

 

¥

764,200

 

 

Except for the 4th convertible bonds, the carrying value of the Company’s borrowings approximates fair value at each balance sheet date because the stated rate of interest of the debt approximates the market interest rate at which the Company can borrow similar debt. The fair value of the 4th convertible bonds as of December 31, 2025 was ¥302,998 thousand (carrying amount of ¥275,000 thousand), measured as the sum of the debt component, discounted at 10.0% per annum, and the embedded conversion option, measured using the Black-Scholes model, and is classified as Level 3. As of December 31, 2025 and 2024, the Company did not have any borrowings measured at fair value.

The following is a summary of maturities of long-term borrowings, corporate bonds and corporate convertible bonds (including the 3rd and 4th convertible bonds included in short-term borrowings) subsequent to December 31, 2025:

 

 

 

Thousands of Yen

 

Year ending December 31:

 

 

 

2026

 

¥

836,321

 

2027

 

 

516,493

 

2028

 

 

95,592

 

2029

 

 

93,509

 

2030

 

 

53,295

 

2031 and thereafter

 

 

41,350

 

Less: unamortized discount

 

 

(280

)

Total

 

¥

1,636,280

 

 

The Company has short-term and long-term borrowings. These borrowings are primarily made under general agreements, which are to provide security and guarantees for present and future indebtedness or to secure a guarantor upon request of the bank, and that the banks shall have the right to offset cash deposits against any debts and obligations that have become due or, in the case of default, against all obligations to the banks. Kouji Eguchi, the representative director and the shareholder of Parent (holds 23.76% of common stock and all Class A common stock as of December 31, 2025) is a guarantor for six loans on behalf of the Company (three bank loans of Parent and three disbursements under the loan agreement between Spirit Advisors and MEDIROM Wellness Co.). As of December 31, 2025, the outstanding amount of loans guaranteed by Mr. Eguchi was ¥339,330 thousand (bank loans of ¥182,800 thousand and loans from Spirit Advisors of ¥156,530 thousand). Kazuyoshi Takahashi, the representative director of ZACC, is the guarantor for two loans on behalf of ZACC, which were borrowed by ZACC from Japan Finance Corporation prior to the acquisition of ZACC. As of December 31, 2025, Mr. Takahashi’s guarantee has not been released and the outstanding amount of loans guaranteed by Mr. Takahashi was ¥25,245 thousand. Yoshio Uekusa, the representative director of MML, is the guarantor for one loan borrowed by MML. As of December 31, 2025, the outstanding amount of the loan guaranteed by Mr. Uekusa was ¥23,556 thousand. None of the borrowing agreements contain any financial covenants. The borrowing agreements contain customary events of default, including non-payment, and certain agreements permit the lender to accelerate repayment upon a significant deterioration in the borrower’s creditworthiness. None of the agreements contains an event of default based on the timely filing of the Company’s annual report or on the Company’s ability to continue as a going concern, and the delay in filing the Company’s annual report and the substantial doubt about the Company’s ability to continue as a going concern did not constitute events of default under the Company’s borrowing agreements. The loan of ¥23,556 thousand obtained by MML passed its original maturity of July 31, 2025 and was past due as of December 31, 2025. Interest at 14.6% per annum applied to this loan from December 2, 2025. On February 27, 2026, MML and the lender agreed to repay the loan, together with accrued interest, in six monthly installments through July 31, 2026, and the loan was repaid in full in 2026. The loan is classified in short-term borrowings.

F-29


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

In addition, the Company entered into a 200 million yen credit facility agreement with a bank on August 7, 2023. As of December 31, 2023, the Company had used 200 million yen of the credit facility. On May 31, 2024, the Company renewed the 200 million yen credit facility agreement, which had reached its maturity date. The credit facility agreement was extended for an additional year on the same terms, with a fixed interest rate of 1.475% and a new maturity date of May 30, 2025. The ¥200 million borrowed under the credit facility was repaid on March 7, 2025 using a portion of the proceeds from the ¥350 million short-term bank loan described above, and the credit facility agreement was terminated on the same date.

7.
Asset Retirement Obligation

Asset retirement obligation primarily consists of estimated costs arising from a contractual obligation to a landlord to remove leasehold improvements from leased properties at the end of the lease contracts for its headquarters and directly-operated salons.

Reconciliation of the beginning and ending amount of asset retirement obligation for the years ended December 31, 2025 and 2024 is as follows:

 

 

 

Thousands of Yen

 

 

 

2025

 

 

2024

 

Beginning balance

 

¥

378,907

 

 

¥

344,346

 

Liabilities incurred

 

 

23,498

 

 

 

45,916

 

Liabilities settled

 

 

(21,727

)

 

 

(15,136

)

Accretion expense

 

 

3,900

 

 

 

3,781

 

Ending balance

 

¥

384,578

 

 

¥

378,907

 

 

The balances as of December 31, 2025 and 2024 are included in asset retirement obligation in the consolidated balance sheets.

8.
Leases

The Company mainly leases commercial space for its relaxation salon from external third parties, which are either operated by the Company or a franchisee and also enters into contracts with franchisees subleasing partial spaces of leased properties under the terms and conditions that are substantially the same as the head lease contracts. As of December 31, 2025, 2024 and 2023, the Company had 234, 245 and 232 leased salons, respectively, of which 65, 81 and 89 salons, respectively, were subleased.

Operating Leases

Lessee

Lease transactions classified as finance leases were immaterial for the years ended December 31, 2025, 2024 and 2023.

The table below summarizes the components of operating lease costs related to operating leases for the years ended December 31, 2025, 2024 and 2023:

 

 

Thousands of Yen

 

 

 

2025

 

 

2024

 

 

2023

 

Fixed lease cost (a)

 

¥

935,278

 

 

¥

913,461

 

 

¥

893,347

 

Variable lease cost (b)

 

 

63,305

 

 

 

40,862

 

 

 

45,410

 

Short-term cost

 

 

23,684

 

 

 

32,324

 

 

 

44,115

 

Total

 

¥

1,022,267

 

 

¥

986,647

 

 

¥

982,872

 

 

(a)
This includes amounts recoverable from sublessees as fixed sublease income. See the table of sublease income in Subleases below for more details.
(b)
This includes amounts recoverable from sublessees as variable sublease income. See the table of sublease income in Subleases below for more details.

There are no sale-and-leaseback transactions conducted in the years ended December 31, 2025, 2024 and 2023.

F-30


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

For the year ended December 31, 2025, the Company recognized impairment losses of ¥462,569 thousand on right-of-use assets related to certain salons in the Relaxation Salon and Luxury Beauty segments (¥380,312 thousand and ¥21,035 thousand, respectively) and the headquarters asset group (¥61,222 thousand), which are included in impairment loss on long-lived assets in the consolidated statements of operations. Following the impairment, the remaining balance of the right-of-use asset of each impaired lease is amortized on a straight-line basis over the remaining lease term. Amortization of right-of-use assets for which impairment losses were recognized was ¥6,321 thousand and ¥6,051 thousand for the years ended December 31, 2025 and 2024, respectively, and is included in depreciation and amortization in the consolidated statements of cash flows. See Notes 1 and 16. No impairment losses were recognized on right-of-use assets for the years ended December 31, 2024 and 2023.

Supplementary information on cash flow and other information for leasing activities for the years ended December 31, 2025, 2024 and 2023 are as follows:

 

 

 

Thousands of Yen

 

 

 

2025

 

 

2024

 

 

2023

 

Cash paid for amounts included in the
   measurement of lease liabilities:

 

 

 

 

 

 

 

 

 

Operating cash flows

 

¥

935,278

 

 

¥

913,461

 

 

¥

893,347

 

Right-of-use assets obtained in exchange
   for lease liabilities

 

 

598,303

 

 

 

901,202

 

 

 

931,521

 

Weighted average remaining lease term (in years)

 

 

3.0

 

 

 

3.4

 

 

 

3.7

 

Weighted average discount rate

 

 

2.53

%

 

 

2.32

%

 

 

2.02

%

 

Maturity analysis of future minimum lease payments under non-cancellable leases subsequent to December 31, 2025 is as follows:

 

 

 

Thousands of Yen

 

Year ending December 31:

 

 

 

2026

 

¥

778,051

 

2027

 

 

514,612

 

2028

 

 

277,026

 

2029

 

 

132,964

 

2030

 

 

65,285

 

2031 and thereafter

 

 

40,008

 

Total

 

 

1,807,946

 

Less: Interest component

 

 

68,318

 

Present value of minimum lease payments

 

¥

1,739,628

 

 

The amount of ¥762,667 thousand and ¥976,961 thousand of the discounted present value of minimum lease payments are included in current portion of lease liability and lease liability - net of current portion, respectively, in the consolidated balance sheets.

Subleases

The Company leases space from commercial facility landlords which in turn it subleases to certain franchisees of its relaxation salons. Sublease revenues are as follows for the years ended December 31, 2025, 2024 and 2023, and included in franchise revenues:

 

 

 

Thousands of Yen

 

 

 

2025

 

 

2024

 

 

2023

 

Fixed sublease income

 

¥

247,248

 

 

¥

294,121

 

 

¥

344,875

 

Variable sublease income

 

 

23,798

 

 

 

14,191

 

 

 

19,492

 

Total

 

¥

271,046

 

 

¥

308,312

 

 

¥

364,367

 

 

F-31


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

Expected future minimum lease collections to be received under non-cancellable subleases subsequent to December 31, 2025 are as follows:

 

 

 

Thousands of Yen

 

Year ending December 31:

 

 

 

2026

 

¥

170,672

 

2027

 

 

96,340

 

2028

 

 

42,063

 

2029

 

 

15,064

 

2030

 

 

3,613

 

2031 and thereafter

 

 

9,371

 

Total

 

¥

337,123

 

 

There are no lease transactions classified as sales-type leases and direct financing leases for the years ended December 31, 2025, 2024 and 2023.

9.
Shareholders’ Equity (Deficit)

Common stock and Class A common stock

Parent’s capital consists of common stock and Class A common stock. On March 29, 2021, the Company held its 21st Ordinary General Meeting of Shareholders, whereby the proposal to amend the Articles of Incorporation to increase the total number of authorized shares was approved. The total number of authorized shares increased to 19,900,000 shares, and the total number of authorized class shares increased to 19,899,999 common shares and one (1) Class A common share.

The same rights are granted to common stock and Class A common stock on the right to claim a dividend and to claim a liquidation distribution.

Class A common stock is entitled to no voting rights at ordinary shareholders’ meetings. However, when Parent makes decisions on the following matters stipulated in laws or regulations or the articles of incorporation that need to be approved by the resolution of the Board of Directors, in addition, Parent needs approval at the Class General Meetings of respective shareholders, which is constituted by the shareholders of Class A common stock.

1.
Subject to a demand for sale of treasury stock from inheritors;
2.
Reverse stock split, stock split, issuance of stock and issuance of stock acquisition right;
3.
Dismissal of Parent’s corporate auditor;
4.
Decrease of common stock;
5.
Dividend paid in property other than money;
6.
Change in the articles of incorporation, business transfer, dissolution and liquidation of Parent; and
7.
Organizational change, merger, stock exchange and stock transfer;

All issued Class A common stock is held by Parent’s representative director, Kouji Eguchi. The holders of Class A common share can claim anytime to acquire Class A common share at market price.

Japanese companies are subject to the Companies Act of Japan (the “Companies Act”). The significant provisions in the Companies Act that affect financial and accounting matters are summarized below:

Common stock

Under the Companies Act, issuances of common stock are required to be credited to the common stock account for at least 50% of the proceeds and to the additional paid-in capital account for the remaining amounts.

Dividends

Under the Companies Act, companies can pay dividends at any time during the year in addition to the year-end dividend upon resolution at the shareholders’ meeting. The Companies Act permits companies to distribute dividends-in-kind (non-cash assets) to shareholders subject to certain limitations and additional requirements. Semiannual dividends may also be paid upon

F-32


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

resolution by the Board of Directors. The Companies Act provides certain limitations on the amounts available for dividends or the purchase of treasury stock. The limitation is defined as the amount available for distribution to the shareholders, but the amount of net assets after dividends must be maintained at no less than ¥3 million.

Increases / decreases and transfer of common stock, reserve and surplus

The Companies Act requires that an amount equal to 10% of dividends must be appropriated as legal reserve (a component of retained earnings) or as additional paid-in capital (a component of capital surplus) depending on the equity account charged upon the payment of such dividends until the total of the aggregate amount of legal reserve and additional paid-in capital equals 25% of common stock. Under the Companies Act, the total amount of additional paid-in capital and legal reserve may be reversed without limitation. The Companies Act also provides that common stock, legal reserve, additional paid-in capital, and other capital surplus and retained earnings can be transferred among the accounts under certain conditions upon resolution of the shareholders.

On March 31, 2023, upon the resolution of the stockholders, a reduction in the registered capital and additional reserved capital amount for common stock was approved in accordance with the Companies Act. As a result, ¥1,203 million and ¥1,306 million were reclassified from registered capital and additional reserved capital for common stock, respectively, to accumulated deficit.

On December 11, 2024, the Company closed its registered offering of 2,860,000 shares of common stock at $1.75 per share for net proceeds received of ¥665,246 thousand after the underwriting discount and expenses deducted by the underwriter, increasing the registered capital of ¥332,623 thousand and the additional paid-in capital of ¥332,623 thousand, respectively. Costs related to the offering, totaling ¥112,982 thousand, were deducted from the additional paid-in capital.

On May 30, 2025, the annual general meeting of shareholders approved a reduction of common stock, which became effective on July 31, 2025. As a result, ¥345,019 thousand was reclassified from common stock to additional paid-in capital. The purpose of the capital reduction was to improve the Company’s financial flexibility and to reduce certain tax burdens under Japanese tax law associated with maintaining a higher registered capital. The reduction does not affect the number of shares outstanding or total shareholders’ equity (deficit).

As of December 31, 2025 and 2024, the Company has 7,994,450 shares issued and 7,901,950 shares outstanding.

Treasury Stock

The Companies Act also provides for companies to purchase treasury stock and dispose of such treasury stock by resolution of the Board of Directors. The amount of treasury stock purchased cannot exceed the amount available for distribution to the shareholders which is determined by a specific formula.

Sale of shares of subsidiary

In November and December 2023, the Company entered into share transfer agreements with several investors and transferred 1,781 out of 50,000 shares of MEDIROM MOTHER Labs Inc. to third-party investors, representing 3.56% of the ownership interest. The Company received the cash proceeds of approximately ¥160 million and the difference between the consideration received and the amount by which the noncontrolling interest was adjusted was recognized as additional paid-in capital. The Company recorded ¥155 million and ¥5 million to additional paid-in capital and noncontrolling interest from the sale of subsidiaries’ shares, respectively.

10.
Stock-based Compensation

The fair value of stock options as part of employee incentive plans is estimated at the date of grant of the purchase rights using the Black-Scholes option-pricing model or a binomial model. The model requires the input of highly subjective assumptions such as the expected stock price volatility and the expected term.

According to the resolutions at the general meetings of shareholders held in December 2015, as Fifth Series of Stock Subscription Rights, stock options to purchase 285,500 shares of common stock were granted to the Company’s employees on December 21, 2015. The exercise term of stock options is 8 years commencing from December 22, 2017 and they must be employed by the Company at the time of exercise to exercise their rights. The stock option’s fair value as of grant date was ¥2.96 per share. The exercise price of the stock option is ¥400 per share.

F-33


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

According to the resolutions at the general meetings of shareholders held in December 2016, as Seventh Series of Stock Subscription Rights, stock options to purchase 174,000 shares of common stock were granted to the Company’s director and the Company’s employees on December 21, 2016. The exercise term of stock options is 8 years commencing from December 22, 2018 and they must be employed by the Company at the time of exercise to exercise their rights. The stock option’s fair value as of grant date was ¥0.82 per share. The exercise price of the stock option is ¥2,000 per share.

According to the resolutions at the extraordinary general meetings of shareholders held in August 2020, as Eighth Series of Stock Subscription Rights, stock options to purchase 150,000 shares of common stock were granted to the Company’s director on October 2, 2020. The amount to be paid in for the stock option was ¥1.00 per share. The exercise term of stock options is 5 years commencing from October 1, 2021 and they must be employed by the Company at the time of exercise to exercise their rights. The stock option’s fair value as of grant date was ¥104.64 per share. The exercise price of the stock option is ¥2,000 per share.

According to the resolutions at the extraordinary general meetings of shareholders held in August 2020, as Ninth Series of Stock Subscription Rights, stock options to purchase 300,000 shares of common stock were granted to the Company’s director, the Company’s corporate auditor, the Company’s employees and outside service providers on October 2, 2020. The amount to be paid in for the stock option was ¥22.00 per share. The exercise term of stock options is 3 years commencing from October 1, 2021 and they must be employed by the Company at the time of exercise to exercise their rights (however, this shall not apply to outside service providers). In addition, the exercise can take place only when the Company achieves an annual consolidated revenue target of ¥3,908,264 thousand under U.S. GAAP in any of our 2020, 2021 or 2022 fiscal years. The stock option’s fair value as of grant date was ¥637.02 per share. The exercise price of the stock option is ¥128 per share.

On December 11, 2024, the Company completed a follow-on offering, and as part of the completion of the offering, the Company granted tenth series Stock Options to its underwriter. These stock options entitle the holder to acquire 143,000 shares of common stock. The amount to be paid in for the stock option was $100 in aggregate. The exercise term of stock options is from June 7, 2025 to December 9, 2029. The stock option’s fair value as of grant date was ¥218 per share. The exercise price of the stock option is $2.1875 per share.

According to the resolution at the annual general meeting of shareholders held in May 2025, as Eleventh Series of Stock Subscription Rights, stock options to purchase 377,000 shares of common stock were granted to directors, corporate auditors, employees and outside service providers of the Company and its subsidiaries on July 18, 2025. The amount to be paid in for the stock option was ¥2 per share. The exercise price of the stock option is US$1.74 per share, and the exercise period is from July 18, 2026 to July 17, 2030. The options become exercisable only if the Company’s adjusted consolidated revenue (consolidated total revenue in the audited consolidated financial statements, excluding revenue of the Digital Preventative Healthcare segment and revenue from the sale of directly-owned salons) exceeds ¥10 billion in any of the fiscal years ending December 31, 2026 through December 31, 2028 (performance condition), and holders must remain directors, corporate auditors, employees or outside service providers of the Company or its subsidiaries at the time of exercise, subject to certain exceptions. The fair value of the stock options at the grant date was US$1.03 per share, estimated using a binomial model with the following assumptions: stock price of US$1.39, expected volatility of 101.48%, expected term of 5 years, expected dividend yield of 0% and risk-free interest rate of 3.947%. As of December 31, 2025, the Company concluded that the achievement of the performance condition was not probable and, accordingly, no compensation expense was recognized for the year ended December 31, 2025. The amount paid in by the holders for the stock options of ¥754 thousand was recorded in additional paid-in capital.

The Company did not grant any stock options during 2023.

F-34


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

A summary of the activity of the Company’s stock option plans as of and for the years ended December 31, 2025, 2024 and 2023 is presented below:

 

 

 

 

 

 

Yen

 

 

Years

 

 

Thousands
of Yen

 

 

 

Number of
shares

 

 

Weighted-average
exercise price

 

 

Weighted-average
remaining
contractual
term

 

 

Aggregate
intrinsic value

 

Outstanding at December 31, 2022

 

 

593,250

 

 

 

865

 

 

 

2.7

 

 

 

150,696

 

Exercisable at December 31, 2022

 

 

593,250

 

 

¥

865

 

 

 

2.7

 

 

¥

150,696

 

Reinstated

 

 

3,200

 

 

 

128

 

 

 

 

 

 

 

Forfeited/Expired

 

 

(6,950

)

 

 

402

 

 

 

 

 

 

 

Outstanding at December 31, 2023

 

 

589,500

 

 

 

867

 

 

 

1.5

 

 

 

228,719

 

Exercisable at December 31, 2023

 

 

589,500

 

 

¥

867

 

 

 

1.5

 

 

¥

228,719

 

Granted

 

 

143,000

 

 

 

344

 

 

 

 

 

 

 

Exercised

 

 

(159,450

)

 

 

134

 

 

 

 

 

 

 

Forfeited/Expired

 

 

(137,050

)

 

 

137

 

 

 

 

 

 

 

Outstanding at December 31, 2024

 

 

436,000

 

 

 

1,193

 

 

 

1.1

 

 

 

68,109

 

Exercisable at December 31, 2024

 

 

436,000

 

 

 

1,193

 

 

 

1.1

 

 

 

68,109

 

Granted

 

 

377,000

 

 

 

272

 

 

 

 

 

 

 

Forfeited/Expired

 

 

(76,500

)

 

 

494

 

 

 

 

 

 

 

Outstanding at December 31, 2025

 

 

736,500

 

 

 

794

 

 

3.3

 

 

 

11,802

 

Exercisable at December 31, 2025

 

 

359,500

 

 

 

1,341

 

 

2.1

 

 

 

—

 

 

On August 29, 2023, the board of directors approved a resolution to waive the forfeiture related to the Fifth Series, Seventh Series, and Ninth Series of Stock Subscription Rights. This resolution retrospectively applies to the employees who resigned after December 31, 2022 for the stock options related to Fifth Series and Seventh Series of Stock Subscription Rights and resigned after April 30, 2022 for the stock options related to Ninth Series of Stock Subscription Rights. The board of directors passed the resolution due to the delay in filing the Form 20-F for the year ended December 31, 2021, which resulted in forfeiting the employees’ opportunity to exercise their options. Considering the fact that the employees paid cash consideration in exchange for the stock options, the Company relieved the stock option forfeiture for the certain employees. The Company retrieved 3,200 forfeited stock options during the year ended December 31, 2023 due to this resolution.

For the years ended December 31, 2025, 2024 and 2023, there was no compensation cost recognized for stock options. The Fifth, Seventh, Eighth, Ninth and Tenth Series stock options were fully vested at grant or in prior years, and no compensation cost was recognized for the Eleventh Series stock options as the performance condition was not considered probable of achievement. As of December 31, 2025, unrecognized compensation cost related to the Eleventh Series stock options was ¥55,644 thousand (grant-date fair value of ¥56,398 thousand, translated at ¥145.24 to US$1.00, less the amount paid in by the holders of ¥754 thousand), which will be recognized if and when achievement of the performance condition becomes probable. The adjusted consolidated revenue for the year ended December 31, 2025 was ¥6,227,437 thousand.

11.
Segment Information

The Company operates its business in three segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty, which are based on the organizational structure and information reviewed by the Company’s Chief Operating Decision Maker (“CODM”), who is the Chief Executive Officer, to evaluate its operating results and allocation of resources. The CODM uses segment operating income (loss), which is reviewed monthly against the budget and forecasts, to assess the performance of each segment and to decide how to allocate resources to each segment.

The accounting policies of the segments are substantially the same as those described in the significant accounting policies in Note 1.

F-35


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

Information about operating results and assets for each segment as of and for the years ended December 31, 2025, 2024 and 2023 is as follows:

 

 

 

Thousands of Yen

 

 

 

Relaxation
Salon

 

 

Digital
Preventative
Healthcare

 

 

Luxury
Beauty

 

 

Corporate
and
elimination

 

 

Consolidated

 

Year ended December 31, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

¥

7,051,584

 

 

¥

168,270

 

 

¥

541,767

 

 

¥

—

 

 

¥

7,761,621

 

Less: (1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

5,507,645

 

 

 

82,080

 

 

 

438,519

 

 

 

—

 

 

 

6,028,244

 

Gross profit

 

 

1,543,939

 

 

 

86,190

 

 

 

103,248

 

 

 

—

 

 

 

1,733,377

 

Less: (1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nonmanufacturing payroll expense (2)

 

 

231,644

 

 

 

72,795

 

 

 

34,380

 

 

 

338,875

 

 

 

677,694

 

Professional services expense

 

 

49,828

 

 

 

24,362

 

 

 

—

 

 

 

380,902

 

 

 

455,092

 

Selling expense

 

 

94,908

 

 

 

12,795

 

 

 

17,561

 

 

 

49,684

 

 

 

174,948

 

Depreciation and amortization

 

 

364,345

 

 

 

5,388

 

 

 

43,419

 

 

 

20,809

 

 

 

433,961

 

Commission fee

 

 

35,446

 

 

 

868

 

 

 

335

 

 

 

125,998

 

 

 

162,647

 

Rent expense

 

 

19,052

 

 

 

—

 

 

 

—

 

 

 

71,442

 

 

 

90,494

 

Recruiting and Training expense

 

 

79,977

 

 

 

153

 

 

 

85

 

 

 

42,895

 

 

 

123,110

 

Impairment loss on goodwill

 

 

179,385

 

 

 

—

 

 

 

167,241

 

 

 

—

 

 

 

346,626

 

Impairment loss on long-lived assets

 

 

1,724,073

 

 

 

96,656

 

 

 

224,838

 

 

 

158,760

 

 

 

2,204,327

 

Other segment items (3)

 

 

117,153

 

 

 

(3,108

)

 

 

2,906

 

 

 

339,248

 

 

 

456,199

 

Operating income (loss)

 

 

(1,351,872

)

 

 

(123,719

)

 

 

(387,517

)

 

 

(1,528,613

)

 

 

(3,391,721

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

433,596

 

 

 

32,428

 

 

 

45,824

 

 

 

20,809

 

 

 

532,657

 

Total assets

 

 

3,883,287

 

 

 

301,072

 

 

 

173,923

 

 

 

325,658

 

 

 

4,683,940

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

¥

7,446,200

 

 

¥

153,633

 

 

¥

699,301

 

 

¥

—

 

 

¥

8,299,134

 

Less: (1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

5,366,603

 

 

 

155,537

 

 

 

518,124

 

 

 

12,585

 

 

 

6,052,849

 

Gross profit

 

 

2,079,597

 

 

 

(1,904

)

 

 

181,177

 

 

 

(12,585

)

 

 

2,246,285

 

Less: (1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nonmanufacturing payroll expense (2)

 

 

304,030

 

 

 

87,447

 

 

 

8,038

 

 

 

318,941

 

 

 

718,456

 

Professional services expense

 

 

42,100

 

 

 

29,587

 

 

 

—

 

 

 

409,820

 

 

 

481,507

 

Selling expense

 

 

113,062

 

 

 

14,784

 

 

 

18,647

 

 

 

34,666

 

 

 

181,159

 

Depreciation and amortization

 

 

116,857

 

 

 

134

 

 

 

30,481

 

 

 

28,941

 

 

 

176,413

 

Commission fee

 

 

36,321

 

 

 

855

 

 

 

35

 

 

 

69,211

 

 

 

106,422

 

Rent expense

 

 

19,369

 

 

 

—

 

 

 

—

 

 

 

69,751

 

 

 

89,120

 

Recruiting and Training expense

 

 

71,213

 

 

 

444

 

 

 

—

 

 

 

27,292

 

 

 

98,949

 

Impairment loss on long-lived assets

 

 

22,872

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

22,872

 

Other segment items (3)

 

 

98,321

 

 

 

103,257

 

 

 

3,797

 

 

 

184,114

 

 

 

389,489

 

Operating income (loss)

 

 

1,255,452

 

 

 

(238,412

)

 

 

120,179

 

 

 

(1,155,321

)

 

 

(18,102

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

192,621

 

 

 

30,279

 

 

 

35,542

 

 

 

31,596

 

 

 

290,038

 

Total assets

 

 

5,710,812

 

 

 

428,201

 

 

 

652,520

 

 

 

1,299,138

 

 

 

8,090,671

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

¥

6,059,851

 

 

¥

200,397

 

 

¥

567,695

 

 

¥

—

 

 

¥

6,827,943

 

Less: (1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

4,579,590

 

 

 

183,299

 

 

 

492,261

 

 

 

3,925

 

 

 

5,259,075

 

Gross profit

 

 

1,480,261

 

 

 

17,098

 

 

 

75,434

 

 

 

(3,925

)

 

 

1,568,868

 

Less: (1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nonmanufacturing payroll expense (2)

 

 

260,680

 

 

 

116,732

 

 

 

33,841

 

 

 

248,456

 

 

 

659,709

 

Professional services expense

 

 

25,034

 

 

 

12,966

 

 

 

3,486

 

 

 

362,156

 

 

 

403,642

 

Selling expense

 

 

115,989

 

 

 

27,030

 

 

 

23,062

 

 

 

28,956

 

 

 

195,037

 

Depreciation and amortization

 

 

90,770

 

 

 

4,160

 

 

 

35,113

 

 

 

30,309

 

 

 

160,352

 

Commission fee

 

 

51,026

 

 

 

4,613

 

 

 

3,507

 

 

 

46,088

 

 

 

105,234

 

Rent expense

 

 

18,954

 

 

 

—

 

 

 

—

 

 

 

75,918

 

 

 

94,872

 

Recruiting and Training expense

 

 

28,598

 

 

 

2,874

 

 

 

5,148

 

 

 

29,409

 

 

 

66,029

 

Other segment items (3)

 

 

41,163

 

 

 

21,861

 

 

 

55,767

 

 

 

156,781

 

 

 

275,572

 

Operating income (loss)

 

 

848,047

 

 

 

(173,138

)

 

 

(84,490

)

 

 

(981,998

)

 

 

(391,579

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

157,804

 

 

 

27,574

 

 

 

35,729

 

 

 

31,488

 

 

 

252,595

 

Total assets

 

 

4,814,248

 

 

 

458,535

 

 

 

611,925

 

 

 

964,481

 

 

 

6,849,189

 

 

(1)
The significant expense categories and amounts align with the segment-level information that is regularly provided to the chief operating decision maker.
(2)
The nonmanufacturing payroll expense does not include amounts capitalized on the balance sheet or included within other expense categories.
(3)
Other segment items for each reportable segment include

F-36


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

Relaxation Salon - Cloud service fee and Travel expenses

Digital Preventative Healthcare - Research and development expenses

Luxury Beauty - Utility expenses

Corporate and elimination - Travel expenses and Taxes and duties

Expenses not directly associated with specific segments are allocated based on the most reasonable measures applicable. Corporate costs and expenses include certain corporate general and administrative expenses and back-office expenses.

For the year ended December 31, 2025, impairment loss on long-lived assets included impairment of store operating rights, right-of-use assets, trademark, customer relationship, property and equipment and telephone rights of ¥224,838 thousand in the Luxury Beauty segment, impairment of property and equipment, right-of-use assets, store operating rights, trademarks and internal-use software of ¥1,724,073 thousand in the Relaxation Salon segment, impairment of internal-use software and property and equipment of ¥96,656 thousand in the Digital Preventative Healthcare segment, and impairment of the headquarters asset group (property and equipment, including construction in progress, right-of-use assets, internal-use software and telephone rights) of ¥158,760 thousand in Corporate and elimination (the remaining ¥14,253 thousand of the ¥173,013 thousand impairment of the headquarters asset group, recorded by entities in the Relaxation Salon and Luxury Beauty segments, is included in those segments). Impairment loss on goodwill of ¥179,385 thousand and ¥167,241 thousand was recognized in the Relaxation Salon and Luxury Beauty segments, respectively.

Total segment operating income (loss), together with corporate and elimination, reconciles to consolidated operating loss as presented above. Consolidated operating loss is reconciled to (loss) income before income taxes by total other income of ¥53,258 thousand, ¥65,815 thousand and ¥412,201 thousand for the years ended December 31, 2025, 2024 and 2023, respectively.

Assets attributed to each segment are accounts receivable-trade, net, accounts receivable-other, net, inventories, prepaid expenses, right-of-use asset - operating lease, property and equipment, goodwill, intangible assets, investments, and lease and guarantee deposits. Corporate assets primarily consist of cash and cash equivalents, time deposits, long-term accounts receivable-other, net, deferred tax assets, and property and equipment.

Substantially all revenues are from customers operating in Japan. Geographic information is omitted due to immateriality of revenue and operating income attributable to international operations for the years ended December 31, 2025, 2024 and 2023.

12.
Income Taxes

The following table shows a summary of income taxes for the years ended December 31, 2025, 2024 and 2023:

 

 

 

Thousands of Yen

 

 

 

2025

 

 

2024

 

 

2023

 

(Loss) income before income taxes

 

¥

(3,338,463

)

 

¥

47,713

 

 

¥

20,622

 

Income taxes

 

 

 

 

 

 

 

 

 

Current

 

 

18,236

 

 

 

98,228

 

 

 

7,209

 

Deferred

 

 

285,882

 

 

 

(188,706

)

 

 

(101,636

)

Total

 

¥

304,118

 

 

¥

(90,478

)

 

¥

(94,427

)

 

Parent and its subsidiaries are subject to a number of taxes based on income, which in the aggregate resulted in an effective statutory rate of approximately 34.6%, 30.6% and 34.6%, for the years ended December 31, 2025, 2024 and 2023, respectively.

The Company is domiciled in Japan. A reconciliation between the income tax computed by applying the Japanese statutory tax rate to the loss before income taxes and the reported income tax expense for the year ended December 31, 2025 is presented below in both amounts and percentages, using the categories required by ASU 2023-09. The statutory tax rate of 34.6% is a combined rate that includes national corporate tax, local corporate tax, inhabitant tax and enterprise tax (including special

F-37


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

corporate enterprise tax). Reconciling items in the categories of nontaxable or nondeductible items and other adjustments that are equal to or greater than 5% of the income tax computed at the statutory tax rate are presented separately by nature.

 

 

 

Thousands
of Yen

 

 

%

 

Income tax benefit computed at the Japanese statutory tax rate

 

¥

(1,154,774

)

 

 

34.6

%

Increases (reductions) in taxes due to:

 

 

 

 

 

 

State and local income taxes (inhabitant tax per capita)*

 

 

17,616

 

 

 

(0.5

)

Effect of changes in tax laws or rates enacted in the current period

 

 

(7,523

)

 

 

0.2

 

Tax credits

 

 

(35,268

)

 

 

1.1

 

Changes in valuation allowances

 

 

1,392,896

 

 

 

(41.7

)

Nontaxable or nondeductible items:

 

 

 

 

 

 

Impairment of goodwill

 

 

109,509

 

 

 

(3.3

)

Other nondeductible expenses

 

 

19,699

 

 

 

(0.6

)

Other adjustments:

 

 

 

 

 

 

Deconsolidation of subsidiary (sale of JOYHANDS WELLNESS Inc.)

 

 

127,435

 

 

 

(3.8

)

Use of operating loss carryforwards

 

 

(128,053

)

 

 

3.8

 

Change in tax status of the Company (capital reduction)

 

 

(23,922

)

 

 

0.7

 

Other, net

 

 

(13,497

)

 

 

0.4

 

Income tax expense and effective income tax rate

 

¥

304,118

 

 

 

(9.1

)%

 

The reconciliation for the years ended December 31, 2024 and 2023, which is presented in the format used prior to the adoption of ASU 2023-09, is as follows:

 

 

 

2024

 

 

2023

 

Statutory tax rate

 

 

30.6

%

 

 

34.6

%

Increases (reductions) in taxes due to:

 

 

 

 

 

 

Change in valuation allowance

 

 

97.5

 

 

 

1,709.3

 

Nondeductible expenses

 

 

6.1

 

 

 

18.8

 

Inhabitant tax-per capita*

 

 

22.0

 

 

 

35.0

 

Difference in tax rate of subsidiary of the Company

 

 

13.8

 

 

―

 

Use of operating loss carryforwards

 

 

(358.2

)

 

 

(1,807.5

)

Change in statutory tax rate

 

 

0.1

 

 

 

(448.1

)

Other-net

 

 

(1.5

)

 

 

0.0

 

Effective income tax rate

 

 

(189.6

)%

 

 

(457.9

)%

 

* Inhabitants tax is imposed on resident corporations in Japan. It consists of the corporation tax calculated as a percentage of national corporation tax and the per capita levy determined based on capital and the number of employees.

F-38


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

The tax effects of the major items of temporary differences giving rise to the deferred tax assets and liabilities as of December 31, 2025 and 2024 are as follows:

 

 

 

Thousands of Yen

 

 

 

2025

 

 

2024

 

Deferred tax assets:

 

 

 

 

 

 

Accounts receivable-trade

 

¥

349,370

 

 

¥

13,485

 

Provision for bad debt

 

 

106,033

 

 

 

54,653

 

Accrued Vacation

 

 

30,135

 

 

 

22,456

 

Investment securities (impairment)

 

 

38,428

 

 

 

—

 

Asset retirement obligation

 

 

134,639

 

 

 

129,523

 

Operating lease liability

 

 

614,580

 

 

 

712,836

 

Operating loss carryforwards

 

 

571,133

 

 

 

658,610

 

Tax credit carryforwards

 

 

35,268

 

 

 

—

 

Impairment losses

 

 

569,567

 

 

 

—

 

Other

 

 

39,067

 

 

 

39,621

 

Gross deferred tax assets

 

 

2,488,220

 

 

 

1,631,184

 

Valuation allowance

 

 

(1,791,291

)

 

 

(497,169

)

Total deferred tax assets

 

 

696,929

 

 

 

1,134,015

 

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

Property and equipment

 

 

(66,623

)

 

 

(67,508

)

Goodwill

 

 

(166,888

)

 

 

(19,524

)

Intangible assets

 

 

—

 

 

 

(48,837

)

Right-of-use asset - operating lease

 

 

(459,754

)

 

 

(712,107

)

Other

 

 

(3,664

)

 

 

(157

)

Total deferred tax liabilities

 

 

(696,929

)

 

 

(848,133

)

Net deferred tax assets

 

¥

—

 

 

¥

285,882

 

 

The deferred tax liability recognized for goodwill of ¥166,888 thousand as of December 31, 2025 (¥19,524 thousand as of December 31, 2024) relates to goodwill recognized for tax purposes on acquisitions of salons, which continues to be amortized for tax purposes. For financial reporting purposes the consideration for those acquisitions is recorded as store operating rights, and the goodwill recognized in the consolidated balance sheets was impaired in full during the year ended December 31, 2025. The deferred tax liability therefore does not relate to the goodwill presented in the consolidated balance sheets. Valuation allowance for deferred tax assets increased by ¥1,294,122 thousand for the year ended December 31, 2025 and decreased by ¥164,931 thousand for the year ended December 31, 2024. This increase differs by ¥98,774 thousand from the ¥1,392,896 thousand presented as changes in valuation allowances in the reconciliation of the statutory tax rate above, because the latter excludes the decrease in the valuation allowance attributable to operating loss carryforwards utilized during the year (¥128,053 thousand), which is presented within “Use of operating loss carryforwards”, and the increase in the valuation allowance on deferred tax assets subject to a full valuation allowance resulting from changes in tax rates (¥29,279 thousand).

In assessing the realizability of deferred tax assets, the Company considered all available positive and negative evidence. Given the significant losses incurred in the year ended December 31, 2025, the cumulative losses in recent years and the uncertainty of the future operating results in the near term, the Company concluded that it is not more likely than not that its deferred tax assets will be realized and recorded a full valuation allowance against its net deferred tax assets as of December 31, 2025.

F-39


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

At December 31, 2025, the Company had operating loss carryforwards of ¥1,656,575 thousand, which are available to offset future taxable income. These carryforwards are scheduled to expire as follows:

 

 

 

Operating loss
carryforwards

 

 

 

(Thousands of Yen)

 

Years ending December 31:

 

 

 

Between 2026 and 2029

 

¥

—

 

Between 2030 and 2033

 

 

925,541

 

2034 and thereafter

 

 

731,034

 

Total

 

¥

1,656,575

 

 

The Company does not recognize any deferred tax liabilities for undistributed earnings of domestic subsidiaries since dividends from these subsidiaries are not subject to taxation under Japanese tax law.

At December 31, 2025, 2024 and 2023, unrecognized tax benefits were not material. The Company does not believe it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within the next 12 months.

The penalties and interest expenses related to income taxes are recognized in the consolidated statements of operations for the years ended December 31, 2025, 2024 and 2023, however, the amounts are immaterial.

In 2023, the Company underwent examination by the tax authorities. The tax authorities routinely challenge certain deductions and credits reported by the Company on its income tax returns. In November 2023, the tax authorities concluded examinations, which did not have a material impact to the Company’s consolidated financial statements.

Parent and its subsidiaries are subject to taxation in Japan and in the local Japanese governments where the Company’s salons or offices are located. As of December 31, 2025, the fiscal year ending December 31, 2020 and subsequent years remain open to examination by the tax authority (National Tax Agency and Tokyo Metropolitan Government).

Income taxes paid (net of refunds) for the year ended December 31, 2025 were ¥59,318 thousand, consisting of national taxes of ¥33,252 thousand and local taxes of ¥26,066 thousand, all of which were paid in Japan.

F-40


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

13.
Revenue Recognition

Disaggregation of revenue

For the years ended December 31, 2025, 2024 and 2023, revenues are disaggregated by revenue stream and reconciled to reportable segment revenues as follows.

 

 

 

Thousands of Yen

 

Revenue Stream*

 

Relaxation
Salon

 

 

Digital
Preventative
Healthcare

 

 

Luxury
Beauty

 

 

Consolidated

 

For the year ended December 31, 2025

 

 

 

 

 

 

 

 

 

 

 

 

Revenue from directly-operated salons

 

¥

5,052,223

 

 

¥

—

 

 

¥

541,167

 

 

¥

5,593,390

 

Revenue from the sale of directly-owned salons

 

 

1,365,914

 

 

 

—

 

 

 

—

 

 

 

1,365,914

 

Franchise fees

 

 

50,897

 

 

 

—

 

 

 

600

 

 

 

51,497

 

Royalty income

 

 

131,526

 

 

 

—

 

 

 

—

 

 

 

131,526

 

Staffing service revenue

 

 

45,052

 

 

 

—

 

 

 

—

 

 

 

45,052

 

Sublease revenue

 

 

271,046

 

 

 

—

 

 

 

—

 

 

 

271,046

 

Other franchise revenues

 

 

134,926

 

 

 

—

 

 

 

—

 

 

 

134,926

 

Other revenues

 

 

—

 

 

 

168,270

 

 

 

—

 

 

 

168,270

 

Total revenues

 

¥

7,051,584

 

 

¥

168,270

 

 

¥

541,767

 

 

¥

7,761,621

 

For the year ended December 31, 2024

 

 

 

 

 

 

 

 

 

 

 

 

Revenue from directly-operated salons

 

¥

4,435,512

 

 

¥

—

 

 

¥

589,351

 

 

¥

5,024,863

 

Revenue from the sale of directly-owned salons

 

 

2,218,605

 

 

 

—

 

 

 

109,400

 

 

 

2,328,005

 

Franchise fees

 

 

71,254

 

 

 

—

 

 

 

550

 

 

 

71,804

 

Royalty income

 

 

156,322

 

 

 

—

 

 

 

—

 

 

 

156,322

 

Staffing service revenue

 

 

76,840

 

 

 

—

 

 

 

—

 

 

 

76,840

 

Sublease revenue

 

 

308,312

 

 

 

—

 

 

 

—

 

 

 

308,312

 

Other franchise revenues

 

 

179,355

 

 

 

—

 

 

 

—

 

 

 

179,355

 

Other revenues

 

 

—

 

 

 

153,633

 

 

 

—

 

 

 

153,633

 

Total revenues

 

¥

7,446,200

 

 

¥

153,633

 

 

¥

699,301

 

 

¥

8,299,134

 

 

 

 

Thousands of Yen

 

Revenue Stream*

 

Relaxation
Salon

 

 

Digital
Preventative
Healthcare

 

 

Luxury
Beauty

 

 

Consolidated

 

For the year ended December 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

Revenue from directly-operated salons

 

¥

4,081,024

 

 

¥

—

 

 

¥

567,695

 

 

¥

4,648,719

 

Revenue from the sale of directly-owned salons

 

 

1,007,800

 

 

 

—

 

 

 

—

 

 

 

1,007,800

 

Franchise fees

 

 

106,916

 

 

 

—

 

 

 

—

 

 

 

106,916

 

Royalty income

 

 

181,417

 

 

 

—

 

 

 

—

 

 

 

181,417

 

Staffing service revenue

 

 

136,570

 

 

 

—

 

 

 

—

 

 

 

136,570

 

Sublease revenue

 

 

364,367

 

 

 

—

 

 

 

—

 

 

 

364,367

 

Other franchise revenues

 

 

181,757

 

 

 

—

 

 

 

—

 

 

 

181,757

 

Other revenues

 

 

—

 

 

 

200,397

 

 

 

—

 

 

 

200,397

 

Total revenues

 

¥

6,059,851

 

 

¥

200,397

 

 

¥

567,695

 

 

¥

6,827,943

 

 

* All revenue streams are recognized over time, with the exception of hiring support within other franchise revenues, revenue from the sale of directly-owned salons, and product sales included in other revenues, which are recognized at a point in time. Revenue related to hiring support and product sales was not material in the periods presented.

Franchise revenue includes sublease income accounted for under ASC 842 of ¥271,046 thousand, ¥308,312 thousand and ¥364,367 thousand for the years ended December 31, 2025, 2024 and 2023, respectively. All other revenues are revenue from contracts with customers under ASC 606.

F-41


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

Contract balance

Information about receivables and contract liabilities from contracts with customers is as follows:

 

 

 

Thousands of Yen

 

 

 

 

 

As of

 

 

As of

 

 

 

 

 

December 31,

 

 

December 31,

 

 

 

 

 

2025

 

 

2024

 

 

Balance sheet classification

Receivables

 

¥

671,663

 

 

¥

1,355,489

 

 

Accounts receivable-trade, net

 

 

 

 

 

 

 

 

Contract liabilities:

 

 

 

 

 

 

 

 

Current

 

 

28,492

 

 

 

53,485

 

 

Current portion of contract liability

Long-term

 

 

16,095

 

 

 

36,913

 

 

Contract liability - net of current portion

Total

 

¥

44,587

 

 

¥

90,398

 

 

 

 

 

 

 

 

 

 

 

Prepaid card liability

 

¥

325,318

 

 

¥

409,710

 

 

Advances received

 

Receivables relate primarily to payments due for the sale of directly-owned salons, royalty income, staffing service revenue and sublease revenue. With respect to the payment term, payment for these revenues is generally collected monthly. As such, no significant financing component has been identified. The receivables balance is presented net of an allowance for expected losses (i.e., doubtful accounts), and is primarily related to receivables from third-party investors and the Company’s franchisees. Refer to “Accounts Receivable—Trade, Net” in Note 1 for details on the components of the receivables balance and the allowance. Contract liabilities primarily represent the Company’s remaining performance obligations under its franchise agreement at the end of the year, for which consideration has been received and revenue had not been recognized, and is generally recognized as revenues ratably over the remaining customer life that the expected services are to be provided. Prepaid card liabilities mainly relate to the unused balance of ReRaKu and SAWAN cards that can be redeemed at company-operated salons for services. Revenue for prepaid cards is recognized and the corresponding liability is reduced as the services are provided. As of December 31, 2025 and 2024, contract assets under contracts with customers were immaterial and they are included in prepaid expenses and other current assets and other assets in the consolidated balance sheets.

Changes in the Company’s contract liabilities for the year ended December 31, 2025 are as follows:

 

 

 

Thousands of Yen

 

 

 

Contract liabilities

 

Balance at December 31, 2024

 

¥

90,398

 

Revenues recognized during 2025 which were included in the contract liabilities balance at December 31, 2024

 

 

(61,842

)

Remaining amounts at December 31, 2025 which were newly recognized as contract liabilities during 2025

 

 

16,031

 

Balance at December 31, 2025

 

¥

44,587

 

 

For the year ended December 31, 2025, there were no revenues recognized under performance obligations which were satisfied for past fiscal years by change of transaction price, etc. Changes in receivables and contract liabilities are primarily due to the timing of revenue recognition, billings and cash collections.

F-42


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

Transaction price allocated to remaining performance obligations

Estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December 31, 2025 is as follows:

 

 

 

Thousands of Yen

 

Year ending December 31:

 

 

 

2026

 

¥

28,492

 

2027

 

 

10,029

 

2028

 

 

3,499

 

2029

 

 

2,042

 

2030

 

 

525

 

2031 and thereafter

 

 

—

 

Total

 

¥

44,587

 

 

The Company applies the optional exemptions in ASC 606-10-50-14 and 50-14A and does not disclose remaining performance obligations for (i) sales-based royalties, (ii) staffing services and cost reimbursements under Service Agreements, for which revenue is recognized in the amount invoiced, and (iii) variable consideration under Service Agreements that is allocated to wholly unsatisfied service periods.

14.
Earnings (Loss) Per Share

Earnings (loss) per common share is allocated based on each right of common stock and Class A common stock, on the assumption that income (loss) from current year has been distributed. Common stock and Class A common stock have equal rights with respect to surplus dividend and residual assets distribution as net income (loss) attributable to shareholders of the Company is allocated proportionally.

Reconciliations of net income (loss) and weighted average number of common shares outstanding used for the computation of basic and diluted earnings (loss) per common share for the years ended December 31, 2025, 2024 and 2023 are as follows:

 

 

 

2025

 

 

2024

 

 

2023

 

 

 

Common

 

 

Class A

 

 

Common

 

 

Class A

 

 

Common

 

 

Class A

 

 

 

(Thousands of Yen)

 

 

(Thousands of Yen)

 

 

(Thousands of Yen)

 

Income (Numerator)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to shareholders of the Company - basic

 

¥

(3,634,280

)

 

 

—

 

 

¥

148,763

 

 

―

 

 

¥

115,404

 

 

―

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Add back interest for convertible bonds, net of tax

 

 

—

 

 

 

—

 

 

 

18,109

 

 

―

 

 

―

 

 

―

 

Net income (loss) attributable to shareholders of the Company - diluted

 

 

(3,634,280

)

 

 

—

 

 

 

166,872

 

 

―

 

 

 

115,404

 

 

―

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(Number of shares)

 

 

(Number of shares)

 

 

(Number of shares)

 

Shares (Denominator)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding - basic

 

 

7,901,950

 

 

 

1

 

 

 

5,107,404

 

 

 

1

 

 

 

4,882,500

 

 

 

1

 

Effect of dilutive instruments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dilutive effect of stock options

 

 

—

 

 

 

—

 

 

 

29,613

 

 

―

 

 

 

284,152

 

 

―

 

Dilutive effect of convertible bonds

 

 

—

 

 

 

—

 

 

 

714,498

 

 

―

 

 

―

 

 

―

 

Weighted average common shares for diluted computation

 

 

7,901,950

 

 

 

1

 

 

 

5,851,515

 

 

 

1

 

 

 

5,166,652

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per common share attributable to shareholders of the Company

 

(Yen)

 

 

 

 

 

(Yen)

 

 

 

 

 

(Yen)

 

 

 

 

Basic

 

¥

(459.92

)

 

¥

(459.92

)

 

¥

29.13

 

 

¥

29.13

 

 

¥

23.64

 

 

¥

23.64

 

Diluted

 

¥

(459.92

)

 

¥

(459.92

)

 

¥

28.52

 

 

¥

28.52

 

 

¥

22.34

 

 

¥

22.34

 

 

F-43


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

For periods in which the Company reports net loss, diluted net loss per common share attributable to common shareholders is the same as basic net loss per common share attributable to common shareholders. For the year ended December 31, 2025, stock options to purchase 736,500 shares and 2,312,987 common shares issuable upon conversion of the corporate convertible bonds outstanding as of December 31, 2025 (313,479 shares for the 2nd, 1,166,175 shares for the 3rd and 833,333 shares for the 4th convertible bonds), and 662,251 common shares issuable upon conversion of the 1st convertible bonds, which were settled on December 31, 2025, were excluded from the computation of diluted net loss per common share because the effect of inclusion would have been anti-dilutive. The share options from the convertible bond were excluded from the diluted net income per common share attributable to common shareholders because the effect of inclusion would have been anti-dilutive for the year ended December 31, 2023.

15.
Fair Value of Financial Instruments

Fair value of financial instruments

The carrying amounts of cash and cash equivalents, time deposits, accounts receivable-trade, accounts receivable-other, lease and guarantee deposits, current portion of borrowings, accounts payable-trade, accrued expenses, deposit received and operating lease liability approximate their fair values. Long-term accounts receivable-other is non-interest bearing and is carried at its principal amount, net of the allowance for credit losses. Investments are disclosed in Note 5.

Borrowings

The Company’s borrowing instruments are classified as Level 2 instruments and valued based on the present value of future cash flows associated with each instrument discounted using current market borrowing rates for similar borrowing instruments of comparable maturity. The value of current portion of borrowings approximates fair value due to the short-term nature of these liabilities, and the carrying value of the Company’s long-term borrowings approximates fair value at each balance sheet date because the stated rate of interest of the debt approximates the market interest rate at which the Company can borrow similar debt. The fair value of the 4th convertible bonds as of December 31, 2025 was ¥302,998 thousand (carrying amount of ¥275,000 thousand), measured as the sum of the debt component, discounted at 10.0% per annum, and the embedded conversion option, measured using the Black-Scholes model, and is classified as Level 3.

Assumptions used in fair value estimates

Fair value estimates are made at a specific point in time, based on relevant market information available and details of the financial instruments. These estimates are practically conducted by the Company which involve uncertainties and matters of significant judgment; therefore, these cannot be determined with precision. Changes in assumptions could significantly affect the estimates.

16.
Fair Value Measurements

Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is as follows:

Level 1

Inputs are quoted prices in active markets for identical assets or liabilities.

Level 2

Inputs are quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3

Inputs are derived from valuation techniques in which one or more significant inputs or value drivers are unobservable, which reflect the reporting entity’s own assumptions about the assumptions that market participants would use in establishing a price.

F-44


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

Long-lived assets and liabilities that have been measured at fair value on a “nonrecurring” basis include leasehold improvements, tools, furniture and fixtures, leased assets, construction in progress, right-of-use assets — operating lease, store operating rights, internal-use software, trademark, customer relationships, telephone rights and goodwill. Assets and liabilities measured at fair value on a “nonrecurring” basis as of December 31, 2025 and 2024 are as follows:

 

 

 

Thousands of Yen

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Impairment loss

 

Year ended December 31, 2025

 

 

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Leasehold improvements

 

¥

—

 

 

¥

—

 

 

¥

5,843

 

 

¥

113,810

 

Tools, furniture and fixtures

 

 

—

 

 

 

—

 

 

 

—

 

 

 

16,885

 

Leased assets

 

 

—

 

 

 

—

 

 

 

—

 

 

 

6,206

 

Construction in progress

 

 

—

 

 

 

—

 

 

 

—

 

 

 

39,930

 

Right-of-use asset - operating lease

 

 

—

 

 

 

—

 

 

 

41,955

 

 

 

462,569

 

Store operating rights

 

 

—

 

 

 

—

 

 

 

371,109

 

 

 

1,284,489

 

Internal-use software (including software in progress)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

120,774

 

Trademark and customer relationships

 

 

—

 

 

 

—

 

 

 

—

 

 

 

159,295

 

Telephone rights

 

 

—

 

 

 

—

 

 

 

—

 

 

 

369

 

Goodwill

 

 

—

 

 

 

—

 

 

 

—

 

 

 

346,626

 

Total

 

¥

—

 

 

¥

—

 

 

¥

418,907

 

 

¥

2,550,953

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 2024

 

 

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Leasehold improvements

 

¥

—

 

 

¥

—

 

 

¥

311,436

 

 

¥

134

 

Store operating rights

 

 

—

 

 

 

—

 

 

 

830,838

 

 

 

22,738

 

Total

 

¥

—

 

 

¥

—

 

 

¥

1,142,274

 

 

¥

22,872

 

 

Impairment of long-lived assets

Significant judgments and unobservable inputs categorized as Level 3 in the fair value hierarchy are inherent in the impairment tests performed and include assumptions about expected future cash flows and the EBITDA multiples observed in the Company’s past salon transactions with investors. The Company believes that the assumptions used in its annual and any interim date impairment tests are reasonable, but variations in any of the assumptions may result in different calculations of fair values and impairment charges.

The Company’s primary business is the operations of Relaxation Salons. It regularly conducts reviews of past performances and future profitability forecast for individual Salons. Based on the evaluation, if the Company determines that the Salon assets are impaired and not fully recoverable, it reduces the carrying amounts of the Salon’s long-lived assets to the estimated fair value. Fair value is determined using Level 3 inputs under ASC 820 Fair Value Measurement, based on the assumptions that market participants would use. For salons with store operating rights reacquired from investors, fair value is estimated by reference to the prices in the Company’s past salon transactions with investors (a multiple of 16.4 times EBITDA, being the median of the salon sales completed in 2025), adjusted by factors of 0.597 (MEDIROM Wellness Co.), 0.277 (SAWAN Co., Ltd.) and 0.152 (ZACC) to reflect the EBITDA achieved by these salons in the six months ended June 30, 2026 relative to 2025. The multiples observed in these transactions ranged from 3.8 to 65.2 times (weighted average of 14.6 times, weighted by the EBITDA of each salon), and the adjustment factors ranged from 0.152 to 0.597 (weighted average of 0.53, weighted by the fair value of the asset groups measured). For other asset groups that generate negative cash flows, the Company concluded that a market participant would not attribute value to the asset group, and fair value is nil. The estimates of future cash flows are based on the 2025 EBITDA of each salon adjusted by the same factors. If the EBITDA of the salons falls below that level or the multiples paid by market participants decline, additional impairment losses may be recognized in the future.

For the year ended December 31, 2025, the Company recognized impairment losses of ¥2,204,327 thousand on property and equipment (including construction in progress), right-of-use assets, store operating rights, internal-use software, trademarks, customer relationships and telephone rights, and ¥346,626 thousand on goodwill. The fair values of these assets were determined based on Level 3 inputs as described above.

In estimating the fair values of these asset groups and of the Luxury Beauty reporting unit as of December 31, 2025, the Company considered the operating results for the six months ended June 30, 2026, which became available before the

F-45


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

consolidated financial statements were issued. The Company concluded that these results provided additional evidence about conditions that existed as of December 31, 2025, because the decline in salon EBITDA resulted from conditions that existed at the balance sheet date, namely continued increases in labor costs and pressure on discretionary consumer spending, the shortfall of salon EBITDA against the Company’s budget had become apparent in the fourth quarter of 2025, and the results are consistent with information that market participants would have considered as of that date. Accordingly, the Company reflected this information in the impairment measurements in accordance with ASC 855-10-25-1.

These assets were measured at fair value on a nonrecurring basis as a result of the impairment tests described in Notes 3 and 4. For the year ended December 31, 2025, the Company changed the valuation technique used to measure the fair value of salon asset groups with store operating rights reacquired from investors from an income approach to a market approach based on EBITDA multiples observed in the Company’s salon transactions with investors. The Company completed 43 salon sale transactions with investors during 2025 (including transactions presented in gain from sales of salons), and the Company believes that the prices in these transactions better reflect the assumptions that market participants would use in pricing comparable salon asset groups. In accordance with ASC 820-10-35-26, the change in valuation technique was accounted for as a change in accounting estimate. The fair values of the Relaxation Salon and Luxury Beauty reporting units were measured using discount rates ranging from 10% to 15% and long-term growth rates ranging from minus 1% to plus 1%.

For the year ended December 31, 2024, the Company recognized impairment loss of ¥22,872 thousand on leasehold improvements and store operating rights related to a relaxation salon that was scheduled to close in January 2025.The Company conducted strategic reviews of its future profitability forecast for the salons. Following these reviews, the Company reduced the corresponding estimated future cash flows of these assets and the estimated ability to recover the carrying amount of the long-lived assets within the period applicable to the impairment determination, resulting in the impairment charges.

For the year ended December 31, 2023, the Company recognized no impairment loss upon conducting strategic reviews of its future profitability forecast for the salons.

17.
Commitments and Contingencies

Operating leases

The Company, in addition to its headquarters facility, mainly leases salon spaces from external third parties, which are either directly-operated salons or franchised salons. Refer to Note 8 Leases and Note 7 Asset Retirement Obligation for details on the components of operating lease costs and future minimum lease payments under non-cancellable leases and asset retirement obligation, respectively.

Borrowings

The Company has borrowings that are primarily made under general agreements. Refer to Note 6 Borrowings for future debt payments.

Planned acquisition

On June 30, 2024, the Company entered into a share transfer agreement to acquire 70% of the shares of Japan Gene Medicine Corporation for ¥2,000,000 thousand, payable in cash, subject to conditions precedent including the Company obtaining a commitment letter from a bank to finance more than 70% of the purchase price. The acquisition had not been completed as of December 31, 2025, and the agreement was terminated in October 2026 (see Note 19).

Guarantees and pledged assets

The ¥350,000 thousand bank loan of Parent is guaranteed by MML, and the loan obtained by MML is guaranteed by Parent; both loans are included in borrowings in the consolidated balance sheet. As of December 31, 2025, time deposits of ¥6,157 thousand were pledged as collateral for borrowings, and the loans from Spirit Advisors were secured by the operating rights of two salons operated by MEDIROM Wellness Co. Subsequent to December 31, 2025, the Company pledged the shares of MML and MRS as collateral for certain borrowings (see Note 19).

F-46


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

Litigation

From time to time, the Company may be involved in claims and legal proceedings arising in the ordinary course of business. The Company records a liability for a loss contingency when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated, and discloses a loss contingency when a loss is reasonably possible. As of December 31, 2025 and 2024, the Company was not a party to any legal proceedings that management believes would have a material adverse effect on its consolidated financial position, results of operations or cash flows, and no provision for loss contingencies was recorded.

18.
Related Party Transactions

Transactions with the Company’s representative director

Mr. Eguchi is the guarantor with respect to some of the Company’s borrowings. See Note 6, Borrowings for more detail. Mr. Eguchi also personally guarantees the loans from Spirit Advisors to MEDIROM Wellness Co. (¥156,530 thousand as of December 31, 2025).

Transactions with the Company’s director

Akira Nojima, Parent’s independent director, is the sole owner of Kabushiki Kaisha No Track.

As of December 31, 2025 and 2024, the outstanding accrued expenses to Kabushiki Kaisha No Track are nil. The Company paid annual consulting fees of nil, nil and ¥150 thousand (included in selling, general and administrative expenses), respectively, to Kabushiki Kaisha No Track, in the years ended December 31, 2025, 2024 and 2023.

Tomoya Ogawa, Parent's independent director and the shareholder of the Company (holds 0.36%, 0.36% and 0.58% of common stock as of December 31, 2025, 2024 and 2023, respectively), is the sole owner of Kabushiki Kaisha LTW.

As of December 31, 2025 and 2024, the outstanding accrued expenses to Kabushiki Kaisha LTW are nil. The Company paid consulting fees of nil, nil and ¥1,200 thousand (included in selling, general and administrative expenses) to Kabushiki Kaisha LTW, in the years ended December 31, 2025, 2024 and 2023, respectively.

Kazuyoshi Takahashi, the representative director of ZACC and the shareholder of Parent, is the guarantor with respect to some of the Company’s borrowings. See Note 6, “Borrowings” for more detail.

Transactions with the Company’s corporate auditor

Osamu Sato, Parent's corporate auditor and the shareholder of Parent (holds 0.22%, 0.22% and 0.36% of common stock as of December 31, 2025, 2024 and 2023), is a part-time employee of Ebis 20 Co., Ltd.

As of December 31, 2025 and 2024, the outstanding accrued expenses to Ebis 20 Co., Ltd were nil. The Company paid annual consulting fees of nil, nil and ¥400 thousand (included in selling, general and administrative expenses), respectively, to Ebis 20 Co., Ltd in the years ended December 31, 2025, 2024 and 2023.

Transactions with Senior Executives in Subsidiary

On September 30, 2024 and October 31, 2024, respectively, Issei Homan, Chief Technology Officer of MEDIROM MOTHER Labs Inc. (“Mother Labs”), a subsidiary of MEDIROM, and Yasuhiro Hayami, Chief Business Officer of Mother Labs, invested ¥45,000 thousand and ¥5,040 thousand in Mother Labs’ Series A financing.

On June 30, 2024, the Company entered into a salon purchase agreement with Issei Homan and the Company purchased a salon for ¥22,800 thousand.

During the year ended December 31, 2025, MML issued series A preferred stock to its directors as follows: 6 shares to Yasuhiro Hayami (paid on March 14, 2025), and 3 shares each to Ryo Saito and Yoshio Uekusa, the representative director of MML (paid on October 31, 2025), in each case at ¥180 thousand per share, for a total of ¥2,160 thousand. The issue price was the same as the price paid by third-party investors in the series A financing.

Yoshio Uekusa, the representative director of MML, is the guarantor with respect to certain borrowings of MML. See Note 6, “Borrowings” for more detail.

F-47


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

Transactions with COZY LLC

On January 20, 2023, the Company’s CEO and major shareholder Kouji Eguchi’s 100% funded joint venture COZY LLC (“COZY”) implemented a stock repurchase program based on the US SEC Rule 10b5-1 through a US investment bank. Under this plan, COZY can purchase up to 50 million yen of the Company’s American Depositary Shares (ADS). This plan was approved by the Company’s board of directors on January 18, 2023. During the period from January to March 2023, COZY repurchased the Company’s 22,543 shares.

19.
Subsequent Events

The Company evaluated subsequent events through November 18, 2026, the date the consolidated financial statements were issued.

Financing arrangements with Kufu Company Holdings Inc. — On January 30, 2026, the Company entered into a loan agreement with Kufu Company Holdings Inc. for the ¥200,000 thousand loan arising from the settlement of the 1st convertible bonds, bearing interest at 10.0% per annum, and pledged all of the shares of MML held by the Company as collateral. On March 31, 2026, the Company and Kufu Company Holdings Inc. entered into a memorandum extending to April 30, 2026 the date by which repayment of the loan in full would cause interest to cease to accrue, and the parties have since entered into further memoranda on substantially the same terms on a monthly basis, under which the Company pays the interest accrued through the preceding month-end. On July 14, 2026, in lieu of cash repayment of the 4th convertible bonds of ¥275,000 thousand, the parties amended the loan agreement to add the principal amount of the 4th convertible bonds to the loan, increasing the principal amount outstanding to ¥475,000 thousand, repayable by December 30, 2026, and amended the share pledge agreement to secure the increased amount.

Refinancing of the 2nd convertible bonds — On August 25, 2026, the Company redeemed all of the 2nd convertible bonds of ¥300,000 thousand prior to maturity and concurrently borrowed ¥300,000 thousand from the holder of the bonds, with the redemption price and the loan proceeds settled by set-off. The loan originally bore interest at 5.0% per annum and had an initial maturity date of September 15, 2026, and was not repaid on that date. On November 11, 2026, the Company and the lender entered into an agreement amending the loan, under which the maturity of the principal was extended to December 30, 2026, ¥5,000 thousand of the principal is repayable on November 30, 2026 and the balance on the maturity date, and interest accruing on and after November 1, 2026 accrues at 14.6% per annum, calculated on a 365-day year, and is payable monthly at each month-end rather than together with the principal at maturity. If the parties agree to extend the maturity further, ¥15,000 thousand of the principal will be repayable on December 30, 2026 and ¥10,000 thousand at each month-end thereafter, with the balance on the extended maturity date. The loan is secured by a pledge of the shares of MRS held by the Company and by security over the operating rights of ten salons operated by the Company when the security was granted.

Extension of the 3rd convertible bonds — The maturity date of the 3rd convertible bonds of ¥400,000 thousand was extended from June 30, 2026 to December 25, 2026 pursuant to the Company’s option under the terms of the bonds, and the conversion period was extended to December 7, 2026.

Nasdaq continued listing — On May 26, 2026, the Company received a notice from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its annual report, and Nasdaq granted the Company an extension until November 12, 2026 to regain compliance. The Company did not file its annual report by that date and, on November 13, 2026, received a letter from the Listing Qualifications Department of Nasdaq notifying the Company that its American Depositary Shares would be subject to delisting from The Nasdaq Capital Market unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). On November 18, 2026, the Company paid the required hearing fee and requested a hearing before the Panel. Under the Nasdaq Listing Rules, the hearing request stays the suspension and delisting of the Company’s American Depositary Shares for 15 calendar days, and the Company has requested that the Panel extend the stay pending the hearing and the issuance of the Panel’s decision. On November 18, 2026, the Company filed its annual report on Form 20-F for the year ended December 31, 2025. There can be no assurance that the Panel will grant the extended stay, that the Panel will determine that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1), or that the Company will satisfy the other requirements for continued listing. On October 6, 2026, the Company received a notice from Nasdaq that it was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and has until April 5, 2027 to regain compliance.

Assignment of long-term accounts receivable — On October 11, 2026, the Company assigned the long-term accounts receivable-other of ¥197,475 thousand, for which a full allowance for credit losses had been recorded as of December 31, 2025, to an unaffiliated individual for ¥100 thousand. The assignment became effective on October 13, 2026.

F-48


Table of Contents

MEDIROM HEALTHCARE TECHNOLOGIES INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS- (CONTINUED)

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023

 

Termination of planned acquisition — In October 2026, the Company and the seller agreed to terminate the share transfer agreement dated June 30, 2024 for the acquisition of 70% of the shares of Japan Gene Medicine Corporation.

Merger of subsidiaries — Medirom Shared Services Inc. merged into MEDIROM Wellness Co., with MEDIROM Wellness Co. as the surviving company, effective November 1, 2026.

Rollover of borrowings — The bank loans of ¥350,000 thousand and ¥191,671 thousand that matured on March 31, 2026 have been rolled over. The ¥191,671 thousand loan now matures on March 31, 2027, and the ¥350,000 thousand loan is currently due on November 30, 2026. The maturity date of the corporate bonds of ¥30,000 thousand was extended from April 30, 2026 to December 31, 2026.

Amendment of the loans from Spirit Advisors — On March 31, 2026, MEDIROM Wellness Co. and Spirit Advisors entered into a loan amendment and restructuring agreement under which the loan that matured on December 31, 2025 (US$400 thousand) was restructured, together with accrued interest of US$15 thousand, into a loan bearing interest at 15.0% per annum from January 1, 2026, repayable in monthly installments from April 2026 with the final installment due in September 2027. The remaining loan of US$600 thousand bears interest at 15.0% per annum and must be repaid by December 31, 2027. The obligations remain guaranteed by the Company and by Mr. Eguchi.

F-49


Table of Contents

 

ITEM 19. EXHIBITS

EXHIBIT INDEX

 

Exhibit

 

Description

1.1

 

Articles of Incorporation of the Registrant (English translation), filed as Exhibit 3.1 to Form F-1 (File No. 333-281771) filed on August 23, 2024 and incorporated herein by reference.

 

 

 

2.1

 

Form of Deposit Agreement among the Registrant, the depositary, and holders of the American Depositary Receipts, filed as Exhibit 4.1 to Form F-1 (File No. 333-250762) filed on November 20, 2020 and incorporated herein by reference.

 

 

 

2.2

 

Specimen American Depositary Receipt of the Registrant, included as Exhibit A in Exhibit 4.1 to Form F-1 (File No. 333-250762), filed on November 20, 2020 and incorporated herein by reference.

 

 

 

2.3

 

Description of Securities, filed herewith.

 

 

 

2.4

 

Purchase Agreement, dated October 8, 2024, between the Company and the Bond Holder Triple One Investment Partnership, filed as Exhibit 4.1 to the Registrant’s Form 6-K filed with the SEC on October 11, 2024 and incorporated herein by reference.

 

 

 

2.5

 

Indenture relating to the convertible bonds issued to Triple One Investment Partnership, filed as Exhibit 4.2 to the Registrant’s Form 6-K filed with the SEC on October 11, 2024 and incorporated herein by reference.

 

 

 

2.6

 

Notice from Kufu Company Inc., dated December 3, 2024, relating to the convertible bonds issued to Kufu Company Inc. (English translation), filed as Exhibit 4.9 to Form F-1 (File No. 333- 281771) filed on December 4, 2024 and incorporated herein by reference.

 

 

 

2.7

 

Form of Representative’s Warrant, filed as Exhibit 4.8 to Form F-1 (File No. 333-281771) filed on December 4, 2024 and incorporated herein by reference.

 

 

 

4.1*

 

Capital Alliance Agreement, dated December 9, 2022, by and between the Company and the Bond Holder Kufu Company Inc., filed as Exhibit 10.1 to the Registrant’s Form 6-K filed with the SEC on December 9, 2022 and incorporated herein by reference.

 

 

 

4.2

 

MEDIROM Healthcare Technologies Inc. 2024 Equity Incentive Compensation Plan, as approved by the shareholders of the Company on March 29, 2024, filed as Exhibit 4.4 to the Company’s Form 20-F filed on June 18, 2024 and incorporated herein by reference.

 

 

 

4.3*

 

Share Transfer Agreement, dated June 30, 2024, between the Company and the seller named therein, filed as Exhibit 10.5 to Form F-1 (File No. 333- 281771) filed on November 7, 2024 and incorporated herein by reference.

 

 

 

4.4*

 

Memorandum of Understanding, dated June 30, 2024, between the Company and the seller named therein, filed as Exhibit 10.6 to Form F-1 (File No. 333- 281771) filed on November 7, 2024 and incorporated herein by reference.

 

 

 

4.5

 

Termination Agreement, dated October 31, 2026, between the Company and the seller named therein, filed herewith.

 

 

 

4.6

 

Indenture relating to the Bonds [English Translation], filed as Exhibit 4.1 to the Registrant’s Form 6-K filed with the SEC on December 12, 2025 and incorporated herein by reference.

 

 

 

4.7

 

Indenture relating to the Bonds [English Translation], filed as Exhibit 4.1 to the Registrant’s Form 6-K filed with the SEC on February 4, 2026 and incorporated herein by reference.

 

 

 

4.8

 

Deemed Loan Agreement, dated January 30, 2026, by and between the Company and the Bond Holder [English Translation], filed as Exhibit 10.1 to the Registrant’s Form 6-K filed with the SEC on February 4, 2026 and incorporated herein by reference.

 

 

 

4.9

 

Memorandum of Understanding, dated January 30, 2026, by and between the Company and the Bond Holder [English Translation], filed as Exhibit 10.2 to the Registrant’s Form 6-K filed with the SEC on February 4, 2026 and incorporated herein by reference.

 

 

 

4.10

 

Share Pledge Agreement, dated January 30, 2026, by and between the Company and the Bond Holder [English Translation], filed as Exhibit 10.3 to the Registrant’s Form 6-K filed with the SEC on February 4, 2026 and incorporated herein by reference.

 

 

 

4.11

 

Memorandum of Understanding, dated March 31, 2026, by and between the Company and the Bond Holder [English Translation], filed as Exhibit 10.1 to the Registrant’s Form 6-K filed with the SEC on April 9, 2026 and incorporated herein by reference.

 

 

 

4.12

 

Amendment Agreement, dated July 14, 2026, by and between the Company and the Bond Holder [English Translation], filed as Exhibit 10.1 to the Registrant’s Form 6-K filed with the SEC on August 7, 2026 and incorporated herein by reference.

99


Table of Contents

 

 

 

 

4.13

 

Money Loan Agreement, dated August 25, 2026, by and between the Company and Triple One Investment Limited Partnership [English Translation], filed herewith.

 

 

 

4.14

 

Security Agreement, dated August 25, 2026, by and between the Company and Triple One Investment Limited Partnership [English Translation], filed herewith.

 

 

 

4.15

 

Agreement on the Purchase and Cancellation of the Second Unsecured Convertible-Type Corporate Bonds With Share Options, dated August 25, 2026, by and between the Company and Triple One Investment Limited Partnership [English Translation], filed herewith.

 

 

 

4.16

 

Set-Off Agreement, dated August 25, 2026, by and between the Company and Triple One Investment Limited Partnership [English Translation], filed herewith.

 

 

 

4.17

 

Agreement on the Amendment of the Repayment Date and Certain Other Terms of the Money Loan Agreement, dated November 11, 2026, by and between the Company and Triple One Investment Limited Partnership [English Translation], filed herewith.

 

 

 

8.1

 

List of Subsidiaries of the Registrant, filed herewith.

 

 

 

11.1

 

Code of Ethics and Business Conduct of the Registrant, filed as Exhibit 11.1 to the Company’s Form 20-F filed on May 17, 2021 and incorporated herein by reference.

 

 

 

11.2

 

Insider Trading Policies of the Registrant, filed as Exhibit 11.2 to the Company’s Form 20-F filed on May 30, 2023 and incorporated herein by reference.

 

 

 

12.1

 

Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934, filed herewith.

 

 

 

12.2

 

Certification of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934, filed herewith.

 

 

 

13.1

 

Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, furnished herewith.

 

 

 

13.2

 

Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, furnished herewith.

 

 

 

23.1

 

Consent of GuzmanGray, filed herewith

 

 

 

23.2

 

Consent of TAAD LLP, filed herewith

 

 

 

97.1

 

Executive Officer Clawback Policy, as approved by the board of directors of the Company on November 28, 2023, filed as Exhibit 97.1 to the Company’s Form 20-F filed on June 18, 2024 and incorporated herein by reference.

 

 

 

101.INS

 

Inline XBRL Instance Document

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* Certain confidential information contained in this exhibit, marked by brackets therein, has been omitted because it is both not material and is the type of information that the registrant treats as private or confidential.

100


Table of Contents

 

SIGNATURE

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

 

 

 

 

MEDIROM Healthcare Technologies Inc.

 

 

November 18, 2026

By:

/s/ Fumitoshi Fujiwara

 

Name:

Fumitoshi Fujiwara

 

Title:

Chief Financial Officer and Director

 

101


Keep reading